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Abstract
Background and Aims The interleukin 18 (IL-18) system consists of a pro- 
inflammatory cytokine (IL-18), a naturally occurring inhibitor (IL-18BP), and a dimeric 
receptor. IL-18 has been implicated in many autoimmune conditions, with elevated 
plasma levels predicting future risk of heart disease in healthy individuals. IL-18 also 
appears to have metabolic consequences, with i l l8~l~  mice having higher bodyweight, 
attributable to increased feeding. The central hypothesis of this work was that genetic 
variation within both IL18 and ILJ8BP,  that influenced their circulating levels, would 
be associated with individual risk for both heart disease and obesity. This was tested by 
measuring IL-18 levels in several study groups and accessing their correlation with nu­
merous single nucleotide polymorphisms (SNPs) (chosen using a tagging SNP (tSNP) 
methodology) within both genes. Any effects (either single SNP or haplotypic) were 
then assessed directly using quantitative PCR (QPCR).
Results For both IL18 and IL18BP,  tSNP sets were chosen that captured greater than 
90% of the common genetic variation seen in a representative European Caucasian sam­
ple. Their association with levels of IL -18 and interleukin 18 binding protein (IL-18BP) 
were assessed in healthy and diseased individuals; genetic variation in 1L18 only was 
associated with differences in plasma IL-18 (and free IL-18 (flL-18)) levels in all co­
horts. Carriage of the rare allele of /L/S-5848 T > C  was associated with, on average 
across all study groups, 44% higher IL-18 levels than TT homozygotes. There was also 
a haplotypic effect, with a common haplotype -  hGTATA (frequency of ~ 20% ) -  being 
associated with 30% lower IL-18 levels. The effect was consistently of greater magni­
tude in diseased than healthy individuals. Despite IL-18 levels being elevated in those 
individuals who went on to suffer an myocardial infarction (MI) over 15 yr of follow-up 
(277.6 pg/ml vs. 239.6 pg/ml, p=0.05), there was no significant difference in genotype, 
or haplotype, frequencies in those who had heart disease compared to those who did 
not. No consistent association between BMI/obesity and IL-18 levels was observed, 
however, in two of the study groups genetic variation in IL18 was associated with sig­
nificant differences in body mass index (BMI). Overall, hGTATA was associated with 
a 9% higher BMI, equating to a 7 kg greater body weight for an average male. In in 
vitro studies of IL18 expression in healthy, male hGTATA carriers, no significant differ­
xxiv
ence in 1L18 messenger RNA (mRNA) concentrations were observed when compared 
to hGCATA controls.
Conclusion The data presented here disagrees with previously published results, 
showing no role for variation within IL18 in establishing heart disease risk. However 
there are novel findings that suggest it may play a role in weight control. Given that 
these effects appear not to be mediated through plasma IL-18 levels, the identification 
of individuals through genetic testing may be especially relevant.
Total thesis word count -  ~ 6 1 000
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Chapter 1 
Introduction
Despite advances in lifestyle and medical management, coronary heart disease (CHD) 
is the leading cause of death in the United Kingdom (UK) and United States (US) 
[Anderson and Smith, 2003; Breslow, 1997], and one of the most important causes of 
years of life lost before the age of 65 yr [Liu et al., 2002; British Heart Foundation, 
1999]. At the age of 4 0 yr, lifetime risk for developing CHD in the West is 49% in 
men and 32% in women [Lloyd-Jones et al., 1999]. In the UK, the total annual cost 
of all CHD related burdens was £7.06 billion in 1999, the highest of all diseases for 
which comparable analyses have been done [Liu et al., 2002], whilst the direct cost of 
cardiovascular disease in the US in 1996 was estimated at $259 billion [Braunwald, 
1997],
As the 20th century began, CHD was the fourth most common disease in the US 
[National Center for Health Statistics, 1995]. By 1910 CHD had reached first place, and 
has remained the most common cause of death in the US since. Following a concerted 
effort to understand and treat CHD, the age-standardized mortality rate (ASMR) from 
CHD actually declined from its peak in 1963. The ASMR from cerebrovascular disease 
(CBVD) has also declined impressively, falling by 70%. In fact, 85% of the reduction in 
ASM R from all causes between 1963 and 1994 can be ascribed to the decline in deaths 
from cardiovascular disease (CVD) and stroke [Braunwald, 1997].
However, despite these remarkable improvements in treatment and prevention, the 
war against CVD is far from over. The “epidemiologic transition” has led to a shift in 
the predominance of nutritional deficiencies and infectious diseases, to those classified 
as degenerative (chronic diseases such as CVD, cancer, and diabetes mellitus) leading 
to dramatic improvements in health and so significant increases in life-expectancy over 
the past century [Yusuf et al., 2001b] (life expectancy at birth has increased from a 
global average of 46 yr in 1950 to 66 yr in 1998 [Sen and Bonita, 2000]). This, coupled 
with increases in population size, has meant the absolute number o f deaths from car­
diovascular disease in the US has remained nearly constant at 750000 per year over the 
last 25 yr.
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Figure 1.1: Projected increase in CVD deaths, 2000-2030, in those under 70 yr 
(Adapted from Mathers and Loncar [2006]).
Predictions of future growth in CVD prevalence are complicated due to the complex 
systems that underlie the disease and the geographical heterogeneity that is often ob­
served. However, recent predictions that use separate models across age and sex groups 
predict that both ischaemic heart disease (IHD) and CBVD will remain as the top two 
global causes of death in 2030, together accounting for 24% of all deaths. In total, the 
predictions showed an 11 % increase in CVD death for those under 70 yr and a 34% in­
crease in CVD death when the over 70 yr age group were included (Mathers and Loncar 
[2006], see figure 1.1). Therefore the need to elucidate and understand the factors that 
predict CHD risk is o f ever-growing importance.
1.1 Ethnic and Geographical Differences in CHD Sus­
ceptibility
Due to the numerous environmental and physiological factors that contribute to CVD 
risk, the prevalence and manner o f disease varies greatly across the globe; the CVD 
death rate in men living within the Russian Federation is almost seven times that o f  
Japan, and 7.5 times higher for women (see figure 1.2 on the next page).
1.1.1 European Origin
People o f European origin include those who originate from diverse backgrounds in 
Northern Europe (eg. Sweden and Norway), Western Europe (eg. UK and France),
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Figure 1.2: International CVD statistics (adapted from Callow [2006])
Southern Europe (eg. Spain and Italy), and Eastern Europe (eg. Poland and Ukraine). 
The region differs greatly in wealth and development as shown in table 1.1 on the fol­
lowing page.
Differences in CHD ASMR vary widely between European populations. Data from 
WHO (European mortality database) indicate that the CHD mortality rate is six-fold 
higher among men and women in the Russian Federation (390/100000) compared with 
those in France (60/100000). Furthermore, Eastern European countries such as the 
Ukraine, the Russian Federation, Hungary, and the Czech Republic have among the 
highest (and increasing) CHD rates in the world, which is in marked contrast to the 
decreases seen in the more economically stable Western European countries [Yusuf 
e ta l., 2001a].
The epidemic of CHD in Eastern Europeans is partly related to high levels of sm ok­
ing and excessive alcohol use, along with diets high in saturated fat [Marmot, 1995] and 
poor social conditions. Research that attempts to explain the relative protection from 
CHD seen in M editerranean [Renaud et al., 1995] and French populations [Artaud-Wild 
et al., 1993] has yielded different hypotheses.
The diet of the Mediterranean region is typified by low saturated fat, high m onoun­
saturated fat, moderate alcohol intake (mainly in the form of wine with meals), high 
consumption of vegetables, fruits, legumes, and cereals, moderate consumption o f fish, 
milk, and dairy products (mostly in the form of cheese), and low consumption of meat 
and meat products [Trichopoulou and Lagiou, 1997]. In total, in spite of the high fat 
content of the diet, saturated fatty acids is less than 10% of energy intake. The diet is 
also high in vitamin E, vitamin C, and antioxidants (particularly flavonoids). The ben­
efit of such a diet has been demonstrated in a number o f intervention studies [Ehnholm 
et al., 1982; Puska et al., 1983; Ferro-Luzzi et al., 1984; Katan et al., 1995; Vissers 
et al., 2001], with improvements in both low-density lipoprotein (LDL)-cholesterol and 
blood pressure levels.
With comparable intakes of dietary cholesterol, the CHD mortality rate for men 
aged 55-59 yr was four times higher in Finland than France in the Seven Countries 
Study [Keys, 1980; Artaud-Wild et al., 1993]. This has been attributed to a higher 
consumption of alcohol, in particular wine; wine ethanol is, to a point, inversely related 
to CHD mortality, but not longevity [Criqui and Ringel, 1994]. But it is also believed 
that the lower rate of CHD mortality may simply be due to a time-lag between increases 
in consumption of animal fat and the resulting elevations in serum cholesterol; increased 
consumption of animal fat has occurred only relatively recently in France but quite some 
time ago in Finland and the UK [Law and Wald, 1999].
4
Table 1.1: Wealth and development statistics for countries within Europe 2001 data; taken from WHO European Health For All Database, accessed 
March 2007.
Country UK France Italy Norway Poland Russian
Federa­
tion
Spain Sweden Ukraine
Population (million) 59.1 59.2 57.0 4.5 38.6 144.4 40.6 8.9 48.8
% of population aged 65+ yr 15.9 16.2 18.4 15.0 12.4 12.8 17.0 17.2 14.1
% urban population 89.5 75.5 67.1 75.0 62.6 72.9 77.8 83.3 68.0
Gross domestic product, US$ 24437 22534 19440 37610 4862 2141 14906 24902 766
per capita
Literacy rate (%) in population 98.5 _ 99.7 99.6 97.7 _ 99.6
aged 15+yr
United Nations Development 0.930 0.925 0.916 0.944 0.841 0.779 0.918 0.941 0.766
Program (UNDP) HDI1 
Life expectancy at birth, yr 78.3 79.4 80.1 79.1 74.4 65.3 79.8 80.0 68.1
Hospitals per 100000 - 5.94 2.29 - 2.15 6.86 1.89 0.87 6.05
'The human development index (HDI) is a comparative worldwide measure o f life expectancy, literacy, education and standard o f living. It is a standard means o f  measuring 
well-being.
1.1.2 Chinese Origin
Deaths from CHD have been increasing in China in recent decades [Woo and Donnan, 
1989]. Although the CVD mortality rate in China is approximately the same as that in 
the US, the CHD mortality rate is approximately 50% lower than the rates observed in 
most Western European countries, with the difference complimented by an increased 
CBVD rate. A case-control study from Hong Kong indicated that the traditional risk 
factors (eg. smoking, hypertension (HT), or diabetes mellitus) are important [Donnan 
et al., 1994], Also, despite mean serum cholesterol being relatively low in the Chinese 
population by Western standards (~ 4 .2 mmol/1), it was still directly related to CHD 
mortality [Chen et al., 1991]. Cigarette smoking is highly prevalent among Chinese 
males (over 60%) and increasing [Yang et al., 1999].
Within China there are differences in CHD mortality rates, with rates in northern 
China (Beijing) higher than in southern China (Shanghai and Guangzhou), and a similar 
disparity between urban and rural areas [Tao et al., 1989; USCEPR and PRC, 1992]. 
The prevalence of HT, mean levels o f serum cholesterol and BMI were all lower in the 
South compared to the North and in rural compared to urban areas.
1.1.3 South Asian Origin
South Asia refers to people who originate from India, Sri Lanka, Bangladesh, Nepal, 
and Pakistan. There are relatively few mortality studies from India, as there is no 
uniform completion of death certificates and no centralized registry of CVD deaths. 
However, the WHO and the World Bank estimate that deaths attributable to CVD have 
increased in parallel with India’s expanding population, and now accounts for a large 
proportion of life years lost [Murray and Lopez, 1996]. O f all deaths in 1990, approx­
imately 25% were attributable to CVD. South Asian migrants to UK, South Africa, 
Singapore, and the US experienced 1.5 to 4.0 times higher CHD mortality compared to 
indigenous populations [Enas et al., 1992].
Compared to Europeans, South Asians (in the UK and Canada) do not display higher 
levels o f smoking, HT, or elevated cholesterol, yet still have higher rates of CHD [Sheth 
et al., 1999; Anand et al., 2000; M cKeigue et al., 1993]. However, smoking, HT, and 
diabetes remain associated with CHD in South Asians [Pais et al., 1996]. Further­
more, South Asian migrants resident in the UK and Canada suffer a high prevalence 
of impaired glucose tolerance (IGT), central obesity, and experience type II diabetes 
mellitus (TIIDM) at rates four to five times higher than Europeans (19% versus 4% by 
age 55 yr) [Anand et al., 2000; M cKeigue et al., 1993, 1991]. In contrast, the preva­
lence of diabetes in rural India is 2-3%, and approximately 8% in urban areas. This 
geographical variation of diabetes within India is matched by the incidence of CHD, 
with, over two decades, a nine-fold increase in CHD rates in Indian urban centres, but
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only a two-fold increase in rural populations [Gupta and Gupta, 1996]. Taken together, 
the available data strongly suggests a genetic predisposition to CVD in South Asians.
1.1.4 Blacks of African Origin
Before 1970, CHD was virtually unknown in black people in Africa, in stark contrast 
with the high rates of CHD in people o f African descent living in typically westernized 
settings [Yusuf et al., 2001a].
1.1.4.1 Blacks in Africa
Collecting CVD mortality data from Sub-Saharan Africa is difficult as only 1.1% of 
deaths are registered with a central agency [Murray and Lopez, 1996], therefore the 
range of analysis is limited. However, data from other sources, such as small population 
studies, indicate that the burden from CHD in 1990 was 4.5 million disability-adjusted 
life years (DALY), with CHD mortality around 41/100000 [Murray and Lopez, 1996], 
levels around four to five times lower than those seen in western countries, but still rep­
resenting a significant proportion of all deaths (CVD -10% ; CH D-3% ). The prevalence 
of most conventional CHD risk factors is lower among blacks than other groups within 
Africa, and the world [Seedat, 1996; Berrios et al., 1997a]. Furthermore, the preva­
lence of multiple risk factors is strikingly lower, with 65% of the population having 
no identifiable risk factors, 30% having only one risk factors, and only 5% having two 
risk factors, compared to 50%, 40%, and 10%, respectively, in the US [Berrios et al., 
1997b]. However, the significance of CVD is increased due to limited access to health 
care.
The INTERHEART study is an international, standardized, case-control study con­
ducted in 52 countries, designed to assess the association of CVD risk factors with MI 
[Yusuf et al., 2004; Rosengren et al., 2004]. Participants for INTERHEART Africa 
were recruited from nine countries (>80%  from South Africa), constituting 578 cases 
and 785 controls, with a mix of black African people (36.3%), coloured African peo­
ple (46.7%), and European and other African people (17%). Overall, African cases 
presented 3.8 yr earlier than the average INTERHEART study cases, with the risk fac­
tors associated with MI not differing between the African sample and the global study. 
However the association between history of HT and MI was significantly stronger in the 
African sample than the global sample [Steyn et al., 2005]. This could be of great im­
portance given that the International Collaborative Study of Hypertension in Blacks (IC- 
SHIB) found the age-adjusted prevalence of HT in Nigeria (the largest black nation in 
the world, with a population of > 120 million) was 14.5% [Cooper et al., 1997].
In 2006, a study of over 400 black South Africans (male and female) suggested that 
the prevalence of risk factors is increasing across the continent. Furthermore, around
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80% of the cases in this study were younger than 65 yr and fell within the working-age 
group; most came from low socio-economic background and had limited education, a 
finding that questions the common belief that CHD occurs predominantly in the wealth­
ier section of society [Loock et al., 2006]. A recent publication showed that in people 
of working age (35-64 yr), CVD mortality rates in South Africa in 2000 had already 
increased to levels higher than those found in US and Portugal. It also reported that 
the projected CVD mortality in South Africa for this age group will increase by 41% 
between 2000 and 2030 (Leeder et al., 2004].
The INTERHEART Africa study showed heterogeneity in relation to the m agni­
tude of the risk for MI among the three ethnic groups, suggesting that the three ethnic 
groups are at different points of the epidemiological transition, and therefore the devel­
opment of the CVD epidemic IGillum, 1996]. Burdens of disease estimates adjusted for 
underregistration and misclassification of cause, show that the black African group in 
South Africa had CHD mortality rates of 70/100000. For the coloured African group, 
this estimate was 171/100000, whilst the estimate was 230/100000 for the white South 
African group [Steyn et al., 2005].
This data suggests that an epidemic of CHD and other atherosclerosis-related CVD 
could become manifest within Africa in the first half of the 21st century, and will 
strike a generation already under the spectre of the human immunodeficiency virus 
(HIV)/acquired immunodeficiency syndrome (AIDS) pandemic.
1.1.4.2 African-Americans
African-Americans are the largest non-white population in the US, representing 12.1% 
of the population (~ 35  million) [US Census Bureau, 2005].
Life expectancy is shorter, and mortality rates greater, for black than for whites in 
America [Cooper, 1993] (see table 1.2 on the next page), and these discrepancies are 
continuing to widen [Mason, 1993]. CVD, the leading cause of death for all Americans, 
is thought to be an important determinant of these disturbing trends [Cooper et al., 2000; 
Geronimus et al., 1996]. For most o f the last century, CHD mortality rates were lower 
in black men than white men. However, although initially the decline in CHD mortality 
happened in parallel across all ethnic groups, the rates of CHD mortality throughout 
the 20th century and into the 21st, have declined more slowly in black men and women 
than white men and women (see figure 1.3 on the following page), such that the ASMR 
(1999-2003) for CVD in blacks and African Americans was 19% higher than American 
whites (see table 1.2 on the next page); in 1980 it was estimated that black men living in 
Harlem had less chance of surviving to the age of 65 than men in Bangladesh [McCord 
and Freeman, 1990].
In a study based upon death certificate information across eight persistently poor ge-
Table 1.2: 1999-2003 ASMR for US, by ethnicity and sex. Data is expressed as mor­
tality per 100000 population and are based on rates age-adjusted to the 2000 standard. 
Data source: US Department of Health and Human Services, National Center for Health 
Statistics, CDC WONDER On-line (http://wonder.cdc.gov), accessed March 2007.
Race % of Total 
Population
ASMR per 100000 
All Cause CVD2
Black or African American Male 6.8 911.8 108.8
Female 6.2 1372.9 164.5
Other Race Male 2.7 439.7 52.4
Female 2.6 638.0 87.2
White Male 41.3 706.4 86.6
Female 40.3 1007.5 142.4
Classified as ICD-10.125, and all subsets
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Figure 1.3: ASMR for CHD by sex and race in US from 1980-1997. Rates are age- 
adjusted to 2000 standard (adapted from Cooper et al. [2000]).
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ographic areas and eight geographically proximate, but more advantaged areas, matched 
for race, diseases of the circulatory system were important to excess mortality in every 
group, and in most cases they were the leading cause [Geronimus et al., 19961 (see 
table 1.3 on the following page). There were substantial differences in the excess mor­
tality rates due to CHD between reasonably well-matched (by geographic location and 
wealth) white and black groups, adjustment for poverty rate accounted for more than 
half of the racial differences in mortality [Geronimus et al., 1996]. This would suggest 
that although the inequality in wealth, along with other socioeconomic status (SES) fac­
tors [Marmot, 2003], account for a large proportion of the differences in CHD mortality, 
there still remains a significant proportion that is yet to be explained.
In a separate study that investigated ASMR in Hispanics, blacks and whites in Los 
Angeles County, California, it was found that deaths from CVD constitute the largest 
category of deaths among each ethnic group, and that there were large differences in 
ASMR between the different groups (see table 1.4 on page 12). In all categories, rela­
tive risks (RRs) for African Americans were higher than that of the white and Hispanic 
populations, with the greatest excess observed in hypertensive disease, CBVD, and car­
diomyopathy [Henderson et al., 2000]. Hispanics in Los Angeles share with African 
Americans important lifestyle disadvantages associated with premature mortality, such 
as inadequate access to medical care and inadequate knowledge of healthful behaviours 
(data from Behavioural Risk Factor Surveillance System, http://www.cdc.gov/brfss/). 
Furthermore, from recent census information, the Hispanic and African American pop­
ulations of Los Angeles County are comparable in terms of socioeconomic status. In 
1989, median income for Hispanic households was $27361 compared to $25827 for 
African American households and a similar proportion of families fell below the poverty 
line in both populations; 22.9% for Hispanics and 21.2% for African Americans [Cen­
sus of Population and Housing, 1990]. Therefore, the difference in CHD mortality 
between Hispanics and African Americans, despite their similarities in socioeconomic 
status and healthcare access and awareness, argues towards other major factors deter­
mining the disparity in CHD mortality between whites and African Americans.
The Charleston Heart Study is a population-based prospective cohort study that be­
gan in 1960, and contains a randomly ascertained sample of blacks and whites 35 yr 
and older. Recent analysis confirmed the consensus that blacks suffered increased CHD 
risk over whites, with the median age at death being three years younger among black 
men than white men and five years younger for black women than white women [Ni- 
etert et al., 2006]. In a model that included SES (based on education and occupation), 
there was no significant difference in survival between white men and black men. How­
ever, this was not the case for women. In a survival model incorporating SES, survival 
rates for white women were significantly higher than black women, although the eth­
nicity effect was attenuated following adjustment for traditional risk factors. In both
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Table 1.3: The contribution o f CVD to excess mortality among poor blacks and whites 15-64yr, according to sex and area, 1989-1991 [Geronimus 
et al., 1996].
Area Race Mean Family % Families No. of Excess Deaths per 100000
Income ($) Below Poverty CVD Total
Level Meni Women Men Women
New York City
Black
White
24174
34208
33.1
21.3
205
15
137
20
1296
208
535
26
Detroit
Black 19841 44.3 192 146 746 355
White 29334 22.0 138 93 421 203
Alabama
Black 17222 48.7 114 118 338 201
W hite 30480 13.6 64 41 127 58
Table 1.4: ASMR and RR for CVD mortality in African American and Hispanic versus 
white men in Los Angeles County, 1988-1992 [Henderson et al., 2000].
Disease and Race RR (95% Cl) ASMR
White 1.00 22.0
HT Hispanic 0.98 (0 .8 2 -  1.17) 23.2
African American 4.50 (3.98 -  5.08) 97.5
White 1.00 163.6
MI Hispanic 0.85 (0.79 -  0.92) 142.5
African American 1 .1 9 (1 .1 0 -1 .2 8 ) 190.6
White 1.00 183.5
IHD Hispanic 0.75 (0 .7 0 -0 .8 1 ) 145.0
African American 1 .2 9 (1 .2 0 -  1.38) 231.1
White 1.00 67.3
CBVD Hispanic 1.21 (1 .0 9 -  1.33) 80.7
African American 2.33 (2 .1 3 -2 .5 4 ) 153.0
White 1.00 7.6Congestive Heart 
Failure Hispanic 1 .1 2 (0 .8 3 -1 .5 3 ) 8.71 dlltll V
African American 2 .2 4 (1 .7 2 -2 .9 2 ) 16.6
White 1.00 29.1
Cardiomyopathy Hispanic 0.98 (0 .8 4 -1 .1 4 ) 30.2
African American 2.56 (2.25 -  2.90) 72.1
White 1.00 221.1
CVD - Other Hispanic 0.84 (0.79 -  0.90) 190.2
African American 1 .8 6 (1 .7 6 - 1.96) 404.8
White 1.00 694.5
Total Hispanic 0.87 (0.84 -  0.90) 620.6
African American 1 .7 2 (1 .6 7 - 1.77) 1165.7
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sexes, models adjusting for traditional risk factors, showed no significant difference in 
survival between races [Nietert et al., 2006].
These findings are consistent with a number of other reports from the Charleston 
Heart Study (South Carolina) [Keil et al., 1993, 1992], and also data from the Evans 
County, Georgia, Heart Study that again showed a difference in black:white CHD sur­
vival between the sexes [Hames et al., 19931. When both studies were combined and 
following adjustment for traditional risk factors, black men experienced around 2 0 - 
30% less CHD mortality than white men, and were largely influenced by the same risk 
factors (Keil et al., 1995]. Both South Carolina and Georgia are notable for their low 
CHD mortality (in both white and black populations) so application of these findings to 
the whole of US is problematic.
With respect to risk factor distributions, blacks have a largely similar profile to 
whites. Lipid levels in black men and women were found to be largely similar, and in 
the Atherosclerosis Risk in Communities Study (ARIC) LDL-Cholesterol levels were 
similarly predictive of CHD risk [Jones et al., 2002], The prevalence of obesity is high 
in both sexes and across ethnic and racial groups [Francis, 1997; American Heart As­
sociation, 2002], as is smoking [American Heart Association, 2002].
HT however has a remarkably high prevalence in blacks, with blacks developing 
HT earlier, and having higher average blood pressure than whites [Joint National Com ­
mittee, 1997]. Inevitably this translates into increased CHD risk, for example in ARIC 
the CHD incidence rate in black women without HT was 1.6 per 1000 person-years, 
compared with 7.6 per 1000 person-years for black women with HT. Furthermore, as 
shown in table 1.4 on the preceding page, the greatest disparity in CHD ASMR in black 
men is due to HT. The underlying causes of HT, and thus o f HT-associated disease 
mortality, remain obscure. W hat does seem clear is that rural native Africans seem to 
be normotensive [Cooper and Rotimi, 1994] and only develop HT upon migration to an 
urban environment [Kaufman et al., 1996]. Therefore it seems likely that although SES 
accounts for much of the differences seen in CHD rates, HT is also a significant factor. 
It is entirely possible that the predisposition to HT among those of African origin is 
due to a genetic susceptibility and only comes to the fore upon interaction with some 
environmental factor, be it smoking or diet (which appear to differ little between races).
1.1.4.3 Blacks in the UK
In the UK, blacks (black African, Caribbean, and others) are the second largest non­
white population, accounting for around 2% of the population (~  1.1 million) [Office 
for National Statistics, 2001J. In similarity to US blacks, UK blacks (both Caribbeans 
and West Africans) have a high incidence of stroke, whereas CHD is less common 
[Balarajan et al., 1989; Balarajan, 1991; Wild and McKeigue, 1997] -  ASMR of 62 and
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100 per 100000 in black men and white European men respectively, and 86 and 100 
in black women and European women respectively [Lip et al., 2007]. Furthermore, the 
major risk factor to differ consistently between UK blacks and white Europeans again 
seems to be HT.
In a study o f over 1000 subjects, age-standardized prevalence o f HT (>140m m H g 
systolic blood pressure (SBP), >90m m H g diastolic blood pressure (DBP), or on HT- 
treatment) was 35% in blacks and 14% in whites, with age-standardized median SBP 
6 mmHg higher in black men than white men; in women this difference was 17 mmHg 
(see figure 1.4). No difference in median blood pressure (BP) were observed between 
black subjects bom in the Caribbean and those bom in West Africa [Chaturvedi et al., 
1993].
Therefore it appears that present day UK may reflect the US some 20 yr ago. CHD 
mortality rates are lower for blacks than whites, however as time progresses we may 
see the gap narrowing, as shown in figure 1.3 on page 9.
Although the data for CVD susceptibility in blacks resident in Africa and western 
populations is confusing, it appears that those of African origin have a distinct predis­
position to HT. Therefore, as HT is a particularly strong risk factor for CHD in these 
populations, it seems likely that as a greater proportion of the population is exposed to 
a western lifestyle this will lead to an overall increase in CHD incidence. Therefore a 
greater understanding of CHD in Africans will lead to improvements in identifying and
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Figure 1.5: Morphology of the healthy arterial wall
treating a population in which CHD is set to increase drastically.
1.2 Pathology of Atherosclerosis
Atherosclerosis can be defined as a chronic vascular disease of medium and large ar­
teries, and includes thickening and remodelling of the vessel wall leading to reduction 
or obstruction of blood flow, through plaque formation and thrombosis [Stuhlinger and 
Tsao, 2003].
1.2.1 Morphology of Normal Artery
The wall of the normal artery consists of three concentric cellular layers: the innermost 
intima, the media, and the outermost adventitia. The layers are separated by rings 
of elastin: the internal elastic lamina, separating the intima from the media, and the 
external elastic lamina, separating the media from the adventitia (see figure 1.5).
The luminal surface of the artery is lined by a single layer of endothelial cells on a 
basement membrane of extracellular matrix. Junctional complexes connect neighbour­
ing endothelial cells. The endothelium forms a barrier between the blood and the arterial 
wall, and although originally thought to be fairly inert, is now seen as a dynamic cellu­
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lar layer regulating a number of functions including vascular tone, leukocyte adhesion, 
and thrombosis.
The media consists of multiple layers of smooth muscle cells (SMCs) that produce 
and are held together by an extracellular matrix, consisting mainly of elastic fibres, col­
lagen, and proteoglycans. The number o f SMCs, and therefore the arterial thickness, 
depends on the location, size and function of the artery. The outermost adventitia typi­
cally consists of a loose matrix of SMC, fibroblast, collagen and elastin [Stuhlinger and 
Tsao, 2003].
1.2.2 Definition and Hypotheses of Atherosclerosis
The term atherosclerosis reflects the two principal components of the lesion; that is 
athero  from the Greek word for gruel, corresponding to the necrotic core area at the 
base of the atherosclerotic plaque and sclerosis from the Greek word for hardening, cor­
responding to the fibrous cap at the luminal edge of the plaque. Atherosclerotic lesions 
mainly contain three components: 1). cholesterol in the form of cholesterol esters; 2). 
cells consisting mainly of SMCs, macrophages and other cell types; 3). connective tis­
sue composed of collagen, elastin and glycosaminoglycans [Tegos et al., 2001; Woolf, 
1990; Davies and Woolf, 1993].
A number of credible hypotheses for atherogenesis have been postulated to explain 
the cell types, behaviours and products observed within the plaque.
1.2.2.1 The Lipid Theory
It is now well established that the early lesions in atherosclerosis, the type I and type 
II lesions (according to the Stary classification [Stary et al., 1995]) are characterized 
by the accumulation of intracellular cholesterol esters within macrophage ‘foam cells’ 
[McGill Jr, 1968]. It has also been shown that the type III lesion is characterized by 
cholesterol ester accumulation in the extracellular space [Stary et al., 1995].
Studies of human arteries and animals fed on cholesterol-rich diets have shown 
that lipids accumulate in the intima [Smith and Slater, 1972]. This accumulation of 
cholesterol, and more precisely LDL-cholesterol, in the intima might be the result of: 1). 
increased plasma LDL concentrations [Smith, 1990]; 2). alteration of the permeability 
of the arterial intima to LDL [Zhang et al., 1993]; 3). increased retention of LDL in the 
intima [Bondjers et al., 1990]; and 4). impeded transport of LDL from the intima to the 
media [Smith, 1990].
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1.2.2.2 The Oxidation theory
Cholesterol-loaded foam cells are present in the earliest detectable lesions. Normally, 
receptor-mediated uptake of LDL, the major carrier of plasma cholesterol, is suppressed 
by down-regulation of LDL receptor (LDLR) in response to increases in cholesterol 
concentrations. Therefore, it was thought LDL may undergo modifications, causing it to 
be internalized via receptors that are not under the control of cholesterol concentrations 
[Jessup et al., 2004].
The relevance of this hypothesis was increased following the observation that pre­
incubation of LDL particles with endothelial cells, increased its subsequent uptake by 
macrophages, causing cholesterol loading [Henriksen et al., 1981]. The modified LDL 
includes oxidized LDL (oxLDL), consisting of both lipid and protein component oxi­
dation, that can be formed via incubation with a number of cell types, including SMCs 
and macrophages [Steinberg, 1997a]. A less modified, but still biologically active, form 
of LDL -  minimally modified LDL (MM-LDL) -  is formed at the early stages o f LDL 
oxidation, however this maintains its ability to bind LDLR and does not result in foam 
cell formation [Jessup et al., 2004].
1.2.2.3 The Hemodynamic Theory
The Hemodynamic theory was first proposed in 1950 and attempts to explain the focal 
nature of atherosclerosis, and suggested that hydrostatic and shear stresses were most 
important in lesion development. The theory drew on evidence that HT predisposes to 
atheroma development, and that the lesions have a predilection for arterial bifurcations 
and other locations where turbulent or relatively stagnant flow, and thus low shear stress, 
is usually detected. The lack of shear stress may delay the clearance of blood and its 
components, allowing prolonged contact of potentially toxic substances with the intima, 
which in turn could potentiate endothelial injury. In addition, altered hemodynamics 
may modify the endothelial permeability to LDL, facilitating their transport into the 
intima [Glagov et al., 1988].
1.2.2.4 The Fibrin Incrustation Theory
First proposed by Rokitansky in the nineteenth century, the theory postulated that fib­
rinogen is converted into fibrin on the luminal surface of the artery thereby forming a 
thrombus, which in turn becomes organized and tissue-like. It was demonstrated by 
two independent investigators that thrombus formation can take place on the surface 
of a plaque and subsequently can be incorporated into its mass and become fibrous, 
thus increasing its size [Duguid, 1946; Hand and Chandler, 1962]. Additionally it was 
proposed that phagocytosis of cholesterol-rich platelets by macrophages will produce 
the lipid-rich foam cells. On the whole, the layered appearance of the atheroma is
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more easily explained by SMC hyperplasia and connective tissue deposition rather than 
thrombus organization. Despite these inadequacies, this theory focused attention on 
the crucial role of thrombogenesis, and proposed the idea of thrombus formation in the 
complicated plaque, leading to its instability [Tegos et al., 2001].
1.2.2.5 The Nonspecific M esenchymal Hypothesis
Atherosclerosis consists of degenerative and regenerative processes. One such regener­
ative event is the proliferation of SMC and the subsequent connective tissue production 
by these cells. The main components of this connective tissue in such settings are pro­
teoglycans and collagen, the principal space-filling agent of the complicated, advanced 
atherosclerotic plaque [Berenson et al., 1984]. This hypothesis proposes that a wide 
range of stimuli at the arterial wall -  whether physical such as shear stress or chem i­
cals such as vasoactive agents -  induce a migration of SMC (mesenchymal cells) from 
the media to the intima, which subsequently proliferate and produce connective tissue 
[Hauss et al., 1962]. The processes described in this hypothesis resemble the healing 
process.
1.2.2.6 The Response to Injury Hypothesis
This hypothesis is a refinement o f the previous theory. A wide array of stimuli (physical 
or chemical) to the arterial wall induce endothelial denudation with subsequent platelet 
adherence to the area. Platelets then release platelet-derived growth factor (PDGF) 
which in turn induces the migration of SMC from the media to the intima. SMC then 
proliferate and produce connective tissue. This theory is particularly pertinent when 
the endothelium has been mechanically removed, such as in angioplasty [Ross and 
Glomset, 1976a,b], however the unequivocal demonstration of intact endothelium dur­
ing atherogenesis [Davies et al., 1976] required an evolution of the theory. Subsequent 
studies have stressed the role of other factors involved in this process, such as paracrine 
or local cell-derived inflammatory factors, and the most recent version emphasizes en­
dothelial dysfunction rather than denudation [Ross, 1986, 1999].
1.2.3 The Sequence of Events in Plaque Development
In reality, the above hypotheses are not mutually exclusive but rather emphasize differ­
ent concepts as the necessary events to support the development of the atherosclerotic 
lesion (see figure 1.6 on the following page). The exact nature of plaque development 
will likely differ between individuals, incorporating aspects from each of the hypothe­
ses described above. The exact time-frame and order of the following steps remains 
a matter of contention, as each of the systems involved often interact with the others,
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Figure 1.6: The stepwise progression o f the atherosclerotic plaque (adapted from Ross 
[1999]).
causing a vicious circle, the beginning o f which is difficult to pinpoint.
1.23.1 Plaque Initiation
Although the endothelium represents only a single layer of cells, the total volume of the 
endothelial cells of the human body is comparable to that of the liver [Huttner and Gab- 
biani, 1983]. As the major regulator of vascular homeostasis, the endothelium main­
tains the balance between vasodilation and vasoconstriction, inhibition and stimulation 
of SMC proliferation and migration (through direct endothelium-SMC myoendothelial 
gap junctions), and thrombogenesis and fibrinolysis [Luscher and Barton, 1997; Kinlay 
et al., 2001]. Damage to the endothelium upsets the balance between vasoconstric­
tion and vasodilation and initiates a number of processes that promote and exacerbate 
atherosclerosis. Endothelial dysfunction is considered an early marker of atheroscle­
rosis, preceding angiographic or ultrasonic evidence of atherosclerosis [Luscher and 
Barton, 1997].
The vessel wall reacts to many chemical and mechanical stimuli in the flowing
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blood. The hallmark of endothelial dysfunction is impaired endothelium-dependent 
vasodilation mediated by nitric oxide (NO), a pivotal endothelium-derived substance. 
Therefore a defect in NO production or activity has been proposed as a major m ech­
anism of endothelial dysfunction and a contributor to the initiation of atherosclerosis 
[Davignon and Ganz, 2004]. Impaired production or activity of NO has been linked 
to numerous actions or events that promote atherosclerosis, such as vasoconstriction, 
platelet aggregation, SMC proliferation and migration, leukocyte adhesion, and oxida­
tive stress [Endres et al., 1998; Davignon and Ganz, 2004]. Furthermore, oxidized 
LDL-cholesterol increases synthesis of caveolin-1, which inhibits production of NO by 
inactivating endothelial nitric oxide synthase (eNOS) [Kinlay et al., 2001]. Oxidative 
stress can also interfere with the production and activity of NO by a number of LDL- 
independent mechanisms [d’Uscio et al., 2003].
That increasing blood flow through arteries results in vasodilation was first observed 
in larger arteries in 1933. However, it was more than 50 years later that the role of 
the endothelium was established, by varying the viscosity of perfusion medium in iso­
lated arteries, thereby showing shear stress to be the important factor [Davies et al., 
2005]. It is a longstanding observation that atherosclerotic lesions are not evenly dis­
tributed through the arterial system, and, as detailed in section 1.2.2.3 on page 17, the 
hemodynamic theory of atherosclerosis was postulated to address this observation. Ev­
idence that low shear stress is a plaque-modulating factor has accumulated, although 
the complex flow characteristics in these regions may be as important as the average 
magnitude of the stress per se [Davies et al., 2005]. As yet, the method by which shear 
stress and turbulence acts on the endothelial and influences atherogenesis (potentially 
LDL-infiltration [Worth Longest and Kleinstreuer, 2003], shear-dependent accum ula­
tion of inflammatory cells [Hsiai et al., 2003], and shear stress dependent gene expres­
sion [Resnick et al., 1997]) is not clear.
The exact nature of endothelial dysfunction, and precisely the relationship between 
inflammation, LDL, and endothelial dysfunction, is still poorly understood, however 
a number of major risk factors are associated with an increase in oxidative stress and 
endothelial dysfunction (eg. dyslipidemia, smoking, aging, diabetes etc.) and there­
fore it poses an attractive therapeutic intervention. To date a number of interventions 
have been shown to be effective in restoring endothelium-dependent vasodilation (eg. 
statins, angiotensin-converting enzyme (ACE) inhibitors, antioxidants, reducing hyper­
glycemia, diet, and exercise [Davignon and Ganz, 2004]). As we gain a greater under­
standing of the role and pathology of endothelial dysfunction, further agents that act on 
endothelial dysfunction may yield therapies that prevent atherosclerosis initiation.
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(a) A freeze-etch micrograph showing the accumulation of 23 nm LDL 
particles (circled) in the matrix of a rabbit atrial-ventricular valve fol­
lowing incubation with LDL. An endothelial cell at lower left shows 
the plasma membrane (MEMB) and cytoplasm (CYTO). Magnifica­
tion xl41732, scale bar 0.1 pm.
(b) Lipoprotein aggrega­
tion in a rabbit intima fol­
lowing administration of a 
bolus of LDL. Magnifi­
cation x57876, scale bar 
0.2 pm.
Figure 1.7: Electron micrographs showing LDL accumulation and aggregation [Lusis, 
2000]).
1.2.3.2 LDL Accumulation and Leukocyte Adhesion
The bulk of circulating cholesterol that circulates in the blood is in LDL particles. Any 
excess of LDL particles not taken up by the cells is rapidly removed by the lymphatic 
system. A striking morphological difference of the arterial intima from other tissues 
is the lack of lymphatic vessels [Groszek and Grundy, 1980]. Therefore to reach the 
lymphatic vessels in the media, LDL must pass through the intima. However, the elastic 
lamina presents a major barrier to its passage. Thus the passage of LDL particles can be 
slow, with more LDL particles entering the intimal fluid than are removed from it. This 
leads to a progressive increase in the concentration of LDL that sees LDL in the intimal 
fluid rise to 10-fold that seen in the interstitial fluids of other tissues [Smith, 1990]. This 
high concentration downregulates LDL receptors and so closes the physiological exit 
of LDL particles into cells [Pentikainen et al., 2000]. Following this accumulation, the 
initial LDL modification occurs, namely LDL aggregation and, often perifibrous, lipid 
droplet formation [Guyton et al., 1985; Guyton and Klemp, 1992] (see figure 1.7).
It is well recognized that leukocytes continually interact with the endothelium as 
part of immune surveillance. However, the endothelial monolayer of the healthy blood 
vessel resists firm adhesion of leukocytes, and the initial tethering of the leukocyte is 
reversible [Butcher, 1991]. It has been reported that monocytes from patients with hy­
percholesterolemia display increased adhesion to endothelial cells [Weber et al., 1997].
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Figure 1.8: Scanning electron micrographs of the intimal surface of the aorta in a hyper- 
lipidemic rabbit showing two macrophages. One is adherent to the plasma membrane 
of the endothelium; the other appears to have in part gained entry to the subendothelial 
space and is transversed by a ‘bridge’ of endothelial cytoplasm, magnification x4900 
[Woolf, 1990].
Circulating LDL is known to damage endothelial cells and cause endothelial dysfunc­
tion [Anderson et al., 1995], as is bacterial or viral infection [Albert, 2000]. Increased 
adhesion to endothelial cells was also seen in human monocytes exposed to LDL ex 
vivo, suggesting that in addition to their effect on endothelial cells, lipoproteins also in­
duce changes in circulating monocytes that may be pertinent to the recruitment process 
[Quehenberger, 2005].
The strong attachment of the monocyte to the endothelium is mediated by the inter­
action of integrins with ligands belonging to the immunoglobulin superfamily, most no­
tably intracellular adhesion m olecule-1 (ICAM-1) and vascular cell adhesion molecule- 
1 (VCAM-1). Normally the integrins are in a low-affinity state, and it has become ap­
parent that they must undergo activation by a chemokine (small, secreted, chemotactic 
proteins) signal to mediate firm adhesion [Chan et al., 2003]. Chemokines also play a 
role in guiding the adherent macrophage across the endothelium [Johnston and Butcher,
2002], particularly monocyte chemoattractant protein-1 (MCP-1) [Gu et al., 1999] (see 
figure 1.8). Once resident in the arterial lamina, the monocytes undergo morphological 
changes and differentiate into macrophages. Locally produced cytokines and growth 
factors not only serve to attract and retain the monocytes but also to govern the differ-
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Figure 1.9: A schematic demonstrating the vicious cycle caused by LDL modification 
in the arterial intima. Taken from Pentikainen et al. [2000].
entiation of the monocytes into mature macrophages [Hansson, 2001; Linton and Fazio,
2003].
1.23.3 LDL Modification
The initial morphological sign of atherosclerosis is the appearance of enlarged LDL 
particles in the sub-endothelial space [Tamminen et al., 1999], and it is of particular 
interest that modified LDL has been observed in aortic samples from human foetuses 
even before signs of inflammation were visible [Napoli et al., 1997] suggesting that 
LDL modification is a very early event in atherogenesis. There are two major effects 
of LDL modification: 1). increased proteoglycan binding causing LDL retardation; and 
2). interactions with intimal cells and upregulation of inflammatory and modifying pro­
cesses. Thus LDL modification is part of a vicious cycle that causes only to exacerbate 
atherogenesis (see figure 1.9).
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Proteolytic Modification o f LDL It appears that apolipoprotein (apo)B-lOO loss 
from proteolysed LDL particles is a prerequisite for their fusion, and two proteases 
that appear to play a role in the proteolysis are chymase and carboxypeptidase A [Pen- 
tikainen et al., 2000]. However, it must be noted that such fragments of apoB-100 can 
also result from oxidative modification of LDL (Hoff and O ’Neil, 1991].
Phospholipolytic Modification of LDL A second possible LDL modification is 
lipolysis. Isolated LDL from atherosclerotic plaques are particularly enriched in sph­
ingomyelin and lysophosphatidylcholine, suggesting hydrolysis of the phosphatidyl­
choline of LDL (Yla-Herttuala et al., 1989]. A potential candidate for such lipolysis 
is secretory typell phospholipase A 2 (SPLA2 ), which has been found in human arterial 
intima, particularly in inflamed areas [Romano et al., 1998].
Oxidative Modification o f LDL Since evidence demonstrating the presence o f ox­
idatively modified LDL particles was presented nearly 2 0 yr ago [Yla-Herttuala et al., 
1989], their role in the pathogenesis of atherosclerosis has been under unceasing inves­
tigation. In the rat, a single injection of human LDL resulted in accumulation of LDL 
in the arterial wall, where it became oxidatively modified within 6 h. The presence of 
oxidized LDL was associated with activation of the transcription factor nuclear factor 
k:B (N F-jcB) (a major regulator in cell proliferation, stress responses and inflammation) 
in the endothelium as well as endothelial expression of ICAM-1 [Calara et al., 1998].
1.2.3.4 Foam Cell Formation and Immune Potentiation
When circulating monocytes migrate from the vasculature into the extravascular com ­
partment, a process o f maturation into macrophages is concomitantly launched. The 
process renders the cells ready for active participation in the inflammatory responses. 
This process is complex, with a role for N F -kB seemingly being central [Takashiba 
et al., 1999; Osterud and Bjorklid, 2003]. Macrophage sensitivity and reactivity is seem­
ingly substantially higher than monocytes, so that although oxidized LDL may fail to 
induce monocyte activation in whole blood [Brand et al., 1994], modified LDL within 
the intima is likely to have a largely different effect [Osterud and Bjorklid, 2003]. One 
such effect is the uptake of modified LDL by monocyte-derived macrophages, turning 
them into fat-laden foam cells that remain in the vessel wall, furthering the local inflam­
matory response (see figure 1.10 on the next page). The mechanisms underlying such 
foam cell generation have been the focus of intensive research for some years [Berliner 
et al., 1995; Brown and Goldstein, 1986; Chisolm III et al., 1999; Steinberg, 1997b; 
Witztum and Steinberg, 1991].
Macrophages are normally protected from the accumulation of toxic cholesterol 
loads, primarily by the downregulation of surface LDL receptor molecules in response
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Figure 1.10: TEM of stained macrophage foam cell with numerous intracellular lipid 
droplets (Vanderbilt Cel Imaging Shared Resource, www.mc.vanderbilt.edu).
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to replete intracellular cholesterol stores [Brown and Goldstein, 1986]. However, modi­
fied LDL is taken up by alternate scavenger receptors (SRs) that are not similarly down- 
regulated [Berliner et al., 1995; Chisolm III et al., 1999; Steinberg, 1997b; Witztum 
and Steinberg, 1991]. A number of different such scavenger receptors have been iden­
tified, comprising several transmembrane receptors that all share a common affinity for 
negatively charged macromolecules or particles, such as modified LDL [Osterud and 
Bjorklid, 2003].
The presence of activated T cells within human atherosclerotic plaques has been 
known for some time [Hansson et al., 1989]. Following this, interferon-y (IFNy) and 
major histocompatibility complex (MHC) class II were found in atherosclerotic lesions 
along with antibodies to oxidized LDL, demonstrating that pathways of the adaptive 
arm of the immune system were also established in atherosclerosis [Hansson et al., 
1989; Palinski et al., 1989]. Both cluster of differentiation (CD)4+ and CD8+ T cells 
are found in human lesions but CD4+ generally dominate in number [Frostegard et al., 
1999]. Furthermore these processes contribute to the overall pathogenesis of the lesion, 
as demonstrated by various animal models enriched or depleted for the numerous T cell 
subsets [Robertson and Hansson, 2006]. The activation of T cells and other antigen pre­
senting cells (APCs) involve not only contact dependent mechanisms but also the secre­
tion of soluble mediators, important in the development of atherosclerosis [Daugherty 
et al., 2005; Tedgui and Mallat, 2006]. Just such a cytokine, IFNy, is produced by most 
T cells in human atherosclerotic plaques and is the principal T helper 1 (Th I) cytokine 
[Hansson et al., 1989; Harvey and Ramji, 2005].
Role of IFNy in Atherosclerosis The interferon (IFN) family of cytokines is divided 
into type I and type II IFNs. Type I IFNs, including IF N a, /3, 0), and 0, share notable 
sequence homology and are synthesized by most cell types. On the other hand, IFN y is 
at present the only type II interferon identified and binds to a distinct type II receptor 
[Harvey and Ramji, 2005]. IFNy itself is secreted mainly by natural killer (NK) cells 
and activated CD4+ Th 1 cells, but recent evidence indicates that it can also be produced 
by monocytes/macrophages and B cells [Schroder et al., 2004]. IFNy has a multitude 
of functions, displaying direct antiviral activity as well as a variety of immunomodu­
latory and inflammatory roles [Schroder et al., 2004; Boehm et al., 1997]. Immuno- 
histochemical studies have shown IFNy within the atherosclerotic lesion [Young et al.,
2002], where it is known to have a range of influences on disease progression, acting 
on all the major cell types of the plaque. Due to the large number of genes affected 
by IFNy, approximately 25% of the macrophage transcriptome is under IFNy control 
[Ehrt et al., 2001 ], the overall effect of IFNy is complex with it assigned both pro- and 
anti-atherogenic effects.
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Potentiation o f Immune Response The lesions of apoe~!~  or ldlr~!~  mice de­
ficient in IFNy have a dramatically reduced content of the key cells in atherogenesis -  
macrophages, T-lymphocytes, and SMCs, and therefore reduced atherosclerosis, indi­
cating a key role for IFNy in their recruitment [Gupta et al., 1997; Buono et al., 2003].
IFNy is responsible for the upregulation of a number of key chemokines and 
chemokine receptors [Charo and Taubman, 2004], most notably being the dramatic in­
duction of MCP-1 by IFNy [Valente et al., 1998]. IFNy also appears to be an important 
mediator of both VCAM-1 and ICAM-1 expression on SMC and endothelial cells [Li 
et al., 1993; Chung et al., 2002], and is able to increase expression of integrins (such 
as OC-5-/3-1 integrin) on the surface of vascular SMCs [Barillari et al., 2001]. There­
fore IFNy plays a role in attracting monocytes, and increasing the available adhesion 
molecules to ensure more monocytes enter the sub-endothelial space. Once there, it 
is well known that IFNy is able to stimulate both the differentiation of monocytes to 
macrophages and the activation of macrophages and T-lymphocytes [Schroder et al., 
2004; Boehm et al., 1997; Harvey and Ramji, 2005].
Foam Cell Formation IFNy regulates the expression of a number of genes known 
to be important in cholesterol metabolism [Harvey and Ramji, 2005]. Overall, incuba­
tion of foam cells with IFNy results in reduced cholesterol efflux, with an increase in 
cholesterol ester accumulation [Panousis and Zuckerman, 2000]. More recently, IFNy 
has been shown to impede reverse cholesterol transport and so promote foam cell form a­
tion in a human acute monocytic leukaemia cell line (THP-1) [Reiss et al., 2004]. More 
specifically IFNy decreases production of apoE (a protein component of lipoproteins 
that is responsible for the transport of cholesterol from the peripheral tissues to the liver 
-  reverse cholesterol transport) in both monocytes and macrophages, and increases its 
intracellular degradation. Because of apoE’s pivotal role in atherosclerosis, this action 
of IFNy is likely to be an important factor in IFNy’s overall atherogenic effect [Harvey 
and Ramji, 2005].
IFNy -  Pro- or Anti-Atherogenic? As well as the potent pro-atherogenic func­
tions of IFNy detailed above, IFN y also has a number o f protective functions. Trans­
plantation of IFNy-deficient bone marrow in LDLR -/- mice increases the extent of 
atherosclerosis development [Niwa et al., 2004], suggesting that IFNy has an athero- 
protective effect.
IFNy has been shown to inhibit two scavenger receptors -  SR-A and CD36 -  specifi­
cally in macrophages [Geng and Hansson, 1992], thereby reducing foam cell formation. 
IFNy is also known to reduce the expression o f lipoprotein lipase (LPL) in macrophages 
at the transcriptional level [Hughes et al., 2002]. LPL’s main physiological role is to 
catalyse the hydrolysis of triacylglycerol to non-esterified fatty acids for tissue utiliza­
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tion. Macrophage derived LPL is believed to be atherogenic, as demonstrated by ani­
mal models, with LPL-null macrophages showing decreased atherogenesis [Mead and 
Ramji, 2002].
IFNy has beneficial effects on oxidative stress within the vascular wall, inhibit­
ing macrophage-mediated LDL oxidation [Fong et al., 1994; Folcik et al., 1997]. In 
particular, signalling by IFNy has been shown to upregulate inducible nitric oxide 
synthase (iNOS) gene expression in a wide variety of cell types, including endothe­
lial cells, SMCs and macrophages [Yokoyama et al., 1996]. IFNy also regulates the 
expression of other genes implicated in the control of oxidative stress, however a con­
sensus on the action of such gene regulation has not been reached [Harvey and Ramji, 
2005].
Thus the majority of evidence from numerous animal studies has identified IFNy as 
a pro-atherogenic cytokine, although it undeniably has some atheroprotective effects. 
The exact role of IFNy may well differ depending on the exact stage of the disease and 
the presence of other factors.
1.2.3.5 Plaque Maturation and Remodelling
Most atherosclerosis is clinically silent, and the consequences of atherosclerosis rarely 
occur before the development of advanced lesions [Clarke and Bennett, 2006]. Seg­
ments of an angiographically-normal coronary artery can harbour many asymptomatic 
plaques that do not encroach on the lumen, termed compensatory enlargement [Var- 
nava, 1998]. The remodelling that occurs is plaque specific rather than patient specific 
[Vamava, 1998]. The exact mechanisms involved in the degree and type of remodelling 
are not well understood, however there appears to be a positive correlation between core 
size and history of remodelling, that suggests hemodynamic forces may be important in 
this process [Davies, 2000].
An important determinant of plaque stability is the nature of the fibrous cap. Many 
advanced lesions comprise a SMC-rich fibrous cap overlying a lipid- and macrophage- 
rich necrotic core, and it is the relative proportion of these two elements that determine 
the clinical manifestation of the plaque; unstable plaques that are particularly prone 
to rupture contain a higher proportion of inflammatory cells and lipid, and a lower 
proportion of SMCs [Davies et al., 1993]. In advanced lesions, fibrous cap thinning 
is due to loss of SMCs, and it is these such thin-capped atheromas that are prone to 
rupture [Virmani et al., 2000]. The impact of SMC apoptosis was elegantly shown in 
an apoe~!~  transgenic mouse model who’s SMCs could undergo inducible apoptosis. 
Such SMC apoptosis induced marked fibrous cap thinning, loss of collagen and extra­
cellular matrix (ECM), and intense intimal inflammation [Clarke et al., 2006].
28
Role o f IFNy in Plaque Maturation Increased expression of pro-inflammatory cy­
tokines has been shown in vulnerable plaques, and IFNy-secreting Th 1 cells frequently 
accumulate at the sites of plaque rupture [Harvey and Ramji, 2005]. The increased cel- 
lularity of the plaque caused by IFNy has already been discussed, but IFNy can also act 
to weaken the fibrous cap by inhibiting the expression of collagen genes, SMC prolif­
eration and matrix synthesis [Amento et al., 1991; Yuan et al., 1999].
The ECM is broken down by matrix metalloproteinases (MMPs), a group o f en­
zymes that therefore contribute to plaque instability, and have been localized to the 
shoulder regions of plaques that are particularly prone to rupture [Galis et al., 1994]. 
IFNy is known to stimulate increased production of MMPs by macrophages and SMCs 
[Schonbeck et al., 1997], and therefore potentially contribute to plaque instability.
1.2.3.6 Necrotic Core Formation and Plaque Rupture
The intensive aggregation of foam cells leads to the formation of an atheromatous core. 
In the centre of the core the destruction of foam cells leads to the extracellular accumu­
lation of lipids and cellular debris [Lusis, 2000; Lusis et al., 2004].
Thrombus formation is triggered by vascular injury secondary to atherosclerotic 
pathology. Such sudden rupture may occur spontaneously without obvious triggers, 
however it may follow a particular event such as extreme physical activity, emotional 
trauma, sexual activity, exposure to narcotics, cold or acute infection [Shah, 2003]. 
Platelets play a central role in this process by adhering to the exposed subendothelium, 
and initiating a cascade of platelet recruitment [Hennerici, 2004]. Pathological studies 
have identified tissue factor (TF), present in cells and in the extracellular debris of 
the atheroma, as a candidate molecule responsible for the thrombogenicity associated 
with plaque rupture [Tremoli et al., 1999]. In some instances, thrombus formation 
may result in growth of a plaque through resolution and incorporation of the thrombus. 
Alternatively, formation of a major thrombus can occlude the vessel and lead to an 
atherothrombotic event, such as stroke, MI or vascular death.
Role o f IFNy in Necrotic Core Formation The function of IFNy in apoptosis is 
complex, however it has been shown that IFNy will stimulate foam cell apoptosis in 
vitro [Inagaki et al., 2002], through activation of various pro-apoptopic pathways.
1.3 IL-18 -  An IFNy-Inducing Factor
In vitro secretion of IFNy from T hI cells is induced by stimulation with antigen or 
antibodies against CD3, however Wada et al. [1985] found IFNy induction by antigen 
in mice pre-treated by Propionibacterium  acnes was significantly greater. Furthermore,
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P. acnes-primed animals were, unusually for mice, susceptible to lipopolysaccharide 
(LPS) injection. It was believed unlikely that LPS stimulated T h I cells directly, and 
most probably an intermediate molecule was involved [Ushio et al., 1996].
That sera from P. acnes-primed mice was able to induce IFNy production from 
anti-CD3 stimulated T cells above that achieved with interleukin 12 (IL-12) alone, sug­
gested that an IFNy-inducing factor was present within the sera [Okamura et al., 1995a]. 
The factor was purified from the sera of mice that had been sequentially treated with 
P. acnes and LPS, and found to be a single peptide [Okamura et al., 1995b]. Human 
IFNy-inducing factor complementary DNA (cDNA) was isolated using murine IFNy- 
inducing factor cDNA as a probe from a normal human liver cDNA library. The amino 
acid sequence included an interleukin 1 (IL-1) signature-like sequence. Subsequently, 
the cloned cDNA was expressed in Escherichia coli and was able to induce IFNy pro­
duction from human peripheral blood mononuclear cells (PBMCs). The factor was 
designated IL-18 [Ushio et al., 1996].
1.3.1 The IL-18 System
Since the discovery of IL -18 a number of other affiliate proteins have been identified, all 
o f which play a role in IL-18 function. Analogous to the IL-1 system, the IL-18 system 
constitutes the ligand (IL-18), a dimeric receptor (constituting IL-18 receptor subunit 
a  (IL -18R a) and IL -18 receptor subunit /3 (IL -18R/3)), and an intrinsic inhibitor protein 
(IL-18BP) that binds strongly to IL-18 and prevents it engaging it’s receptor.
1.3.1.1 IL-18
Protein Structure IL -18 is a single peptide with a molecular weight o f around 18 000, 
and an isoelectric point (pi) of 4.8. Both mouse and human IL-18 lack the usual leader 
sequence necessary for secretion, but instead have an unusual N-terminal leader se­
quence of 35 amino acids [Okamura et al., 1995b]. The protein also lacks any N- 
glycosylation sites or putative hydrophobic signal peptide [Okamura et al., 1995b]. It’s 
tertiary structure was solved by nuclear magnetic resonance (NMR) spectroscopy by 
Kato et al. [2003] and found to consist of three twisted four-stranded /3-sheets, one 
short a-helix  and one 3 io helix. The /3-sheets form the distinctive /3-trefoil structure 
(see figure 1.11 on the following page).
IL-18 has only moderate sequence identity to IL-1 (17%) but when the protein se­
quence was threaded through protein fold databases it consistently drew top matches to 
the interleukin 1/3 (IL -1/3) structure, particularly the /3-trefoil structure detailed above 
[Kato et al., 2003]. That the two proteins matched so well suggested that the unusual 
leader sequence is analogous to the IL-1/3 pro-domain which must be enzymatically 
cleaved, by caspase-1, for optimal secretion and biological activity.
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Figure 1.11: IL-18 protein structure as determined by NMR spectroscopy [Kato et al.,
2003].
IL-18-Produeing Tissues and  I t ’s Post-Translational Processing IL-18 is widely 
expressed in both immune system cells and non-immune cells. Human PBMCs se­
crete proIL-18 under normal conditions suggesting that it may be cleaved extracellu- 
larly, yet dendritic cells constitutively express IL-18 mRNA and produce mature IL-18. 
Epidermal cells, particularly keratinocytes, can secrete IL-18, along with IL-12, in re­
sponse to stimulation with contact allergens. However, under normal circumstances, 
keratinocytes do not produce caspase-1 suggesting that IL -18 secretion by keratinocytes 
might be via a caspase-1-independent manner [Nakanishi et al., 2001a].
Intestinal, along with airway, epithelial cells express IL-18, as do osteoblastic stro­
mal cells. IL-18 secretion occurs in the central nervous system and endocrine system, 
moreover IL-18 and IL-18 receptor (IL-18R) can be detected in the brains of adult rats, 
suggesting IL-18 may play an important role in connecting the immune system to the 
endocrine and nervous systems [Nakanishi et al., 2001a].
ProIL-18 processing is via the IL -1 j3/IL-18 inflammosome, the initiation of which is 
the binding of pathogen to one of the intracellular pathogen-sensing NOD-like receptors 
(NLRs). The NLRs are a family of proteins that share similar structural features with 
Toll-like receptor (TLR) and IL-1 receptor (IL-1R) and are involved in the regulation of 
apoptosis, inflammation, and host defence; their ability to activate or inhibit caspases 
is at the basis of these functions. They contain an N-terminal effector-binding domain 
and a C-terminal ligand-recognition domain, mostly a leucine-rich repeat similar to that 
seen in TLR [Boraschi and Dinarello, 2006] (see figure 1.12 on the next page).
Mutations in NLR family, pyrin-domain containing 3 (NLRP3), are involved in a 
series of autosomal dominant, severe pathologies characterized by persistent and gener-
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Figure 1.12: The IL-18/IL-1/3 inflammosome. Activation of an intracellular NLR (here 
NLRP3) via the LRR domain causes the inflammosome to form, ultimately resulting in 
maturation of caspase-1 via sequential cleavages by active caspase-1 molecules. Active 
caspase-1 then cleaves pro-IL-18 allowing it to leave the cell.
alized inflammation and is therefore a good candidate for caspase-1 activation in IL-18 
processing. NLRP3 contains an N-terminal PYR effector binding domain which inter­
acts with the PYR domain of the adapter protein, PYR and CARD domain containing 
protein (PYCARD), which in turn activates caspase-1 maturation by sequential cleav­
ages by active enzyme molecules. Activated caspase-1 is then able to cleave proIL-18 
(and IL-1/3) and so allows it’s extracellular export [Boraschi and Dinarello, 2006].
IL-18 Isoform s IL-18 is expressed in a number of ovarian carcinoma cell lines and 
fresh tumour samples, but the expression of caspase-1 is more variable. Nevertheless, 
in those ovarian carcinoma cells that expressed both IL-18 and caspase-1, no mature 
IL-18 was detectable in the cell culture supernatants, yet in normal ovarian epithelial 
cells mature IL-18 is produced [Wang et al., 2002]. Recombinant caspase-1 digestion 
of lysates from two ovarian cell lines, IGROV-1 (negative for caspase-1 expression) and 
OVCAR-3 (positive for caspase-1 production), resulted in mature IL-18 and a band of 
unprocessed pro-IL-18 that did not disappear at higher concentrations of caspase-1. By 
QPCR on OVCAR-3 total ribonucleic acid (RNA), two different IL-18 cDNAs were 
revealed -  one with exon 3, and one without (Aex3). Exon 3 consists of 12 nucleotides, 
therefore the Aex3 cDNA translates into a protein that lacks four amino acids -  AEDD.
The caspase-1 and caspase-4 cleavage site is located within exon 4 and is therefore 
preserved in IL-18Aex3, yet it is completely resistant to caspase-1 and caspase-4 pro­
cessing. IL-18Aex3 is still able to make a complex with caspase-1, as evidenced by 
immunoprecipitation experiments, therefore it is likely that IL-18Aex3 could inhibit 
classical processing via sequestering of caspase-1. IL-18Aex3 mRNA was detectable 
in 3/3 fresh tumour samples and IL-18Aex3 protein was isolated from ascitic fluid of 
ovarian carcinoma patients, but not normal ovarian epithelia [Gaggero et al., 2004].
1.3.1.2 IL-18BP
An inhibitor of IL-18 was discovered by Novick et al. [1999] after passing a preparation 
of proteins, concentrated from 5001 of human urine, through an IL-18 agarose column. 
Bound proteins were eluted at low pH, revealing a 40kD a IL-18BP that was able to 
inhibit IFNy induction (by IL-18 alone) in human PBMCs at a similar concentration to 
IL -18 itself. Protein microsequencing was used to match the protein to a cDNA from a 
human Jurkat T cell cDNA library, coding for a protein of unknown function. Further 
examination of other cDNA libraries revealed four splice variants -  a,b,c, and d [Novick 
et al., 1999]. The protein was constitutively expressed by the spleen and had no obvious 
homology to other human proteins, but did have homology (up to 47% homology) with 
various poxvirus proteins.
S tru c tu re  The amino acid sequence of IL -18BP suggested that the polypeptide be­
longed to the immunoglobulin (Ig) super-family, and had an Ig domain homologous 
to that found in IL-1 decoy receptor (IL-1RII) along with numerous potential N- 
glycosylation sites [Novick et al., 1999].
IL-18BP-Producing Tissues IL-18BP is highly expressed in the spleen and intesti­
nal tract [Boraschi and Dinarello, 2006], is constitutively expressed by PBMCs [Hurgin 
et al., 2002], and circulates at plasma concentrations of around 2.5 ng/ml [Novick et al.,
2001]. There is evidence to suggest that IL-18BP gene expression is under the reg­
ulation of IFNy. In a colon carcinoma/epithelial cell line -  DLD-1 -  IFNy induced 
IL -18BPa mRNA upregulation in parallel with an increase in IL -18BPa protein secre­
tion, this was also the case in a keratinocyte cell line (HaCaT). The histone deacetylase 
inhibitor, sodium butyrate, suppressed the upregulation [Paulukat et al., 2001]. Similar 
experiments in the liver carcinoma cell line, HepG2, and in human PBMCs supported 
these observations [Hurgin et al., 2002], indicating that de novo protein synthesis is 
required for IFNy-mediated IL-18BP upregulation.
IL-18BP Isoforms The IL18BP  gene encodes for at least four distinct isoforms de­
rived from mRNA splice variants, isolated from several cDNA libraries. They differ
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Figure 1.13: Titration of human and murine IL-18BP isoforms on IL-18 activity [Kim 
et al., 2000].
primarily in their carboxyl termini whereas the N-terminal is largely identical [Novick 
et al., 1999; Kim et al., 2000]. Using COS cells transiently transfected for six different 
IL-18BP isoforms (two murine and four human), Kim et al. [2000] assessed the ability 
of each isoform to bind IL-18 and prevent IFNy induction. As shown in figure 1.13, 
complete inhibition of IL -18 was achieved with a two-fold molar excess of both IL- 
18BPa and c, in contrast there was no inhibition by IL-18BPb or d (even at six-fold 
molar excess). Such binding is remarkably strong, given that IL-1RII requires a molar 
excess of five for inhibition of IL-1/3 [Arend et al., 1994].
1.3.1.3 The IL-18 Receptor
An IL-18R was purified from a Hodgkin’s disease cell line, with 125I-labelled IL-18 
showing a single class of binding site for IL-18 [Torigoe et al., 1997]. That addition 
of IL-lj3 did not inhibit the binding demonstrated that the IL-18R was distinct from 
IL-1R. IL-18R was purified from membrane extracts using a monoclonal antibody 
(mAb) clone that inhibited IL -18:IL -18R formation. N-term sequencing showed that 
the purified protein matched a previously identified member of the IL-1R family that 
failed to bind interleukin 1 a  (IL-1 a ) , IL -1 /3 or IL-1 receptor antagonist (IL-IR a) -  
IL-1 receptor related protein (IL -lR rp) [Pamet et al., 1996]. Expression of IL -lR rp in 
COS cells and subsequent addition of IL -18 (but not IL -1/3) caused activation of NF- fcB 
deoxyribonucleic acid (DNA)-binding ability [Torigoe et al., 1997], and was therefore 
a good candidate for IL-18R despite a relatively weak affinity for IL-18. Further proof
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was provided by studies in i l l 8 r a ~ /~  mice, showing that they were not responsive to, 
and did not bind, IL-18 [Hoshino et al., 1999].
Upon identification of a novel member of the IL-1R family (accessory protein 
like (AcPL)) that had no role in IL-1 induced activation of NF-fcB, Bom et al. [1998] 
examined whether AcPL might function in a similar way to IL-1 receptor accessory 
protein (IL-lRA cP), namely recruit intracellular signalling molecules following IL- 
1 R :IL-1 formation, for IL-lR rp. They were able to show that both IL -lR rp and AcPL 
were needed for both N F-kB and c-Jun N-terminal kinase (JNK) activation in response 
to IL-18. Further immunoprecipitation studies showed AcPL was unable to bind IL-18 
itself, yet a dominant-negative version (lacking the cytoplasmic domain required for 
signalling) of AcPL specifically inhibited IL-18 signalling. It was therefore proposed 
that both IL -lR rp and AcPL were needed for a functional IL-18R [Bom et al., 1998], 
as such IL -lR rp and AcPL were renamed IL-18R a and IL-18R/3, respectively. The 
synergy of IL-12 and IL-18 is mediated via induction o f IL -18R a on naive T cells and 
NK cells, and then subsequent up-regulation of IL-12 receptor /3-2 (IL-12R/32) by IL- 
18 [Yoshimoto et al., 1998]. In the human NK cell line -  NKO -  both IL -18R a and 
IL-18R/3 mRNA levels were up-regulated by IL-12 [Kim et al., 2001].
Downstream Signalling That both IL -18 R a  and IL -18R/3 are required for signalling, 
was further illustrated by C O S-1 cells that do not respond to IL -18 despite abundant ex­
pression of IL-18Ra. Yet transient transfection with IL-18R/3 and a luciferase reporter, 
gave IL-18 responsiveness [Kim et al., 2001].
Following IL -I8 ’s binding to IL -18R a, IL-18R/3 is recruited into a signalling 
complex. Signal transduction is initiated by the approximation of of the Toll-IL-1 
receptor (TIR) domains present in the intracellular portions of both receptor chains. 
The signalling pathway, shared with other receptors of the TLR/IL-1R family, in­
volves recruitment of the adaptor molecule, myeloid differentiation primary response 
gene 88 (MyD88) and of IL-1 receptor associated kinase (IRAK), followed by interac­
tion with TNF-receptor associated factor 6 (TRAF6). The resultant activation of I?cB 
kinase (IKK) causes degradation of inhibitor of N F-kB (IkB) and subsequent activation 
ofNF-xrB [Boraschi and Dinarello, 2006; Bowie and O ’Neill, 2000] (see figure 1.14 on 
the next page). An additional signalling pathway has been described that involves the 
activation of mitogen-activated protein kinase (MAPK) p38 [Wyman et al., 2002].
There also appears the potential for IL-18-independent engagement of IL-18R 
in autoimmune inflammation. H18~l~  mice were susceptible to autoimmune en­
cephalomyelitis, yet i l l8 r a ~ l~  were resistant, suggesting that IL -18R a may have an, 
as yet unknown (mice do not express IL-1 family, member 7 (IL-1F7)), natural ligand 
other than IL-18.
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Figure 1.14: The IL-18R signalling cascade. Upon binding of IL-18 to IL-18Rce, IL- 
18R/5 is recruited. Through approximation of the TIR domains MyD88 is recruited, 
initiating a signalling cascade that ultimately leads to N F-kB entering the nucleus and 
changes in gene expression.
1.3.1.4 IL-1F7 and SIGIRR
IL-1F7 The IL-1 homologue IL-1F7 was discovered from expressed sequence tag 
database searches. One of a number of splice variants is matured by caspase-1 and is 
then able to bind IL -18R a with low affinity (about 100-fold lower than IL-18). How­
ever, likely due to its low affinity, IL-1F7 is not able to initiate signalling [Kumar et al., 
2002; Boraschi and Dinarello, 2006]. A potential down-regulatory role has been as­
signed to IL-1F7 given its ability to bind IL-18BP, amplifying IL-18 inhibition by IL- 
18BP [Bufler et al., 2002]. That IL-1F7 is expressed by monocytes suggests a real role 
for it in immunomodulation.
SIGIRR The single Ig domain-containing IL -1 R-related protein (SIGIRR) is a 
widely-expressed (though not in leukocytes) member of the IL-1R super-family with 
high similarity, in its intracellular domain, to MyD88. It has been shown not to inter­
act with IL-1 a ,  IL-1/3 or IL-lR a. It is likely that it plays a role in down-regulating 
signalling by IL-1R and IL-18R, as deficient mice are more susceptible to stimulation 
with IL-1 and IL-18, whilst overexpressing cells were less susceptible. The method of 
inhibition is likely to be through competition for MyD88 and TRAF6 [Boraschi and 
Dinarello, 2006].
1.3.2 Biological Functions
Macrophages are versatile and plastic cells, that are among the first to be recruited 
to the site of injury. Classically they are activated in response to microbial products, 
giving rise to M l macrophages. However, there is an alternate activation pathway, 
following stimulation with interleukin 4 (IL-4) and interleukin-13 (IL-13), which gives 
rise to M2 macrophages. The M1/M2 macrophage definition is analogous to the Th 1/T 
helper 2 (Th2) system in T cell responses. Recent data suggests a pivotal role for 
interleukin-17 (IL-17)-producing T cells -  T helper 17 (Th 17). Production of T h 17 
polarizing cytokines (transforming growth factor (3 (TGF/3) and interleukin 6 (IL-6)) 
depends on the macrophage response to certain pathogenic stimuli, and it is possible 
there is an M17 macrophage subtype [Boraschi and Dinarello, 2006]. IL-18 is able to 
cause differentiation of nai ve T cells into Th 1, Th2, or Th 17, dependent on the cytokine 
milieu (see figure 1.15 on the following page).
1.3.2.1 IL-18 in Th I Responses
Generally, IFNy production by T cells requires T cell receptor (TCR)-mediated T cell 
activation. However, IL -18 and IL -12 synergistically induce IFNy production by T cells 
without TCR engagement. Such induction is not enhanced by additional anti-CD3 (i.e.
37
+ IL-12 / IL-15
/IL-2
IFNy responses
IL-18 + IL-23 IL-17 Th17responses
without IL-12 
or IL-23
Th2
Figure 1.15: IL-18 is able to activate Th I, T h2, or Th 17 responses dependant on the 
cytokine milieu (adapted from Boraschi and Dinarello [2006]).
TCR engagement), nor inhibition of TCR signalling (with cyclosporin A). However, 
TCR signalling is required for differentiation from naive T cells to T h 1 cells -  in T cells 
stimulated with IL-18 and IL-12, and with, or without, anti-CD3, only those stimulated 
with anti-CD3 developed into Th I cells [Nakanishi et al., 2001a].
13.2.2 IL-18 in Th2 Responses
IL-18 entirely fails to act on mature Th2 cells. Naive T cells express a low level of EL- 
18Ra, and recently naive T cells cultured with interleukin 2 (IL-2) and IL-18 for four 
days, even without antigen, produce modest amounts of IL-4 (a major T h2 cytokine). 
While IL-4 production is markedly enhanced with antigen co-stimulation, co-culture 
with anti-IL-4 causes naive T cells to produce trace amounts of IL-4, but large amounts 
of IFNy. Therefore, IL-18 has the ability to induce Th2 differentiation in an IL-4- 
dependent manner [Nakanishi et al., 2001b].
1.3.2.3 IL-18 in Th 17 Responses
T h I7 cells have been recently classified as a new effector T cell subset, distinct from 
ThI and Th2 cells. They have been linked to interleukin 23 (IL-23), as il23~f~  mice 
have very few T h I7 cells, and are protected from autoimmune diseases. It also appears 
that TGF/3 and IL-6 are factors responsible for the differentiation of this subset from 
naive T cells [Stockinger and Veldhoen, 2007]. The role of IL-18 appears to be to am­
plify/activate EL-17 production in already polarized T h I7 cells, in a TCR-independent 
manner, similar to its role in TCR-independent activation of ThI in synergy with IL-12
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[Boraschi and Dinarello, 2006].
1.3.2.4 IL-18 in T c and NK Cell Responses
IL-18 is also able to act on CD8+ T cells (cytotoxic T (Tc) cells). IL-18 and IL-12 (but 
also IL-2 [Son et al., 2001]) synergistically induced the production of IFNy from Tc 
cells as well as NK cells. Both T c cells and NK cells exert cytotoxicity by numerous 
pathways [Nakanishi et al., 2001b]:
•  Exocytosis of cytocidal substances, mainly perforin (a potent pore- 
forming molecule acting against the target cell’s membrane) and 
granzyme (serine proteases that participate directly in the killing of 
the target cell)
•  Expressing FAS ligand thereby inducing apoptosis in FAS-expressing 
target cells
•  TNF-related apoptosis-inducing ligand (TRAIL) expression causing 
apoptopic death in a wide variety of tumour cell lines
IL-18 up-regulates perforin-mediated and FAS ligand-mediated cell death by NK 
cells, but not TRAIL-mediated pathways. No IL-18/IL-12 synergy is required for these 
actions suggesting different pathways from those used by T h I cells, are responsible 
[Nakanishi et al., 2001b].
1.3.3 The IL-18 System Genes
1.3.3.1 IL18
As shown in figure 1.16 on the next page, IL18 consists of six exons on chrl 1 (q23.1), 
totalling 21 kbp.
IL18 gene expression is unlike many other cytokines. Firstly, cytokine gene expres­
sion is often tightly controlled by TATA-type promoters, however 7L78’s promoter is 
TATA-less allowing more widespread expression [Tone et al., 1997]. That IL-18 pro­
tein production remains specific despite extensive gene expression could be reconciled 
by tight caspase-1 regulation, yet IL-1/3 is also caspase-1 dependent but is still con­
trolled by a TATA-type promoter [Hunninghake et al., 1992]. Secondly, the structure of 
IL18  mRNA is unusual. To ensure tight control of cytokine expression it is generally 
considered advantageous to have mRNA with a short half-life. Therefore, many cy­
tokine mRNAs contain RNA-destabilizing elements in the 3’untranslated region (UTR), 
namely multiple AUUUA sequences and overall AU rich mRNA. However, IL18  has 
no AUUUA sequences and the 3 ’UTR is not particularly AU rich [Tone et al., 1997].
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Figure 1.16: The genomic context of IL18  taken from UCSC Genome Browser (May 
2004 assembly), accessed July 20073.
3The known genes track shows known protein-coding genes taken from the National Centre for 
Biotechnology Information (NCBI) mRNA RefSeq collection. The level o f  shading indicates the level 
o f review the RefSeq record has undergone (predicted-light, provisional-medium, reviewed-dark). The 
conservation track displays vertebrate sequence conservation between human and mouse, rat, rabbit, dog, 
armadillo, elephant, opossum, and chicken. The SNP database (dbSNP) track shows data from dbSNP  
build 125. Untranslated SNPs are shown in blue, SNPs o f  unknown function are in black, whilst synony­
mous coding SNPs are shown in green. The human haplotype-mapping project (HapMap) tracks show  
data from HapMap phase II release 21a. The SNPs are displayed in grey using a color gradient based on 
allele frequency (a higher allele frequency has a darker color). The HapMap linkage disequilibrium (LD) 
plot uses the standard colour scheme used elsewhere in this thesis (see section 2.4.2 on page 90). The 
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The structure of the IL18 promoter suggests that the haematopoietic transcription 
factor PU.l might be a critical regulator of its activity (as it is for HJ8's promoter). 
However studies using the promoters of myeloid specific genes have shown that PU.l 
acts only as a weak transactivator, and that it requires cooperation with other transcrip­
tion factors to promote transcription [Tenen et al., 19971. An investigation into sodium 
butyrate (a bacterial fermentation product)-induced IL18 expression demonstrated that 
the PU. 1 binding site was active in vitro and that over-expression of PU. 1 led to activa­
tion of IL18 through this site. However mutation analysis showed that a GC-rich region 
within the proximal promoter, and not the PU.l site, was involved in in vivo sodium 
butyrate-induced activation. DNA pull-down experiments and changes in spacing be­
tween the two elements suggested that formation of a protein complex, involving both 
cis-elements and their respective proteins might be crucial for IL18 expression [Koyama 
et al., 2004].
Using the M atlnspector computer program (www.genomatix.de), Kalina et al. 
[2000] identified possible activator protein 1 (AP-1) and GATA-binding protein sites, 
as well as three specific signal transducer and activator o f transcription (STAT)-binding 
sites. STAT5 was found to bind specifically to the STAT-binding sites, and co­
transfection of STAT5 into THP-1 and human leukaemic monocyte lymphoma cell 
line (U937) cells caused a two-fold elevation in IL18 promoter activity. That STAT5 
is also able to bind regions of the IL2 promoter suggests that it could be important in 
the IL -18/IL-2 synergism needed for enhancement of cytotoxicity and production of 
IFNy by NK cells [Kalina et al., 2000; Son et al., 2001].
1.3.3.2 IL18BP
As shown in figure 1.17 on the following page, IL18BP  consists of 5 exons on chrl 1 
(ql3.4), totalling 3 .6 kbp. The exact way in which the splice variants are formed is 
unclear at the moment, with no firm consensus on the chromosomal arrangement of the 
exons, furthermore whether or not all four splice variants identified (see section 1.3.1.2 
on page 33) are translated in vivo is also unclear.
The 1L18BP promoter, was mapped by Hurgin et al. [2002] using rapid amplifi­
cation of 5 ’ complementary DNA ends (5’RACE). A 1.6 kbp fragment, constituting 
the proximal promoter, was shown to have basal promoter activity when cloned into 
luciferase reporter vectors. The prom oter lacks a TATA-box but has several GC-rich re­
gions near to the transcriptional start site. Analysis of the promoter using a transcription 
factor search algorithm, found a gamma-interferon activated site (GAS), an IFN regula­
tory factor (IRF) element, and two CCAAT/enhancer binding protein /3 (CEBP/3) sites. 
Mutating these sites completely abolished basal activity. Studying the IFNy induction 
of IL-18BP production, it appeared that the IRF element and GAS were crucial, but that
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the CEBP/3 pair increased the induction. Sera from IRF-1 deficient mice lacked basal 
and IFN/-induced IL-18BP production, and in electromobility shift assay (EMSA) ex­
periments IRF-1 was shown to bind the IRF element [Hurgin et al., 2002].
1.3.3.3 IL18Ra  and IL18Rj5
As shown in figure 1.18 on the following page and figure 1.19 on page 45, IL18R a  
covers 36.1 kbp on chr2 (ql 1.2), whilst IL18R(5 neighbours it, covering 33.7 kbp. There 
is no published data on the regulation of either gene.
1.4 IL-18 in Disease
Since IL-18’s discovery and the unravelling of its pleiotropic inflammatory affects, it 
has been investigated in many diseases of which the majority are those concerned with 
inflammatory imbalance. Furthermore, the effect of genetic variation within IL18, hy­
pothesized to alter location or extent of gene expression, has also been assessed in these 
diseases.
1.4.1 Cardiovascular Disease
Interleukins are considered to be key players in the chronic vascular inflammatory re­
sponse that is typical of atherosclerosis. The expression of interleukins and their re­
ceptors has been demonstrated within atheromas, and their levels are often positively 
correlated with arterial disease and its sequelae [der Thusen et al., 2003].
1.4.1.1 Animal Studies
Il-18bp reduces atherosclerosis in apoe~!~ mice [Mallat et al., 2001b] To investi­
gate the effect of both IL-18BP and IL-18 on atherosclerosis development, M allat et al. 
[2001b] studied their effects in apoe~!~  mice -  a well-validated model of atheroscle­
rosis. Fourteen week-old mice received il-18bp supplementation via an intramuscular 
electrotransfer of an expression-plasmid encoding i l l8bp .  This was repeated regularly 
before the animals were sacrificed at 23 weeks of age. In control mice, who received 
empty plasmids, il-18bp was below the detection limit of the assay, whilst a single in­
jection resulted in high levels, with a 1:90 serum dilution completely abrogating IF N / 
induction in a murine spleen cell bioassay. Interestingly there was a modest, but signif­
icant, increase in mean animal weight in the i l l8 b p  plasmid group compared with the 
control group (31.8 g vs. 28.6 g, p<0.05).
Examination of the thoracic aorta showed a marked reduction in lipid deposition in 
those mice treated with il!8bp  plasmid compared to controls. Quantitative computer-
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assisted image analysis showed a 69% reduction in the extent of atherosclerotic lesions 
(p<0.0001). Also, evaluation of aortic plaque size showed a 24% reduction in plaque 
size in the i l l8 b p  plasmid-treated animals compared to the controls (p<0.01).
As might be expected, the elevation of il-18bp levels had marked effects on plaque 
phenotype. The lesions of mice treated with ilJ8bp plasmid had a significantly lower 
macrophage infiltration (50% reduction) compared to controls (p<0.0001), contained 
fewer T cells (67% fewer, p<0.005), and had a two-fold increase in SMC accumulation 
(p<0.05). In addition to these improvements, i l-18bp administration was also associ­
ated with an 85% increase in collagen content (p<0.0005), and an overall decrease in 
total lipid content, all suggestive of an increase in plaque stability. Therefore substan­
tial attenuation of IL-18 signalling caused extensive changes in plaque composition, 
morphology and size, that ultimately limited expansion and the thrombogenicity of the 
plaque.
IL-18 exacerbates atherosclerosis in apoe~!~ mice through IFNy [W hitman et al.,
2002] The above data gives only associative evidence for IL-18 in atherosclerosis 
development. The first direct evidence that IL-18 is pro-atherogenic were carried out 
by Whitman et al. [2002], again using the apoe~!~  mouse model.
Having already established that intraperitoneal injection of rIFNy in apoe~!~  mice 
for 30 days increased lesion size two-fold, presumably through significant increases 
in number of T, and MHC class II-positive, cells [Whitman et al., 2000], the role 
of IL-18 was investigated in this model. Intraperitoneal ril-18 injection in male 
apoe~!~  mice for 30 days, caused a two-fold increase in plaque area, compared to 
saline injected controls, in both the ascending aorta (m eanistandard  error (SE) -  
112399±13227 pm2 vs. 50642±12515 pm2, p=0.004) and the aortic arch (lesion area 
in en face preparations±SE -  6 .2±0.9%  vs. 3.1 ±0.3% , p=0.006), despite not affecting 
lipid concentrations. Exogenous il-18 administration promoted a four-fold increase in 
the number of T, and MHC class II-positive, cells within the lesion. To investigate the 
role of IFNy, the experiment was repeated in apoe~!~  mice. Lesion develop­
ment in these mice was reduced compared to apoe~!~  mice, and the pro-atherosclerotic 
effects of il-18 were ablated in this model [Whitman et al., 2002].
U18~ I ~ mice have decreased atherosclerosis and changes in immune responses [El- 
hage et al., 2003] The above findings suggest that IL-18 aggravates atherosclerosis, 
however the effects of IL -18 on disease development was unclear since the studies were 
limited by the time frame during which the plasmid or recombinant protein was admin­
istered. The crossing of apoe~!~  mice with i l l8 ~ /~  mice produced the first model for 
studying IL-18’s role in early disease development. 24-week old apoe~!~ i l l8 ~ /~  mice 
exhibited substantially reduced m ean±SE lesion size, compared to apoe~!~  mice, in
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the aortic root (9 3 8 6 6 ± 1 1 273 pm2 vs. 1440193=9667 fim2, p=0.005).
In immunohistochemical analysis, lesions of apoe~!~ i l l 8 ~ I mice had signifi­
cantly lower expression of the IFNy inducible gene I-A^ (p<0.001). Furthermore, in 
studies to estimate the degree to which IL -18 loss affected T cell phenotypes, analyses 
of the IgG isotypes produced by each mouse in response to modified LDL were con­
ducted. A 50% reduction in the IgG2a/IgGl ratio suggested a switch from the T hI to 
Th2 response to the auto-antigen. In agreement with previous data, a p o e ~ I ~ i l l8 ~ I" 
had a significantly higher mean body weight than their apoe~!~  counterparts (33.3 g 
vs. 28.1 g, p=0.0035).
Myd88~l~  mice linked cholesterol level to innate immunity [Bjorkbacka et al.,
2004] To establish whether macrophage innate immunity signalling pathways, nor­
mally activated by pathogens, could also be activated in response to hyperlipi- 
demia, Bjorkbacka et al. [2004] fed apoe~ / “ m yd88~ / -  mice a western-type diet. 
Apoe~!~myd88~I~  mice had serum cholesterol modestly above those of apoe~!~  
(although not statistically significant), with changes in LDL and very low-density 
lipoprotein (VLDL), but not high-density lipoprotein (HDL), responsible. This would 
be expected to result in increased atherosclerosis, but apoe~!~m yd88~!~ mice had 
marked reductions in lesion size, with males having a 65% reduction in lesion size 
compared to apoe~!~  (40% in females). Lesion pathology showed fewer foams 
cells in apoe~t~ m yd88~ !~ mice, with macrophages from these mice having impaired 
chemokine expression in response to both IL-1/3 and IL -18.
1.4.1.2 Human Studies -  IL-18 Protein
A number of studies have attempted to establish the role of IL-18 in human atheroscle­
rosis.
Increased IL>18 in patients with acute MI correlates with severity of myocardial 
damage [Seta et al., 2000] To elucidate the changes in the release of IL -18 in pa­
tients with advanced disease, Seta et al. [2000] examined the correlation between IL-18 
concentrations and serum activities of myocardial enzymes -  creatine kinase-MB (CK- 
MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH), with the hope 
that measurement of IL-18 could be used as a new indicator of myocardial damage in 
patients with acute MI.
The study comprised 24 male and female patients with acute MI (all aged 39-79 yr), 
and a control group of 12 age- and sex-matched patients with no coronary stenosis 
observed on angiography. A blood sample was taken immediately following patient ad­
mission, and then at 1 h, 2 h, 3 h, 6 h, and 9 h after admission, followed by samples every 
12 h until five days after admission. Baseline serum IL-18 (m eanistandard  deviation
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(SD)) was significantly higher in patients with acute MI than controls (46± 16pg/m l 
vs. 26±10pg/m l, p<0.05). The peak level of IL-18 correlated significantly with 
serum activities of CK-MB (r=0.54, p<0.05), AST (r=0.48, p<0.01), and LDH (r=0.55, 
p<0.05). Therefore suggesting that IL-18 may be useful as a novel marker of cardiac 
damage in acute MI.
IL-18 is found in atherosclerotic plaques and is related to plaque instability [Mallat 
et al., 2001a] Following on from their animal studies that had suggested that IL -18 is 
an important factor in plaque development (see section 1.4.1.1 on page 43), M allat et al. 
[2001a] investigated the expression and cellular localization of IL-18 in human carotid 
atherosclerotic plaques, and attempted to relate its expression to plaque vulnerability 
and stability.
A total of 40 human plaques were taken from 35 patients undergoing carotid en- 
darterectomy. As controls, two carotid and three internal mammary arteries, free 
from atherosclerosis, were obtained at autopsy or during coronary artery bypass graft 
(CABG) surgery. Western blots were performed on protein extracts, showing that both 
pro- and mature forms of IL -18 were highly expressed in most atherosclerotic plaques, 
whilst little or no expression were seen in normal arteries. Detection of the active form 
of IL -18 seemed to correlate with expression of caspase-1. Furthermore, IL -18Rce ex­
pression was detected in all atherosclerotic plaques whilst its expression in normal ar­
teries was low.
Immunohistochemical analysis showed IL-18 expression was mainly in 
macrophages, but also in some intimal (but not medial) SMCs and the occa­
sional endothelial cell. IL -18R a was highly expressed in both plaque macrophages and 
endothelial cells. Semi-quantitative polymerase chain reaction (PCR) showed IL-18 
mRNA expression in all atherosclerotic plaques although the degree of expression was 
fairly heterogenous. When the plaques were characterized clinically and pathologically 
as either symptomatic (stable, n=13) or asymptomatic (unstable, n=9), the amount of 
IL-18 mRNA was greater than three-fold higher in symptomatic over asymptomatic 
plaques (p<0.007). These results suggested that IL-18 might play a major role in 
atherosclerotic plaque destabilization, and that its upregulation could lead to acute 
disease.
IL-18 is predictive of future cardiovascular events, independent of other serum in­
flammatory factors [Blankenberg et al., 2002] To evaluate whether baseline serum 
levels of IL-18 might be predictive of future fatal cardiovascular events in patients with 
angiographically-proven CHD, Blankenberg et al. [2002] measured IL-18 levels in the 
Atherogene cohort.
The Atherogene cohort recruited from November 1996 to June 2000, selecting pa­
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tients undergoing coronary angiography who had at least one stenosis of greater than 
30% [Blankenberg et al., 2001]. The cohort of 1229 individuals had an average age of 
6 2 yr, with 75% being male. These patients were followed up for a median o f 3.9 yr, 
during which a number of individuals suffered a fatal event (n=95), non-fatal MI (n=43), 
or died from other causes (n=l 8).
Median serum concentrations of IL-18 were significantly higher in those who had 
a fatal CHD event during follow-up than those who did not (68.4pg/m l vs. 58.7 pg/ml, 
p<0.0001). Each quartile increase in baseline IL-18 was associated with a 1.46 (95% 
Cl 1.21 to 1.76, p<0.0001) increase in risk for future CVD death. Adjustment for C- 
reactive protein (CRP), IL-6, or fibrinogen had no effect on this association. In a final 
model that included all the inflammatory variables and other classical risk factors (eg. 
age, sex, smoking status, BMI etc.), the upper quartile of IL-18 still showed a 3.3-fold 
increase in risk compared to the lowest quartile.
This study was the first to show a strong and independent association between serum 
IL -18 and future CVD events in patients with a broad spectrum of CVD, thereby sug­
gesting, along with the results from Mallat et al. [2001a], that IL-18 might be a novel 
therapeutic strategy for plaque stabilization.
IL-18 levels associate with carotid IMT in an asymptomatic cohort [Yamagami 
et al., 2005] For this study, 366 (equally comprising men and women) patients w ith­
out history of any cardiovascular events were recruited form those undergoing carotid 
ultrasound examination at Osaka University, Japan.
Mean (SD) IL-18 levels were significantly higher in men than women 
(208±85 pg/ml vs. 180±74 pg/ml, p<0.001), in those with hypertension than those 
without (p<0.001), and in smokers than non-smokers (p=0.008). Furthermore, IL-18 
positively correlated with age (r=0.17, p=0.001), and BMI (r=0.11, p=0.041), and in­
versely correlated with HDL (r=—0.17, p=0.001). O f note, a strong correlation for 
IL-18 was observed with both IL-6 (r=0.23, p<0.001) and CRP (r=0.29, p<0.001), but 
there were no statistically significant correlations between IL-18 and common CHD 
medication (aspirin, statin, or ACE inhibitors).
IL -18 was very strongly correlated with mean carotid max-intima-media thickness 
(IMT) (r=0.36, p<0.001), which remained significant following adjustment for age, 
sex, and other traditional risk factors (including IL-6 and CRP). Conversely, correla­
tions between both IL-6 and CRP, and max-IMT, were lost when adjusted for IL-18. 
Analysis by tertiles of IL -18 showed mean max-IMT was around 0.2 mm higher in the 
top tertile than the lowest tertile (p<0.001, see figure 1.20 on the next page). These 
associations did not differ greatly in men and women.
These results suggest that IL-18, independent of other known pro-inflammatory cy­
tokines, is associated with early asymptomatic atherosclerosis.
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Figure 1.20: Mean max-IMT by to tertiles of EL-18. Error bars are 95% Cl [Yamagami 
et al., 2005].
IL-18 levels are  h igher in those with advanced CHD and  are independently related 
to disease severity [H ulthe et al., 2006] Hulthe et al. [2006] studied a cohort of 387 
first-MI survivors, all less than 60 years, from the northern region of Sweden. For each 
case, a sex- and age-matched control was also recruited from the general population. 
Three months after the index event, blood was taken and a patient interview undertaken.
IL-18 levels were positively correlated with IFNy in the whole cohort (r=0.34, 
p<0.001), and mean (SD) IL-18 levels were higher in the post-infarct patients than con­
trols (309.6± 138.6 pg/ml vs. 285.4± 115.7 pg/ml, p=0.014). No significant difference 
in IL-18 levels were observed by lipid-lowering or ACE inhibitor treatment. Plaque 
area, assessed by quantitative coronary angiography (n=236), was positively correlated 
with IL-18 (r=0.17, p=0.009), a correlation that remained significant following adjust­
ment for EL-6 and CRP. No other quantitative angiography measures correlated with 
IL-18.
This study suggests an independent role for IL-18 in determining disease severity, 
and also illustrates its close relationship with IFNy production.
In a  population-based sam ple, IL-18 levels do not independently associate with 
subclinical carotid  atherosclerosis [C hapm an et al., 2006] The Carotid Ultrasound 
Disease Assessment Study (CUDAS) is a random electoral roll sample of 1111 subjects
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aged 22-77 yr from Perth, Western Australia, with no previous CHD events or surgery. 
Each participant was assessed for sub-clinical carotid atherosclerosis by high-resolution 
B-mode carotid ultrasonography.
In this study, men had higher mean (95% Cl) IL-18 levels than women 
(340.4[329.1-352.0]pg/m l vs. 266.1 [257.0-275.5]pg/ml, p<0.0001), with plaque be­
ing observed in 22% of women and 29% of men. In agreement with past data, IL -18 was 
correlated weakly with CRP and IL-6, and also with fibrinogen. IL-18 was correlated 
with IMT (r=0.17, p<0.001), and was higher in those with evidence of carotid plaques 
than those without (322.1 [306.3-338.8]pg/ml vs. 292.7[284.3 -301 .2]pg/ml, p=0.001). 
However, once IL-18 levels were adjusted for traditional risk factors this association 
was ablated.
Higher levels of IL-18 are found in those with late restenosis [Kawasaki et al., 
2003] A group of 21 patients undergoing CABG surgery (12 men, and 9 women) were 
recruited, along with 10 control patients with normal cardiac function, to investigate 
whether IL-18 concentrations were associated with restenosis after angioplasty. Blood 
samples were drawn immediately after admission, and at four hours, twenty-four hours, 
three days, one week, and six months following admission. Restenosis was defined as 
greater than 50% reduction in percent diameter stenosis (percent diameter stenosis = 
1-(minimal luminal diameter/reference diameter) xlOO) at the target lesion.
There was no significant difference in age, BMI, stenting procedure, or traditional 
risk factors between the no-restenosis and restenosis groups. There was no significant 
difference in reference vessel diameter, but minimal luminal diameter was significantly 
greater, and percent diameter stenosis significantly smaller, in the restenosis group than 
the no-restenosis group.
Mean (SD) plasma levels of IL-18 at admission were significantly higher in the 
patient group than control group (231.5±98.4pg/m l vs. 59.3±40.0pg/m l, p<0.001). 
IL -18 levels in the intervention group decreased at four hours (immediately after angio­
plasty) and reached their peak at three days. Levels of IL-18 were significantly higher 
at all time-points, except 24 hours, in the restenosis group than the no-restenosis group 
(see figure 1.21 on the following page). This data suggests that IL-18 can act as in 
independent predictor of future restenosis.
IL-18 levels predict future coronary events in healthy men, independent o f other 
risk factors [Blankenberg et al., 2003] This study assessed the impact of circulating 
IL-18 in a study concerned with primary prevention. The Prospective Epidemiological 
Study of Myocardial Infarction (PRIME) study recruited 10600 men aged 50-69 yr liv­
ing in Lille, Strasbourg, Toulouse, and Belfast. A five-year follow-up was accomplished 
on more than 98% of all subjects. The outcome was a combined endpoint that included
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Figure 1.21: Circulating IL-18 levels in the patient groups. All data are expressed as 
mean±SD. * -  p<0.01 vs. patient without restenosis; f  -  p<0.05 vs. patients without 
restenosis. Arrows denotes time of percutaneous coronary intervention; Ad. -  admis­
sion; FU -  follow-up.
non-fatal MI, coronary deaths and angina.
The baseline characteristics of cases compared to controls were as expected with 
cases having a higher incidence of traditional CHD risk factors. Baseline measures of 
IL-18 did not differ by smoking, hypertension, diabetes status, age or sex (unlike IL- 
6 or CRP). IL-18 was not correlated with fibrinogen, but did modestly correlate with 
both EL-6 and CRP. Furthermore, IL-18 was not associated with statin, ACE inhibitor, 
or /J-blocker use, all suggesting a degree of independence for IL-18.
Baseline IL-18 was significantly higher in those who had an event during follow- 
up than those who did not (225.1 pg/ml vs. 203.9 pg/ml, p=0.005). The RR (95% Cl) 
for the combined endpoint was 1.32 (0.90-1.93, p=0.16) for second vs. first tertile, and 
2.07 (1.40-3.05, p<0.001) for the third vs. first tertile. These were similar risks as those 
found for both IL-6, CRP, and fibrinogen, however these were significantly attenuated 
when adjusted for coronary risk factors (see figure 1.22 on the next page). Conversely, 
the association with IL-18 was not lost when adjusted for coronary risk factors, or for 
CRP (as a representative of the acute phase reactants). The association between IL-18 
and risk was strongest in Northern Ireland, however this is likely due to the increased 
levels of IL-18 and increased incidence of CHD .seen, compared to the French partic­
ipants. Importantly, EL-18 added to the predictive ability of the common risk factors, 
as demonstrated by an increase in risk when elevation of IL-18 was associated with 
another risk factor.
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Figure 1.22: RRs for combined coronary events according to tertiles of IL-18, IL-6, 
CRP and fibrinogen. Tertiles were derived from control distribution, lowest tertile as 
reference group. ■  indicates crude RRs; ♦ indicate RRs adjusted for BMI, smoking 
status, diabetes, hypertension, total cholesterol, HDL, and triglycerides; •  indicate RRs 
further adjusted for CRP (in case of IL -18) or IL -18 (in other cases) [Blankenberg et al.,
2003].
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Elevated CRP and IL-6, but not IL-18, were independently associated with risk o f  
CHD in a large case-control cohort [Koenig et al., 2006] A prospective (follow-up 
of 11 yr) case-control cohort was assembled from within the population-based M ON­
ICA/KORA Augsburg studies, part of the multinational WHO MONICA project. A 
combined endpoint that included fatal/non-fatal MI and sudden cardiac death occur­
ring before 75 yr was used. This study considered 2362 participants -  295 men and 87 
women with incident CHD, and 1009 men and 971 women without incident CHD.
A standard risk factor baseline profile was seen in cases over controls. Mean 
(SE) plasma levels of IL-18 were higher, but not significantly, in cases than controls 
(172 .4± 1 .0 pg/ml vs. 161.3±1.0pg/m l, p=0.11), whilst both CRP and IL-6 were signif­
icantly higher in cases than controls. There was no correlation between IL -18 and age or 
BMI, but there were significant correlations with CRP, IL-6, waist to hip ratio (WTHR), 
DBP, and inversely with HDL. In age- and survey-adjusted analysis, there was a signif­
icant association between elevated IL -18 and incident CHD in men (tertile 3 vs. tertile 1 
-  1.43 (1.05-1.96) p=0.02). There was a similar sized association in women, although 
this did not reach statistical significance (p=0.11). Inclusion of traditional risk factors 
attenuated these associations, however associations for both IL-6 and CRP remained 
significant in multivariate analysis.
In conclusion, there is much data to suggest that IL -18 is active during both early and 
late atherosclerosis and acts largely independently from other inflammatory mediators, 
although more data is required to establish its true effects. That a number of groups 
have found IL-18 to be associated with plaque instability suggests it may control the 
numerous physiological pathways that ultimately lead to plaque rupture.
1.4.1.3 Human Studies-IL18  Gene
Variation with IL18 is independently associated with CHD mortality [Tiret et al.,
2005] To attempt to identify potential disease-causing variation within the four IL-18 
system genes, Tiret et al. [2005] screened all regulatory, coding, and intronic regions 
in IL18 by both sequencing and single strand conformational polymorphism (SSCP) 
analysis. Innate Immunity - Programs for Genomics Applications (IIPGA) data was 
used for the three other genes -  IL18BP, IL18Ra,  and IL18R.fi.
Within IL18, 11 polymorphisms were found and confirmed in IIPGA. Taking com ­
mon SNPs and those that marked areas of LD, five SNPs were eventually carried for­
ward for genotyping. These five SNPs were in relatively strong LD and together defined 
six major haplotypes. For IL18Ra,  nine SNPs were chosen that together defined seven 
haplotypes, whilst for lL18Rfi eight SNPs were genotyped giving eight haplotypes. 
Only one SNP was found in IL18BP, but as it was of relatively low frequency (<2% ),
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it was excluded.
In the Atherogene cohort, there was a significant global association between ILJ8  
haplotypes and age- and sex-adjusted IL-18 levels (p<0.001). One IL18 haplotype 
(hGCAGT) was associated with 9% lower IL-18 levels when compared to the most 
common (p<0.001). Further adjustment for variables that were correlated with IL-18 
(smoking, HDL, and triglycerides), did not attenuate this association. In total, hap­
lotypes explained 1.8% of the variance in IL-18 levels, which was more than each of 
the single SNPs. None of the IL18Ra  haplotypes or single SNPs were associated with 
IL-18 levels, however IL18R(3 haplotypes were globally associated with IL-18 levels 
(p=0.04) although none of the individual haplotypes reached significance.
The Atherogene cohort had continued follow-up with the number of CHD events 
increasing to 142. IL-18 remained predictive as detailed above. IL18 single SNPs were 
not associated with CHD mortality, although IL18 haplotypes were globally associ­
ated with mortality (p=0.045). Adjustment for traditional risk factors strengthened the 
association (p=0.006), whilst adjustment for IL-18 attenuated it. Both hGCAGT and 
one other haplotype (hGCCAT) were associated with CHD risk (95% Cl) but in oppo­
site directions -  0.57 (0.36-0.92, p=0.021) and 3.01 (1.27-7.13, p=0.012) respectively. 
Adjustment for IL-18 levels attenuated that association of hGCAGT, but not that of 
hGCCAT. Neither IL18Ra  nor IL18Rj3 were associated with CHD mortality.
hGCAGT under-expresses IL18 mRNA compared to the reference haplotype [Bar- 
baux et al., 2007] To further investigate the associations found by Tiret et al. [2005], 
Barbaux et al. [2007] examined IL18  expression levels in lymphoblastoid cell lines 
with known haplotypes. The haplotypes were reduced to just two SNPs -  C-105T and 
A+183G (the second and third SNPs in the haplotypes above) -  as they were located in 
functional regions (5’UTR and 3’UTR, respectively). An allelic imbalance method was 
used to investigate differential allelic expression. It was found that hCG (equivalent 
to hGCAGT) significantly under-expresses (p=0.005) compared to hCA (equivalent to 
hGCAAC, the reference haplotype). In homozygous cells, using standard QPCR pro­
tocols, the results were repeated. In further studies, there appeared no difference in 
promoter activity or mRNA stability between the haplotype.
Therefore both Tiret et al. [2005] and Barbaux et al. [2007] have provided com­
pelling evidence that variation within IL18 is associated with CHD risk. Allied with 
the information concerning levels of IL-18 and risk of CHD, it suggests that IL-18 is 
causative in heart disease, and that common variation within IL18 predisposes to CHD.
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1.4.2 The Metabolic Syndrome
The metabolic syndrome represents a combination of CHD risk determinants that con­
trasts it to isolated cigarette smoking, hypertension, hypercholesterolemia, or diabetes. 
Its components include atherogenic dyslipidemia, high blood pressure, elevated glu­
cose, a prothrombotic and proinflammatory state. In an advanced state, TIIDM is 
present. As a multiple component condition, the metabolic syndrome can be called 
a multiplex CHD risk factor. Even without diabetes, the metabolic syndrome imparts a 
doubling of risk for CHD, with diabetes the risk is even greater [Grundy, 2007]. Several 
cross-sectional studies show acute phase reactants such as CRP, and cytokines such as 
IL-6 and tumor necrosis factor a  (T N Fa), associate with features of the metabolic syn­
drome and may be the link between the metabolic syndrome, diabetes and atheroscle­
rosis [Grundy, 2007].
1.4.2.1 Obesity
A number of studies have suggested IL-18 has a role in maintaining caloric control, 
thereby giving it a potential role in the interaction between obesity and CHD.
The i l l8~ /~  mouse has a markedly increased body weight [Netea et al., 2006] Up
to three months of age the bodyweights of i l l8 ~ /~  and wild-type mice did not differ 
significantly. However, at six months i l l8 ~ l~  mice were 18.5% heavier, at twelve 
months they were 38.1% heavier, and 24 months they were 27.6% heavier. In dual 
energy X-ray absorbitometry (DEXA) analysis the i l!8~ /~  animals had significantly 
higher percent fat mass. The knockout mice ate significantly more, although there was 
no significant difference in metabolic rates, and both i l l8 ~ /~  and wild-type animals 
had similar body temperatures.
Leptin (an adipocytokine that regulates food intake and energy expenditure) con­
centrations were significantly higher in knockout animals and strongly correlated with 
body weight (r2=0.72), however leptin:body weight ratios did not differ between the 
iU 8~ l~  and wild-type animals. Such results were suggestive o f leptin resistance, how­
ever injection of leptin decreased food intake similarly in both knockout and wild-type 
animals. IL-18 injection also decreased food intake in both i l l8 ~ /~  and wild-type ani­
mals, however only intracerebral (not intravenous) injection had an effect. Histological 
analysis of the aorta of i l l8 ~ l~  animals showed increased lipid deposition.
At three months, there was no difference in fasting plasma glucose, however at six 
months fasting plasma glucose was significantly higher in H18~l~ than wild-type mice. 
Furthermore, these mice had severely impaired glucose tolerance and insulin resistance, 
although this resistance appeared to be at the muscle and adipose, not liver, level.
The i l l8 r a ~ /~  mice were phenocopies of U 18~l~ , being significantly heavier from
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Figure 1.23: Obesity in an i l l 8  ! (left) mouse compared to a wild-type (right) mouse, 
photographed at 1 yr [Netea et al., 2006].
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six months onwards, and showing abnormal glucose and insulin tolerance. Transgenic 
i l l8 b p  mice were obese and also developed insulin resistance.
1118 suppresses appetite and feed efficiency [Zorrilla et al., 2007] Both male and 
female i l l8 ~ /~  mice ate more chow over a one week study period, than wild-type mice. 
This hyperphagia predated the body weight differences detailed above, occurring at 15 
weeks, and increased into adulthood in both males and females. Normalizing for body 
weight, i l l8 ~ /~  animals still ate more than wild-type animals. This hyperphagia in il- 
18-deficient mice varied according to the time of day in both sexes, being greater in the 
last 6 h  of the dark cycle, and first 3 h of the light cycle. In the other 15 h, their food 
intake did not differ from that of the wild-types.
Across a ten day study period, both female and male i l l8 ~ /~  mice gained 2- to 
3-fold more body weight per unit energy consumed of purified low-fat, or high-fat 
diet, suggesting increased feed efficiency and decreased whole-body energy expendi­
ture. Brown fat mass did not differ between the animals, whilst white fat mass was 
greater, in absolute and relative terms, in i l l8 ~ f~  mice than wild-type mice. Collective 
white fat mass was 2- to 3-fold greater in i l l8 ~ /~  mice than wild-type mice. Intra- 
peritoneal and intra-cerebral injection of mature IL-18 reduced body weight gain and 
chow intake after food deprivation in i l l8 ~ /~  mice, whilst injection of pro-IL-18 did not 
have an effect, suggesting the effect was pharmacologically specific to mature IL-18.
Weight loss reduces plasma IL-18 levels [Esposito et al., 2002c, 2003b; Vilarrasa 
et al., 2007] In a study comprising 40 obese, and 40 age-matched, normal weight, pre­
menopausal women (aged 25^40 yr) undergoing a calorie controlled diet, body weight 
was reduced to 90% of their baseline. All participants were free from a history of dia­
betes and CHD, were non-smokers, and had normal insulin sensitivity (as shown by a 
glucose tolerance test).
Median (25th to 75th percentile) IL-18 levels were high in obese women than 
controls (247[204-309]pg/ml vs. 127[98-170]pg/ml, p<0.01) and IL-18 levels were 
positively correlated with body weight. Weight loss significantly reduced IL-18 levels 
(247[204-309]pg/ml vs. 147[11 l-210]pg/m l, p<0.01, Esposito et al. [2002c]).
A subsequent study recruited 60 obese women, using the same criteria as above, 
into either a control (advice on exercise at baseline, and at monthly visits) or inter­
vention (personal tailored information on how to reduce weight by 10%) groups. Af­
ter two years of follow-up, both the control and intervention group showed weight 
loss, and improvements in BMI, WTHR, BP, fasting glucose and insulin, homeosta­
sis model assessment of insulin resistance index (HOMA-IR), triglyceride levels, and 
free fatty acid levels. The change in mean (SD) BMI was larger in the intervention 
group (35±2.3 kg/m2=>30±2.1 kg/m2, p (for mean decrease) <0.001) than the control
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group (34±2.4  kg/m 2 =>34±2.4 kg/m2, p (for mean decrease) =0.04). Median (25th to 
75th percentile) IL-18 at two years were significantly lower in the intervention group 
compared to the control group (157[ 112—212]pg/ml vs. 206[165-274]pg/ml, p=0.02, 
Esposito et al. [2003b]).
In 65 morbidly obese white subjects (5 men, 60 women), who under­
went gastric bypass to reduce stomach volume to 20 ml, BMI (SD) was de­
creased massively (49.2±7.7 kg/m2=*>31.9±4.8 kg/m2). Fasting glucose, insulin 
and HOMA-IR decreased significantly following this weight loss. Median 
(75th percentile) IL-18 levels decreased significantly 12 months post-operative 
(229.8[346.8]pg/ml=*>168.9[240.1]pg/ml, p<0.01), whilst levels of adiponectin in­
creased [Vilarrasa et al., 2007].
This data strengthens the evidence for assigning a metabolic role to IL-18. That 
IL-18 is reactive to weight changes suggests it is linked to adipose tissue mass.
IL-18 is associated with CHD risk factors and factors associated with the metabolic 
syndrome, but does not add to current risk prediction [Zirlik et al., 2007] The
Dallas Heart Study is a multiethnic population-based probability sample of Dallas 
County, with intentional over-sampling of self-identified African-Americans so that 
they comprise ~50%  of the final cohort. For analyses with IL-18, patients with suf­
ficient plasma volume (n=2331) were included. Their median age was 44 yr, and me­
dian BMI was 30 kg/m2, 39% were white. A coronary artery calcification (CAC) score 
greater than 10 was present in 21% of the cohort and aortic plaque was present in 38% 
of the sample.
Subjects with high IL-18 were more frequently older, Caucasian, and obese. Also 
they more frequently had a history of diabetes and hypertension, were smokers, had low 
HDL, high triglycerides (all p<0.001), or a history of previous Mis (p=0.036). Subjects 
with highest IL-18 also more frequently took aspirin, however there was no difference 
in statin use. These differences were largely similar in males and females.
IL-18 levels were correlated with a number of metabolic syndrome factors and geo­
metric means of IL -18 rose progressively with the number of metabolic syndrome fac­
tors present (see figure 1.24 on page 61). IL-18 was significantly higher in those with 
CA C>10 (561 pg/ml vs. 503 pg/ml, p=0.005) and those with prevalent aortic plaque 
(536 pg/ml vs. 478 pg/ml, p not given). However, adjustment for traditional risk factors 
attenuated these associations. As shown in table 1.5 on the next page, a number of 
markers of obesity and insulin resistance correlated with IL-18.
This well-powered study shows that IL-18, although associated with markers of 
atherosclerosis, is not independently so. However, IL-18 is shown to correlate well 
with a number of factors involved in the metabolic syndrome.
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Table 1.5: Correlation of IL-18 plasma levels with markers of obesity and insulin resistance [Zirlik et al., 2007].
BMI Total Fat Mass Lean Mass % Fat Mass WTHR Waist Circ. HOMA-IR Glucose
r 0 .1 1 0.06 0 . 1 2 0.0016 0 . 2 0.18 0.17 0.13
All patients P < 0 . 0 0 0 1 0.007 < 0 .0 0 0 1 0.95 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1
n 1920 1863 1863 1863 1919 1920 1878 2231
r 0.15 0 . 1 2 0.08 0 . 1 2 0 .2 1 0 .2 1 0 .2 1 0.14
Females P < 0 .0 0 0 1 < 0 .0 0 0 1 0.005 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1
n 1176 1144 1144 1144 1175 1176 1154 1378
r 0.09 0 . 1 2 0.05 0.13 0 .1 2 0 . 1 1 0.14 0.08
Males P 0 .0 1 0 . 0 0 2 0 .2 1 0.0005 0.0008 0 . 0 0 2 0.0003 0.03
n 744 719 719 719 744 744 724 853
r 0 .1 0.05 0 . 1 2 -0 .0 1 0 . 2 0.17 0.13 0.07
No TIIDM P < 0 .0 0 0 1 0.048 < 0 .0 0 0 1 0.62 < 0 .0 0 0 1 < 0 .0 0 0 1 < 0 .0 0 0 1 0 . 0 0 2
n 1680 1645 1645 1645 1679 1680 1649 1960
r 0 .0 1 0.03 -0.004 0.05 0.04 0.04 0.25 0 .1
TIIDM P 0.9 0.69 0.95 0.46 0.57 0.56 < 0 .0 0 0 1 0 .1
n 240 218 218 218 240 240 229 271
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Figure 1.24: IL-18 plasma levels with increasing number of components of the 
metabolic syndrome. Box is median and whiskers are 25th and 75th percentile. Taken 
from Zirlik et al. [2007].
IL-18 is secreted by adipocytes [Skurk et al., 2005; Wood et al., 2005] To assess
whether IL-18 was produced by adipocytes, adipose tissue samples were obtained from 
mammary adipose tissue of lean to slightly overweight adult females, undergoing elec­
tive mammary reduction. The cells were cultured for 12 days, allowing differentiation 
from preadipocytes to mature adipocytes. These cells secreted IL-18 protein sponta­
neously and without any significant change over a 16 day period [Skurk et al., 2005].
In conditions that favoured adipocyte maturation, EL-18 secretion was signifi­
cantly elevated. Production was also observed in male donors and did not dif­
fer depending on which fat depot was used. Mean (SD) EL-18 production from 
obese donors (B M I>30kg/m 2) was greater than non-obese donors (5 .5±4.2pg/m l vs. 
1.8±0.9 pg/ml) although this was not significant (p=0.09). QPCR analysis showed that 
IL -18 expression was evident during adipocyte maturation, and immunohistochemical 
studies showed strongest staining in cells with lipid droplets, demonstrating that it is 
not the stromal-vascular fraction that is responsible for this expression.
Further studies from other groups [Wood et al., 2005] also showed, by QPCR anal­
ysis, that IL -18 is expressed in subcutaneous and omental adipose tissue (in both the 
mature adipocyte and the stromal-vascular fraction). The same pattern of expression 
was also seen for IL-18BP, IL-18R a, and EL-18R/3.
IL-18 is associated with hypoadiponectinem ia and obesity [Straczkowski et al., 
2007; V ilarrasa et al., 2006] Adiponectin is a protein secreted by adipose tissue 
which has insulin-sensitizing, antiatherogenic, and anti-inflammatory effects. Circulat­
ing adiponectin is decreased in obesity, TIIDM, and lean offspring of TIIDM subjects,
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and is positively related to insulin action. To investigate the relationship between IL -18 
and adiponectin, 130 subjects (54 men and 76 women) were recruited. Of these, 62 
were lean (BM I<25 kg/m2) and 6 8  were overweight or obese. None were morbidly 
obese (B M I>40kg/m 2), and all were free of cardiovascular disease and TIIDM.
Mean (SD) IL-18 levels were significantly higher in obese individuals than lean 
(308.0 ±  126.1 pg/ml vs. 240 .4±  106.2pg/ml, p=0.0006). IL-18 was significantly pos­
itively correlated with BMI, W THR, percentage body fat, fat mass, fat-free mass, in­
sulin, triglycerides, and CRP. IL-18 was also significantly negatively correlated with 
insulin sensitivity, HDL, and adiponectin (r=—0.31, p=0.0003). This correlation with 
adiponectin was not observed in the lean individuals, and remained significant follow­
ing adjustment for age, sex, BMI, insulin, glucose, total cholesterol, HDL, triglycerides, 
IL-6 , and CRP (r= -0 .3 8 , p=0.005).
To investigate the distribution of plasma IL-18 levels across the sexes and decades 
of adult life, Vilarrasa et al. [2006] recruited 134 healthy men and 127 healthy women. 
There were no significant differences in IL-18 distribution between the sexes or across 
decades of life, but IL-18 levels were significantly higher in obese than normal weight 
men and women. IL -18 was also higher in those with hypertension than those without. 
IL-18 was significantly correlated with WTHR, but this association, not surprisingly, 
lost significance following adjustment for age, sex, and BMI.
Both obesity and insulin resistance are associated with increased adipose tissue 
I  L I 8  expression [Leick et al., 2007] To test whether I LI 8  mRNA expression was 
related to obesity and insulin resistance, a cohort of obese (n= 13) and non-obese 
(B M I<30kg/m 2, n=29) men and women were recruited. Adipose tissue biopsies were 
taken from all subjects, and IL18 mRNA levels were 80% higher in obese men (p<0.05) 
and 130% higher in obese women (p<0.05), compared to the non-obese. Both IL18 
mRNA, and plasma IL-18, were significantly positively correlated with HOM A-IR in 
men and women (p<0.05), and importantly mRNA levels correlated with IL-18 plasma 
levels (men -  r2=0.46, p<0.05; women -  r2=0.28, p<0.05).
1.4.2.2 Type II Diabetes
TIIDM is associated with an increased risk of premature atherosclerosis, and both 
prospective studies and clinical trials of intensive glucose control have found a link 
between high glucose levels and cardiovascular disease, without any apparent threshold 
[Laakso, 1999).
IL-18 is reactive to hyperglycemia through oxidative stress [Esposito et al., 2002a]
In investigating the effect of hyperglycemia on IL -18 expression, Esposito et al. [2002a] 
recruited 20 control subjects and 12 subjects with impaired glucose tolerance. During
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Figure l .25: Circulating IL-18 levels after consecutive glucose pulses in 20 control 
subjects (•) and in 12 subjects with impaired glucose tolerance (o) [Esposito et al., 
2 0 0 2 a]
a hyperglycemic clamp (with glucose stabilized to 15 mmol/1 for 5 h) IL-18 levels (SD) 
rose in controls from a basal value of 116±28 pg/ml to a peak of 140±31 pg/ml at 2 h 
(p<0.01), before returning to basal levels by 3h. Those subjects with impaired glu­
cose tolerance had similar glucose and insulin levels during the clamp, and the levels of 
IL-18 observed were not significantly different from control subjects. In further stud­
ies using glucose pulses, rises in IL-18 appeared to correlate with glucose pulses (see 
figure 1.25). When glutathione, an antioxidant, was administered the glucose pulses 
remained unchanged but IL-18 lost its reactivity, suggesting the effect was mediated by 
an oxidative mechanism.
IL-18 levels are modulated by familiar foodstuffs in humans [Esposito et al., 2003a]
Mean (SD) IL-18 levels were significantly higher in 30 TIIDM patients (15 men and 15 
women) than in 30 age- sex- and bodyweight-matched control subjects (205±39 pg/ml 
vs. 120±25 pg/ml, p<0.01), whilst serum adiponectin levels were significantly lower. 
In the diabetic patients, serum IL-18 increased significantly 4 h after ingestion of a high 
fat meal (p<0.05), but decreased significantly after a high carbohydrate high fibre meal 
(p<0.05). IL-18 was significantly correlated with triglycerides following the high fat 
meal (r=0.29, p<0.05). In the control subjects, changes in IL-18 mirrored that of the 
diabetic patients, but were significantly lower (p<0.05).
IL-18 is an independent predictor o f HOMA-IR in diabetic patients [Fischer et al., 
2005] To establish whether IL-18 is associated with insulin resistance, Fischer et al.
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[2005] measured IL-18 levels in 97 patients with TIIDM and 84 healthy age-matched 
controls. The diabetic patients had higher weight, BMI, SBP, plasma glucose, in­
sulin, and HOMA-IR than the controls. As with other inflammatory mediators mea­
sured (CRP, IL-6 , and T N F a), mean (95% Cl) levels of IL-18 were significantly higher 
in the diabetic patients than the controls (307[286-329]pg/ml vs. 258[240-278]pg/ml, 
p=0.001). IL-18 was linearly associated with HOMA-IR quartiles, as was CRP, but 
not IL-6 . The linear association of IL-18 remained significant following adjustment 
for age, sex, BMI, and smoking, whereas CRP did not. After adjustment, a 50% in­
crease in IL-18 was associated with a 26% increase in HOMA-IR in controls (p=0.014) 
and a 25% increase in diabetics (p=0.003), suggesting an independent role for IL-18 in 
TIIDM development.
Elevated levels of IL-18 predict the development o f TIIDM [Thorand et al., 2005]
In the MONICA/KORA Augsburg Study, mean (SE) IL-18 levels were significantly 
elevated in subjects who went on to develop TIIDM compared to those who did not 
(188.1 ±  1.0 pg/ml vs. 159.4 ±  1.0 pg/ml, p<0.001), as were levels of IL- 6  and CRP. In 
contrast to IL - 6  and CRP, IL-18 was not strongly associated with most of the diabetic 
risk factors, and only weak correlations (r< 0 . 1) were observed with smoking, hyper­
tension, SBP, DBP, HDL, W THR, IL-6 , and CRP.
Elevated concentrations of IL -18 were strongly associated with an increased risk 
of TIIDM, with crude hazard ratios (HRs) (95% Cl) for the fourth quartile being 
1.96[1.49-2.58] and for the third quartile being 1 .57[ 1.18—2.09] (see table 1.6 on the 
next page). Adjustment for age, sex and survey had no influence on the HRs, whilst 
fuller adjustment slightly attenuated the associations but they remained highly signif­
icant, even with adjustment for IL - 6  and CRP, again suggesting IL-18 may indepen­
dently contribute to TIIDM disease risk.
Therefore, taken together, the data suggests IL-18 is associated with both obesity 
and TIIDM development. Furthermore there is evidence to suggest that this role is 
independent from other inflammatory markers. It seems likely that functional genetic 
variation within IL18 could be o f use in TIIDM or obesity risk prediction.
1.4.3 Other Diseases
Because of its potent proinflammatory properties, IL-18 has been implicated in a num ­
ber of other diseases, particularly those associated with autoimmunity [Boraschi and 
Dinarello, 2006]. As such there has also been a great number of studies concerned with 
estimating the effect of genetic variation in IL18, on disease susceptibility. A summary 
of this data is provided in table 1.7 on page 6 6 .
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Table 1.6: HRs (95% Cl) of developing diabetes comparing quartiles of IL-18 in the MONICA/KORA Augsburg Study [Thorand et al., 2005]. 
Model 1 -  crude; model 2 -  adjusted for age, sex, and survey; model 3 -  model 2 + BMI, SBP, ratio of total cholesterol to HDL, physical activity, 
alcohol intake, smoking status, an parental history of diabetes; model 4 -  model 3 + CRP and IL-6 .
Quartile of IL-18
1 2 3 4
Median (lower, upper limit) (pg/ml) 80.09 (4.9, 116.7) 145.18 (116.8, 173.5) 205.04(173.6, 244.6) 322.08 (244.7, 8792.4) p for trend
n (nondiabetic/diabetic) 424/95 429/108 417/146 428/178
Model 1 1 1.13[0.84-1.52] 1.57[1.18-2.09] 1.96[1.49-2.58] < 0 .0 0 1
M odel 2 1 1.18[0.87-1.60] 1.64[1.22-2.20] 1.9311.45-2.56] < 0 .0 0 1
Model 3 1 1.1010.78-1.57] 1.62[1.16-2.25] 1.73[1.25-2.40] < 0 .0 0 1
Model 4 1 1.1010.78-1.57] 1.6111.16-2.24] 1.7311.25-2.40] < 0 .0 0 1
Table 1.7: Sum m ary o f  current 1L18 gene association  data for autoim m une d isease. N S -  non-significant.
Disease Population SNP Test Genotype Effect P value Reference
Asthma
221 asthmatic children, 276 asthmatic adults, 
85 adult controls + 105
IL-18 serum levels (±SD , pg/ml)
Minor allele odds ratio (OR) 
(95% Cl)
AA
AC
220± 148 
224± 102 
1.83(1.37-2.26]
NS
0.0062
Higa et al. [2003]
228 asthmatic children. 270 controls -607, -137, + il3 ,  
+ 127.-133
Armiiage trend test All NS Heinzmann et al. [2004]
435 Korean asthmatics. 140 controls -'607. -137. +105 Allele frequency (%) vs. control All NS Shinet al. [2005]
SAPALDlA -  268 atopic asthmatics. 5204 
controls -137 Allele frequency (%) vs. control
G
C
77.6 vs. 73.2 
22.4 vs. 26.8
0.012 Imboden et al. [2006]
Type I
diabetes
(T1DM)
201 T1DM patients, 194 healthy controls
-607
-137
Allele frequency (%) vs. control
C
A
G
C
67.9 vs. 66.0 
32.1 vs. 34.0 
62.4 vs. 72.7 
37.6 vs. 27.3
0.564
0.002
Kretowski et al. [2002]
116 Japanese TIDM patients, 114 healthy 
controls
-607
-137
Allele frequency (%) vs. control
C
A
G
C
53.4 vs. 44.7 
46.6 vs. 55.3 
87.9 vs. 88.6 
12.1 vs. 11.4
0.062
0.825
Ide et al. [2004]
1560 cases, 1715 controls -607-137
Minor Allele OR (95% Cl) 1.06(0.95-1.19j 1.00(0.93-1.07]
0.27
0.94 Szeszko et al. [2006]
53 late onset Iranian TIDM patients, 194 
controls
-607
-137
Allele frequency (%) vs. control
C
A
G
C
51.9 vs. 58.8 
48.1 vs. 41.2 
66 vs. 76 
34 vs. 24
NS
0.038
Mojtahedi et al. [2006]
Multiple
sclerosis 208 cases, 139 controls
-607
-137
Allele frequency (%) vs. control
C
A
G
C
59 vs. 62 
41 vs. 38 
70 vs. 75 
30 vs. 25
0.64
0.17
Giedraitis et al. [2001]
Rheumatoid 
arthritis (RA)
106 cases, 273 controls
-607
-137
Allele frequency (%) vs. control
C
A
G
C
63 vs. 55 
37 vs. 45 
86 vs. 87 
14 vs. 13
NS
NS
Sivalingam et al. [2003]
309 Polish RA patients. 305 controls
-607
-607
Genotype OR (95% Cl)
CC
AC
AA
GG
GC
CC
1.27(0.92-1.77] 
0.95(0.71-1.57] 
0 71(0.45-1.10] 
1.07(0.78-1.46] 
1.14(0.82-1.58] 
0.51(0.28-0.95]
0.146
0.754
0.126
0.695
0.432
0.045
Pawlik et al. [2006]
Juvenile SOI/SOI 78683±22778
idiopathic 33 JIA patients, 173 controls Haplotypes of 13 SNPs
IL-18 serum levels (SD. pg/ml) Others 10 122±28 210 0.017 Sugiura et al. [2006]
arthritis Haplotype frequency (%) vs. con­ SOI 54.5 vs. 37.9 0.011
(JIA) trols
CD
134 cases, 110 controls + 105 Minor allele OR (95% Cl) 2.19(1.24—3.87] 0.006 Tamura et al. [2002]
210 CD patients. 265 controls -607,-137,+105 Allele frequency (%) vs. control All NS Glas et al. [2005]
Graft-versus- 157 patient-donor pairs 
host disease
Haplotypes of -656, - Cox regression non-relapse sur- No GCG 2.09(1.24-3.51] <0.01 Cardoso et al. [2004]
607,-137 vival (95% Cl) haplotype
1.4.4 Potential For Therapy
That IL -18 appears involved in a number of diseases makes it an attractive therapeutic 
strategy. Therapeutic options under investigation to inhibit IL-18 include the use of 
neutralizing antibodies to IL-18, and IL-18R, IL-18BP, and caspase-1 inhibitors.
With regard to IL-18BP, a human IL-18BP:IgGl Fc fusion protein binds and neu­
tralizes IL -18. Using E. co/t'-derived endotoxin, administration of IL -18BP:IgG 1 10 min 
prior to the endotoxin significantly reduced mortality. Furthermore, IL-18BP:IgGl has 
a long plasma half-life, being effective when injected 6  d prior to challenge.
A number of caspase-1 inhibitors have been into clinical trials for their efficacy. 
VX-765 is currently in trials for the treatment of psoriasis and is reported to be effective 
in blocking the hyperreactivity to inflammatory stimulation of monocytes from familial 
cold autoinflammatory syndrome (FCAS) patients.
Although promising, each potential approach has their drawbacks and must be care­
fully optimized to obtain a reduction, not an abolishment, of IL-18. In fact, as IL-18 
plays a key role in balancing Th 1 and T h 2  responses, complete down-regulation could 
lead to immunosuppression with severe consequences.
1.5 Study Aims
Hypothesis Common genetic variants within IL18 or IL18BP  cause inter-individual 
differences in serum fIL-18 concentrations, therefore contributing to individual risk for 
CHD and obesity.
Aims
1. Identify tSNP sets that capture whole gene variation within both IL18  and 
IL18BP.
2. Assess causality for the IL-18 system in both obesity and CHD, by applying a 
Mendelian randomization approach in numerous study groups.
3. Investigate the impact of any potentially functional genetic variants on 1L18 or 
IL18BP  mRNA production.
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Chapter 2 
Materials and Methods
Detailed below are the reagents and protocols used throughout this study. Care has been 
taken to standardize methods throughout, however deviations from the given protocol 
are noted in the relevant results sections.
2.1 Genotyping Methods
A variety of genotyping methods were used in this study, all of which were high- 
throughput and designed to offer the greatest efficiency whilst maintaining accuracy.
2.1.1 DNA Extraction, the ‘Salting Out’ Method
Reagents
Sucrose Lysis Buffer 0.32 mol/1 sucrose; 5 mmol/1 M gCl2 ; 10 mmol/1 Tris-HCl 
pH 7.5; 1% Triton-X-100.
Nuclei Lysis Buffer 10mmol/1 Tris-HCl pH 8.2; 0 .4 mol/1 NaCl; 2 mmol/1 
Na2ethylenediaminetetraacetic acid (EDTA) pH 8.0; 1% SDS.
TE Buffer 10 mmol/1 Tris; 1 mmol/1 EDTA; pH to 7.6 with HC1.
Protocol Genomic DNA was isolated from potassium-EDTA-anti-coagulated whole 
blood (stored at - 2 0  °C) by an adaptation of the ‘salting out’ method, described by 
Miller et al. [ 19881. The salting out protocol involves cellular lysis using a sucrose lysis 
buffer, and nuclear lysis using a lysis buffer containing 10% (w/v) SDS. The DNA is 
finally ethanol-precipitated following a deproteinisation step.
Blood was thawed (at room temperature) and transferred to a 30 ml centrifuge tube 
containing 12 ml cold (4 °C) sucrose lysis buffer and mixed several times by inversion.
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After centrifugation at 1300G, 4°C  for lOmin (Sorvall RC5C centrifuge, rotor SA- 
600), the supernatant was discarded and the pellet resuspended in 12 ml cold (4°C ) 
sucrose lysis buffer, then re-centrifuged at 1300 G.
Following centrifugation, the supernatant was discarded and 2 ml nuclei buffer was 
added then mixed thoroughly with a pipette (or by incubation at 37 °C). 5 mol/1 sodium 
perchlorate (1 ml) was added and the tube mixed by inversion before addition o f 2  ml 
ice-cold chloroform. The sample was then mixed by inversion and centrifuged at 
1300 G for 3 min at room temperature. The upper aqueous phase was transferred to 
a fresh 30 ml centrifuge tube without disturbing the organic phase, and 10 ml ice-cold 
100% ethanol gently added to it. The precipitated DNA, apparent on the interface be­
tween the two phases as a fine wooly network, was spooled off with a Pasteur pipette 
and washed in 70% ethanol. It was then transferred to a sterile microtube containing 
1 ml TE buffer. To allow the DNA to fully dissolve, it was incubated at 37 °C overnight.
2.1.2 Standardization of DNA Arrays
All DNA samples were standardized to 15ng/pl. Initially a 1/10 dilution (to 100 pi) 
of each sample was made into a 96-weII Costar UV plate with dF^O , and briefly cen­
trifuged at 200 G. The plate was then loaded into the Tecan GENios plate reader and the 
absorption of each sample read at both 260 nm (for dsDNA) and 280 nm (for protein). 
Given that 1 O.D. at 260 nm for dsDNA equates to 50ng/pl, the volume of sample re­
quired for an end concentration of 15 ng/pl could be calculated. Dilutions were made to 
750 pi with dH2 0  into 96-well arrays (Matrix Technologies Corp., NH, US). All DNA 
samples were stored at — 20 °C.
2.1.3 PCR
The technique of PCR relies on double stranded DNA being denatured into single 
strands by heat, consequent annealing with oligonucleotides (primers), and, via the ad­
dition of DNA polymerase and nucleotide bases, the synthesis of a double strand upon 
cooling [Mullis et al., 1986]. This cycle leads to binary (base 2) replication, generating 
large quantities of specific DNA in a short period of time.
The first step is a period of high temperature (normally 95 °C) to denature or ‘m elt’ 
the double-stranded ‘tem plate’ DNA to single strands. This is followed by cooling 
to a primer-pair-specific temperature, allowing short oligonucleotides (typically 2 0 -  
30 bp), complementary to sequences either side of the area of interest, to anneal to the 
template strands. The temperature is then increased to 72 °C and a DNA polymerase 
then adds nucleotides, complimentary to the template sequence, replicating the DNA 
base by base. The polymerase used is derived from the bacterium Thermus aquaticus, it
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is heat stable and therefore does not need replenishing following each cycle of heating 
and cooling.
Reagents
lOx Polmix Buffer 5 0 0 mmol/1 KC1; 100mmol/1 Tris-HCl pH 8.3; 0.01% gela­
tine; 2 mmol/1 dATP; 2 mmol/1 dTTP; 2 mmol/1 dGTP; 2 mmol/1 dCTP.
lOx NH4 Polmix Buffer 16mmol/1 [N H ^SC U ; 67 mmol/1 Tris-HCl pH 8.4; 
0.01% Tween 20; 2 mmol/1 dATP; 2 mmol/1 dTTP; 2 mmol/1 dGTP; 2 mmol/1 dCTP.
Protocol Following extraction and arrangement into 96-well arrays, DNA samples 
were prepared for PCR by centrifuging the working array at 1000G for 1 min. This 
ensures the collection of DNA samples at the bottom of their respective wells, reduc­
ing the possibility of cross-well contamination. Typically, around 20 ng of DNA was 
removed for each PCR reaction using a Finnpipette multichannel dispenser (Life Sci­
ences, Basingstoke, Hants, UK) and placed into a corresponding position in a standard 
96-well PCR plate (Coming Inc., Hemel Hempstead, UK). Extreme care was taken to 
ensure the accurate transfer of DNA from the working array to the PCR plate. Nega­
tive and, where necessary, positive controls were utilized to ensure accuracy. Loaded 
plates were then centrifuged at 200 G for 1 min to ensure that the DNA was collected 
at the bottom of each well, reducing the possibility of cross-contamination during the 
dispensing of the PCR mix.
The PCR mix was made up freshly for each separate PCR reaction. PCRs were 
performed in a total volume of 20 pi, with each reaction containing either lx  Polmix or 
1 x NH4 Polmix, the optimum concentration of M gC ^, 8  pmol of each primer, and 0.6 U 
of T. aquaticus polymerase. The PCR mix was added to each well of the PCR plate 
using an automatic Biohit repeating dispenser (Alpha Laboratories, UK). Each sample 
was overlaid with 20 pi mineral oil to prevent evaporation. The microtitre plate was then 
sealed with a clear sticky plastic lid and carefully labelled. Plates were centrifuged at 
200 G for 1 min to ensure correct placement of the reaction components before cycling. 
Thermal cycling was performed on an MJ Tetrad DNA Engine Thermocycler with the 
following protocol:
95 °C 5 min
95 °C 30 s '
xx°C 45s
7 2 °C 45s >
75 °C 5 min
> x30-40 cycles
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The PCR was cycled between 30^40 cycles, depending on the individual PCR ef­
ficiency. The final polymerization step, ensured all partial DNA products were fully 
extended by T. aquaticus polymerase.
Upon receipt of new primer pairs, or prior to the genotyping of whole studies, an op­
timization procedure was conducted; MgCU concentration and annealing temperature 
were altered in a gradient across the plate, and the most effective combination of both 
was assessed for each primer pair. A higher annealing temperature increases the speci­
ficity of the primer, while a higher MgCU concentration (in the order of 2.5 mmol/1) 
lowers the specificity. If the above measures failed to produce a cleanly and correctly 
amplified PCR product, the optimization was repeated with a different PCR buffer -  
NH4 Polmix, and with the addition of 5% dimethyl sulfoxide (DM SO)1. O ligonu­
cleotides were designed using Primer3 software [Rozen and Skaletsky, 2000], freely 
available at http://frodo.wi.mit.edu. Primer3 chooses primer pairs taking into consider­
ation primer melting temperature, length, GC content, 3’ stability, estimated secondary 
structure, the likelihood of primer-dimer formation between two copies of the same 
primer, and the accuracy of the source sequence.
If primer pairs failed to amplify cleanly and correctly, they were redesigned. If this 
was not possible a ready-made PCR mix -  MegaMix Blue (Microzone Ltd. Haywards 
Heath, UK) -  was used that required only the addition of both primers and template 
DNA. This mix uses a set M gCl2 concentration and T. aquaticus polymerase, and 
also offers an accompanying clean-up mix -  m/croCLEAN (Microzone Ltd., Haywards 
Heath, UK) -  that can be used in place of the methods detailed in section 2.1.7 on 
page 81. Simply, an equal volume of mtcroCLEAN is added and mixed with the com ­
plete PCR reaction. The mixture is spun for 7 min at 13 000 r/min in a microfuge and the 
supernatant removed. The tubes are re-spun and any remaining dregs removed, before 
resuspension of the pellet in the appropriate volume of dH 2 0 .
2.1.4 RFLP Genotyping
Derived from bacteria, restriction enzymes (REs) function to destroy foreign DNA 
(such as bacteriophages). They are a widely used tool in molecular biology as they 
recognize and cut at specific short sequences. Numerous such enzymes have been iden­
tified and the list of recognition sites is long, so that it is often possible that a genetic 
variant of interest occurs within an RE site. The enzymes are sensitive enough that a 
single base change within the recognition site will prevent its recognition, and there­
fore they represent a reliable and efficient method for genetic variant identification and 
genotyping.
1 DMSO facilitates strand separation, thereby preventing non-specific binding o f primers.
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Protocol Primer pairs were designed to flank the restriction enzyme site and PCR 
performed as detailed in section 2.1.3 on page 69. If the sequence variant did not occur 
within a recognition site, one of the primers was designed to anneal exactly adjacent to 
the sequence change and certain bases altered to introduce a recognition site through 
purposeful sequence mismatch (via a ‘forcing’ primer).
An RE digest mix with the recommended buffer for the enzyme being used, was 
made up in a 1.5 ml Eppendorf tube on each occasion. Typical quantities per well were 
3.3 pi dP^O, 1.5 pi buffer, and 2 U enzyme (~ 0 .2  pi) per sample. 5 pi of digestion mix 
was added to 8  pi of PCR product in a 96-well microtitre plate with lid (Bibby-Sterilin, 
Staffordshire, UK). Each plate was centrifuged at 200 G for 1 min to collect the reac­
tants, before being incubated at 37 °C overnight in a box sitting on moistened paper 
towel to prevent excessive evaporation. For those enzymes requiring higher tempera­
tures, the reaction was prepared in a PCR plate, overlayed with 10 pi mineral oil and 
sealed with a sticky lid, before incubation on a heated PCR block at the specified tem ­
perature overnight.
Primer pairs and PCR conditions for the commonly used IL18 genotyping assays 
are shown in table 2.1 on the next page, and RE digest details are given in table 2.2 on 
page 74.
2.1.5 DNA Separation and Visualization
PCR products were visualized using both agarose and microtitre array diagonal gel 
electrophoresis (MADGE) gels.
R eagents
M AD G E Loading Dye 0.0015% bromophenol blue; 0.015% xylene cyanol; 10% 
glycerol; 10 mmol/1 EDTA
Sticky Silane 0.5% v/v y methacryloxy-propyl-trimethoxysilane
lOx TBE B uffer 0.04 mol/1 tris-borate; 1 mmol/1 EDTA pH 7.4
TE  B uffer 10 mmol/1 tris-HCl; 1 mmol/1 EDTA pH 7.6
7.5%  M A DG E M ix 25 ml lOx TBE buffer; 62.5 ml 19:1 
acrylamide:N,N’-methylenebenebisacrylamide; 162.5ml distilled water; 900pl 
tetramethylethylenediamine (TEMED)
Protocol
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Table 2.1: Primer pairs and PCR conditions for commonly used IL18 genotyping assays.
SNP Forward Primer Reverse Primer MgCl2 (mmol/1) Annealing Cycles 
Temp.
(°C))
Product Size (bp)
7L75-9731 G > T GCC CTC TTA CCT GAA 
TTT TGG AA 2
AGC CAC ACG GAT ACC 
ATC ATT
1.5 56 38 104
77,75-5848 T > C GAG GAA TGG GGA TGA 
GAA CA
AAA CTT TCC CTC CAC 
CTG AAA
1.5 58 35 239
77,75+105 A > C TGT TTA TTG TAG AAA 
ACC TGG AAT T 3
CCT CTA CAG TCA GAA 
TCA GT
1.5 52 40 148
77,75+8855 T > A CCC TTA TGT GCT CAC 
CTT TCA
CCC AAG TGC ACT GGA 
A A G TC
1.5 60 35 203
IL18+ \ 1015 A >C CTT GAG CAA ATG TGG 
ACA CC
CAG CAG TAC TGA CCT 
CCT CTC C
1.5 55 40 153
77,75-11238 0 A TAG CCT AGA TAA CTA 
TGG CGA AG
TTT TCC CTT CAT TTT 
ACC ACA GA
1 .0 60 38 1 0 2
2Primer forces a Hinfl site -  GATAC—>GATTC 
3Primer forces a TaqI site -  CCGA—>TCGA
Table 2.2: RE digest details for commonly used RFLP assays; NEB -  New England 
Biolabs UK Ltd., Hertfordshire, UK.
SNP Enzyme Supplier Buffer Temp. (°C) Fragment 
sizes (bp)
IL18 -9 1 3 1 G > T Hinfl NEB NEB 2 37 83,21
7L/5-5848 T >C R sal NEB NEB 1 37 195,44
/L/S+105 A >C TaqI NEB TaqI Buffer 65 123,25
IL18+8855 T > A Hinfl NEB NEB 2 37 113,90
IL18+\ 1015 A >C Bfal NEB NEB 4 37 84, 69
IL I8 -11238 C > A BsmAl NEB NEB 3 55 31,71
Agarose gels Where determining the size and relative intensities of PCR products, 
agarose gels were used. For a 2% (effective visualization range -  80-200 bp) gel, 2 g 
of agarose (Helena Biosciences, Sunderland, UK) was mixed with 100 ml of lx  TBE. 
The agarose was dissolved by heating the mix in a microwave oven at full power for 
2 min. 10pi of lOpg/ml ethidium bromide (EtBr) was added as the mix cooled to stain 
DNA within the gel. When the mix had cooled but remained molten it was poured 
into a gel tray (10x14 cm) with combs, and allowed to set for 1 h. For separation of 
larger PCR products, the percentage agarose used was adjusted correspondingly (1% -  
500 b p - 1 kbp; 0.5% -  1-30 kbp).
Solid gels were placed into an electrophoresis tank containing lx  TBE. Typically 
2 pi of MADGE loading dye was added to 5 pi of PCR product and the entire volume 
was mixed and placed in the separate submerged wells of the gel. 1 pi of 1 kbp ladder 
(Invitrogen, Paisley, UK) was added to the two outer wells as a size standard. Gels were 
typically electrophoresed at 100 V for 30 min.
MADGE To visualize a full 96-well PCR plate or products from an RE digest, 
DNA fragments were also separated on a non-denaturing polyacrylamide gel using 
MADGE [Day and Humphries, 1994], This technique allows all 96 wells to be run 
on a single gel slab by loading the samples at an angle, thus running them diago­
nally between their neighbours. The technique allows the 96-well format to be retained 
throughout the genotyping process and improves throughput and accuracy.
MADGE consists of an open arrangement of 8 x 12 wells each 2 mm deep. The wells 
are arranged at an angle of 71.6 °to the array. With this arrangement the maximum track 
length is 26.5 mm, allowing sufficient travel for genotype resolution (see figure 2.1 on 
the next page).
Glass plates of appropriate size (160x120x2 mm) were cleaned and dried 
rigourously. Five drops of sticky silane were spread across the plates and left to air-dry
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Figure 2.1: Schematic showing the arrangements of wells (A) on a MADGE gel, tilted 
at 71.2 ° (B) allowing a 26.5 mm track length (C) for the DNA fragments.
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briefly in a fume-hood. Sticky si lane ensures that the acrylamide mix would adhere to 
the glass plate. Polymerization of the acrylamide was initiated by the addition o f 150 pi 
25% w/v ammonium persulphate (APS) per 40 ml MADGE mix, quickly mixed, then 
poured into the MADGE former. A glass plate was then placed upon the former (sticky 
silane side adjacent to the MADGE mix), taking care not to trap any air bubbles and 
that the plate is in-line with the former. This was then left to set for around 10 min with 
a small weight upon it. When set, excess polyacrylamide was trimmed from the former, 
and the glass plate (with gel attached) was then prized from the former. M ADGE gels 
were stored in a foil-wrapped plastic tupperware box containing lx TBE, and 0.5 pg/ml 
EtBr.
Upon use, an individual MADGE gel was placed into an electrophoresis tank con­
taining 1 x TBE. Typically 5 pi of sample was mixed with 2 pi MADGE loading dye and 
loaded into the gel wells using a multichannel pipette, ensuring to maintain the partic­
ular arrangement of the 96-well plate. The gel was then electrophoresed at 100 V for 
30 min.
Gel Visualization Following electrophoresis the gel was viewed and pho­
tographed under ultraviolet light using the Syngene Gel Documentation System, and 
Genesnap v6.04 software. Care was once more taken to ensure the correct orientation 
of the gel
Genotyping Gel Control All genotyping was performed using negative controls. 
MADGE results were read by two independent observers blinded to clinical details, 
and entered onto the computer database under observation. Any genotype dropouts or 
discrepancies were resolved by repeat PCR if possible.
2.1.6 TaqMan Genotyping
The TaqMan method involves the inclusion of two fluorescent, dye-labelled probes for 
each allele of the specific variant being investigated. The allele specific probes each 
contain a short sequence complementary to the allele and surrounding sequence being 
investigated, a fluorescent reporter dye (labelled either VIC or FAM for each allele) at 
the 5’ end, and a non-fluorescent quencher (NFQ) at the 3’ end that prevents the 5 ’ 
dye from fluorescing. During the PCR cycle, the forward/reverse primer pair anneals 
to the template DNA, along with the respective allelic probe. Amplitaq Gold DNA 
polymerase replicates the single strand of DNA up to the allele-specific probe. If the 
probe is entirely complementary to the target sequence (ie. the correct allele probe), the 
5 ’ to 3 ’ exonuclease activity of the enzyme releases the 5’ fluorescent dye. Therefore 
as PCR cycle increases so does the level of VIC or FAM fluorescence dependant on the
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sample genotype (see figure 2.2 on the following page). A 7900HT Sequence Detection 
machine (Applied Biosystems, California, US) is able to read each sample following 
PCR and determine the levels of both VIC and FAM, so determining the genotype of 
each sample.
Sample Preparation In contrast to the other genotyping methods detailed here, 
the TaqMan system enables high-throughput genotyping in a 384-well format. Typi­
cally DNA was standardized to 1.25 ng/pl as detailed in section 2.1.2 on page 69, and 
an aliquot of 5 ng used in each reaction. A Biomek 2000 robot (Beckman-Coulter, High 
Wycombe, UK) transferred DNA from four 96-well plates to one Thermofast 384-well 
PCR plate (ABgene, Surrey, UK) thereby reducing pipetting error. A data sheet detail­
ing the plate layout and the unique plate identifier was prepared and the plate left to dry 
out overnight, or until further use, at room temperature in a sterile paper bag.
TaqMan M aster Mix Forward and reverse oligonucleotides and their respective 
labelled probe pairs were ordered using the ‘Assay by Design’ service from Applied 
Biosystems Online (www.appliedbiosystems.com). A master mix comprising 2.5 pi 
TaqMan Absolute QPCR Rox Mix (ABgene, Surrey, UK), 0.125 pi 40x Assay, 2.375 pi 
Sigma dH2 0  per well was prepared and a 5 pi aliquot was added to each well using 
an 8 -channel pipette. A clear plastic lid (ABgene, Surrey, UK) was applied to seal the 
plate and prevent excess evaporation, then each plate was centrifuged at 200 G for 30 s. 
Each plate then underwent the following standard PCR program on a Thermohybaid 
(Basingstoke, UK) 384-well heated block:
95 °C 10 min
All plates were then read on a 7900HT Sequence Detection machine, and SDS v2.1 
(Applied Biosystems) was used to differentiate the different genotypes. SDS v2.1 pro­
duces an allelic discrimination plot (see figure 2.3 on page 79) as well as assigning 
genotypes automatically to plate coordinate in a text output file. The file was then con­
verted from 384-well to four 96-well plates in Microsoft Excel, and merged with the 
study database. To ensure no incorrect data input, a second researcher validated the 
entire process.
The IL18 and IL18BP  primer and probe sets used in this study are detailed in ta­
ble 2.3 on page 80.
Protocol
95 °C 
60 °C
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Figure 2.2; Schematic of the TaqMan assay system. The Probe containing allele specific 
5 ’ fluorescent dye (F) and 3’ quencher (Q) anneals to the target sequence, and primer 
elongation begins (A). As the T. aquaticus polymerase meets the fluorescent dye (B) its 
exonuclease activity cleaves the dye from the probe, freeing it from the quencher and 
therefore allowing it to fluoresce (C). The rest of the probe is digested and elongation 
can continue (D).
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Figure 2.3: Screen capture from SDS v2.1, showing a typical allelic discrimination 
plot, with successful separation of the three genotype groups -  homozygotes (•  & •) 
and heterozygotes (•)  -  and the NTCs (■). Unassigned genotypes were those that did 
not cluster with other samples (x ) .
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Table 2.3: IL18  and IL18BP  TaqMan primer and probe pairs used. The interrogated base change is underlined.
SNP Forward Primer Reverse Primer Probe 1 (VIC) Probe 2 (FAM)
7L/S-9731 G>T TGC AAG TAA ATA GCT GTA TCA GAT ATT TTG GTA GCC AAT TTT GGT A1C
TTT GCC CTC TTA GCA AGC CAC A CTC TCC CCT CTC C
CCT
/L/8-5848 T>C GGA AAA TTG AGG TGT GTT GAT TTT CTT GTT AGT TCT TTG TTA GTT CTC
AGA GGA GGA ATG G GAA TTC TTC ATT 
CTT ATT TTC TTA 
CAA T
CAA TAC ATC AGT ACA TC
/L/5+105 A>C AAC TAA AAT ATA GAC TGA TAA TTT CCT GGA ATC AGA CCT GGA ATC CGA
TAG CAT ACT TAT AGA TTC AAG CTT TTA C TTA C
TTG TCA ATT AAC GCC AAA
AAA GAA ACT ATG
7L/5+8855 T>A TTG ACA ACA CTA CCA AGT GCA CTG CTG TCA GTG TCT CTG TCA GAG TCT
AGA GGG ATT TGC T GAA AGT CTG A GTT TC GTT TC
IL18+11015 A>C GAG AGG AGA GAA CTG TCA TGG GAT CAG GCC TCT AGT AGG CCT CTA TTT TT
GTA AGC TGT TTG A GCA TAT TCA GTT C TTT
IL18-1368 A>G CCT GGG TGA CAG TGC TCA TCT AAG ATG TTA TCT AAA TTA TCT AAA TAA
AGT GAG ACT TGC GAA CAG TT TAA GAT AAA TTT GGT AAA TTT
IL18BP-M65 T>C CTG GAC TGT CTC CCA GCA TCT CCA CAG CCT TGC CTC CAG CCT TGC TTC
TCT CAG AAA CC GGA GTT AGG CTG A CTG A
IL18BP-559 T>G GAG ACT CAT CTA CCA GCA TCT CCA CAG ACT GGG ATC ACT GGG ATC GCT
GTT CAT ACC CTA GGA GTT AGG TCT AAT AAT
GGT
IL18BP+3041 C>T CCC CAA CCC CAC CAC CTG CCA GAG ATG GGC CCT GTG ATG GGC CCT ATG
TCC TG GAT GCT TCT TCT
2.1.7 Sequencing
Sequencing was carried out using a modification of the dimethylsulfoxide chain term i­
nator method [Sanger and Coulson, 1975] in which chain terminating nucleotides are 
labelled with fluorescent dyes for automated detection. The DYEnamic ET Terminator 
kit (Amersham Biosciences UK Ltd., Buckinghamshire, UK) uses two dyes to label 
each dideoxy terminator; fluorescein and one of four different rhodamine dyes (rho- 
damine 110, rhodamine-6 -G, tetramethyl rhodamine, and rhodamine X). Fluorescein 
absorbs energy from the incident laser light and transfers it to the rhodamine acceptor 
dye on the same terminator molecule. Each acceptor dye then emits light at its charac­
teristic wavelength for detection, so identifying the nucleotide that terminated extension 
of the DNA fragment.
Protocol
Sample PCR Preparation Sequencing primer pairs were designed to flank the 
region of interest. Generally acceptable sequencing read-length tended to be around 
500 bp. Therefore if the area o f interest extended over 500 bp, overlapping primer pairs 
were designed to cover the entire region. A summary of the primer pairs used in this 
project are detailed in table 2.4 on the following page. Separate PCR product was gen­
erated for each primer pair as detailed in section 2.1.3 on page 69. The product was 
then visualized on an agarose gel to ensure that the product was of correct size and high 
enough quality to proceed. High stringency was placed on PCR quality as any ‘shadow- 
bands’ present would likely interfere with sequencing accuracy. If it proved impossible 
to produce a single product band for a particular primer pair, the band of interest was 
gel purified using the QIAquick Gel Extraction kit (Qiagen Inc., US) according to the 
manufacturer’s instructions.
Sequencing Reaction The DYEnamic ET Dye Terminator kit contains all dNTPs 
and ddNTPs needed, along with Thermo Sequenase DNA polymerase, and therefore 
simply requires the addition of template PCR, and sequencing primer. Typically the 
sequencing reaction comprised:
Template PCR 5 pi
10pmol/l F or R primer 0.5 pi
dH20 8.5 pi
14 pi
8 1
Table 2.4: IL18 sequencing primers used.
Primer Forward Reverse MgCl2
(mmol/1)
Annealing 
Temp (°C)
Cycles Product 
Size (bp)
IL1 <5-9731 seq GGT CAG TCT TTG CTA TCA 
TTC CA
TTC AGT GGA ACA GGA 
GTC CA
1.5 58 40 226
IL18-5S4S seq TTA AAG CAA AGA AAC 
ACG GAT G
CTA ATG TCT TCT CCA TTT 
TTC CCT A
1.5 58 40 200
IL18+105 seq CAA GAA ATT GAG TGT GCC 
TTT G
ATA GAG GCC GAT TTC CTT 
GG
1.5 58 40 284
7L7S+8855 seq TAG GCT GCA GTG AGC TGA 
GA
CTG GCC AAG CCT GGA TAT 
AG
1.5 63 38 267
IL18+11015 seq AGA GCG AGA CCC TGT 
CTC AA
CTC CCT GTC ATG GGA TGC 1.5 58 38 270
Based on the agarose gel, the proportions of template PCR:dH2 0  was adjusted to 
ensure that roughly equal amounts of PCR product was included in each reaction. Two 
separate sequencing reactions were carried out for each sample -  forward and reverse, 
so the target region is sequenced in both directions to improve accuracy. The mix was
Clean-Up -  Magnetic Separation The sequencing reaction is not cycled until 
completion, and therefore there remains a surplus of unincorporated fluorescent nu­
cleotides (along with excess primers and enzyme) that must be removed prior to elec­
trophoresis. The AMPure PCR Purification system (Agencourt Bioscience Corpora­
tion, Massachusetts, US) utilizes an optimized buffer to selectively bind PCR amplicons 
100 bp and larger to small microparticles. The paramagnetic beads are then captured by 
magnet, whilst all contaminants are washed from the sample. The beads are small and 
do not interfere with subsequent electrophoresis.
Initially 36 pi of AMPure bead mixture was added to the sample, and mixed thor­
oughly. The sample is then placed upon the SPRIPlate 96R magnet for 10 min to sep­
arate the beads from the sample and bring them out of solution. W hilst the sample 
remains upon the magnet, the cleared solution was aspirated and discarded. 2 0 0  pi of 
70% ethanol was added to the sample and incubated at room temperature for 30 s, this 
wash step was repeated twice more. Once washed the sample was taken from the m ag­
net and left to air-dry for 1 h. To elute the sample from the beads, 10 pi of MegaBACE 
loading solution was added and the sample thoroughly mixed.
Electrophoresis The MegaBACE 1000 DNA Analysis System (Amersham Bio­
sciences UK Ltd., Buckinghamshire, UK) is a high-throughput, fluorescence-based 
DNA system utilizing capillary-based electrophoresis in a 96-well plate arrangement 
-  6  arrays of 16 capillaries. The system uses high-pressure nitrogen gas to inject the 
capillaries with linear polyacrylamide (MegaBACE Long Read Matrix -  Amersham 
Biosciences UK Ltd., Buckinghamshire, UK), excreting the used acrylamide sim ulta­
neously. To load samples, a current is set up at the tip of the capillaries where it contacts 
the sample. DNA (and other charged particles in the sample) are electro-kinetically ‘in­
jected’ into the gel. Both ends o f the capillary are then placed in buffer (MegaBACE 
LPA Buffer), and a voltage applied across the capillary, moving the charged DNA frag­
ments through the matrix. Analogous to an agarose gel, the chain terminator fragments 
separate by size, effectively reading base by base along the target sequence. Typical run 
conditions for the sequencing protocol was 3 kV injection potential for 45 s, followed
then placed in a thermal cycler and the following program run:
95 °C 
50 °C 
60 °C
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by 100 min electrophoresis. Should the first run fail, a second run could be done with 
the same samples with a 3 kV, 100 s injection protocol.
As the fragments pass a window in the capillary a laser excites the fluorescein dye, 
which then passes energy to the rhodamine dye, causing it to emit at its particular fre­
quency. Therefore as the fragments pass, the typical ladder pattern forms from which 
the sequence can be read. The electrophoretogram from each dye is overlayed and in­
terpreted by Sequence Analyser (Amersham Biosciences UK Ltd.), with Cimarron 3.12 
base calling. Traces reading for the forward and reverse strands were compared m anu­
ally to improve sequence accuracy and confirm any potential polymorphisms found.
2.2 QPCR
Reverse transcription followed by PCR (QPCR) is the most suitable method for the de­
tection and quantification o f mRNA. It offers high sensitivity, good reproducibility and 
a wide quantification range. Below are detailed the laboratory methods and statistical 
tests used in this study.
2.2.1 PBMC Isolation
A common technique for separating PBMCs from whole blood is to mix the blood 
with a compound (Lymphoprep, Axis-Shield, Norway) that aggregates the erythro­
cytes, thereby increasing their sedimentation rate. The sedimentation of PBMCs is only 
slightly affected and can be easily removed from the upper phase of the tube. RNAlater 
(Ambion, US) was then used to stabilize and protect cellular RNA.
Approximately 16 ml of blood was drawn into two tubes (BD Vacutainer, NJ, US; 
K3E, 0.12 ml EDTA) and mixed with 8  ml phosphate buffered saline (PBS) (at 37 °C). 
6  ml of this mix was then carefully layered onto 3 ml of Lymphoprep in four separate 
15 ml Falcon tubes. This was then centrifuged at 2000 r/min for 30 min at room tem per­
ature. Following centrifugation the PBMCs form a distinct band at the sample/medium 
interface, and these cells were carefully removed using a Pasteur pipette into two 15 ml 
Falcon tubes. An equal volume of PBS was added to both tubes before they were cen­
trifuged at 1100 r/min for 10 min at room temperature. Following this centrifugation all 
steps were performed on ice to minimize RNA degradation. The supernatant was re­
moved from each tube before the PBMC pellets were resuspended in 100 pi PBS. 1 ml 
of RNAlater was added to each tube, and mixed before being transferred to a 1.5 ml 
Eppendorf tube. This mix was stored at 4 °C overnight. The PBMCs were then pelleted 
by spinning at maximum speed for 1 min in a microfuge, before removing the majority 
of the supernatant, leaving around 100 pi in which the pellet was resuspended. This was 
then stored at — 80 °C until further use.
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2.2.2 mRNA Extraction
Reagents
DEPC-Treated Water 1 ml diethylpyrocarbonate (DEPC ) 4 was added to 11 
dH 2 0 , and shaken vigorously to bring it into solution. The solution was then incubated 
for 12 h at 37 °C, before autoclaving to remove any traces of DEPC.
Protocol All materials were handled with gloves, and surfaces and pipettes cleaned 
thoroughly with RNase Zap (Ambion Inc., Austin, US), a detergent that completely 
removes RNase contamination from glass and pipette. mRNA was isolated using the 
RNeasy kit (Qiagen, Crawley, UK) spin protocol. This uses a high-salt buffer system 
which allows up to lOOpg of RNA, longer than 200 bp, to bind to a silica-gel based 
membrane within a mini column.
The PBMC:RNAlater mix was thawed before spinning for 1 min at maximum speed 
to pellet the cells. The supernatant was removed and the pellet resuspended in 350 pi 
of lysis buffer (RLT buffer)-/3-mercaptoethanol (/3-ME) mix (1 0 pi /3-ME:l ml RLT 
buffer). 350 pi of 70% ethanol was added to the sample and the entire mix pipetted 
onto an RNeasy column. The column was placed in a 2 ml collection tube and spun in 
a microfuge at 10000 r/min for 15 s. All flow through was discarded, and 700 pi of the 
first wash buffer (RW 1 buffer) added to the column and spun through at 10000 r/min for 
15 s. The column was placed in a fresh collection tube and 500 pi of the second wash 
buffer (RPE buffer) was added and spun through at 10 000 r/min for 15 s. Flow through 
was discarded and the RPE wash repeated at 10000 r/min for 2 min. The column was 
dried by spinning at maximum speed for 1 min, before being placed in a fresh 1.5 ml 
collection tube. The RNA was eluted by addition of 50 pi of DEPC-treated water, and 
spinning at 10 000 r/min for 1 min. To improve yield and increase RNA concentration, 
the flow through was added back on to the column and spun again. The resulting sample 
was immediately divided into 5 pi aliquots, and stored at — 80 °C until use.
2.2.3 cDNA Synthesis
Protocol The concentration of mRNA was determined using a NanoDrop ND-1000 
Spectrophotometer. The NanoDrop ND-1000 has a unique sample retention system that 
requires only 1 pi of sample to be loaded for reading, allowing direct determination of 
RNA concentration. Therefore error due to dilution preparation is eliminated giving a 
more reliable and accurate measure than that given by cuvette-type spectrophotometers.
4DEPC is a strong but not absolute inhibitor o f RNases that inactivates by covalent modification o f  
the enzyme. Any traces must be com pletely removed as DEPC will also modify purine residues by 
carboxymethylation
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RNA absorbs at 260 nm, whilst protein at 280 nm, and salts, solvents, and other impuri­
ties (eg. carbohydrate) absorbs at 230 nm. Therefore 260:280 nm and 260:230 nm ratios 
give an idea of the overall purity of the sample, with values in the order of 2  consid­
ered highly pure. Ensuring that equal quantities of RNA enter the cDNA synthesis and 
subsequent processes is important, therefore NanoDrop measurements were made in 
triplicate to increase accuracy.
cDNA was generated for each RNA sample using the Superscript II Reverse Tran­
scriptase (Invitrogen, Paisley, UK), and all components were kept on ice during initial 
preparation. An aliquot of each sample was diluted appropriately in DEPC-treated wa­
ter to 1 0  pi, to be of equal quantity as all others. 2  pi of random hexamer primers (pd[N ]6  
-  lOOng/pl) were added to the sample along with 1 pi dNTP mix (10 mmol/1). The sam ­
ple was then heated to 65 °C for 5 min, and cooled briefly (10 s) on ice, before adding 
4 pi First-Strand buffer and 2 pi 0.1 mol/1 dithiothreitol (DTT)5. The sample was then 
heated to 42 °C for 2 min and then 1 pi of Superscript II reverse transcriptase added, 
before further incubation at 42 °C for 2 h. The enzyme was then heat-inactivated by 
heating to 70 °C for 15 min.
2.2.4 RNA Quantification
TaqMan QPCR uses the same chemistry and principles as TaqMan genotyping (see 
section 2.1.6 on page 76), with the exception that QPCR uses just a single FAM- 
labelled probe. To distinguish between remaining genomic DNA contaminants and 
cDNA copies of mature mRNA species, the probe for each gene of interest was de­
signed to span across introns and therefore will anneal only to the cDNA of interest. 
Forward and reverse oligonucleotides and the probe sequences were ordered and sup­
plied through the Applied Biosystems ‘Assay on Demand’ service (www.allgenes.com). 
All gene expression assays used are detailed in table 2.5 on the next page. As the PCR 
reaction continues, the relative quantities of the target gene between samples is con­
served. More FAM is released as cycle number increases, the level of fluorescence 
eventually reaching a threshold and rising above the background. Once established the 
relationship between cycle number (C) and fluorescence (Rn) describes a sigmoidal 
curve. The fractional PCR cycle at which the sample fluorescence crosses a particular 
threshold (Ct), is directly related to the initial concentration of the mRNA species. The 
fluorescence threshold was set automatically as the point at which all samples being 
measured for that target gene went into logarithmic growth. Using endogenous controls 
(housekeeping genes) whose levels remain stable between samples, it was possible to 
control for differing amounts of starting material, and its quality. Therefore compar­
isons between C t’s generated from different samples and experiments can be made.
5DTT is used in this instance to stabilize the reverse transcriptase
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Table 2.5: Commonly used TaqMan QPCR probes and Assay ID ’s.
Gene Assay ID Probe Sequence
1L18
IL18 A e\3
IFNy
UBC
GAPDH
BACT
Hs00155517_ml 
Hs01038787_ml 
Hs99999041 _m 1 
Hs00824723_ml 
Hs99999905_ml 
Hs99999903_ml
ATT TCC TTT AAG GAA ATG AAT CCT C 
AAT ACG CTT TAC TTT ATA GAA AAC C 
AAT TAT TCG GTA ACT GAC TTG AAT G 
GTG ATC GTC ACT TGA CAA TGC AGA T 
TTG GGC GCC TGG TCA CCA GGG CTG C 
TCG CCT TTG CCG ATC CGC CGC CGC CCG T
Protocol Freshly made cDNA product was used as a template for QPCR, with the 
following mix made for each well of a 384-well plate:
TaqMan Absolute QPCR ROX Mix 2.5 pi
cDNA 1 pi
Assay 0.25 pi
Sigma dH 20 1.25 pi
5 pi
Each cDNA sample was run in triplicate for each probe and each experiment trip­
licated on sequential days, thereby improving accuracy and decreasing any differences 
caused by pipetting or experimental error. Once assembled the plate was sealed with a 
clear plastic lid (ABgene, Surrey, UK), and spun briefly to collect all reagents. Data was 
collected by the ABI 7900HT TaqMan machine and recorded by SDS v2.1 software, as 
the sample underwent the following PCR protocol:
50 °C 2 min
95 °C 10 min
95 °C 15s
60 °C 1 min
x 40 cycles
2.3 Measurement of IL-18 and IL-18BP
Both IL -18 and IL -18BP were measured by Daniella Novick at The Weizmann Institute 
of Science, in Rehovot, Israel, using enzyme-linked immunosorbent assay (ELISA) 
methods.
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Figure 2.4: Cross-reactivity of IL -18BP isoforms with the IL -18BPa ELISA, taken from 
Novick et al. [2001].
2.3.1 IL-18
Total IL-18 was measured by a commercially available ELISA kit (MBL, Naka-Ku 
Nagoya, Japan), according to the manufacturer’s instructions.
2.3.2 IL-18BP
A sandwich ELISA for IL -18BPa (the most abundant isoform of IL -18BP [Novick et al., 
1999; Kim et al., 2000]) was developed by Novick et al. [2001], using two anti-rlL- 
18BP-His6 antibodies for capture and detection. There was no effect of IL -18 on the IL- 
18BP ELISA, at those concentrations seen in sera. The IL-18BP ELISA was tested with 
the three other IL -18BP splice variants, IL -18BPc gave a 10-fold lower signal compared 
with IL-18BPa, whereas isoforms b and d gave very low signal (see figure 2.4).
2.3.3 Calculation of fIL-18
The formation of the IL-18:IL-18BP complex can be thought of as a reaction between 
a receptor, R, and it’s ligand, L, with a 1:1 stoichiometry:
R +  L ^ R : L (2 .1 )
At equilibrium the concentrations of free ligand, free receptor and the complex is 
given by the law of mass action:
Kn  =  (2.2)
[R:L]
With the dissociation constant being a constant for this reaction. However, in this 
case we only know the original concentration of R, [R]o, and L, [L]o. The concentra­
tions of free R and L are given by:
[tf] =  [*]o- [ / ? :£ ]  (2.3)
and:
[L] =  [L ]o -[/? :L ] (2.4)
From this the concentration of complex R:L can be calculated by:
\ R - . L } = [R]o +  [L^ + Kd  +  ]J { W° + [LJ° + Kd)1 -  [*]„ ■ [L\o (2.5)
Therefore the concentration of free ligand (fIL-18) can be calculated by:
[L] =  [t ]0 - [ * : * . ] =  +  . / ( W o  +  M o  +  f t >)2 _  [ J l ]o . [L ]o ( 2 _6 )
2.4 Data Analysis Software and Resources
Detailed below are the numerous packages, tools, and resources used throughout this 
study.
2.4.1 Haplotype Inference
Haplotype information is an essential ingredient of data analysis when multiple loci are 
being used in a population genetics approach. Routine genotypes do not provide geno­
type phase (haplotype) information. This can be obtained to some degree, at increased 
expense, via genotyping of additional family members [Sobel and Lange, 1996]. Alter­
natively, a statistical method can be used to infer phase from genotype of linked loci.
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PHASE v2.1 One method for inferring genotype phase is via an implementation of 
maximum likelihood using the expectation-maximization (EM) algorithm [Excoffier 
and Slatkin, 1995; Hawley and Kidd, 1995; Long et al., 1995], however PHASE uses a 
Bayesian-based statistical method for reconstructing haplotypes from population geno­
type data. In direct comparisons [Stephens et al., 2001] PHASE has been shown to 
be more accurate than the EM algorithm, correctly reconstructing >80%  of the sample 
with a reduction in error rate of >50% .
Implementation PHASE is able to accept input genotypes in a variety of different 
formats, and is also able to accept missing data. As output it generates many different 
files with the main output file showing the haplotypes inferred and their counts, as well 
as suggesting the most likely haplotype pair for each individual.
Availability The latest version of PHASE is available from http://www.stat. 
washington.edu/stephens/software.html.
2.4.2 tSNP Selection
The pattern of LD varies across the genome [Reich et al., 2001], and studies suggests 
that discrete regions of high LD, haplotype blocks, exist that are characterized by re­
stricted haplotype diversity [Alper et al., 2006; Cardon and Abecasis, 2003]. In regions 
of high LD within these blocks, a reduced set of tSNPs may be selected to efficiently 
identify the common haplotypes [Johnson et al., 2001].
STRAM Given the haplotype structure of a population, STRAM optimizes the pre­
dictability of the common haplotypes by selecting potential tSNPs based on a statistic 
analogous to the usual coefficient of determination, R2. For a given set of true haplo­
types, a formal calculation of the squared correlation, R^, between the estimate haplo­
types (those inferred using the tSNPs being tested) and the true haplotypes can be made. 
The set of tSNPs that gives sufficiently high R^ (typically >0.95) across all common 
haplotypes is then selected and can be assumed to accurately ‘tag’ >95%  of the genetic 
variation present in the haplotypes.
Implementation Input data for STRAM can be either population genotype or 
haplotype data, as the program can also utilize an EM algorithm to estimate haplotype 
frequencies. However, as detailed in section 2.4.1 on the previous page, the accuracy 
of PHASE is greater than the EM algorithm so routinely STRAM input was haplotypes 
from PHASE and not population genotype data.
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The input file format in this case is a simple listing of binary haplotypes and their 
relative frequencies. An optional ‘rsq force in’ command allows the user to specify 
which SNPs must be included in the first tSNP set. The output file lists the tSNP set 
tested and the values for each haplotype for that test. The number of SNPs being 
tested rises incrementally and the most suitable (best improvement in Rfy SNP is chosen 
at each round.
The selection of the most suitable tSNP set is a decision taking into account a mini­
mum R^ threshold, and the balance of increases in Rjj via increases in number o f tSNPs 
(and the consequent decrease in genotyping efficiency). The exact sigmoidal relation­
ship between R^ and number of tSNPs differs greatly between genes and populations 
since it is derived from the nature of LD and population structure. Therefore, although 
tSNPs do appear to translate well between ethnic groups [Tenesa and Dunlop, 2006], it 
is considered best practice to derive ethnic group-specific tSNP sets; otherwise a spe­
cific tSNP set can be derived for cross-populational analysis [Howie et al., 2006].
Availability STRAM is freely available at http://www-rcf.usc.edu/~stram/.
BEST
Background Best Enumeration of SNP Tags (BEST) implements a different strat­
egy to tSNP identification than STRAM, using an exact algorithm-based method over 
the statistical approach used by the latter [Sebastiani et al., 2003].
The initial step is to convert the haplotype set into a binary form. SNPs that share the 
same binary representation, are termed binary equivalents. After the initial binary con­
version only one of the binary equivalents is taken forward in the algorithm. The algo­
rithm then searches for SNP subsets that together show within-set redundancy ( ‘deriv­
able’ SNPs). From each set, set-tSNPs are taken forward and then superset-SNPs can 
then be derived. Using this method ensures minimal tSNP numbers and no loss of 
information.
Implementation BEST runs through a graphical user interface (GUI), that re­
quires only one input file describing the allelic structure of the haplotypes identified. 
The results of the algorithm are presented in a schematic format showing the haplo­
types being interrogated and the result o f the algorithm for each SNP. A SNP labelled 
with an ‘X ’ is a derivable SNP, whilst a numbered label designates the first SNP in the 
haplotype to which that SNP is a binary equivalent. No label shown designates a tSNP.
Availability BEST is freely available at http://genomethods.org/best/.
91
Haploview
Background Haploview [Barrett et al., 2005] is designed to provide a com pre­
hensive suite of tools for haplotype analysis, providing marker quality statistics, LD 
information, haplotype blocks, population haplotype frequencies and single marker as­
sociation statistics in a relatively user-friendly format. Haploview also directly accepts 
genotype data ‘dumped’ from the HapMap website (see section 2.4.3).
Implementation Haploview accepts data in a variety of formats. Pedigree data 
can be loaded as either partially or fully phased chromosomes or as unphased diplo- 
types. The majority of the Haploview analysis in this study concentrated on LD calcu­
lations and therefore data input was in the form of unphased diplotypes.
The Haploview LD plot summarizes the extent and pattern of LD between the m ark­
ers. Data is presented as D ’ with the background colour denoting a scale of logarithm 
of odds (LOD) score.
Availability Haploview is available for download from http://www.broad.mit.edu/ 
mpg/haploview/.
2.4.3 Online Genomic Resources
UCSC Genome Browser The UCSC Genome Browser [Kent et al., 2002] provides 
an online portal to reference sequence and working draft assemblies for a large collec­
tion of genomes. The Genome Browser zooms and scrolls over chromosomes, showing 
a browser window that can be changed to display a number of different ‘tracks’ and 
annotations. Once a region or gene is selected annotated genomic sequence can be 
downloaded in a variety of formats.
Availability UCSC Genome Browser can be accessed at http://genome.ucsc.edu/.
The HapMap Project The goal of the HapMap project [HapMap, 2003] was to de­
termine the common patterns of DNA sequence variation in the human genome. The 
project is a collaboration between scientists and funding agencies from Japan, US, 
Canada, Nigeria, China and UK, with all of the information generated by the project 
being released into the public domain.
The project has genotyped over six million SNPs in a total of 270 samples: 90 (30 
trios of two parents and an adult child) Centre d ’Etude du Polymorphisme Humain 
(CEPH) samples; 90 Yoruban (West African) samples (YRI); 45 Japanese samples
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(JPT); and 45 Chinese samples (CHB). A high density of SNPs is needed to de­
scribe adequately the genetic variation across the entire genome. Initially the project 
genotyped 600000 SNPs spaced at approximately 5 kbp intervals with a minor allele 
frequency (MAF) of at least 5%. The LD was then analysed, and a hierarchical ap­
proach taken to ensure that regions of low LD were genotyped to a greater density (up 
to 1 kbp per SNP).
All data is now available online and can be downloaded either to a text file or can 
be downloaded to Haploview. The data browser is a searchable resource that shows 
genotyped SNPs and basic genome architecture, as well as a number of other possible 
tracks including dbSNP SNP, LD, and recombination rates, amongst others.
Availability The HapMap data can be accessed at http://www.hapmap.org/.
IIPGA The goal of the IIPGA is to discover and model the associations between nu­
cleotide sequence variations, primarily SNPs and insertion/deletion variations (Indels), 
in the genes of the innate immunity pathway in humans. The program has two phases, 
initially the candidate genes are re-sequenced in both European American and African 
American populations to gather allele frequencies and haplotypes. Second to this, the 
variants are then used in case:control association studies of airways disease. Therefore 
IIPGA is a useful resource for identifying the extent of genetic variation in a number 
of different inflammation-related genes. An extensive array of genotype data ranging 
from individual genotypes to PHASE-derived haplotypes or LD plots are freely avail­
able within the site.
Availability IIPGA data is freely available at http://innateimmunity.net/.
2.4.4 Comparative Genomics
VISTA Alignment of genomic sequence from different organisms is an increasingly 
powerful method in biology and has been used for many purposes. Comparative se­
quence analysis has enabled identification of regulatory regions [Dubchak et al., 2000; 
Loots et al., 2000], and coding exons [Batzoglou et al., 2000], using purely computa­
tional methods.
VISTA [Frazer et al., 2004] is a comprehensive suite of programs and databases 
for comparative analysis of genomic sequences, using the VISTA curve-based visual 
front-end to present multiple alignments. The program mVISTA uses three separate 
alignment programs to align up to 1 0 0  different sequences:
AVID works by recursively finding strong anchors from the collection of 
maximal matches in the sequences [Bray et al., 2003]
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LAGAN performs progressive pairwise alignments, guided by a phyloge­
netic tree [Brudno et al., 2003a]
Shuffle-LAGAN is able to find rearrangements (inversions, transpositions 
and some duplications) that are then aligned using LAGAN [Brudno 
et al., 2003b]
The results of these alignments are then visualized with VISTA.
Implementation Sequences are prepared in FASTA format with an annotation 
file that details the presence of genes, direction of their transcription and presence of 
exons. Once complete, the results of the alignment are presented as percentage identity 
against sequence position. The example shown in figure 2.5 on the next page shows a 
70 kbp alignment of four sequences: human/mouse in the upper pane, human/rat in the 
middle pane, and human/chimp in the lower pane. Those regions with greater than 75% 
sequence identity (arbitrarily considered to be of significance) within a sliding 1 0 0  bp 
window are highlighted in light pink. In this example there is near complete sequence 
identity between human and chimp, whilst little identity with mouse and rat, and human 
(although there are similar patterns of identity between them).
Availability Various generations of VISTA are available for use at http://genome. 
lbl.gov/vista.
2.4.5 Quantitative Data Analysis
Thesias Thesias is a statistical program that performs haplotype-based association 
analysis in unrelated individuals [Tregouet et al., 2004]. The program is based on a 
maximum likelihood model [Tregouet et al., 2002], and is linked to a stochastic ver­
sion of the EM algorithm (SEM) [Tregouet et al., 2004]. Thesias, therefore allows the 
simultaneous estimation of haplotype frequencies and of their associated effects on the 
phenotype of interest. Quantitative, qualitative and survival analysis can be carried-out 
as well as covariate-adjusted effects and interactions.
Implementation The input file is prepared with genotypes coded as ‘11’, ‘12’, 
‘22’ and ‘O’ for missing genotypes. The phenotype and covariates must have no missing 
data. The initial Thesias run must be a null run, allowing the algorithm to generate 
haplotypes, this information is stored in the ‘para.txt’ file which must be edited by the 
user to select which haplotype effects are to be tested.
The next run is then the analysis run, during which the phenotype and covariate 
variables are defined and specific analyses (homogeneity of allelic effects, additivity
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Figure 2.5: Example of VISTA output showing three alignments (mouse, rat and chimp) against a 7 0 kbp human reference sequence. Those 
sections with greater than 75% identity are shown in light pink ( ).
Output 2.1: Exam ple o f  Thesias output.
Haplotype Effects
(Haplotypic effect by comparison to the reference with its 95'/, Cl)
Estimation StError T-Test
Haplotype 4 21112 0.03232 0.042593 0.758888
Diff = 0.03232 [-0.05116 - 0.11581] p=0.447920
Haplotype 2 21222 -0.00728 0.033473 -0.217506
Diff = -0.00728 [-0.07289 - 0.05833] p=0.827814
Haplotype 5 22111 0.00704 0.493146 0.014284
Diff = 0.00704 [-0.95952 - 0.97361] p=0.988604
Haplotype 6 11112 -0.07791 0.196738 -0.396000
Diff = -0.07791 [-0.46352 - 0.30770] p=0.692105
Haplotype 3 11111 -0.05036 0.039056 -1.289473
Diff = -0.05036 [-0.12691 - 0.02619] p=0.197234
Intercept 1 12111 1.760565
Haplotype 7 12222 0.00000
0.063524
Global Standard Error 0.168511 
Residual Standard Error 0.151306
Expected Phenotypic Mean [95*/, Cl] According to Estimated Haplotypes 
12111 1.76057 [1.63606 - 1.88507]
21222 1.75328 [1.64173 - 1.86484]
11111 1.71020 [1.57112 - 1.84928]
21112 1.79289 [1.65210 - 1.93368]
22111 1.76761 [0.79573 - 2.73949]
11112 1.68266 [1.28125 - 2.08406]
of effects etc.) selected. Once complete, Thesias generates a file containing the re­
sults from the analysis. The first part details the number of individuals used in the 
analysis, the allele frequencies and the estimated haplotype frequencies under linkage 
equilibrium and disequilibrium. The second section then details the haplotype effects, 
covariate adjustment and estimated haplotypic means. All haplotype effects are tested 
against a reference (Intercept 1) -  the most common haplotype (see output 2.1).
Thesias assumes additivity of haplotype effects, ie. that the effect of a haplotypic 
pair hahb compared to the reference hoho is equal to the sum of their haplotype effects, 
b(ha) +  This assumption can be tested in Thesias and allows a greater understand­
ing of the nature of the haplotype effect. Thesias also provides the log-likelihood which 
allows the overall impact of haplotypes on the phenotype of interest, to be tested using 
the likelihood ratio test (LRT). The input for LRT is the log-likelihood provided by
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thesias without estimating haplotype effects (InLi), and with haplotype effects (lnL2 ):
LR =  2(lnLl - l n L 2) (2.7)
The likelihood ratio (LR) approximately follows a x 2 distribution, with the degrees 
of freedom (df) being the number of haplotypes studied. It is also possible to assess 
the degree of variation in the phenotype, explained by the haplotypes (R2). Using the 
residual standard error with (SEj), and without (SE2 ) estimating haplotype effects, R2 
can be calculated:
r 2  =  ' - © ) 2  ( 2 - 8 )
Availability Thesias is freely available at http://genecanvas.ecgene.net/ 
downloads.php?cat_id= 1 .
Arlequin Arlequin is a complete package of methods and statistical tests for ex­
tracting information on genetic and demographic features of a collection of population 
samples. In this study, Arlequin was used mainly to calculate the F statistic in multi- 
populational analysis.
Founder effects acting on different demes generally lead to subpopulations with 
allele frequencies that are different from the population as a whole. Furthermore these 
demes are smaller in size than the larger population; since allele frequency in each 
generation represents a sample of the previous generation’s allele frequency, there will 
be greater sampling error in these small populations. Therefore, genetic drift will push 
these smaller demes towards differing allele frequencies.
The decline in heterozygosity due to subdivision within a population (see table 2.6 
on the next page) can be quantified using an index known as W right’s F statistic (also 
known as the fixation index). The F statistic is a measure of the difference between the 
mean heterozygosity among the subdivisions ( F I ^ )  in a population, and the potential 
frequency of heterozygotes if all members of the population mixed freely (HTotal) and 
takes the form:
HTotal ~  Hsub
F =  7j  (2.9)
**Total
F ranges from 0 (indicating no differentiation between the overall population and 
its subpopulations) to a theoretical maximum 1, though observed F ’s tend to be much 
less than 1 in highly differentiated populations. Both inbreeding and subdivision both 
lead to an apparent deficiency o f heterozygotes over Hardy-Weinberg expectations, thus 
nothing can be said about the cause of an observed deficiency without more information.
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Table 2.6: An example of the loss of heterozygosity of a single SNP in a divided popu­
lation.
P PP P<1 m
Freq. in subpop. 1 l4
1
16
3
8
9
16
Freq. in subpop. 2 34
9
16
3
8
1
16
Freq. in species 12
5
16
3
8
5
16
HW E freqs 12
1
4
1
2
1
4
Implementation Arlequin is able to support a broad range of input data types, 
including simple genotypes, DNA sequences, microsatellite data, and RFLP data. The 
result file describes the pair-wise F across all populations and its p value. The sig­
nificance of F is tested using a non-parametric permutation approach [Excoffier et al., 
1992], whereby individuals are permuted among populations or groups of populations. 
After each round, all statistics are re-computed to establish a null distribution (after 
1 0 0 0 + permutations).
Availability Arlequin is freely available at http://lgb.unige.ch/arlequin/.
MDR Analysis The multifactor dimensionality reduction (MDR) approach is a non- 
parametric alternative to logistic regression for detecting non-linear interactions among 
genetic and environmental factors. Essentially MDR is a data-mining tool that assesses 
the impact of grouping numerous genetic variables to produce high-risk or low-risk 
attributes. The effectiveness of this grouping is tested against a permuted null distribu­
tion.
Implementation For each MDR run the testing balanced accuracy (TBA) and 
cross-validation consistency (CVC) was recorded for the top-performing SNP com bi­
nation. Only 1-5 order interactions were considered. For each analysis, 10 separate runs 
were conducted on the same dataset using random seeds generated by www.random.org 
(a random number generator that uses atmospheric noise as its random source). To as­
sess the significance of each analysis, the program MDRperm was used to produce 
a null distribution of TBA and CVC by permuting individuals between classes. The 
average TBA from the 10 runs was then used to generate a p-value for each order of 
interaction.
Availability MDR and MDRperm are freely available from www.epistasis.org/ 
mdr.html.
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SPSS All data management and statistical analysis was study carried out using SPSS 
v 15 (SPSS Inc.).
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Chapter 3 
tSNP Selection
The aim of this chapter is to assemble tSNP sets for both IL18 and IL18BP, that mark 
gene-wide variation identified by IIPGA. Also, computational techniques will be used 
to identify important variation away from the immediate gene region that could be of 
importance in gene regulation.
3.1 Introduction
Traditionally, disease-causing genetic variations have been identified using family- 
based linkage analysis. However, it is now well-recognized that there are limitations 
to this approach when applied to complex diseases. For assessing the effect of risk fac­
tors on overall risk, a large study cohort is required. This allied with the observation 
that many complex diseases are late-onset, means there is great difficulty in collecting 
pedigrees with sufficient cases for linkage analysis. Therefore, studies are carried out 
in completely unrelated individuals, large numbers of parent-offspring trios, or case- 
siblings pairs.
Such studies rely upon LD to identify genes or regions involved in disease sus­
ceptibility. They are also heavily reliant on the large-scale genotyping resources that 
have mapped LD and common SNP haplotypes across the genome (eg. HapMap). Such 
approaches operate under four primary assumptions:
1. An important fraction of susceptibility to disease may be explained 
by relatively modest effects of a small number of relatively common 
variants.
2. Much of the causal variants are SNPs themselves, or are thought to 
arise or mutate at rates no greater than that at which SNPs tend to 
appear.
3. The rate at which SNPs or other variants arise and become common
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within the population are low enough that carriers today of a given 
common variant inherited this variant from a single ancestor.
4. Recombination rates are low enough that carriers of a common 
disease-related variant will also tend to carry a pattern of surrounding 
SNPs that reflects the SNPs that appeared on the ancestral chromo­
some locus surrounding the causal variant.
The most controversial of these assumptions is point 1; the common-disease 
common-variant hypothesis. It is possible that common disease could also be caused by 
there being many rare mutations that have large effects. However, the current knowl­
edge of patterns of common variation across the genome has tended to motivate studies 
along the earlier hypothesis.
Recombination adds to the number of haplotypes that exist in the population in 
a particular chromosomal region, and will also add to the uncertainty when genotyped 
SNPs are reassembled into haplotypes -  haplotype inference. However it is now becom­
ing clear that recombination does not occur equally and randomly across the genome, 
and that there is considerable local variation. Indeed it has been estimated that 50% of 
recombination occurs in less than 10% of the sequence [McVean et al., 2004]. This phe­
nomenon gives the genome a ‘haplotype block’ structure, with large regions (haplotype 
blocks) of little recombination (and consequently few haplotypes), interspersed with 
areas undergoing high rates of recombination -  recombination hotspots (see figure 3.1 
on the following page).
Denser and denser genotyping of a haplotype block tends to reveal fewer and fewer 
SNPs that split haplotypes. Almost always the observed maximum number of haplo­
types is considerably smaller than the theoretical maximum of non-recombinant haplo­
types. Such an observation is consistent with population genetics theory, in that, without 
recombination, only a fraction of haplotypes appearing as new mutations are expected 
to avoid random drift towards extinction.
Given this, and the assumption described in point 4, to test whether certain genetic 
variants within a region are associated with disease risk there is no need to genotype the 
actual causal variant, as other variants on the ancestral haplotype will act as a marker for 
the causal variant. To extend this further, there is no need to genotype all SNPs within 
a region to capture its total genetic variation, as many will prove redundant. Therefore, 
the redundancy in genetic variation at the candidate gene level, allows efficient (in time 
and cost) capturing of genetic variation using informative SNPs -  tSNPs. The methods 
used to select tSNP sets fall under two separate groups -  haplotype-tagging SNP selec­
tion and SNP-tagging SNP selection. As detailed in section 2.4.2 on page 90, the two 
programs used here exploit either one of these approaches.
101
£- 1000
Sperm analysis 
Population data
100
10
1
~o
to 0.1
0.01co
0 50 100 150 200
Position (kbp)
Figure 3.1: Local recombination rates from population genetic data and sperm analysis 
in the HLA region (adapted from McVean et al. [2004]).
3.2 tSNP Selection in IL18
As detailed in table 1.7 on page 6 6 , a number of SNPs had been discovered at the time of 
this analysis, with the most commonly studied being 7L7S-607 C >A , 7L7S-137 G >C , 
and 7L75+105 A >C . The resequencing consortium, IIPGA had also resequenced the 
IL18 region -  a total of 23.5 kbp from 2 kbp upstream to 1 kbp downstream. The IIPGA 
numbering is relative to the start of translation, and as such +105=+4860, -607=-9682, 
and -137=-9212.
3.2.1 IIPGA - The Ascertainment Panel
IL18 resequencing was carried out in Coriell DNA Samples from 23 CEPH individuals 
as well as an African-American sample, using standard PCR-based sequencing meth­
ods. The data was then freely available online as raw genotypes, and also as phased 
haplotypes (the data used here). As expected, the genetic variation within the African- 
American sample exceeded that of the European sample, and as the majority of the 
study groups upon which the tSNPs would be used were of European origin, this anal­
ysis was concerned with the European samples alone.
A total of 56 variants were found in IL18. When selecting for SNPs that had a MAF 
of >10% in the European samples, 31 SNPs were found within the IL18 region, and it is
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Table 3.1: The possib le tSN P sets identified by BEST. A ll sets are equivalent.
Potential set IIPGA SNPs
1 . -10373 -9731 -5848 -139
2 . -9731 -5848 -3987 -139
3. -9731 -5848 -139 +8855
4. -10373 -9731 -5848 +11015
5. -9731 -5848 -3987 +11015
6 . -9731 -5848 +8855 +11015
7. -10373 -9731 -139 +11015
8 . -9731 -3987 -139 +11015
9. -9731 -139 +8855 +11015
1 0 . -9731 -3987 -139 +8855
these SNPs that the IIPGA consortium took forward and used for haplotype inference, 
therefore forming the basis for tSNP selection here.
As can be seen from figure 3.2 on the next page, LD was extremely strong between 
many of the SNPs, and consequently the number of haplotypes was low (n=13), see 
figure 3.3 on page 105. O f the 13 haplotypes inferred, six were rare (estimated to occur 
only once in 46 chromosomes). Such rare haplotypes were excluded from analyses, and 
therefore seven haplotypes were taken forward as the data-set for tSNP analysis.
3.2.2 BEST and STRAM Analysis
BEST Analysis BEST was run with common (frequency >2% ) haplotypes inferred 
from resequencing data, using SNPs found in European individuals with MAF exceed­
ing 10%. The BEST output is shown in figure 3.4 on page 106. Analysis revealed that 
the minimum number of SNPs required to tag the haplotypes was four. The possible 
SNP combinations are shown in table 3.1.
It must be noted that, using the BEST analysis ILJ8+X05 (SNP23 in figure 3.4) 
is equivalent to tSNP2, as is 1L18-X51 (SNP5). Therefore by genotyping ILJ8+105, 
IL18-X37 is ‘captured’, and, according to BEST only a further three SNPs are needed 
to capture all common genetic variation within IL18. Furthermore, ILJ8-607  (SNP4 in 
figure 3.4) is equivalent to tSNP3.
STRAM  Analysis The results from analysis using STRAM can be seen in output 3.1 
on page 107. STRAM found that to mark all the genetic variation within the haplotypes, 
five SNPs were required, with four SNPs performing well but only marking 8 8 .6 % of 
the variation in one of the haplotypes (see figure 3.5 on page 108).
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Figure 3.2: Haploview LD plot of common (M AF>10% ) SNPs found in the IL18 region by IIPGA resequencing.
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Figure 3.3: Schematic of gene-wide haplotypes inferred from IIPGA genotyping. Common allele -  ■ ; rare allele -  ■ . Rare haplotypes not used 
for tSNP selection are shown in a lighter colour. ???? -  SNP with unknown position.
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Figure 3.4: Result from BEST analysis using common European haplotypes from IIPGA resequencing.
Output 3.1: STRAM output from IIPGA European samples, using common haplotypes 
inferred by IIPGA. SNPs are coded so that alleles present on the most common haplo­
type are 0 , and the alternative alleles are 1 .
B es t c h o ic e  o f 1 SNPS= 3
Hnuni H ap lo ty p e Prob CumProb V ar(H ap lo ) V ar(E (H IG )) R2
1 0000000000000000000000000000000 0 .3 2 5 0 0 .3 2 5 0 0 .43875 0 .19113 0 .4 3 5 6
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0 .34875 0 .11191 0 .3 2 0 9
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0 .02827 0 .1 2 9 3
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8 0 0 0 0 .21875 0 .03454 0 .1 5 7 9
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8 7 5 0 0 .13875 0 .0 1018 0 .0 7 3 4
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9 5 0 0 0 .13875 0 .01243 0 .0 8 9 6
7 0011000000000000000000000000000 
B in  RSQ* 0 .0 5 8 2
B e s t c h o ic e  o f 2 SNPS= 3 29
0 .0 5 0 0 1.0000 0 .09500 0 .00553 0 .0 5 8 2
Hnum H ap lo ty p e Prob CumProb V ar(H ap lo ) V ar(E (H IG )) R2
1 0000000000000000000000000000000 0 .3 2 5 0 0 .3250 0 .43875 0 .24896 0 .5 6 7 4
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0 .34875 0 .18072 0 .5 1 8 2
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0 .03683 0 .1 6 8 4
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8000 0 .21875 0 .05578 0 .2 5 5 0
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8750 0 .13875 0 .12105 0 .8 7 2 5
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9 5 0 0 0 .13875 0.07238 0 .5 2 1 7
7 0011000000000000000000000000000 
min RSQ= 0 .1684
B e s t c h o ic e  o f  3 SNPS= 1 3 29
0 .0 5 0 0 1.0000 0 .09500 0 .03217 0 .3 3 8 6
Hnum H ap lo ty p e Prob CumProb V ar(H ap lo ) V ar(E (H lG )) R2
1 0000000000000000000000000000000 0 .3 2 5 0 0 .3 2 5 0 0 .43875 0 .43875 1 .0000
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0.34875 0.18165 0 .5 2 0 9
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0.20331 0 .9 2 9 4
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8 0 0 0 0 .21875 0 .05607 0 .2 5 6 3
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8 7 5 0 0 .13875 0 .12331 0 .8 8 8 7
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9 5 0 0 0 .13875 0 .07319 0 .5 2 7 5
7 0011000000000000000000000000000 0 .0 5 0 0  
min RSq= 0 .2 5 6 3
B e s t c h o ic e  o f 4 SNPS= 2 3 9 25
1.0000 0 .09500 0 .0 3253 0 .3 4 2 4
Hnum H ap lo ty p e  
** * •
0000000000000000000000000000000
Prob CumProb V ar(H ap lo ) V ar(E (H |G )) R2
1 0 .3 2 5 0 0 .3 2 5 0 0 .43875 0 .42792 0 .9 7 5 3
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0 .34875 0 .33938 0 .9731
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0 .19854 0 .9 0 7 6
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8000 0 .21875 0 .20792 0 .9 5 0 5
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8750 0 .13875 0 .12937 0 .9 3 2 4
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9500 0 .13875 0 .12937 0 .9 3 2 4
7
min 1 
B es t <
0011000000000000000000000000000 
Rsq= 0.8860
c h o ic e  o f  5 SNPS= 2 3 9
0 .0 5 0 0  
13 25
1.0000 0 .09500 0 .08417 0 .8 8 6 0
Hnum H ap lo ty p e Prob CumProb V ar(H aplo) V a r(E (H |G )) R2
1 0000000000000000000000000000000 0 .3 2 5 0 0 .3 2 5 0 0 .43875 0 .43875 1 .0000
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0 .34875 0 .34875 1 .0000
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0 .21875 1.0000
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8 0 0 0 0 .21875 0 .21875 1 .0000
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8750 0 .13875 0 .13875 1 .0000
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9 5 0 0 0 .13875 0.13875 1 .0000
7
min 1
0011000000000000000000000000000 
Rsq= i . oooo
0 .0 5 0 0 1.0000 0 .09500 0 .09500 1.0000
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Figure 3.5: STRAM analysis on common European IIPGA haplotypes, showing an 
increase in minimum Rjt with the number of SNPs entered into the tSNP set.
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Output 3.2: STRAM output from IIPGA European common haplotypes, forcing in 
/L/tf-9731, -5848, +105, +8855, and +11015.
Hnum H ap lo ty p e Prob CumProb V ar(H ap lo ) V ar(E (H 1G )) R2
1 0000000000000000000000000000000 0 .3 2 5 0 0 .3 2 5 0 0 .43875 0 .43875 1 .0000
2 0111111011010010000010101010101 0 .2 2 5 0 0 .5 5 0 0 0 .34875 0 .33938 0 .9731
3 1000000110011001101101000111011 0 .1 2 5 0 0 .6 7 5 0 0 .21875 0 .20937 0 .9571
4 0011000010110100010000010010101 0 .1 2 5 0 0 .8 0 0 0 0 .21875 0 .21875 1 .0000
5 1000000110010000000001001010101 0 .0 7 5 0 0 .8 7 5 0 0.13875 0 .12937 0 .9 3 2 4
6 0111111011010011101110100111011 0 .0 7 5 0 0 .9 5 0 0 0 .13875 0 .12937 0 .9 3 2 4
7 0011000000000000000000000000000 0 .0 5 0 0 1.0000 0.09500 0 .09500 1 .0000
min RSQ= 0 .9324
Set Selection Neither BEST nor STRAM were in agreement over a single tSNP set to 
select, though each assigned importance to particular SNPs; SNPs 2 (-10373), 3 (-9731), 
9 (-5848), 25 (+8855), and 29 (+11015) were repeatedly chosen by each program. In­
deed, BEST identified /L /5-9731, -5848, +8855, and +11015 as a potential tSNP set. 
However, with this particular set neither /L /8-137 nor +105 (equivalent SNPs previ­
ously genotyped and potentially functional) are directly marked. Therefore, STRAM 
was used to ‘force in’ -9731, -5848, +105, +8855, and +11015 and assess how well they 
performed as a set. The results of this analysis are shown in output 3.2. With these five 
SNPs, over 90% of the common genetic variation in IL18 is captured, and it is this tSNP 
set that was used as the core IL18 tSNP set throughout the remainder of this work:
-9731 G > T rs 1946519
-5848 T > C rs2043055
+ 105 A >C rs549908
+8855 T > A rs360729
+ 11015 A >C rs3882891
3.2.3 tSNP Validation
Without genotyping all 31 SNPs from which the tSNP set is derived, there is no way 
to directly test how well the tSNPs mark variation within the study populations used 
here. However, if haplotype architecture and allele and haplotype frequencies match 
well, then it is reasonable to assume that the IIPGA sample and the study populations 
are fairly genetically homogenous. Therefore the tSNP set will mark genetic variation 
as efficiently as it did in the IIPGA sample set.
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Table 3.2: tSNP genotype data comparing 100 European CABG study subjects to 23 
European IIPGA samples. Comparison between MAFs carried out in Thesias.
SNP Count n (%) 
CABG IIPGA
p CABG vs. 
IIPGA
GG 36 (36.4) 4 (17 .4 )
-9731 GT 48 (48.5) 17(73.9) 0.087
TT 15 (15.2) 2(8 .7 )
MAF (%) 39.4 45.6 0.501
TT 37 (37.0) 10(43.5)
-5848 TC 49 (49.0) 9(39 .1) 0.691
CC 14(14.0) 4(17 .4)
MAF (%) 38.5 37.0 0.838
AA 38 (38.0) 8(34.8)
+ 105 AC 47 (47.0) 15(65.2) 0.094
CC 15(15.0) 0  (0 .0 )
MAF (%) 38.5 32.6 0.548
TT 39 (39.0) 8  (34.8)
+8855 TA 48 (48.0) 15(65.2) 0.125
AA 13(13.0) 0  (0 .0 )
MAF (%) 37.0 32.6 0.640
AA 28 (28.0) 5(21.7)
+11015 AC 51 (51.0) 16(69.6) 0.226
CC 2 1  (2 1 .0 ) 2(8 .7 )
MAF (%) 46.5 43.5 0.742
3.2.3.1 European Populations
To test the tSNP set and its efficiency in European samples, 100 European samples from 
the CABG study, were genotyped for the tSNP set and compared to IIPGA data. All 
genotype counts in CABG were in agreement with Hardy-Weinberg equilibrium (HWE) 
(p>0.05).
As can be seen from table 3.2, there were no significant differences in genotype 
counts, or allele frequency between the two groups. Furthermore, there were no signif­
icant differences in haplotype frequencies or architecture between the two samples sets 
(see table 3.3 on the next page). It can therefore be concluded that the tSNP set selected 
transfered well, and that with this tSNP set >90%  of the common genetic variation 
within IL18 can be captured in the study samples of European ancestry used here.
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Table 3.3: 1L18 haplotype (ordered -9731;-5848;+105;+8855;+l 1015) frequencies in 
100 European CABG study subjects and the European IIPGA samples. Haplotype fre­
quencies inferred in Thesias, using a binary outcome variable (IIPGA or CABG) to test 
for differences in frequencies between the two groups.
Haplotype Frequency (%) p CABG vs.
CABG IIPGA IIPGA
hGCATA h 1 2 1 11 28.3 30.3 —
hTTCAC h2 1 2 2 2 26.9 30.3 0.495
hGTATA hi 1 1 1 1 19.0 21.7 0.414
hTTATC h2 1 1 1 2 8 . 0 10.9 0.363
hTCATA h2 2 1 11 2 . 6 4.5 0.353
hGCCAC hi 2 2 2 2 5.0 2 . 2 0.579
3.2.3.2 African American Populations
The vast majority of the cohorts used in this thesis specifically recruited participants 
of Caucasian origin. However, these study groups included a minority of individuals 
o f African origin, therefore an appreciation of how well the tSNP set performs in this 
population was important. The IIPGA resequenced I LI 8 in both Europeans and 24 
Coriell Repository African Americans.
Applying the same selection criteria as used when selecting the tSNP set (SNP 
M A F>10% ), 30 SNPs were used to infer 8  common haplotypes (and 8  rare haplo­
types) by PHASE. All five tSNPs were common in the African American sample and 
therefore it was possible to ‘force in’ these SNPs in STRAM analysis. As shown in out­
put 3.3 on the following page, the tSNP set performed poorly in the African American 
sample. It successfully distinguished only one haplotype (hTTCAC), whilst R^ for the 
other seven haplotypes ranged from 0.065 to 0.813. To satisfactorily capture variation 
in all haplotypes, at least another three SNPs were required -  SNP24 (+9262), SNP25 
(+9583), SNP26 (IIPGA21446). These results imply that haplotype analysis in African 
Americans using this tSNP set would be under-powered, due to the great deal of genetic 
variation present within IL18 in Africa, to which these tSNPs are naive.
3.2.4 Identifying Important Variation Outside of the IL18 Region
The IL18 region resequenced by IIPGA stretches from 2 kbp upstream to 1 kbp down­
stream. Although this region covers the proximal promoter, it is possible that there are 
other elements, further upstream of IL18, that are important in determining gene reg­
ulation and expression. Because it is likely that these elements are conserved across 
species, the area further upstream of IL18 was investigated using Vista, a program that
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Output 3.3: STRAM output from IIPGA African Americans haplotypes. The first pass 
is the five tSNPs alone, the next four passes build on this set until R ^ = l.
Hnum H ap lo ty p e Prob CumProb V ar(H ap lo ) V ar(E (H 1G )) R2
1 000000001000100000000001000001 0 .3 9 9 8 0 .3 9 9 8 0 .47990 0.39036 0 .8 1 3 4
2 000000110000011011010000001000 0 .1501 0 .5 4 9 8 0 .25508 0 .13532 0 .5 3 0 5
3 000000000000001001000000101000 0 .0 9 9 6 0 .6 4 9 5 0 .17942 0 .05966 0 .3325
4 111111000100000100101010001000 0 .0 9 9 6 0 .7491 0 .17942 0 .17942 1 .0000
5 011000000011001001000100011110 0 .0 9 9 6 0 .8 4 8 7 0 .17942 0 .07919 0 .4 4 1 3
6 011000000011001001000000001000 0 .0 5 0 4 0 .8 9 9 2 0 .09576 0 .02028 0 .2 1 1 8
7 011000000011001001000100101000 0 .0 5 0 4 0 .9 4 9 6 0 .09576 0 .02028 0 .2 1 1 8
8 000000001000100000000000000001 0 .0 5 0 4 1.0000 0 .09576 0 .00621 0 .0 6 4 8
min RSQ* 0 .0 6 4 8
B es t c h o ic e  o f 6 SNPS* 2 9 21 
Hnum H ap lo ty p e
23 24 
P rob
27
CumProb V ar(H aplo) V ar(E (H |G )) R2
1
» • » ** *
000000001000100000000001000001 0 .3 9 9 8 0 .3 9 9 8 0 .47990 0 .47990 1.0000
2 000000110000011011010000001000 0 .1501 0 .5498 0 .25508 0 .13532 0 .5 3 0 5
3 000000000000001001000000101000 0 .0 9 9 6 0 .6495 0 .17942 0 .05966 0 .3 3 2 5
4 111111000100000100101010001000 0 .0 9 9 6 0 .7491 0 .17942 0 .17942 1.0000
5 011000000011001001000100011110 0 .0 9 9 6 0 .8487 0 .17942 0 .07919 0 .4 4 1 3
6 011000000011001001000000001000 0 .0 5 0 4 0 .8992 0 .09576 0 .02028 0 .2 1 1 8
7 011000000011001001000100101000 0 .0 5 0 4 0 .9 4 9 6 0 .09576 0 .0 2028 0 .2 1 1 8
8 000000001000100000000000000001 0 .0 5 0 4 1.0000 0 .09576 0 .09576 1 .0000
min RSQ* 0 .2 1 1 8
B es t c h o ic e  o f 7 SNPS= 2 9 21 
Hnum H ap lo ty p e
23 24 
P rob
26 27 
CumProb V ar(H ap lo ) V ar(E (H IG )) R2
1
• * * ** **
000000001000100000000001000001 0 .3 9 9 8 0 .3 9 9 8 0.47990 0 .47990 1.0000
2 000000110000011011010000001000 0 .1501 0 .5 4 9 8 0 .25508 0 .13532 0 .5 3 0 5
3 000000000000001001000000101000 0 .0 9 9 6 0 .6 4 9 5 0.17942 0 .05966 0 .3325
4 111111000100000100101010001000 0 .0 9 9 6 0 .7491 0 .17942 0 .1 7942 1 .0000
5 011000000011001001000100011110 0 .0 9 9 6 0 .8 4 8 7 0.17942 0 .17942 1 .0000
6 011000000011001001000000001000 0 .0 5 0 4 0 .8 9 9 2 0.09576 0 .04534 0 .4 7 3 5
7 011000000011001001000100101000 0 .0 5 0 4 0 .9 4 9 6 0.09576 0 .04534 0 .4735
8 000000001000100000000000000001 0 .0 5 0 4 1.0000 0 .09576 0 .09576 1.0000
min RSQ= 0 .3 3 2 5
B e s t c h o ic e  o f  8 SNPS* 2 9 21 23 24 25 26 27
Hnum H ap lo ty p e  
* * * *****
Prob CumProb V ar(H aplo) V ar(E (H IG )) R2
1 000000001000100000000001000001 0 .3 9 9 8 0 .3 9 9 8 0 .47990 0 .4 7 9 9 0 1 .0000
2 000000110000011011010000001000 0 .1501 0 .5 4 9 8 0 .25508 0 .24905 0 .9 7 6 3
3 000000000000001001000000101000 0 .0 9 9 6 0 .6495 0 .17942 0 .17339 0 .9 6 6 3
4 111111000100000100101010001000 0 .0 9 9 6 0.7491 0 .17942 0 .1 7942 1 .0000
5 011000000011001001000100011110 0 .0 9 9 6 0 .8487 0 .17942 0 .17942 1 .0000
6 011000000011001001000000001000 0 .0 5 0 4 0 .8992 0 .09576 0 .08972 0 .9 3 6 9
7 011000000011001001000100101000 0 .0 5 0 4 0 .9496 0 .09576 0 .08972 0 .9 3 6 9
8 000000001000100000000000000001 0 .0 5 0 4 1 .0000 0 .09576 0 .09576 1 .0000
min RSQ* 0 .9 3 6 9
B e s t ich o ice  o f 9 SNPS* 2 7 9 21 23 24 25 26 27
Hnum H ap lo ty p e  
* * * * *****
Prob CumProb V ar(H ap lo ) V ar(E (H IG )) R2
1 000000001000100000000001000001 0 .3 9 9 8 0 .3 9 9 8 0 .47990 0 .4 7 9 9 0 l . (
2 000000110000011011010000001000 0 .1501 0 .5 4 9 8 0 .2 5508 0 .2 5 5 0 8 l . i
3 000000000000001001000000101000 0 .0 9 9 6 0 .6 4 9 5 0 .17942 0 .17942 l . i
4 111111000100000100101010001000 0 .0 9 9 6 0.7491 0 .17942 0 .17942 l . l
5 011000000011001001000100011110 0 .0 9 9 6 0 .8487 0 .17942 0 .17942 l . i
6 011000000011001001000000001000 0 .0 5 0 4 0 .8992 0 .09576 0 .09576 l . i
7 011000000011001001000100101000 0 .0 5 0 4 0 .9 4 9 6 0 .09576 0 .09576 l . i
8 000000001000100000000000000001 0 .0 5 0 4 1 .0000 0 .09576 0 .09576 l . i
min RSQ* 1 .0000
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assesses sequence similarity across species.
The genomic sequence 10 kbp upstream of IL18, from human and mouse, was sub­
mitted to Vista. This region includes testis-expressed gene 12 (TE X ]2), which tran­
scribes away from IL18 and therefore shares the promoter region. There is currently 
no literature describing functional polymorphisms within the TEX 12 promoter. The 
resulting Vista plot for the IL18  gene and 10 kbp upstream, is shown in figure 3.6 on 
the next page. The plot shows no areas of significant sequence conservation between 
mouse and human, other than those in exonic regions and the area already resequenced 
by IIPGA. Therefore, with the absence of evidence suggesting areas outside of the im ­
mediate IL18 region that may be important in gene regulation, this study deals solely 
with genetic variation within, and immediately surrounding, the IL18 gene.
3.2.5 Evolutionary History of IL18
Having an understanding o f the process of haplotype evolution, ie. the ancestral haplo­
type and the interrelatedness of the other common haplotypes, can aid later data analysis 
IBardel et al., 2005], With an accurate tree of haplotype evolution haplotypes can be 
grouped according to common ancestors, and furthermore knowing how haplotypes re­
late to one another can help to assess likely functional variants for any haplotype differ­
ences seen. Therefore, to establish the ancestral IL18 haplotype, each tSN P’s genotype 
was ascertained in a panel o f primate samples. To establish the phylogenetic relation­
ship of the haplotypes, haplotypes present in the CABG study and 95 Ethiopians, were 
used.
3.2.5.1 Ancestral Haplotype
That polymorphisms found in human samples, are also polymorphic in primate popula­
tions is highly unlikely, as it is expected that the forces of genetic drift and selection will 
cause one or other of the primate alleles to become extinct. However, some forms of 
selection will protect genetic variation and increase the average lifespan of a polymor­
phism, possibly indefinitely. Collectively such forces are called ‘balancing selection’ 
and can arise by a number of causes [Asthana et al., 2005]:
Overdominance or heterozygote advantage The heterozygous form of 
the polymorphism has an advantage over either homozygous form.
This therefore often maintains a deleterious phenotype in the popula­
tion.
Frequency dependence An advantage is conferred by a rare feature; for 
example, mate preference for unique phenotype.
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Figure 3.6: Vista plot for IL18  and the region 10 kbp upstream. The plot compares human to mouse, and shows areas of significant conservation in 
both exonic (■ ) and non-exonic ( ) regions.
Variable environments If an organism occupies multiple environments, 
polymorphisms might be maintained in the population if the posses­
sion of either allele is advantageous in a different environment.
If balancing selection is strong enough then the lifetime of a polymorphism could 
be extended and observed in closely related species. To establish how common trans­
species polymorphisms were, Asthana et al. [2005] studied variation in several large 
chimp transcript datasets and aligned the variation onto dbSNP. They found eight trans­
species polymorphisms (out o f 1 x 104 identified human SNPs within the region), of 
which only three occurred at non-synonymous sites, suggesting that polymorphisms 
found in humans are very rarely seen in chimps.
Given that trans-species (chimp=>human) variation is extremely rare, and the lack 
of easily available chimp population cohorts, the tSNP sequence was established in 
a single member of a number of different primate species. The species used, and their 
phylogenetic relation to humans and each other are shown in figure 3.7 on the following 
page. Two members of each of the New World monkeys (golden headed lion tamarin 
and spider monkey), Old World monkeys (black ape and entellus langur), Hominidae 
(chimp and gorilla), and gibbon (lar gibbon and concolor gibbon) families were chosen 
as close relatives to the human.
Post-mortem primate blood samples (300 pi) were obtained from the London Zoo­
logical Society. DNA was extracted using the standard protocol, adjusted for sample 
volume. Genotyping was carried out by forward and reverse sequencing, with primers 
designed in regions of high hum anxhim p sequence conservation, using a hum anxhim p 
BLAT (Kent, 2002] alignment of the areas surrounding each tSNP. In all samples, DNA 
was of relatively low quality, making obtaining a strong PCR product difficult. How­
ever, sequence of reasonable quality was obtained for each of the tSNPs, although it 
was not possible to obtain sequence for all five tSNPs in a single sample. Given that it 
is highly likely that the polymorphism occurred long after humans and these primates 
shared a common ancestor, and that the chances of two independent variants occurring 
at the same genomic position is extremely small, it is satisfactory to take the genotype 
information from each sample and so form a composite haplotype. In doing so, the 
ancestral haplotype was found to be hTTATC.
3.2.5.2 Haplotype Phylogenetic Network
Due to various pressures on haplotype frequencies, the current haplotypes observed in 
the CABG cohort will not accurately reflect all haplotypes derived from the ancestral 
one. Therefore, in order to gain greater information on haplotypes derived from the an­
cestral haplotype, a sample of 95 Ethiopians was selected and analysed in tandem with 
the CABG samples genotyped above, giving a more accurate picture of the relationship
1 1 5
Figure 3.7: Phylogenetic tree of the primate samples used. Two members of the New 
World monkeys ( ■), Old World monkeys ( ), hominides (■ ), and gibbons (■ ) were 
chosen as close relatives to humans (■ ).
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Table 3.4: IL18  tSN P  gen otypes and frequency data for Ethiopian sam ples.
SNP Count n (%) HW E p
-9731
GG
GT
TT
MAF (%)
55 (57.9) 
34 (35.8) 
6  (6.3) 
24.2
0.809
-5848
TT
TC
CC
M AF (%)
12(13.3) 
39 (43.3) 
39 (43.3) 
35.0
0.651
+ 105
AA
AC
CC
M AF (%)
76 (81.7) 
17(18.3)
9.1
0.332
+8855
TT
TA
AA
M AF (%)
76(81.7) 
16(17.2) 
1 ( 1 -1) 
9.7
0.878
+11015
AA
AC
CC
M AF (%)
15(17.4) 
41 (47.7) 
30 (34.9) 
58.7
0.878
between the common haplotypes.
Genotypes for all five tSNPs were obtained for > 9 0 %  of the Ethiopian samples, the 
genotype and allele frequencies are shown in table 3.4. The genotype distribution for 
all SNPs was in agreement with a population in HWE. As expected there were major 
differences in allele frequencies between the Ethiopian and CABG samples, such obser­
vations will be explored in more detail elsewhere in this thesis. Haplotype frequencies 
for the Ethiopian sample were inferred using PHASE. The common haplotypes (>  1%) 
are shown in table 3.5 on page 119, and again, as expected, there were significant dif­
ferences in frequency between the Ethiopian and CABG samples.
Assessing haplotype frequency and architecture in two different population gives 
a more accurate picture of the haplotypes currently in existence. From this, and the 
primate data (that identifies the ancestral haplotype), it is possible to infer a haplotype 
tree that illustrates how each haplotype coalesces back to the ancestral. Haplotypes ap­
pear to be derived from two separate clades, with SNPs +8855 and +105 occurring in 
one clade and -9731, -5848, and +11015 occurring on the other. Two remaining haplo­
types, apparently not possibly formed by mutations on haplotypes alone, are seemingly 
formed by recombination events (see figure 3.8 on the next page). hTCATA appears to
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Figure 3.8: An inferred haplotype tree for IL18 common haplotypes. Structure is derived from common haplotypes in both Ehtiopian and European 
samples. Closed square (■ ) indicates same allele as ancestral haplotype, whilst open square (□ ) indicates variant allele. Haplotypes are ordered 
-9731 (■ ); -5848 (■ ); +105 ( ); +8855 (■ ); +11015 (■ ), and recombination events are indicated by dotted arrows.
Table 3.5: Common IL18 haplotype frequencies in an Ethiopian sample. Haplotypes 
are ordered -9731; -5848; +105; +8855; +11015 with 1/2 designation related to allele 
frequencies within the European populations.
Haplotype Frequency (%)
hGCATA h 1 2 1 1 1 38.3
hGCATC h 1 2 1 1 2 23.8
hGTATC hi 1 1 1 2 13.7
hTTATC h2 1 1 1 2 11 .1
hTTCAC h2 1 2 2 2 9.4
hTCATA h2 2 1 11 2.5
hTTAAC h2 1 1 2 2 1.1
be formed by recombination between the two clades (hTTCAC and hGCATA). The re­
maining haplotype, hGTATA is most likely formed by recombination between hGTATC 
and hGCATA.
3.2.6 Retrospective Analysis
The work detailed above was carried out in 2004. In the years since, the field has pro­
gressed and both PHASE and STRAM have undergone improvements, the implications 
of which are discussed below. Furthermore, the publication of significant associations 
between IL18 tSNP haplotypes and CHD risk (see section 1.4.1.3 on page 54, Tiret et al. 
[2005]) has necessitated an evaluation of the relationship between the two tSNPs set.
3.2.6.1 Analysis Using Newer Versions o f PHASE and STRAM
The tSNP set above was selected based on haplotypes inferred using PHASE v. 1 . Sig­
nificant improvements were made in later versions of PHASE, and therefore, as a better 
estimate of the tSNP set’s ability to mark variation, the tSNP set was assessed using 
haplotypes inferred with PHASE v 2 .1.
Inferring haplotypes using the same SNPs as those used in section 3.2.1 on page 102, 
PHASE v2.1 reconstructed 8  haplotypes of which two were rare (occurring on only 
one chromosome). When STRAM was run forcing in the tSNP set, the set performed 
fairly well marking four haplotypes completely. However, overall the minimum R^ was 
0.388, whilst another haplotype had an R^ of only 0.499 (see output 3.4 on the following 
page). With the addition of one other SNP, -1368 A >G , all haplotypes reached an Rj; 
o f 1. Using STRAM v2 had no effect on these results, returning the same results as 
those with STRAM v 1.
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Output 3.4: STRAM output from IIPGA European common haplotypes, inferred using 
PHASE v2 .1. The first pass is the result of forcing in the tSNP set, with the second pass 
building on this.
Hnum H ap lo ty p e  P rob  CumProb V ar(H ap lo ) Var(ECHIG)) R2
1 0111111001000010000010101000100 0 .3 1 8 0 0 .3 1 8 0 0 .43375 0 .43375 1.0000
2 0000000010010000000000000010001 0 .3 1 8 0 0 .6 3 6 0 0 .43375 0 .43375 1.0000
3 1000000100001001101101000101010 0 .1 1 4 0 0 .7 5 0 0 0 .20201 0 .10080 0 .4 9 9 0
4 0011000000100100010000010000100 0 .1 1 4 0 0 .8 6 4 0 0.20201 0.20201 1.0000
5 1000000100000001101101000101010 0 .0 9 1 0 0 .9 5 5 0 0 .16544 0 .06423 0 .3 8 8 2
6 0011000010010000000000000010001 0 .0 4 5 0 1 .0000 0 .08595 0 .08595 1.0000
min RSQ- 0 .3 8 8 2  
B es t c h o ic e  o f 6 SNPS- 3 9 13 23 25 29
Hnum H ap lo ty p e Prob CumProb V ar(H ap lo ) Var(E(H IG)) R2
1 0111111001000010000010101000100 0 .3 1 8 0 0 .3 1 8 0 0 .43375 0 .43375 1.0000
2 0000000010010000000000000010001 0 .3 1 8 0 0 .6 3 6 0 0 .43375 0 .43375 1.0000
3 1000000100001001101101000101010 0 .1 1 4 0 0 .7500 0.20201 0 .20201 1.0000
4 0011000000100100010000010000100 0 .1 1 4 0 0 .8640 0 .20201 0.20201 1.0000
5 1000000100000001101101000101010 0 .0 9 1 0 0 .9 5 5 0 0 .16544 0 .16544 1 .0000
6 0011000010010000000000000010001 0 .0 4 5 0 1.0000 0 .08595 0 .08595 1 .0000
min RSQ= 1 .0000
3.2.6.2 tSNP Relevance to Tiret et al. [2005]
The only study to have investigated the relevance of IL18 SNPs in CHD risk, found a 
significant association between one IL18 haplotype, hGCAGT, IL-18 levels, and CHD 
risk [Tiret et al., 2005]. The haplotypes were formed of 7L/5G-887T, C-105T, S35S, 
A+183G, and T+533C, equivalent to IIPGA SNPs -9731, -8949, +105, +11640, and 
+ 11990. When Tiret et al. [2005] SNPs were aligned onto haplotypes inferred (by 
PHASE v 2 .1) from IIPGA data, hGCAGT was found to be equivalent to the tSNP hap­
lotype hGTATA (see figure 3.9 on the next page). In this retrospective analysis using 
PHASE v2.1, hGTATA marked two, common, gene-wide haplotypes, along with one 
rarer haplotype. Tiret’s hGCAGT marked the same two common gene-wide haplo­
types as hGTATA, therefore hGTATA marked the very same genetic variation as Tiret’s 
hGCAGT does. In Tiret et al. [2005], hGCAGT was associated with lower production 
of IL-18 compared to the reference (most common) haplotype, hGCAAC. hGCAAC 
is equivalent to tSNP haplotype hGCATA, and hGCATA only. Therefore in conclu­
sion, while the tSNP set used here is distinct from that used by Tiret et al. [2005], the 
haplotypes derived from both sets are closely related and can be easily related to one 
another.
3.3 tSNP Selection in IL18BP
1L18BP tSNP selection was carried out by Carmel Stock at The Department of Im­
munology and Molecular Pathology, University College London. Genotyping data for
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Figure 3.9: The relationship between Tiret et al. [2005] haplotypes (fc) and the tSNP haplotypes used here (■ ). Both -9731 and +105 (+4860) 
were used by Tiret et al. [2005] and in this thesis. Haplotypes were inferred from IIPGA European samples, using PHASE v2.1.
all the SNPs within the gene, and the surrounding sequence both upstream (1.5 kbp) 
and downstream (3 kbp) to the next flanking genes (in total 8 . 8  kbp) were obtained for 
the CEPH population from HapMap (data release 18/phaseII) and IIPGA. The com ­
bined data set for all SNPs with M A F>0.05 was opened in Haploview version 3.0, and 
Tagger [de Bakker et ah, 2005] used to select a tSNP set, using pairwise tagging with 
a minimum R2 of 0.8. From a total of 31 eligible SNPs, three SNPs were selected and 
form the tSNP set used here:
3.4 Discussion
The results from this chapter demonstrate that with a panel of only eight SNPs, a sub­
stantial proportion of common genetic variation within the immediate genomic area of 
both 1L18 and 1L18BP, can be captured. For IL18, a total of 31 common European poly­
morphisms were found in the gene region. Using two subtly different approaches, the 
number of SNPs required to capture greater than 90% was reduced to just five. A total 
of 31 SNPs were also found within the IL18BP  region when including common Euro­
pean SNPs. Three tSNPs were isolated that captured greater than 80% of the genetic 
variation represented by the 31 SNPs.
For IL18, both BEST and STRAM returned results that shared a number of SNPs. 
The STRAM results suggested that a five-SNP set represented the start of a plateau 
in the number of SNP required to capture total genetic variation. By combining the 
results from both STRAM and BEST, a tSNP set was isolated that, when ‘forced in’ in 
STRAM, was shown to mark greater than 93% of the common variation in IL18.
To test this set, the five tSNPs were genotyped in 100 participants from the CABG 
study. As expected, the genotype and allele frequencies did not differ significantly 
from the IIPGA samples, furthermore the haplotype frequencies did not differ either. 
These results suggest that the individuals resequenced by IIPGA, and those recruited 
into the study groups used here, were genetically homogenous and therefore the tSNP 
set should translate well. However, it appears that certain inaccuracies in the initial 
haplotype inference have significantly weakened the strength of the tSNP set.
Using haplotypes inferred by a more recent version of PHASE, the tSNP set was 
found to perform poorly, capturing a minimum of 39% of the variation within the com ­
mon European haplotypes. However, only one more SNP was required to completely 
distinguish all of the the identified genetic variation -  -1368 A >G . The importance of
-1765 T > C  
-559 T > G  
+3041 C > T
rs3814721 
rs2298455 
rs 1541304
1 2 2
this in the results presented later will be discussed in the following chapters.
The region of the genome resequenced by IIPGA begins 2 kbp upstream of IL18  
and ends 1 kbp downstream of the gene. It is entirely possible that there are areas of 
the genome, outside of this region, that have a major effect on IL18  gene expression. 
Therefore comparative genomics was used to find regions of the genome, surround­
ing IL18, that have been conserved across species and therefore may contain important 
regulatory sequences. TEX12 is located 3 kbp upstream from IL18, and the genes tran­
scribe away from each other, therefore sharing immediate promoters. The only regions 
that appeared to be significantly conserved between humans and mouse, within the 
10 kbp region studied, were the exons of TEX 12. Without any evidence for important 
sequences in this region, the subject of this thesis relates to genetic variation found only 
in the immediate gene region.
To gain a greater understanding of the evolutionary relationship between the com ­
mon tSNP haplotypes, a haplotype network was formed using haplotypes seen in both 
European and African individuals. The starting point of the haplotype network was the 
ancestral haplotype, that was established using a number of primate samples. This an­
cestral haplotype was hTTATC, which was observed at relatively common frequencies 
(~  10%) in both European and African populations. Given the assumptions that a muta­
tion can only occur once and that recombination events were to be kept to a minimum, 
a haplotype network connecting each of the common haplotypes was drawn. In this 
scheme recombination events formed both hGTATA and hTCATA.
The origin of the recombinatory event that formed hGTATA is not clear from this 
data. That hGTATA is not evident in the Ethiopian sample could suggest that this event 
may have occurred following hum an’s migration out of Africa, however that one of the 
haplotypes involved, hGTATC, is not found in European populations could suggest that 
the event occurred in Africa but that hGTATA was subsequently lost, or that the event 
occurred outside of Africa but that hGTATC was subsequently lost. Without further 
study of African and Asian populations, this cannot be resolved.
The only other study to investigate IL18 whole-gene variation was that by Tiret et al. 
[2005]. They showed a significant association between a single haplotype and both IL- 
18 levels and CHD risk. Their tSNP was not identical to that selected here, but using 
the IIPGA data it was possible to show that there is good correspondence between the 
haplotypes they identified and those identified here.
In conclusion, in this chapter we have established a set of SNPs that allow whole- 
gene variation within both IL18 and IL18BP to be studied. The following chapters use 
this tool to assess the impact of variation within IL18 on IL-18 levels and individual 
risk for CHD and obesity.
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Chapter 4
Variation Within I  LI 8’s Impact on 
IL-18 Levels
The aim of this chapter is to assess the impact of genetic variation in 1L18 and 1L18BP , 
marked by the tSNP sets selected in the previous chapter, on levels of IL-18 and IL- 
18BP in a number of different studies. Given that in some studies both IL-18 and IL- 
18BP have been measured, it is possible to calculate the amount of fIL-18. Therefore 
any genetic variation, associated with differences in either IL-18 or IL-18BP produc­
tion, may also influence fIL-18 levels and so have pathological consequences.
4.1 Introduction
To fully take advantage of all genetic information held within the tSNP set, a number 
of new approaches, building on traditional statistical techniques, are needed.
4.1.1 Haplotype Association Analysis
In order to better characterize the role of genetic variation in the etiology of complex 
traits, full haplotypic information should be exploited. However, without family data, 
haplotypic information is not readily obtained, except from individuals homozygous at 
all loci, or heterozygous at only one. Therefore such information must be estimated, 
or inferred, and there has been a good deal of interest in developing statistical methods 
and algorithms for performing such analyses. One of the major algorithms used is the 
EM algorithm. A stochastic version of the EM algorithm, the SEM algorithm, was 
developed and shown to be computationally less burdensome and more appropriate in 
coping with missing data [Tregouet et al., 2004],
The SEM algorithm is an iterative procedure. At each iteration, an ambiguous hap­
lotype pair, considered as a type of missing data, is replaced by a simulated value drawn
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from a distribution, given the observed data and the parameters estimated from the pre­
vious iteration. The starting point for the algorithm is haplotype frequencies assuming 
linkage equilibrium, and then a stochastic-expectation step is carried out whereby the 
unobserved haplotypic pair of an ambiguous set of genotypes is set at a single draw 
from the distribution of compatible haplotype pairs. Following this, the maximization 
step updates the haplotype frequencies given the pseudo-observed haplotypes, and takes 
these into another stochastic-expectation step. The result is that, after a sufficiently 
long ‘burn-in’ period, the haplotype distribution reaches stationarity, and therefore the 
estimated haplotype frequency is simply the mean of the frequency in this stationary 
distribution [Tregouet et al., 2004],
To perform association analysis, the end haplotype distribution is associated with 
the phenotype, assuming an equal contribution of each haplotype in the haplotype pair 
(additivity), and a normal distribution to the trait. This therefore yields haplotype ORs, 
or haplotypic means, for the phenotype. Assessments of significance are carried out 
using a t-test comparing each haplotype to the reference haplotype (the most common 
haplotype) [Tregouet et al., 2002].
In simulation studies, the bias o f haplotype frequencies was negligible in large sam ­
ples, whatever the number of polymorphisms involved and the true haplotype frequency. 
However, rare haplotype (<2% ) determination became challenging, especially as the 
number of polymorphisms increased, since the number of compatible haplotypes as­
sociated with the genotypic data also increased. The same conclusions could also be 
drawn for the estimation of haplotypic effects, with these being most accurate in large 
samples (n = 1 0 0 0 ) with common haplotypes, and slightly less accurate in moderate sam ­
ples (n=400) when the ORs are associated with rare haplotypes. Overall the SEM algo­
rithm performed well and was more trustworthy than alternative approaches [Tregouet 
et al., 2004].
4.1.2 Searching for Epistasis
It is inevitable that to understand the genetic susceptibility to common human disease, 
such as CHD, the possibility of gene-gene interactions (epistasis) must be considered. 
Indeed, epistasis is arguably a ubiquitous component of the genetic architecture of dis­
ease susceptibility [Moore, 2003].
Epistasis exists both as a statistical and biological phenomenon. Biological epistasis 
is the result of interactions between biomolecules within gene regulatory networks in 
an individual, such that the effect of a gene is dependent on one or more other genes. 
In contrast, statistical epistasis is a mathematical observation, where the relationship 
between genotype and phenotype is not predictable solely considering the single geno­
type. It is the fusion o f these two forms of epistasis that is at the basis of systems
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Table 4.1: Penetrance values of genotypes for two SNPs exhibiting interactions in the 
absence of independent main effects.
AA (0.25)
SNP1 
Aa (0.50) aa (0.25)
Margin
penetrance
BB (0.25) 0 1 0 0.5
SNP2 Bb (0.50) 1 0 1 0.5
bb (0.25) 0 1 0 0.5
Margin penetrance 0.5 0.5 0.5
biology, and has much promise for the future.
The importance of statistical epistasis is best illustrated using a simple penetrance 
function, detailing the probability of disease, given a genotype. The example shown in 
table 4.1 details an extreme model whereby two SNPs, in linkage equilibrium, interact 
such that neither SNP alone has a main effect, but when only Aa or Bb, but not both, 
are present are subjects at high risk o f disease (p= 1). Otherwise individuals are at low 
risk (p=0). The margin penetrances show that these do not differ between single SNP 
genotypes [Moore and Williams, 2005].
4.1.2.1 Assessing Epistasis with MDR
As the evidence for statistical epistasis in complex disease research increases, a number 
of statistical tools have been developed to characterize this phenomenon. The MDR 
approach has identified significant epistasis in a number of diseases including hyper­
tension and TIIDM [Moore and Williams, 2005]. MDR is a nonparametric data-mining 
alternative to logistic regression for identifying nonlinear interactions among discrete 
genetic variations and environmental factors. With MDR, multilocus genotypes are 
pooled into high-risk and low-risk combinations, thereby reducing the dimensionality 
of the genotype predictors (attributes) from n dimensions to one dimension. This new 
multilocus genotype attribute can then be evaluated to see how well it predicts disease 
status [Moore et al., 2006].
A schematic of the MDR process is illustrated in figure 4.1 on the next page. The 
first step is to randomly split the sample into ten, forms the training set and ^  the 
testing set. The training set is used to classify each genotype combination as either 
low- or high-risk depending on the ratios of cases and controls that are present in that 
genotype combination (model), compared to the total ratio of cases to controls. This 
analysis is repeated ten times to use each possible testing set. For each genotype com bi­
nation, TBA and CVC are reported. The TBA is the mean of sensitivity and specificity 
(as shown in equation (4 .1) on the following page, where TP is true positives, FN -false
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Figure 4.1: A Schematic of the M DR approach in identifying SNP:SNP interactions.
negatives, TN -true negatives). TBA assesses the performance of each model in the 
testing set, while the CVC is the number of times a particular combination of loci is 
identified as a high-risk combination in each testing set. The data presented here is of 
the SNP combination which produces the highest TBA in each run.
T B A  _  ('T P /{TP + F N )+ TN /(TN + TP ))
2 (4.1)_  sensitivity+specificity 
— 2
To assess the magnitude and significance of TBA, the status of cases and controls in 
the sample can be permuted 1000 times and therefore a distribution for TBA and CVC 
for each genotype combination can be formed.
Although, at present the M DR approach appears to be of great promise, the results 
are difficult to interpret. If a strong main effect is present then it is difficult to understand 
the contributions o f other polymorphisms, and if there are multidimensional interactions
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then there is no way to assess the importance of each SNP, and how they interact. Also, 
MDR assumes that there is no genetic heterogeneity. If there is genetic heterogeneity 
within cases, and if the nature of epistasis differs between these groups then the MDR 
method can fail to find the correct models [Manuguerra et al., 2007J.
4.1.3 The Study Samples Used
A number of different study samples were used to assess the impact of the identified 
variation in IL18.
4.1.3.1 CABG
The CABG cohort comprises 439 patients recruited prospectively from those undergo­
ing first time elective coronary artery bypass surgery between October 1999 and July 
2003 [Brull et al., 20011. Non-fasting venous blood samples were initially drawn be­
fore surgery and then again 6  h and 24 h post-operatively, with some patients also having 
samples taken at 72 h. These were immediately centrifuged and plasma was separated, 
aliquoted and frozen at —20 °C until analysis. Aspirin was routinely omitted 10 d before 
surgery, and those with evidence of a preexisting inflammatory state (infection, active 
arthritis, or malignancy), active unstable CHD, or concurrent use of anti-inflammatory 
agents other than aspirin (including steroids), were excluded. All operations were per­
formed by only four experienced senior surgical staff who followed standard operating 
procedures. Perioperative anticoagulation with heparin was reversed after surgery with 
the use of protamine sulfate. At recruitment, a 5 ml EDTA sample of peripheral blood 
was drawn, from which DNA was extracted by use of the salting out method (see sec­
tion 2.1.1 on page 6 8 ). W ritten informed consent was obtained from all participants. 
IL-18 and IL-18BP was measured by Daniella Novick (Weizmann Institute of Science, 
Israel) using a commercially available ELISA (MBL Co. Ltd.) and a novel ELISA 
method [Novick et al., 2001], respectively (see section 2.3 on page 87). The IL18  tSNP 
set was genotyped using RFLP, whilst the IL18BP tSNPs was genotyped using TaqMan 
protocols. IL - 6  and CRP were measured by Gordon Lowe, Department of Medicine, 
University of Glasgow, using a standard commercial assay (R&D Systems) and a BN 
Prospec (Dade Behring) respectively.
4.1.3.2 NPHSII
The second Northwick Park Heart Study (NPHSII) is a large prospective study of 
healthy middle-aged (50-61 yr) men from nine UK general practices, totalling 3052 
men [Miller et al., 1996]. The study has been ongoing for 15 yr and men were followed- 
up throughout the study for CHD events. All men with a history of unstable angina, MI,
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CBVD, life-threatening malignancy, or regular medication with aspirin or anticoagu­
lants were excluded. A fasting blood sample was taken upon enrollment, and baseline 
characteristics and demographic information was obtained by means of a questionnaire 
completed at entry to the study. IL-18 and IL-18BP was again measured by Daniella 
Novick using the same methods as above. Both IL18 and IL18BP  tSNPs were geno­
typed using TaqMan protocols. CRP was measured using a commercial assay (Cordia 
High Sensitivity CRP) by Dave Howarth, Wolfson Institute, St. Bartholomew’s Hospi­
tal, London.
4.1.3.3 CUDAS
The CUDAS cohort was a random electoral roll sample of 1111 subjects (558 men and 
553 women) aged 27-77 yr from Perth, Western Australia [McQuillan et al., 1999]. 
Subjects who had previous carotid artery surgery were excluded. A self-administered 
questionnaire was used to record a history of smoking, hypertension, hyperlipidemia, 
diabetes, angina, MI, stroke, or a family history of premature-onset MI or stroke by 
age 55 yr in first degree relatives. Anthropometric measurements and the lower of two 
BP measurements recorded. W ritten informed consent was obtained from all study 
participants. A fasting blood sample was obtained from each subject, and IL-18 was 
measured at the University of Western Australia by ELISA (MBL Co. Ltd.). The I LI 8 
tSNP set was genotyped using TaqMan.
4.1.3.4 CUPID
The Carotid Ultrasound in Patients with Ischaemic Heart Disease Study (CUPID) was 
collected in Perth, Western Australia, in 1995, and consisted of 556 predominantly male 
subjects, 26-60 yr, with CHD. All subjects were medically stable at the time of data 
collection but had a history of angina, unstable angina, or MI and angiographically 
demonstrated CHD with at least one coronary vessel with >5%  stenosis [McCaskie 
et al., 2006]. IL-18 was measured at the University of Western Australia by ELISA 
(MBL Co. Ltd.). The IL18 tSNP set was genotyped using TaqMan protocols.
4.1.3.5 SCARF
The Stockholm Coronary Artery Risk Factor Study (SCARF) is a case-control co­
hort of survivors of a first MI before 60 yr, who were admitted to the coronary care 
units (CCUs) of three hospitals in the northern part o f Stockholm. Exclusion criteria 
were TIDM, renal insufficiency, any known chronic inflammatory disease, drug addic­
tion, psychiatric disease, or inability to comply with the protocol. For each postinfarc­
tion patient a sex- and age-matched control was recruited from the general population 
of the same catchment area [Eriksson et al., 2004]. Venous blood samples were drawn
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in the morning after a 1 2  h fasting period, and immediately centrifuged with aliquots of 
plasma stored at — 80 °C until use. IL-18 was measured by Per Eriksson, A therosclero­
sis Research Unit, Karolinska Hospital, using a commercially available ELISA (R&D 
systems Inc.). Both IL - 6  and CRP were also measured at the Atherosclerosis Research 
Unit using a commercially available ELISA (R&D Systems) and the BN system (Dade 
Behring) respectively. The IL18 tSNP set was genotyped using TaqMan.
4.2 Results
4.2.1 Study Baseline Characteristics
As can be seen from table 4.2 on the next page, the six studies used here represent, 
in total, a cross-section of the European population. As expected, the studies us­
ing exclusively diseased individuals (CABG and CUPID) have a less favourable risk 
profile. Both CABG and CUPID participants have higher BMI, more diabetes, and 
higher triglycerides than the healthy/population-based cohorts (NPHSII and CUDAS), 
and were also, on the whole, older. Total cholesterol was lower in both CABG and 
CUPID than either CUDAS and NPHSII, although this is likely due to the pervasive 
use of cholesterol-lowering medication in these cohorts. The baseline characteristics in 
SCARF are those of both cases and controls; all variables are in the same range as the 
other studies, suggesting that comparisons are possible between the studies.
4.2.2 Single SNP Univariate Analysis
Raw IL -18 measurements from all populations used here were not normally distributed, 
therefore ln-transformation was carried out for both total IL-18 and fIL-18 so that para­
metric tests could be applied. Raw IL-18BP levels were also non-normally distributed 
and required a square root transformation for normality.
4.2.2.1 CABG
For measurements of IL-18 and IL-18BP in CABG, only those samples with sufficient 
plasma still available from baseline, 6 h, and 24 h were used (n=248). For these in­
dividuals who also had sufficient plasma from 48 h, measurements were made at this 
time-point also. The analysis presented in this chapter is based upon this subset.
IL-18 As can be seen from table 4.3 on page 132, all tSNPs were in HWE within 
the CABG subset and genotypes were ascertained for >99%  of all individuals for all 
tSNPs. IL-18 levels were significantly different by IL18-5848T>C  only, with levels 
higher in carriers of the C allele. This effect was observed at both baseline and 6 h, but
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Table 4.2: Baseline characteristics of the study groups used. Data is presented as geometric mean[95% Cl].
Variable CABG (491) NPHSII (3052) CUDAS (1109) CUPID (556) SCARF (774)
Males, %[n] 70.1 [344] 100[ 3052] 50.3[558] 87.6[487] 82.3[637]
Age (yr) 64[63-65] 56[56—56] 53[52—54] 50[50-50] 52[52—53 ]
BMI (kg/m2) 28.1 [27.6-28.6] 26.2[26.1-26.3] 26.1 [25.9-26.3] 28.2[27.9—28.5] 26.4[26.1-26.7]
SBP (mmHg) N D 1 137[136-138] 12 8 [127—129] 126[125-127] 128[ 127-130]
DBP (mmHg) ND 84[83—84] 80[79—81] 81 [80-82] 81 [80-82]
Diabetes, %[n] 15.9[78] 2.5[75] 2.1 [23] 15.8[88] ND
Past History of MI %[n] 30.8[ 151] 0 [0 ] 5.7[63] 61.3[341] ND
Cholesterol-lowering medication, %[n] 64.0[314] 0 [0 ] 6.8[75] 66.7[371 ] ND
Ever smoked, %[n] 64.4[316] 68.9[2104] 6.8[75] 72.8[406] 67.1 [520]
Total cholesterol (mmol/1) 4.5[4.4-4.6] 5.6[5.6—5.6] 5.6[5.5-5.7] 5.2  [ 5 .1 —5.3 ] 5 .2[5 .1-5.2]
LDL (mmol/1) 2.5[2.4-2.6] 1.8[1.8-1.9] 3.6[3.5-3.7] 3.2[3.1-3.3] 3.3[3.2-3.4]
HDL (mmol/1) 1 -2[ 1.2—1.3] 0 .8 [0 .8 - 0 .8 ] 1.3[ 1.3—1.3] 1 . 1 [ 1 . 1- 1 . 1 ] 1 .2 [ 1 .2 —1 .2 ]
Triglycerides (mmol/1) ND 1 .8 [ 1 .8 —1 .8 ] 1.3[ 1.3—1.3] 2 .0 [ 1 .9-2.1] 1.4[1.4-1.5]
1 No data
Table 4.3: G eom etric mean [95% C l] IL-18 levels by IL18  genotype, at baseline, 6 h , 2 4 h, and 48 h. G enotype com p leten ess and frequency data is
also provided.
tSNP (f/r 
types)
geno- Count. 9C[n] HW Ep Baseline p/ R2
(%)
6 h
IL-18[95% Cl] (pg/ml) 
p /R 2 24 h p/ R2 Count. %[n] 48 h p/ R2
-9731
(99.2)
GG
GT
TT
35.4(87]
46.7(115]
17.9(44]
0.58
222.5(161.7-306.3]
183.8(147.8-228.6]
179.9(123.0-263.2]
0.53/
0.7
461.8(401.3-531.6] 
391.5(334.9-457.7] 
443 3(351.2-559.6]
0.30/
1.1
220.4(165.7-293.2)
273.1(223.9-333.2]
267.7(189.9-377.3]
0.41/
0.9
44.1(26]
42.4(25]
13.6(8]
413.9(272.8-627.9]
503.7(361.6-701.6]
692.4(493.3-971.8]
0.34/
3.8
-5848
(100.0)
TT
TC
CC
35.9(89]
52.4(130]
11.7(29]
0.07
136.9(105.9-176.8]
229.0(186.9-280.7]
312.3(158.9-613.7]
0.0021 
6.3
344.8(289.8-410.3] 
469.2(413.0-533.0] 
523.7(408.5-671.4]
0.004/
5.0
235.0(180.9-305.3]
262.9(217.4-317.8]
266.6(159.9^444.4]
0.77/
0.3
25.4(15]
59.3(35]
15.3(9]
674.0(557.9-814.2]
459.8(335.8-629.5]
332.5(130.5-847.4]
0.14/
6.7
+ 105 
(99.6)
AA
AC
CC
47.0(116]
42.9(106]
10.1(25]
0.91
181.7(138.4-238.5]
212.8(168.5-268.8]
200.1(134.4-298.0]
0.67/
0.4
450.5(395.8-512.9]
404.8(342.0-479.1]
406.2(311.7-529.4]
0.56/
0.5
230.1 [ 182.6-289.9] 
285.5(233.8-348.7] 
229.2(129.3-406.5]
0.36/
1.0
55.9(33]
35.6(21]
8.5(5]
430.2(313.9-589.7] 
551.8(357.0-853.1] 
582.4(406.3-834.9]
0.54/
2.2
+8855
(99.2)
TT
TA
AA
45.1(111]
44.3(109]
10.6(26]
0.92
197.7(150.9-258.9] 
203.8(160.6-258.7] 
180.4(119.3-272.8]
0.91/
0.1
462.8(405.4-528.3]
401.5(341.0-472.6]
383.3(289.2-508.2]
0.31/
1.1
216.5(168.4-278.4]
302.3(250.6-364.6]
210.3(130.1-340.1]
0.08/
2.6
51.7(30]
39.7(23]
8.6(5]
420.0(297.5-592.9] 
535.2(360.2-795.3] 
617.1 (423.4-899.6]
0.50/
2.5
+11015
(99.2)
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CC
32.1(79]
48.8(120]
19.1(47]
0.91
206.4(145.2-293.3]
199.6(161.6-246.6]
188.7(131.5-270.7]
0.93/
0.1
486.8(419.6-564.6]
386.4(332.6-448.8]
445.1(356.4-555.8]
0.11/
2.0
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Figure 4.2: A boxplot of raw IL-18 levels by 7L/5-5848 T > C  genotypes at both baseline 
and 6  h in CABG. Line -  Median; Box -  75th to 25th percentile; o -  outlier (>1 .5  box 
lengths out of box); ★ -  extreme (> 3  box lengths out of box); whisker -  last value not 
an outlier.
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not at 24 h or 48 h. The effect at baseline was such that at baseline those with -5848 
CC genotype had mean IL-18 levels 128% greater than those with -5848 TT genotype. 
The effect appeared additive, since those with -5848 TC genotype had levels midway 
between the two homozygote groups, 67% higher than -5848 TT individuals. At 6 h, 
those with -5848 TC genotype, had levels 36% higher than those with TT genotype, and 
those homozygotes for the C allele had levels 52% higher than those homozygotes for 
the T allele (see figure 4.2 on the previous page). At 24 h, those with CC genotype tend 
to have higher levels than those with TT genotype, however this difference was slight 
(13.4%), and did not reach significance (p=0.77). At 48 h the pattern was reversed; the 
TT genotype was associated with higher IL-18 levels than the CC genotype, however 
this did not reach statistical significance (p=0.14). /L /S-5848 T > C  consistently ex­
plained the highest percentage of variance in IL-18 levels across all time-points, except 
24 h. None of the other genotypes showed consistent patterns across all time-points.
IL-18BP As shown in table 4.4 on the following page, all but IL18BP- 1765 T > C  had 
genotype frequencies in agreement with HWE. Comparing the expected vs. observed 
genotype counts showed fewer heterozygotes and more homozygotes than expected 
(TT-214 vs. 217; T C -30  vs. 24; C C -4  vs. 1). This tSNP was genotyped using Taq­
Man protocols, and the allelic discrimination plots showed good genotype separation 
suggesting this was not due to poor genotype discrimination. The CABG study is a 
heavily selected study containing patients of differing ethnicity, it is possible that these 
two factors have contributed to this deviation, however it is also possible that it is due 
to chance alone.
Each IL18BP  tSNP shows significant differences in IL-18BP levels by genotype 
group, but all at different time-points (see figure 4.3 on page 136). -1765 T > C  shows 
a significant association with IL-18BP levels at 48 h with heterozygotes having levels 
201% higher than TT homozygotes (p=0.005). At all other time-points, carriers of the 
-1765 C allele had consistently higher IL-18BP levels than TT homozygotes, however 
these differences were not significantly different. IL18BP-559  T > G  was associated 
with significant differences in IL-18BP levels at 24 h (p=0.009), with the effect seem­
ingly due to heterozygotes having higher levels than homozygotes. This pattern was 
consistent across all other time-points but did not reach statistical significance. Those 
patients heterozygous at IL18BP+3041 C > T  had 193% higher IL-18BP levels at 48 h 
than CC homozygotes (p=0.01), a pattern that was again consistent across all other 
time-points but did not reach statistical significance. On the whole each SNP explains 
very little of the variation in IL -18BP levels, except at 48 h where both -1765 and +3041 
explain >  1 0 %.
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Table 4.4: G eom etric m ean [95% C l] IL -18B P  levels by IL18BP  genotype, at baseline, 6 h , 24  h, and 48  h in C A B G . G enotype com p leten ess and
frequency data is a lso  provided.
tSNP (9c 
types)
geno- Count. 9c[n] H W Ep Baseline p/R2 6h p/R2
IL-18BP[95c/r Cl] (pg/ml) 
24 h p/R2 Count. %[n] 48 h p/R2
-1765
(98.8)
TT
TC
CC
88.6[217]
9.8(24]
1.6(4]
0.002
4783(4421-5159]
5162(4265-6145]
5142(1762-10289]
0.79/
0.2
2805(2532-3093]
2864(2188-3631]
3215(1945-4804]
0.92/ 
0.1
12943(12336-13565]
13712(11974-15569]
15827(9961-23046]
0.38/
0.8
85.0(51]
15.0(9]
0(0]
11480(10116-12931]
17199(13311-21585] 0.005/13.7
-559(98.8)
TT
TG
GG
77.9(190]
21.3(52]
0.8(2]
0.44
4772(4413-5144]
5069(4195-6026]
4264(0-56871]
0.75/
0.2
2748(2466-3045]
3079(2501-3717]
2370(208-6879]
0.57/
0.5
12600(11974-13241]
14815(13518-16170]
11925(3915-78945]
0.009/
3.9
81.7(49]
18.3(11]
0(0]
12157(10652-13763]
12940(9390-17058] 0.67/0.3
+3041
(98.4)
CC
CT
TT
95.1(233]
4.9(12]
0(0]
0.69
4798(4452-5158]
5379(4164-6750] 0.48/
0.2
2788(2531-3058]
2970(1996-4137] 0.76/<0.1
13004(12417— 13604]
14279(12076-16666] 0.37/0.3
90.2(55]
9.8(6]
0(0]
11709(10390-13106]
17769(12024-24634] 0.01/10.6
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Figure 4.3: Boxplots of the significant associations between 1L18BP tSNPs and IL-18BP levels in CABG (raw data shown).
Table 4.5: G eom etric mean [95%  C l] fIL -18 levels by IL18  and ILJ8BP  genotype, at baseline, 6 h , 24  h, and 48 h.
tSNP Baseline p/R2 6 h
flL -18(95% Cl] (pg/ml) 
p/R2 24 h p/R2 Count, %(n] 48 h p/R2
44.1(26]
42.4(25]
13.6[8]
161.5(105.2-247.9]
198.5[143.5-274.7]
226.3(162 .0-316 .1]
0.56/2.1
25.4(15]
59.3(35]
15.3(9]
255 .3(215.4-302.6]  
178.5[130.9-243.3] 
122.2(46.0-324.8]
0.13/7.0
55.9(33]
35.6(21]
8.5(5]
168.2(121.6-232.6]
203.9(133 .6-311 .2]
223.0[152 .1-326 .9]
0.66/1.5
51.7(30]
39.7(23]
8.6(5]
163.5(114.7-233.0]
203.4(138 .3-299 .2]
217.11154.0-306.3]
0.61/1.1
34.5(20]
50.0(29]
15.5(9]
144.3(87.1-239.0]
196.5(142.5-271.1]
243.9(196 .7-302 .4]
0.28/4.5
85.0(51]
15.0(9]
0(0]
180.7(136.7-238.9]
188.7(122.7-290.0] 0 .90 /< 0 .1
81.7(49]
18.3(11]
0(0]
190.9(144.4-252.6]
149.3(90.9-245.2] 0.42/1.2
90.2(55] 
1 9.8(6] 
0(0]
183.3(141.4-237.6]
163.5(90.0-297.3] 0.77/0.2
GG 133.7(97.3-183.8]
-9731 GT 105.9(85.4-131.1]
TT 110.3(76.6-159.7]
TT 83.7(64 .8-108 .2]
-5848 TC 133.9(109.4-163.9]
CC 175.2(90.5-339.3]
oc AA 108.4(82.6-142.2]
-J + 105 AC 123.2(98.2-154.6]
CC 123.6(83.4-183.0]
TT 118.0(90.2-154.4]
+8855 TA 117.7(93.1-148.7]
AA 112.4(75.5-167.4]
AA 123.3(86.9-175.0]
+11015 AC 114.8(93.2-141.4]
CC 117.8(82.9-167.4]
TT 119.3(101.7-140.0]
-1765 TC 84.1(38 .8-182 .4]
CC 199.1(5.9-6694.5]
Q,
oa TT 113.6(94.7-136.2]°o -559 TG 129.5(87.5-191.8]
2 GG 86.2(2 .1-3560 .0]
CC 120.2(103.1-140.2]
+3041 CT 60.3(15 .0-241 .4]
TT —
0.43/0.9
0.005/5.3
0.74/0.3
0 .98/< 0.1
0.93/0.1
335.8[290.
283.51243
323.6[251.
255.81214.
339.2(297.
364.11281.
332.8(292.
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84 .1(67 .0-105 .5]
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Figure 4.4: A boxplot of raw fIL-18 levels by 7L75-5848 T > C  genotypes at both base­
line and 6 h in CABG. Line -  M edian; Box -  75th to 25th percentile; o  -  outlier (>1.5 
box lengths out of box); * -  extreme (> 3  box lengths out of box); whisker -  last value 
not an outlier.
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fIL-18 As shown in table 4.5 on page 137 and figure 4.4 on the previous page, only 
IL18-5848 T > C  was significantly associated with differences in fIL-18 levels and ex­
plained the most of their variation (except at 24 h). At baseline, CC homozygotes had 
fIL-18 levels 109% higher than TT homozygotes. As shown in figure 4.4 on the pre­
ceding page, the effect appeared additive, with heterozygotes falling in between the 
two homozygote groups, having levels 60% higher than TT homozygotes (p=0.005). A 
similar effect was seen at 6  h, with CC homozygotes having levels 42% higher than TT 
homozygotes, whilst heterozygotes had fIL-18 levels 33% higher (p=0.02). At 24 h C 
allele carriers had higher mean fIL-18 levels than TT homozygotes, however the addi­
tive pattern seen at baseline and 6  h was disrupted. This additive pattern was reversed 
at 48 h, where TT homozygotes had levels higher than CC homozygotes, although this 
difference was not statistically significant (p=0.13).
Transitions IL-18 and IL-18BP, and therefore fIL-18, undergo dynamic changes in 
the 48 h following surgery (see figure 4.5 on the next page). To analyse such differences, 
the ratio of time-point:baseline was calculated and then log-transformed to achieve nor­
mally distributed data. The quoted values are geometric mean and 95% Cl.
IL-18 reaches its peak at 6 h, undergoing, on average, a 1.47(1.07-2.02] -fold 
change from baseline (p<0.001). In concert with a 0.49(0.40-0.60] -fold drop in IL- 
18BP levels (p<0.001), this causes flL -18 levels to undergo a 1.83(1.33-2.50] -fold 
rise from baseline (p<0.001). By 24 h, IL-18BP reaches it’s peak, 2.71(2.29-3.20] 
-fold higher than baseline, equivalent to an, on average, 10254pg/m l increase in pro­
tein production from 6 h to 24 h (2784=>13038pg/m l, p<0.001). With IL-18 levels, on 
average, decreasing from 6 h to 24 h (460.4=^251.6 pg/ml, p<0.001), fIL-18 therefore 
undergoes a large decrease by 24 h to levels below those at baseline (24 h vs. baseline, 
p=0.04). However a slight, but significant, decrease in IL-18BP levels from 24 h to 
48 h (p=0.02), causes flL -18 to rise slightly to levels that are not significantly different 
from those observed at baseline (p=0.97), despite both IL-18 and IL-18BP remaining 
at levels above those observed at baseline (p=0.01 and p<0.001, respectively). There­
fore, the IL-18 system was activated in the period immediately following surgery and 
reached its peak (in terms of peak fIL-18 levels) at 6  h. However, largely due to a highly 
significant activation of IL-18BP, levels of fIL-18 returned to baseline levels by 48 h. 
At 48 h, both IL-18 and IL-18BP levels remained elevated, and only with observations 
beyond 48 h would it be possible to see how long it took for these two proteins to return 
to pre-operative levels.
In assessing whether there were significant differences, by genotype, in the changes 
from baseline to peak for IL-18, IL-18BP, and fIL-18, no significant differences by 
1L18 or ILI8BP  tSNP were found (data not shown).
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Table 4.6: G eom etric m ean [95% C l] IL-18 levels by IL18  genotype in N PH SII.
tSNP (% genotypes) Count, %[n] H W E p IL-18 [95% Cl] 
(pg/ml)
P R 2
-9731 (91.0)
GG
GT
TT
42.3[164]
42.0(163]
15.7(61]
0.06
261.6(242.8-281.8]
246.5(229.1-265.1]
228.2(202.6-257.1]
0.15 1 . 0
-5848 (91.3)
TT
TC
CC
44.2(172]
42.7(166]
13.1(51]
0.28
226.3(210.5-243.3]
260.7(243.5-279.0]
295.7(257.4-339.8]
< 0 . 0 0 1 3.9
+ 105 (92.0)
AA
AC
CC
48.7(191]
41.6(163]
9.7(38]
0.71
252.6(235.7-270.7]
254.3(237.4-272.4]
218.5(184.4-259.0]
0.19 0 . 8
+8855 (88.5)
TT
TA
AA
49.3(186]
40.6(153]
10.1(38]
0.43
253.2(235.8-271.9]
255.4(237.5-274.6]
218.5(184.4-259.0]
0.19 0.9
+ 11015(92.3)
AA
AC
CC
36.6(144]
47.8(188]
15.5(61]
0.98
251.3(231.2-273.2]
249.3(233.6-265.9]
238.5(210.8-269.9]
0.77 0 . 1
4 .2 2 .2  NPHSII
IL-18 and IL-18BP levels were measured in 426 men from NPHSII, assembled as a 
nested case-control study. Plasma either from baseline (n=314), or if this was unavail­
able, after 1 yr of follow-up was used; neither IL-18 or IL-18BP differed significantly 
between baseline and 1 yr samples (p=0.14 and p=0.32, respectively), therefore the two 
sets were grouped.
IL-18 As in CABG, /L75-5848 T > C  was the only SNP significantly associated 
with differences in IL-18 levels (p<0.001, see table 4.6). The effect was additive 
with heterozygotes having mean IL-18 levels 34.4pg/m l higher than TT homozygotes 
(p=0.005), whilst for CC homozygotes this differences was 69.4pg/m l (p=0.001, see 
figure 4.6 on the next page). /L /S-5848 explained 3.9% of the variation in IL-18 levels 
whilst all other SNPs explained less than 1%.
IL-18BP As can be seen from table 4.7 on the following page, none of the IL18BP  
tSNPs showed significant associations with IL-18BP levels. However the ranking of 
genotypes by their mean IL-18BP levels is similar to that seen in CABG at baseline, 
with the heterozygote group consistently being associated with higher mean IL-18BP 
levels than the homozygote groups.
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Table 4.7: Geometric mean [95% Cl] IL-18BP levels by IL18BP genotype in NPHSII.
tSNP (% genotypes) Count, %[n] H W Ep IL-18BP(95% Cl] 
(pg/ml)
P R2
TT 92.9[367] 5620[5165-6096]
-1765 (92.7) TC 6.6[26] 0.05 6364[4669-8322] 0.27 0.7
CC 0.5[2] 2031 [416-4863]
TT 76.6[301] 5566[5069-6086]
-559 (92.3) TG 22.6[89] 0.19 6022[5059-7068] 0.69 0 . 2
GG 0.8[3] 4973[594-13612]
CC 97.5[384] 5629[5191-6084]
+3041 (92.5) CT 2.5[ 10] 0.80 6821 [2552-13147] 0.43 0 . 2
TT 0 [0 ] —
142
Table 4.8: Geometric mean [95% Cl] fIL-18 levels by IL18 and IL18BP  genotype in 
NPHSII.
tSNP flL -18[95% Cl] (pg/ml) P R2
-9731
GG
GT
TT
148.3(136.6-161.0] 
137.91127.0-149.7] 
134.6[118.5-152.9]
0.26 0.7
-5848
TT
TC
CC
132.2(122.1-143.1]
145.5(134.2-157.9]
164.0(142.7-188.4]
0.04 1 . 6
+ 105
AA
AC
CC
143.9(133.6-155.0]
142.3(130.8-154.7]
130.0(109.2-154.7]
0.51 0.3
+8855
TT
TA
AA
143.9(133.6-155.0]
142.3(130.8-154.7]
130.0(109.2-154.7]
0.53 0.3
+11015
AA
AC
CC
143.7(131.6-156.8]
140.1(129.7-151.3]
142.2(124.5-162.4]
0.80 0 . 1
-1765
TT
TC
CC
141.8(134.3-149.8]
141.2(115.5-172.8] 0.94 < 0 . 1
-559
TT
TG
GG
142.2(133.7-151.3]
141.6(128.0-156.6]
105.9(19.7-570.3]
0.60 0.3
+3041
CC
CT
TT
142.1(134.7-149.8]
130.1(82.2-206.0] 0.44 0 . 2
fIL-18 IL18-5848 T > C  was the only SNP associated with fIL-18 levels (see ta­
ble 4.8). The difference is such that CC homozygotes had levels 24% higher than TT 
homozygotes, and heterozygotes have levels 10% higher than TT homozygotes (see fig­
ure 4.6 on the preceding page). The level of fIL-18 across the genotype groups is in a 
similar, but blunted, pattern to that seen with IL-18 levels.
4.2.2.3 CUDAS
IL-18 levels and all five IL18  tSNPs were determined in the whole CUDAS sample. 
Data analysis was carried out by Pamela McCaskie (Laboratory for Genetic Epidemiol­
ogy, University of Western Australia) using SimHap. Three of the five ILI8  tSNPs were 
found to be out of HWE, with consistently fewer heterozygotes observed than expected. 
That the CUDAS is a random electoral roll samples argues against selection as a cause
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Table 4.9: G eom etric m ean [95%  C l] IL -18 levels by IL18 genotype in C U D A S .
tSNP (% genotypes) Count, %[n] HWE p IL -18(95% 
(pg/ml)
Cl] p
-9731 (99.9)
-5848 (99.7)
+ 105 (99.9)
+8855 (99.8)
+ 11015(99.9)
GG 36.8(407] 298.7(286.6-311.4]
GT 46.2(511] 0.19 299.0(288.0-310.4] 0.65 < 0 . 1
TT 17.1(189] 308.4(290.2-327.8]
TT 41.0(454] 286.5(275.5-298.0]
TC 45.7(505] 0.73 306.5(295.4-318.1] 0.003 0.9
CC 13.3(147] 324.3(302.8-347.3]
AA 48.5(537] 296.6(286.0-307.5]
AC 40.3(447] 0.04 303.5(291.7-315.8] 0.57 < 0 . 1
CC 11.2(124] 307.4(285.1-331.5]
TT 48.8(540] 297.1(286.6-308.0]
TA 40.0(443] 0 . 0 2 304.1(292.1-316.6] 0.42 < 0 . 1
AA 11.2(124] 303.7(281.4-327.7]
AA 34.8(386] 295.1(282.7-308.0]
AC 45.8(508] 0.04 301.7(290.8-313.1] 0 . 6 6 < 0 . 1
CC 19.3(214] 307.8(290.5-326.1]
of this disequilibrium. That fewer heterozygotes than expected were observed strongly 
suggests that it is due to poor heterozygote group discrimination, a common problem 
with TaqMan genotyping. It is likely therefore that the assigned genotypes are accurate, 
and that of those undetermined samples it is most likely that proportionally more were 
heterozygotes.
Only 7L78-5848 T > C  was significantly associated with IL-18 levels (p=0.003, see 
table 4.9), with C allele carriers having higher IL-18 levels than TT homozygotes. The 
effect appeared additive, with CC homozygotes having levels 13% higher than TT 
homozygotes (p=0.002), and heterozygotes having levels 7% higher (p=0.01). Over­
all, none of the SNPs explained large proportions of the variance in IL-18 levels (all 
SNPs<0.9% ), yet -5848 T > C  explained more than the other SNPs (0.9% vs. <0.1% ).
4.2.2.4 CU PID
This analysis was carried out by Pam McCaskie. As shown in table 4.10 on the follow­
ing page, both 7L7S-9731 G > T  (p=0.02) and +11015 A > C  (p=0.01) were significantly 
associated with differences in IL-18 levels. In both cases the effects had additive pat­
terns, with the rare allele associated with higher IL-18 levels. 7L7S-5848 T > C  was not 
globally associated with differences in IL-18 levels in CUPID, but those heterozygous 
at -5848 had borderline significantly higher IL-18 levels (p=0.05). As in CUDAS, none
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Table 4.10: G eom etric m ean [95% C l] IL-18 levels by IL18  genotype in C U PID .
tSNP (% genotypes) Count, %[n] HWE p IL-18[95%
(pg/ml)
Cl] p R"
-9731 (99.6)
-5848 (99.1)
+ 105 (99.6)
+8855 (99.5)
+ 11015(99.6)
GG 32.5[180] 322.5(304.1-342.0]
GT 50.9(282] 0.30 335.5(320.1-351.6] 0 . 0 2 1 . 0
TT 16.6(92] 372.4(342.9-404.5]
TT 39.2(216] 324.0(307.0-342.1]
TC 48.3(266] 0.35 348.4(331.8-365.8] 0.13 0.4
CC 12.5(69] 330.1(300.2-363.1]
AA 44.6(247] 334.3(317.9-351.7]
AC 46.9(260] 0.06 338.2(321.8-355.4] 0.89 < 0 . 1
CC 8.5(47] 343.9(305.9-386.5]
TT 44.3(245] 332.4(316.0-349.6]
TA 47.2(261] 0.05 339.4(323.1-356.5] 0.79 < 0 . 1
AA 8.5(47] 343.9(305.9-386.5]
AA 31.0(172] 314.4(296.1-333.9]
AC 52.5(291] 0.08 343.2(327.6-359.5] 0 . 0 1 1 . 2
CC 16.4(91] 362.7(333.8-394.1]
of the SNPs explained a large proportion of the variance in IL-18 levels (all SN Ps< 1.2).
4.2.2.5 SCA RF
The IL18 tSNP set was genotyped in the SCARF cohort, and only 7L7S-5848 T > C  was 
found to be associated with significantly different IL-18 levels (p<0.001, see table 4 .1 1 
on the next page). The association appeared additive, with CC homozygotes having lev­
els 18% higher than TT homozygotes (p<0.001), whilst in heterozygotes the difference 
was 11% (p=0.001). When the cohort was divided into cases and controls the asso­
ciation was significant in cases only (controls-p=0.13; cases-p<0.001). Although the 
difference between CC homozygotes and TT homozygotes in controls was borderline 
significant (p=0.06, see figure 4.7 on page 147).
4.2.3 Single SNP Multivariate Analysis
In selecting covariate sets across each study, care was taken to select appropriate vari­
ables that could be used across studies and that were biologically plausible. As such, 
four models were selected, each building on the previous covariate set:
M odel 1 Sex and age
M odel 2 Sex, age, smoking and statin use
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Table 4.11: G eom etric m ean [95% C l] IL-18 levels by IL18  genotype in SC A R F.
tSNP
geno­
types)
(% Count, %[n]
Total study (n=774)
H W E p 1L-18[95% Cl] 
(pg/ml)
p/ R2 Count, %[n]
Controls (n=387)
IL-18(95% Cl] 
(pg/ml)
p /R 2 Count, %[n]
Cases (n=387)
IL-18(95% Cl] 
(pg/ml)
p /R 2
-9731
(98.4)
GG
GT
TT
35.8[273] 
47.5[362] 
16.7[ 127]
0.71
273.7[261.0 -287 .0 ] 
278.9[267 .7-290 .6] 
270.2[255 .0-286 .3]
0.66/
0.1
35.8[ 138] 
49.7[ 192] 
14.5[56]
259.3(243 .7-275 .9]
268.5(254 .8-283 .0]
280.6(254 .4-309 .6]
0 .39/
0.5
35.9(135]
45.2(170]
18.9(71]
289.3(269 .4-310 .8]
291.7(273 .5-311 .0]
262.5(244 .6-281 .8]
0.14/
1.1
-5848
(98.3)
TT
TC
CC
38.4[292] 
47.8[364] 
13.8[ 105]
0.62
2 56 .8 [246 .1-268.1] 
284.0[272 .8-295 .7] 
3 0 2 .6 [281.7-325.0]
< 0 .0 0 1 /
2.5
39.5[ 152] 
47.8[ 184] 
12.7[49]
256.0(241 .4-271 .4]
270.7(256 .9-285 .3]
286.6(256 .6-320 .1]
0 .13/
1.1
37.2(140]
47.9(180]
14.9(56]
257.7(241 .9-274 .6]
298.9(281 .1-317 .9]
318.1(289 .7-349 .3]
< 0 .0 0 1 /
4.5
+ 105 
(98.6)
AA
AC
CC
44.3[338] 
44.6[340] 
11.1[85]
0.97
276.2[264.4—288.4]
278.2[267 .2-289 .6]
262.8[244 .5-282 .5]
0 .46/
0.2
4 3 .8 [169] 
46.6[ 180] 
9.6[37]
260.5(246 .3-275 .6]
274.8(260 .4-290 .0]
257.8(228 .4-291 .0]
0.35/
0.6
44.8(169]
42.4(160]
12.7(48]
293.3(274 .6-313 .2]
282.0(265 .3-299 .8]
266 .7(243 .4-292 .3]
0.31/
0.6
+8855
(98.6)
TT
TA
AA
44.4[339] 
44.3[338] 
11.3[86]
0.90
276.2[264 .4-288 .4] 
278.3[267 .3-289 .8] 
262.5 [244.4-281.9]
0.43/
0.2
44.0[170] 
46.4[ 179] 
9.6[37]
260.5(246 .3-275 .6]
274.8(260 .4-290 .0]
257.8(228 .4-291 .0]
0.33/
0.6
44.8(169]
42.2(159]
13.0(49]
293.3(274 .6-313 .2]
282.3(265 .5-300 .2]
266.0(243 .2-290 .9]
0.29/
0.7
+11015
(98.7)
AA
AC
CC
33.8[258] 
46.7[357] 
19 .5[149]
0 .20
270 .6[257.8-283 .9]  
279.9[268.4—2 9 1.9] 
273.9[259 .7-288 .8]
0 .54/
0.2
33.3[ 129] 
50.4(195] 
16.3[63]
257.8(241 .7-274 .9]
269.3(255 .5-283 .8]
278.7(254 .8-304 .7]
0 .34/
0.6
34.2(129]
43.0(162]
22.8(86]
284.2(264 .5-305 .4]
293.7(274 .4-314 .2]
270.5(253 .1-289 .1]
0.28/
0.7
1000 H
750 -
O)
CL
oo
5 0 0 -
2 5 0 -
p<0.001
p=0.001
p=0.06 O
p=0.16
©
8 ©
IL18-5848 T>C
Figure 4.7: A boxplot of raw SCARF IL -18 levels by IL18-5848 T > C  genotype in both 
cases and controls. Line -  Median; Box -  75th to 25th percentile; o -  outlier (>1.5  box 
lengths out of box); * -  extreme (> 3  box lengths out of box); whisker -  last value not 
an outlier.
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Model 3 Sex, age, smoking, statin use, IL-6 , and CRP
Model 4 Sex, age, smoking, statin use, IL-6 , CRP, and IL-18/IL-18BP 
(where appropriate)
As the IL18BP  tSNPs failed to show any consistent associations across studies, they 
were not included in multivariate analysis.
4.2.3.1 CABG
The associations between 7L7S-5848 T > C  and both IL -18 and fIL-18 at baseline and 
6 h remain across all four models (see table 4.12 on the next page). That adjustment for 
both IL - 6  and CRP do not attenuate the associations suggests a degree o f independence 
for IL -18, from these inflammatory pathways.
4.2.3.2 NPHSII
As NPHSII is a strictly male cohort, model 1 contains age only as a covariate, and statin 
use was an exclusion criteria in NPHSII, and so this variable has been excluded from 
model 2. Furthermore, IL - 6  levels have not been measured in NPHSII, therefore it can 
not be included in model 3.
As can be seen in table 4.13 on page 150, the associations between 7L7S-5848 T > C  
and both IL -18 and fIL -18 levels, were not significantly attenuated by covariate adjust­
ment. As in CABG, adjustment for CRP only very slightly attenuated the association, 
suggesting that IL -18 is not regulated by such inflammatory pathways.
4.2.3.3 CUDAS
Multivariate analysis was carried out by Pam McCaskie, and therefore the models used 
above were not applied. In this case, IL -18 levels were adjusted for age, sex, pres­
ence of hypertension, HDL, W THR, and Alcohol consumption. These factors did not 
significantly attenuate the association between 7L7S-5848 T > C  and IL -18 levels (see 
table 4.14 on page 150).
4.2.3.4 CUPID
Multivariate analysis was carried out by Pam McCaskie, and therefore, as in CUDAS, 
the models used in the other studies were not applied. In CUPID, IL -18 levels were 
adjusted for age, sex, BMI, LDL, and triglycerides. As shown in table 4.15 on page 150, 
the associations between 7L7S-9731 G > T  and +11015 A > C  were not attenuated by 
adjustment for traditional CHD risk factors.
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Table 4.12: P values from m ultivariate analysis o f  IL -18 and fIL-18 levels by IL18 genotype in C A B G .
Model 1 Model 2 Model 3 Model 4
sex and age Model 1 + smoking, and statin use Model 2 + IL-63, and CRP Model 3 + IL-I8BP
SNP Baseline 6 h 24 h Baseline 6 h 24 h Baseline 6 h 24 h Baseline 6 h 24 h
-9731 0.39 0.15 0.59 0.54 0.14 0.58 0.39 0.26 0.39 0.37 0.26 0.34
tVi -5848 0 . 0 0 1 0 . 0 0 2 0.72 0 . 0 0 2 0.003 0.70 0.005 0.004 0.54 0.008 0.004 0.54
1 + 105 0.74 0.40 0.47 0.70 0.25 0.51 0.85 0.17 0.37 0.87 0 . 1 2 0.37
J +8855 0.89 0.23 0.09 0.94 0.16 0.14 0 . 8 8 0.08 0.30 0.84 0.06 0.30
+11015 0.82 0.07 0.29 0 . 8 6 0.06 0.33 0 . 6 6 0.23 0.52 0.73 0.23 0.51
-9731 0.33 0.18 0.60 0.51 0.18 0.63 0.35 0.27 0.29 __4 — —
QO -5848 0.004 0 . 0 1 0.49 0.005 0 . 0 2 0.45 0.009 0.007 0.52 — — —
+ 105 0.79 0.26 0.59 0.76 0.14 0 . 6 6 0.87 0.09 0.36 — — —
c +8855 0.96 0.26 0.15 0.95 0 . 1 2 0 . 2 2 0.83 0.05 0.29 — — —
+11015 0.84 0.08 0.40 0.93 0.06 0.47 0.75 0.25 0.48 — — —
3For IL-6, CRP and IL-18BP, the covariates match the dependent variable, ie. in baseline IL -18 analysis, baseline IL-6, CRP, and IL-18BP are used, whilst for 6 h  analysis, 
measurements made at 6 h were used as covariates
4As fIL-18 is derived from IL-18BP, model 4  was not used in fIL-18 analysis
Table 4.13: P values from multivariate analysis o f  IL -18 and fIL -18 levels by IL18
genotype in N PH SII.
SNP
Model 1
age
Model 2
Model 1 + smoking
Model 3
Model 2 + CRP
Model 4
Model 3 + IL-18BP
-9731 0.19 0 . 2 2 0.43 0.56
oo
-5848 0 . 0 0 1 0 . 0 0 1 0 . 0 0 1 0 . 0 0 2
1 + 105 0 . 2 1 0 . 2 2 0.43 0.54
J-J +8855 0 . 2 1 0 . 2 2 0.46 0.56
+11015 0.80 0.81 0.85 0.92
-9731 0.24 0.28 0.76 —
oo -5848 0.04 0.05 0.05 —
J + 105 0.49 0.50 0.77 —
C +8855 0.51 0.52 0.78 —
+11015 0.81 0.85 0.87 —
Table 4.14: P values from multivariate analysis of IL -18 levels by IL18 genotype in 
CUDAS.
IL-18 multivariate analysis
SNP Adjusted for age. sex. presence of hyperten­
sion, HDL, WTHR. and Alcohol consump­
tion
-9731 0.82
-5848 0.003
+ 105 0.71
+8855 0.82
+ 11015 0.44
Table 4.15: P values from multivariate analysis of IL-18 levels by IL18 genotype in 
CUPID.
IL-18 multivariate analysis
SNP Adjusted for age, sex, BMI, LDL, and
triglycerides
-9731 0.01
-5848 0.19
+ 105 0.95
+8855 0.84
+ 11015 0.03
150
4.2.3.5 SCARF
No data for statin use or IL-18BP levels were available in SCARF, therefore model 
2 was adjusted accordingly and model 4 was not used. The associations previously 
identified in univariate analysis remained in multivariate analysis (see table 4.16 on the 
next page), with the association between 7L/5-5848 T > C  identified in the total cohort 
significantly stronger in cases than in controls. Interestingly, the association of -5848 
and IL-18 levels in controls was stronger in multivariate analysis (p=0.13=>0.06).
4.2.4 Haplotype Univariate Analysis
Haplotype analysis was limited to the four most common haplotypes in each study.
4.2.4.1 CABG
To avoid errors in haplotype inference caused by genetic heterogeneity between ethnic­
ities, haplotype analysis in CABG was limited to those of Caucasian origin (n=197).
IL-18 Common IL18 haplotypes explained 5.2% of the variance in IL-18 levels at 
baseline, but were only borderline significantly associated with IL-18 levels (p=0.08, 
see table 4.17 on page 153) possibly due to the reduced sample size. Only one haplo­
type, hGTATA, was significantly associated with IL-18 levels at baseline (p=0.01). The 
effect of this haplotype did not significantly deviate from additivity (p=0.73). hGTATA 
was also significantly associated with lower IL-18 levels at 6 h (p=0.03), but not 24 h 
(p=0.15), although at 24 h the IL-18 haplotypic mean for hGTATA was lower than that 
of hGCATA (the reference haplotype). The effect of this haplotype was such that those 
homozygous for hGTATA would be expected to have baseline IL -18 levels 35% of those 
for hGCATA homozygotes, whilst at 6  h this was 55% (see figure 4.8 on page 154).
IL-18BP As can be seen in table 4.18 on page 153, IL18BP  haplotypes explained little 
of the variation in IL-18BP levels across all time points compared to IL18  haplotypes, 
and no haplotype was associated with significantly different levels from that of the 
reference haplotype.
fIL-18 IL18 haplotypes consistently explained a greater amount of the variation in 
fIL-18 levels across all time points, than IL18BP  haplotypes. The haplotype found to 
be significantly associated with IL-18 levels, hGTATA, was also associated with sig­
nificantly lower fIL-18 levels than the reference haplotype (hGCATA) at both baseline 
and 6  h. The difference was such that those homozygous for hGTATA had an estimated 
mean level of fIL-18 at baseline, 48% of that of hGCATA homozygotes, at 6  h it was
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Table 4.16: M ultivariate analysis o f  IL-18 levels by IL18  genotype in SC A R F.
SNP Total
Model 1
sex and age
Controls Cases Total
Model 2
Model 1 + smoking
Controls Cases Total
Model 3
Model 2 + IL-6 and CRP
Controls Cases
-9731 0.55 0.48 0.15 0.57 0.44 0.16 0.50 0.47 0.18
-5848 < 0 . 0 0 1 0.07 < 0 . 0 0 1 < 0 . 0 0 1 0.06 < 0 . 0 0 1 < 0 . 0 0 1 0.06 0 . 0 0 1
+ 105 0.38 0.26 0.33 0.38 0.25 0.34 0.30 0.24 0.37
+8855 0.35 0.24 0.31 0.36 0.23 0.32 0.28 0 . 2 2 0.35
+11015 0.43 0.40 0.30 0.44 0.37 0.28 0.38 0.36 0.30
Table 4.17: H aplotypic m ean [95%  C l] lnIL-18 levels by IL18  haplotype, at baseline, 6 h , and 24  h in C A B G .
Haplotypic mean lnIL-185[95% Cl]
Haplotype Frequency (%) Baseline p 6  h p 24 h p
hGCATA h 1 2 1 1 1 27.3 2.81 [2.62-3.00] Ref 3.18[3.01—3.34] Ref 2.79[2.60-2.97] Ref
hTTCAC h2 1 2 2 2 26.8 2.63[2.39—2.88] 0.31 2.97[2.85-3.09] 0.09 2.81 [2.51 —3.11] 0.90
hGTATA hi 1 1 1 1 2 0 . 6 2.29[2.00-2.58] 0 . 0 1 2.88[2.71-3.05] 0.03 2.57(2.39—2.76] 0.15
hTTATC h2 1 1 1 2 10.4 2.66[2.24-3.08] 0.55 3.13[2.87—3.40] 0.95 2.81(2.44-3.18] 0.91
Global p/R2 0.08/5.2 0.15/4.0 0.67/1.5
Table 4.18: Haplotypic mean [95% Cl] sqrtIL-18BP levels by 1L18BP haplotype, at baseline, 6 h, and 24 h in CABG.
Haplotypic mean sqrtIL-18BP[95% Cl]
Haplotype Frequency (%) Baseline P 6 h P 24 h P
hTTC h i l l 85.6 34.1(32.7-35.5] R ef 25.8(24.3-27.3] R ef 56.2(54.7-57.7] Ref
hTGC h 121 9.5 34.6(28.0-41.3] 0.87 26.2(19.6-32.9] 0.90 59.8(53.9-65.8] 0.27
hCTT h212 1. 8 42.9(24.2-61.6] 0.36 26.4(11.2-41.6] 0.94 56.5(27.0-86.0] 0.99
hCTC h211 1.7 33.5(6.4-60.6] 0.97 24.4(6.5-42.2] 0 . 8 8 51.4(35.4-67.3] 0.56
Global p/R2 0.57/1.6 0.89/0.7 0.34/2.5
5Due to the laws o f logarithms, geometric haplotypic means are difficult to interpret and therefore data is presented as transformed data throughout.
p= 0 . 0 1 p=0.03 p=0.15
8 0 0 -
6 0 0 -
CD
=d 4 0 0 -
200 -
Baseline 6 h 24 h
Figure 4.8: Estimated homozygote IL-18 levels for common IL18 haplotypes in CABG. 
Data is double the estimated haplotypic mean (o), with 95% CIs (whiskers), p values 
are those relating to haplotypic means.
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Table 4.19: H aplotypic m ean [95% C l] lnfIL-18 levels by IL18  and IL18BP  haplotype, at baseline, 6 h , and 24 h in C A B G .
Haplotypic mean lnfIL-18[95% Cl]
Haplotype Frequency (%) Baseline p 6  h p 24 h p
hGCATA h 1 2 1 1 1 27.3 2.54[2.35-2.73] Ref 2 .99[2 .84-3 .13] Ref 2.29[2.09-2.49] Ref
Oo hTTCAC h2 1 2 2 2 26.8 2.36[2.12-2.60] 0.28 2.75[2.60-2.91] 0.06 2.29[2.00-2.58] 0.99
hGTATA hi 1 1 1 1 2 0 . 6 2.07[ 1.79-2.35] 0 . 0 2 2.74[2.56-2.93] 0.05 2.07[ 1.88-2.26] 0.15
hTTATC h2 1 1 1 2 10.4 2.40[ 1.99-2.81] 0.54 2.97[2.71—3.23] 0.92 2.31 [1.94-2.67] 0.95
Global p/R2 0.14/4.5 0.17/3.9 0.69/1.5
hTTC h i l l 85.6 2.39[2.29-2.49] Ref 2.88[2.82-2.95] Ref 2.26[2.16-2.36] Ref
OQ hTGC h 12 1 9.5 2.45[2.04-2.85] 0.81 2.84[2.61-3.08] 0.77 2 .13[ 1.75-2.51] 0.54OO hCTT h2 1 2 1 . 8 1.43 [0.80-2.07] 0.004 2.86[ 1.88-3.83] 0.97 2.23[ 1.06-3.39] 0.96
hCTC h2 1 1 1.7 2.23[ 1.54-2.93] 0 . 6 6 2.67[ 1.98-3.36] 0.56 2.15[ 1.28—3.02] 0.81
Global p/R2 0.23/3.5 0.94/0.5 0.98/0.5
p=0 . 0 2 p=0.15
6 0 0 -
f * 4 0 0 -
O)
00
200 -
Baseline 6 h 24 h
Figure 4.9: Estimated homozygote fIL-18 levels for common IL18 haplotypes in 
CABG. Data is double the estimated haplotypic mean (o), with the 95% CIs (whiskers), 
p values are those relating to haplotypic means.
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Table 4.20: H aplotypic mean [95% C l] lnIL-18 levels by IL18 haplotype in N PH SII.
Haplotype Frequency (%) Haplotypic mean 
InIL-18[95% Cl
P
hGCATA h 12111 28.2 2.84(2.79-2.89] Ref
hTTCAC h 2 1222 24.8 2.71[2.65-2.77] 0 . 0 0 2
hGTATA hi 1111 29.9 2.70[2.65-2.75] < 0 . 0 0 1
hTTATC h 2 1112 8.9 2.77[2.65-2.89] 0.29
Global p/R2 0.003/4.1
67% (see figure 4.9 on the previous page). Only IL18BP  hCTT was associated with 
significantly different fIL-18 levels at baseline (p=0.004), however, this haplotype was 
not associated with IL-18BP levels, therefore this may be a spurious result.
4.2.4.2 NPHSII
Haplotype architecture and identity of both IL18 and IL18BP haplotypes were similar 
between CABG and NPHSII. Frequencies were also similar, however hGTATA was 
greatly more common in NPHSII (29.9%) than CABG (20.6%). Given that the two 
studies represent a diseased and a healthy cohort, and that hGTATA is associated with 
lower IL-18 and fIL-18, this suggests hGTATA may be protective from CHD. This 
finding will be investigated in greater detail in later chapters.
IL-18 IL18  haplotypes were globally associated with IL-18 levels (p=0.003) and 
explained 4.1% of the variation in IL-18 levels (see table 4.20). Specifically, both 
hTTCAC and hGTATA were associated with significantly lower IL-18 levels, than the 
reference haplotype, hGCATA (p=0.002, and p<0.001, respectively). The differences 
were such that individuals homozygous for hGTATA were estimated to have IL-18 lev­
els 75% of those homozygous for hGCATA. For hTTCAC this was 76% (see figure 4.10 
on page 160). Both haplotype effects did not deviate from additivity (hGTATA-p=0.37; 
hTTC A C -p=0.16).
IL-18BP As shown in table 4.21 on the following page, IL18BP  haplotypes explained 
only 0.5% of the variation in IL-18BP levels in NPHSII. None of the common IL18BP  
haplotypes were associated with levels significantly different from those of the refer­
ence haplotype.
flL -18 IL18, but not IL18BP, haplotypes were significantly associated with differ­
ences in fIL-18 levels (p=0.04, see table 4.22 on the next page). This was seemingly
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Table 4.21: Haplotypic mean [95% Cl] sqrtIL-18BP levels by IL18BP  haplotype in 
NPHSII.
Haplotype Frequency (%) Haplotypic mean 
sqrtIL-18BP[95% Cl]
P
hTTC h i l l 85.2 37.3[35.5-39.0] Ref
hTGC h 121 1 1 . 0 39.5[33.2-45.8] 0.53
hCTT h 2 12 1.3 44.9131.6-58.1] 0.27
hCTC h2 1 1 1.4 30.3[0-65.7] 0.70
Global p/R2 0.77/0.5
Table 4.22: Haplotypic mean [95% Cl] lnfIL-18 levels by IL18  and IL18BP  haplotype 
in NPHSII.
Haplotype Frequency (%) Haplotypic mean 
InfIL-18[95% Cl]
P
hGCATA h 1 2 1 1 1 28.2 2.54[2.48-2.59] Ref
OO hTTCAC h 2 1 2 2 2 24.8 2.42[2.35-2.48] 0 . 0 1
2 hGTATA hi 1 1 1 1 29.9 2.4312.38-2.48] 0 . 0 1
hTTATC h2 1 1 1 2 8.9 2.53[2.41-2.66] 0.95
Global p/R2 0.04/2.6
hTTC hi 11 85.2 2.48[2.45-2.51] Ref
On
CQ hTGC h 1 2 1 1 1 . 0 2.4612.36-2.57] 0.81OO hCTT h2 12 1.3 2.35[2.07-2.64] 0.39
2 hCTC h2 1 1 1.4 2.63[2.23-3.02] 0.46
Global p/R2 0.65/0.7
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Table 4.23: Geometric mean [95% Cl] IL-18 levels (pg/ml) by IL18  haplotype in C U ­
DAS.
Haplotype Copies Geometric mean IL- 
18[95% Cl] (pg/ml)
P R 2
0 291.4(280.9—302.3]
hGCATA h 1 2 1 1 1 1 305.7(294.2-317.7] 0.04 0.4
2 322.8(298.1-349.5]
0 301.1(290.9-311.6]
hTTCAC h2 1 2 2 2 1 298.2(286.1-310.8] 0.82 < 0 .1
2 307.1(281.5-335.1]
0 314.8(304.7-325.2]
hGTATA hi 1 111 1 283.6(271.7-296.0] < 0 . 0 0 1 1.7
2 269.1(245.2-295.3]
0 299.2(290.9-307.6]
hTTATC h2 1 1 1 2 1 309.1(291.6-327.6] 0.35 < 0 . 1
2 268.8(218.0-331.4]
due to both hGTATA and hTTCAC being associated with significantly lower fIL -18 lev­
els than the reference haplotype (p=0.01 for both). The effects for these two haplotypes 
were such that homozygotes for both were estimated to have fIL-18 levels 81% and 
79%, respectively, of those estimated for hGCATA homozygotes (see figure 4.10 on the 
following page).
4.2.4.3 CUDAS
Haplotype analysis in CUDAS was carried out by Pam McCaskie using SimHap, there­
fore data is presented as estimated geometric means for carriers of 0 , 1 , or 2  copies of 
each haplotype. In CUDAS, hGCATA was associated with significant differences in IL- 
18 levels (p=0.04, see table 4.23) with homozygotes having levels, on average, 1.1-fold 
higher than those without a copy of hGCATA. hGTATA was also significantly associated 
with differences in IL-18 levels (p<0.001), with those homozygous for the haplotype 
having average levels 85% of those with no copies (see figure 4.11 on page 161). In 
both cases the effect appeared additive, with those carrying one copy of the haplotype 
having mean IL -18 levels midway between the two homozygote groups.
4.2.4.4 CUPID
Haplotype analysis in CUPID was carried out by Pam McCaskie using SimHap, there­
fore data is presented as estimated geometric means for carriers of 0 , 1 , or 2  copies of 
each haplotype. In CUPID, both hGTATA and hTTATC were significantly associated
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Figure 4.10: Estimated IL-18 and fIL-18 levels for homozygotes of IL18 haplotypes in 
NPHSII. Data is double the estimated haplotypic mean (o), with 95% CIs (whiskers), p 
values are those relating to haplotypic means.
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Figure 4.11: Estimated IL-18 levels for carriers of 0,1 or 2 copies of either IL18 hG­
CATA or hGTATA in CUDAS. Data is from SimHap analysis and shows estimated 
mean (o), with 95% CIs (whiskers).
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Table 4.24: G eom etric mean [95% C l] IL-18 levels (pg/m l) by IL18  haplotype in C U ­
PID.
Haplotype Copies Geometric mean IL- 
18[95% Cl] (pg/ml)
P R 2
0 334.2(319.4-349.6]
hGCATA h 1 2 1 1 1 1 340.4[322.5-359.4] 0 . 8 8 < 0 . 1
2 335.7[301.3-374.1]
0 338.1(321.7-355.3]
hTTCAC h2 1 2 2 2 1 333.4(317.3-350.4] 0.72 < 0 .1
2 353.2(308.5-404.4]
0 358.1(342.3-374.6]
hGTATA hi 1 1 1 1 1 314.1(297.5-331.5] < 0 . 0 0 1 3.0
2 279.3(237.4-328.5]
0 327.3(315.7-339.4]
hTTATC h2 1 1 1 2 1 373.3(345.7-403.0] 0 . 0 0 1 2 .1
2 507.0(356.5-720.9]
with differences in IL-18 levels (p<0.001 and p=0.001 respectively, see table 4.24). In 
the case of hGTATA, carrying the haplotype was associated with a lower level of IL- 
18, with those homozygote for the haplotype having levels 78% of those not carrying 
a copy of the haplotype. Those heterozygotic for the haplotype had levels midway be­
tween the two homozygote group. For hTTATC, those homozygotic for the haplotype, 
on average, had IL -18 levels 1.5-fold higher than those not carrying a copy of hTTATC. 
Again, those carrying a single copy of hTTATC had levels between the two sets of 
homozygotes (see figure 4.12 on the following page).
4.2.4.5 SCA RF
IL18 haplotypes were associated with significant differences in IL-18 levels in the total 
SCARF cohort (p<0.001), and also in cases (p<0.001) and controls (p=0.006) sepa­
rately (see table 4.25 on page 165), explaining more of the variation in IL-18 levels in 
cases (5.9%) than controls (3.8%). Specifically, both hTTCAC and hGTATA were as­
sociated with significantly lower IL -18 levels in the total cohort (p=0.001 and p<0.001, 
respectively). These associations remained to the same extent when only cases were 
analysed, however, in controls hTTCAC was no longer associated with differences 
in IL-18 levels (p=0.44), yet hGTATA showed a similar association to that observed 
in the cases (p=0.001). The differences were such that in the total SCARF cohort, 
those homozygous for hGTATA were estimated to have IL -18 levels 76% of the aver­
age for homozygotes of hGCATA (controls-80% , cases-77% ), for hTTCAC this was
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Figure 4.12: Estimated IL-18 levels for carriers of 0,1 or 2 copies of either 1L18 hG­
TATA or hTTATC in CUPID. Data is from SimHap analysis and shows estimated mean 
(o), with 95% CIs (whiskers).
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84% (cases-77% , see figure 4.13).
4.2.5 Haplotype Multivariate Analysis
The same four models used in single SNP multivariate analysis (see section 4.2.3 on 
page 145) were used in haplotype multivariate analysis.
4.2.5.1 CABG
IL-18 In multivariate analysis, the association between hGTATA and IL-18 levels at 
both baseline and 6  h remained (see table 4.26 on page 167). However, the associations 
were greatly affected when adjusted for IL-6 , CRP (model 3), and IL-18BP (model 
4), such that the association with baseline EL-18 levels was only borderline in model 
3 and model 4 (p=0.04 and p=0.05, respectively). The association with levels at 6  h
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Table 4.25: Haplotypic mean [95% Cl] lnIL-18 levels by IL18 haplotype in SCARF. Analysis is presented for the total cohort and also for cases 
and controls separately.
Haplotype Frequency (%) Total P
Haplotypic mean lnIL-18[95% Cl] 
Controls p Cases P
hGCATA h 12111 33.2 2.87[2.84—2.89] Ref 2.82[2.79-2.86] Ref 2.90[2.86-2.95] Ref
hTTCAC h21222 30.0 2.78[2.75—2.82] 0 . 0 0 1 2.80[2.76-2.84] 0.44 2.77[2.72-2.83] 0 . 0 0 1
hGTATA h l l l l l 22.9 2.73[2.69-2.77] < 0 . 0 0 1 2.71 [2.66-2.76] 0 . 0 0 1 2.75[2.70-2.80] < 0 . 0 0 1
hTTATC h 2 1112 8.9 2.86[2.80-2.93] 0.98 2.86[2.77-2.95] 0.46 2.87[2.78-2.96] 0.54
Global p/R2 <0.001/4.4 0.006/3.8 <0.001/5.9
were no longer significant in model 3 or model 4 (p=0.07 and p=0.12, respectively). 
Interestingly, in both model 3 and model 4, hGTATA was significantly associated with 
IL-18 levels at 24 h (p=0.04 in both cases), whilst in univariate analysis, despite being 
associated with lower IL-18 levels, this association was not significant (p=0.15, see 
table 4.17 on page 153).
IL-18BP As in univariate analysis, IL18BP  haplotypes did not significantly associate 
with IL-18BP levels in multivariate analysis (see table 4.27 on page 168).
fIL-18 Similar to those associations seen in IL-18 analysis, the association between 
hGTATA and fIL -18 levels (when compared to hGCATA) remained in multivariate anal­
ysis (see table 4.26 on the next page). In both model 1 and model 2, hGTATA was 
associated with a significantly lower haplotypic mean fIL-18 level at both baseline and 
at 6  h, however in model 3, when levels were additionally adjusted for IL - 6  and CRP, 
the association at 6 h was no longer significant (p=0.12). Furthermore, in model 3, hG­
TATA was associated with a borderline significant association (p=0.05) with differences 
in fIL -18 levels at 24 h, an association which was not seen in univariate analysis.
For IL18BP, hCTT was significantly associated with differences in fIL-18 levels at 
baseline in all models (see table 4.27 on page 168). However, this haplotype was not 
significantly associated with differences in IL-18BP levels (p=0.36) therefore interrupt­
ing this result is difficult and it seems likely that this is a type I error.
4.2.5.2 NPHSII
IL-18 As shown in table 4.28 on page 169, in multivariate analysis both associations 
with hTTCAC and hGTATA remained in all four models. Furthermore, haplotypes 
remained globally associated with IL-18 levels in all models.
IL-18BP Common 1L18BP haplotypes were not associated with IL-18BP levels in 
multivariate analysis (see table 4.29 on page 169).
fIL-18 IL18  haplotypes were globally associated with differences in fIL-18 levels in 
all multivariate models. Specifically, as in univariate analysis, both hTTCAC and hG­
TATA were associated with fIL-18 levels. The associations were equally strong in both 
model 1 and model 2 (p=0.01 for all), however when further adjusted for CRP the asso­
ciation with hTTCAC was significantly attenuated and was only borderline significant 
(p=0.05), whilst that with hGTATA was made more significant (p=0.003, see table 4.28 
on page 169).
No IL18BP haplotype was significantly associated with fIL-18 levels in NPHSII 
(see table 4.29 on page 169).
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Table 4.26: P values from multivariate analysis o f  IL-18 and fIL -18 levels by IL18  haplotype in C A B G .
Model 1 Model 2 Model 3 Model 4
sex and age Model 1 + smoking, and statin use Model 2 + IL-6. and CRP Model 3 + 1L-18BP
Haplotype Base. 6 h 24 h Base. 6 h 24 h Base. 6 h 24 h Base. 6 h 24 h
hGCATA h 1 2 1 1 1 Ref Ref Ref Ref R ef Ref Ref Ref Ref Ref Ref Ref
oo hTTCAC h2 1 2 2 2 0.36 0.08 0.98 0.39 0.13 0.97 0.31 0 . 2 0 0.98 0.23 0.19 0.97
1
_} hGTATA hi 1 1 1 1 0 . 0 1 0 . 0 2 0.09 0.007 0 . 0 2 0 . 1 2 0.04 0.07 0.04 0.05 0 . 1 2 0.04M hTTATC h2 1 1 1 2 0.34 0.75 0.81 0.32 0.82 0.56 0.15 0 . 8 8 0.65 0.32 0.95 0 . 6 8
Global p 0 . 1 0 0 . 1 1 0.61 0.06 0 . 1 1 0.61 0.14 0.13 0.33 0 . 2 2 0 . 2 0 0.34
hGCATA h 1 2 1 1 1 Ref Ref Ref Ref Ref Ref Ref Ref Ref — — —
oo hTTCAC h2 1 2 2 2 0.36 0.05 0 . 8 8 0.52 0.09 0 . 8 6 0 . 2 2 0.14 0.95 — — —
1 hGTATA h i 1 1 1 1 0 . 0 2 0.04 0.08 0.03 0.05 0.14 0.04 0 . 1 2 0.05 — — —
C hTTATC h2 1 1 1 2 0.43 0 . 8 8 0.76 0.29 0.81 0.70 0.32 0.97 0.72 — — —
Global p 0.19 0.07 0.60 0.18 0.13 0 . 6 6 0 . 2 1 0.16 0.36 — — —
Table 4.27: P values from multivariate analysis o f  IL -18B P  and fIL-18 levels by IL18BP  haplotype in C A B G .
Haplotype Base.
Model 1
sex and age
6 h 24 h
Model 2
Model 1 + smoking, and statin use
Base. 6  h 24 h
Model 3
Model 2 + IL-6. and CRP
Base. 6  h 24 h Base.
Model 4
Model 3 + IL-18
6 h 24 h
hTTC h i l l Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Oh
PQ hTGC h 121 0.90 0.79 0.45 0.91 0.79 0.45 0.69 0.41 0 . 2 1 0.75 0.40 0.48OO hCTT h2 12 0.49 0.95 0.96 0.52 0.98 0.89 0.50 0.89 0.96 0.46 0.91 0.99
Jit-H hCTC h2 1 1 0.99 0.89 0.52 0.99 0 . 8 6 0.55 0.99 0.81 0.81 0.69 0.76 0.77
Global p 0.75 0.95 0.59 0.76 0.89 0.55 0.80 0.84 0.55 0.91 0.94 0.98
hTTC h i l l Ref Ref Ref Ref Ref Ref Ref Ref Ref — — —
oo hTGC h 12 1 0.73 0.58 0.61 0.82 0.61 0.61 0.55 0.13 0.91 — — —
1
hJ hCTT h2 1 2 0.007 0.92 0.87 0.005 0.84 0.81 0.006 0.95 0.98 — — —
G hCTC h2 1 1 0.67 0.52 0.80 0.67 0.57 0.83 0.64 0.61 0.99 — — —
Global p 0.37 0.97 0.99 0.30 0.97 0.99 0.27 0 . 6 6 0.99 — — —
Table 4.28: P values from multivariate analysis of IL-18 and fIL-18 levels by IL18 
haplotype in NPHSII.
Haplotype
Model 1
age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + CRP
Model 4
Model 3 + IL- 
18BP
hGCATA h 1 2 1 1 1 Ref Ref Ref Ref
oo hTTCAC h2 1 2 2 2 0 . 0 0 2 0 . 0 0 2 0.006 0 . 0 1
1_) hGTATA hi 1 1 1 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1
hTTATC h2 1 1 1 2 0.28 0.32 0.43 0.63
Global p 0.003 0.004 0 . 0 0 1 0.003
hGCATA h 1 2 1 1 1 Ref Ref Ref —
oo hTTCAC h2 1 2 2 2 0 . 0 1 0 . 0 1 0.05 —
1
J hGTATA hi 1 1 1 1 0 . 0 1 0 . 0 1 0.003 —
G hTTATC h2 1 1 1 2 0.98 0.93 0.94 —
Global p 0.04 0.04 0.03 —
Table 4.29: P values from multivariate analysis of IL -18BP and fIL-18 levels by IL18BP  
haplotype in NPHSII.
Haplotype
Model 1
age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + CRP
Model 4
Model 3 +IL-18
hTTC h i l l R ef Ref Ref Ref
Oh
ffl hTGC h 121 0.60 0.60 0.38 0.38
OO hCTT h2 1 2 0.24 0.24 0.26 0.23
j hCTC h2 1 1 0.67 0 . 6 8 0.65 0.67
Global p 0.84 0.84 0.81 0.74
hTTC h i l l R ef Ref Ref —
oo hTGC h 121 0.83 0.81 0.65 —
1 hCTT h 2 12 0.38 0.40 0.42 —
G hCTC h2 1 1 0.43 0.46 0.49 —
Global p 0.71 0.77 0 . 8 8 —
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Table 4.30: P values from multivariate analysis of IL-18 levels by IL18 haplotype in 
CUDAS.
Haplotype
IL-18 multivariate analysis
Adjusted for age, sex. presence of hyperten­
sion. HDL, WTHR, and Alcohol consump­
tion
hGCATA h l 2 1 11 0.04
hTTCAC h2 1 2 2 2 0.81
hGTATA hi 1 1 1 1 < 0 . 0 0 1
hTTATC h2 1 1 1 2 0 . 1 2
Table 4.31: P values from multivariate analysis of IL-18 levels by IL18 haplotype in 
CUPID.
IL-18 multivariate analysis
Haplotype Adjusted for age, sex, BMI. LDL, and
triglycerides
hGCATA h 1 2 1 1 1 0.80
hTTCAC h2 1 2 2 2 0.70
hGTATA hi 1 1 1 1 < 0 . 0 0 1
hTTATC h2 1 1 1 2 < 0 . 0 0 1
4.2.5.3 CUDAS
Multivariate haplotype analysis in CUDAS was carried out by Pam McCaskie using 
SimHap. As such the four models presented above were not used and IL-18 levels were 
adjusted for age, sex, presence of hypertension, HDL, WTHR, and alcohol consump­
tion.
Adjustment of IL -18 levels for these parameters had no effect on the 1L18 haplotype 
associations described in section 4.2.3.3 on page 148. Both hGCATA and hGTATA were 
associated with significant differences in IL-18 levels with the effect of hGTATA being 
more significant (p<0.001) than that of hGCATA (p=0.04).
4.2.5.4 C U PID
Multivariate haplotype analysis in CUPID was carried out by Pam M cCaskie using 
SimHap. As such the four models presented above were not used and IL -18 levels were 
adjusted for age, sex, BMI, LDL, and triglycerides.
As in CUDAS, multivariate analysis had little impact on the associations seen in 
univariate analysis. Both hGTATA and hTTATC were significantly associated with dif­
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ferences in IL-18 levels (both p<0.001) when adjusted for numerous factors seen to 
correlate with IL-18 levels (see table 4.31 on the preceding page).
4.2.5.5 SC A R F
Haplotypes remained globally associated with differences in IL-18 levels in both the en­
tire SCARF study, and in cases and controls separately, in all three multivariate models 
(p<0.003 in all analyses, see table 4.32 on the next page). Specifically, both hTTCAC 
and hGTATA showed significantly different IL-18 levels from those associated with the 
reference haplotype (hGCATA). However, the level of IL-18 associated with hTTCAC 
was only significantly different from that associated with hGCATA in cases (p<0.002 
in all models), not controls (p>0.28 in all models). This was not the case for hGTATA, 
with this haplotype being significantly associated with IL-18 levels in both the total 
cohort and cases and controls separately (p < 0 . 0 0 1  in all samples across all models).
4.2.6 MDR Analysis
MDR analysis was carried out in both CABG and NPHSII as these were the only studies 
that had both IL18 and IL18BP  SNPs genotyped. The binary variable used was top 
tertile of lnIL-18, sqrtIL-18BP, or lnfIL-18, vs. the bottom two tertiles. To ease data 
interpretation and presentation only five-way interactions were investigated.
4.2.6.1 CABG
Given that, in total, 45 sets of data are presented, two or more results would be expected 
to exceed p=0.05. In this case there were three, with two of these exceeding p=0.01 
(see figure 4.14 on page 173). The four and five SNP combination sets for fIL-18 at 
6  h were highly significant (p=0.004, and p=0.002, respectively), and had high average 
CVC over ten runs (7.8 and 7.1, respectively). The four SNP set was 7L7S-9731;- 
5848;+105;7L7#Z7P-559, whilst the five SNP set built on this adding IL18BP-1165, both 
were identified in each one of the ten runs as the best performing model. The five SNP 
set was a common combination being identified also in each run for baseline fIL-18 
(p=0.44), and IL -18 at 6  h (p=0.04), and all but one run for baseline IL -18 (p=0.60).
4.2.6.2 N PH SII
The same five SNP combination was also identified in each of the ten runs for IL-18 in 
NPHSII (p=0.49) with an average CVC of 10, and for fIL-18 (p=0.05), again with an 
average CVC of 10. The only other significant result was the identification of a four 
SNP set, 7L7S-5848:+l 1015:7L7Sfl7M765:-559, associated with IL-18BP in NPHSII, 
which had an average TBA over ten runs that was equivalent to p=0.03, with an average
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Table 4.32: P values from multivariate analysis o f  IL-18 levels by IL18  haplotype in SCA R F.
Haplotype Total
Model 1
sex and age
Controls Cases Total
Model 2
Model 1 + smoking
Controls Cases
Model 3
Model 2 + 1L-6 and CRP
Total Controls Cases
hGCATA h 12 1 1 1 Ref Ref Ref Ref Ref Ref Ref Ref Ref
hTTCAC h2 1 2 2 2 < 0 . 0 0 1 0.28 < 0 . 0 0 1 < 0 . 0 0 1 0.28 0 . 0 0 1 < 0 . 0 0 1 0.30 0 . 0 0 2
hGTATA h i 1 1 1 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1
hTTATC h2 1 1 1 2 0.95 0.50 0.54 0.93 0.48 0.56 0.85 0.48 0.48
Global p < 0 . 0 0 1 0.003 < 0 . 0 0 1 < 0 . 0 0 1 0 . 0 0 1 < 0 . 0 0 1 < 0 . 0 0 1 0 . 0 0 2 < 0 . 0 0 1
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Figure 4.14: MDR analysis in CABG using 1-5 SNP combinations. Data presented is the p value associated with the mean TBA (o) and SD 
(whiskers) of the best performing SNP combinations across ten runs with differing random seeds.
O 1 SNP 
O 2 SNPs 
O 3 SNPs 
O 4 SNPs 
O 5 SNPs
IL-18 IL-18BP flL-18
Figure 4.15: MDR analysis in NPHSII using 1-5 SNP combinations. Data presented is 
the p value associated with the mean TBA (o) and SD (whiskers) of the best performing 
SNP combinations across ten runs with differing random seeds.
p=0.05
0.4
0.8
174
CVC of 6  (see figure 4.15 on the previous page). This set was not identified in any of 
the CABG IL-18BP runs at any time-point.
4.3 Discussion
The primary finding of this chapter is that common genetic variation within IL18 , but 
not IL18BP, is associated with significant and substantial differences in plasma fIL-18 
levels, and that this effect occurs in both diseased and healthy individuals. Further­
more, this effect is independent of other inflammatory mediators and remains following 
adjustment for traditional CHD risk factors.
In single SNP analysis, this effect is seen solely through 7L/8-5848 T > C , with this 
SNP associated with significant differences in IL-18 levels in all but one (CUPID) of 
the studies used here. In all studies the CC homozygotes had, on average, higher levels 
than IL-18, and those heterozygote at -5848 T > C  had levels midway between the two 
groups (see figure 4.16 on the following page). The effect was present in both healthy 
and diseased individuals, however the effect seemed strongest in diseased individuals. 
CUPID was the only study in which -5848 T > C  was not significantly associated with 
IL-18 levels, however CC homozygotes had elevated IL-18 levels when compared to 
TT homozygotes, and heterozygotes had borderline significantly higher levels.
In CABG there was no evidence to suggest that the difference between baseline 
and peak IL-18 production differed by genotype group, so the effect appears not to be 
influenced by immediate gene activation. Therefore, the most likely explanation for 
the difference in the size of the effect between healthy and diseased individuals, is that 
IL18 regulation in disease differs from that in healthy individuals. O f interest is the 
observation that at 48 h in CABG, the pattern of IL-18 levels by -5848 T > C  genotype 
was reversed, although these differences were not significant (p=0.14). This may be 
due to the IL-18 levels in CC homozygotes reaching their peak sooner than others, and 
therefore beginning to decline earlier also. However, the number of individuals with 
measures of IL -18 levels at 48 h is small and the CIs are wide, therefore more data is 
required to study this hypothesis.
In the studies where both IL -18 and IL -18BP measurements were made (CABG and 
NPHSII) it was possible to calculate, based on known stoichiometry and dissociation 
constants, the likely amount of IL-18 able to bind IL-18R and have pathophysiological 
effects-fIL -18. In both studies, -5848 T > C  was the only IL18 tSNP associated with 
significant differences in fIL-18 levels, showing a similar, but blunted, pattern to that 
seen with IL-18 levels. Given that the concentration of IL-18BP vastly exceeded that 
o f IL-18 and also appeared to have a greater range during activation (see figure 4.5 on 
page 140), it was important to ascertain whether the effect of /L/S-5848 T > C  remained 
in flL -18 analysis. That the effect was strong enough to remain in fIL-18 analysis
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Figure 4.16: Summary of the significant /L/S-5848 T > C  associations. Data presented 
is ratio of mean IL-18 level compared to TT homozygotes, with bar (— ) showing 
average of cohorts. Studies split into healthy (H) and diseased (D) study groups.
suggests that CC homozygotes might be at greater risk of CHD, as IL -18 is a potentially 
causal factor in disease. That the effect also remained following adjustment for both IL- 
6  and CRP shows that it is independent o f these inflammatory factors.
Genetic variation within IL18BP  did not appear to play a significant role in dictating 
plasma IL-18BP levels. Although there were significant associations for each of the 
ILI8BP  tSNPs in CABG, these were not consistent across time-points or other studies. 
Furthermore, the patterns seen in each case were not consistent with a straightforward 
additive effect. All three IL18BP  variants are relatively rare variants (all M A F< 12%), 
and therefore it is possible that the cohorts used here were inadequately powered to pick 
up either a genotypic, or haplotypic effect (given that one haplotype alone accounted 
for >85%  of all chromosomes).
In haplotype analysis, there was a consistent association between IL18 haplotypes 
and IL-18 levels. Specifically, the effect was between hGTATA and the reference hap­
lotype, hGCATA. The two haplotypes differ by -5848 genotype alone, therefore the 
haplotype effect mirrors that of the genotype effect. In all studies presented here, this 
haplotype was associated with a significantly lower IL-18 concentration when com ­
pared to the reference haplotype (hGCATA). Importantly, this haplotype is the same 
haplotype as that identified by both Tiret et al. [2005] and Barbaux et al. [2007], as 
being associated with differing IL-18 concentrations and IL18 transcription (see fig­
ure 3.9 on page 121), as well as a decreased risk of CHD. Therefore, in total data from 
six studies has associated hGCATA with significantly lower IL-18 levels. In the studies 
in which fIL-18 could be calculated, hGTATA was also associated with fIL-18 levels.
Similar to the genotype association, the association between hGTATA and IL-18 
levels appears amplified by disease, with hGTATA being associated with lower IL-18 
levels in the diseased cohorts than the healthy cohorts. In healthy individuals, using all 
the study groups together, on average those homozygous for hGTATA had IL -18 levels 
80% of those who are homozygous for hGCATA, in those with CHD this figure was 
61% (see figure 4.17 on the next page). However, heterogeneity between the studies 
means that this estimate may not truly reflect the size of the effect; in CABG the haplo­
typic effect appears particularly strong, perhaps due to other influences besides underly­
ing disease. In both SCARF, CUDAS and CUPID, diseased and healthy individuals had 
IL-18 levels measured in tandem. In these two studies the difference (between healthy 
and diseased individuals) in the effect of hGTATA is modest. However, IL-18 levels 
are higher in SCARF cases than controls (309.6 vs. 2 85 .4pg/ml, p=0.01), as they are 
in CUPID compared to CUDAS (366.2 vs. 327.8 pg/ml), so truly assessing the relative 
impact of hGTATA in diseased vs. healthy individuals is difficult. This is made more 
difficult given that hGCATA (the reference haplotype in most analyses) appears to also 
be associated with differences in IL-18 levels in CUDAS (see figure 4 .1 1 on page 161).
Multivariate analysis had only minor effects on the univariate haplotype results de-
177
1.0
0.800 . 8 -
I
CD
I 0.61k  0 . 6 -  
o
CDsz
o
03
CC
0 .4 -
0.2
DH
O NPHSII 
O  CUDAS 
O SCARF Controls 
O CABG Baseline 
O CABG 6 h 
O SCARF C ases  
O  CUPID
Figure 4.17: Ratio between the estimated serum IL-18 concentration of those homozy­
gote for both IL18 hGCATA and hGTATA. Studies are separated into healthy (H) and 
diseased cohorts (D). The mean for each group is also shown (— ).
178
tailed. In most cases the associations remained but were attenuated. As in the genotype 
associations, these remained following adjustment for other inflammatory factors-IL - 6  
and CRP (although this was not necessarily the case in CABG), and also when IL-18 
levels were adjusted for IL-18BP levels, suggesting that IL18 transcription is not under 
the control of IL -18BP.
It is not possible to say exactly where the functional variant/variants are within or 
around IL18 since LD is strong across the gene and each of the tSNPs are chosen for 
their ability to mark other SNPs. However, /L/S-5848 T > C  itself looks unlikely to be 
functional itself as it is sits centrally within intron 1. Referring to the haplotypic tree 
inferred in section 3.2.5.2 on page 115 (see figure 3.8 on page 118), hGTATA seems 
to be a haplotype formed by recombination between hGTATC and hGCATA. There­
fore, given that there was a significant difference in IL-18 levels between hGCATA and 
hGTATA, the functional variant/variants on hGTATA could be in the region of the chro­
mosome derived from hGTATC, or due to a polymorphism occurring on hGTATA after 
this recombinatory event.
Across the region resequenced by IIPGA, hGTATA differs from hGCATA at a total 
of 14 SNPs and one insertion/deletion variant (including -5848 T > C , see figure 3.9 
on page 121). O f these, 10 SNPs occur only on hGTATA (thereby strengthening the 
assumption that hGCATA and hGTATA are related by recombination, not by the -5848 
mutation occurring on hGCATA) and are therefore in complete LD:
-11238 0 A  
-1368 A > G  
-139 A >G  
+470 T > G  
+ 1949 G >C  
+2928 T > C  
+4009 G > C  
+8905 G > C  
+ 10790 G >A  
+ 11640 A >G
As hGTATA is the only haplotype to be consistently associated with differences in 
IL-18 levels it would seem that these SNPs, of the ones identified by IIPGA, are the 
most likely functional changes. However, unless these SNPs ‘split’ hGTATA, each SNP 
will mark the effect of -5848 T > C  and can therefore not be independently studied. One 
SNP that does appear to split hGTATA (when using haplotypes inferred using PHASE 
v2.1) is -1368 A > G , and this was therefore the one extra SNP that was needed, in later 
analysis, to mark all variation within IL18  when using haplotypes inferred with PHASE
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Figure 4.18: Haplotypes inferred using IL18- 1368 A > G  in addition to the tSNP set; 
■  -  common allele, □  -  rare allele. Haplotypes are ordered -9731 G >T; -5848 T > C ; 
(-1368 A >G ); +105 A >C ; +8855 T > A ; +11015 A >C.
v2.1 (see section 3.2.6.1 on page 119). To assess their impact on the associations de­
tailed within this chapter, both -1368 A > G  and -11238 C > A  (as a variant within the 
promoter) were genotyped in CABG. IL18- 11238 C > A  did not help to distinguish 
extra haplotypes (and is therefore not included in subsequent analysis) but by adding 
-1368 A >G , hGTATA, and hGTATA only, was split into two common haplotypes (see 
figure 4.18).
Inclusion of -1368 A > G  also had an effect on the association between IL18 haplo­
types and DL-18 levels. The SNP itself was not associated with significant differences 
in either IL-18 or fIL-18 at baseline or 6 h, but was associated with significant dif­
ferences in both IL-18 and fIL-18 at 24 h, with GG homozygotes having significantly 
lower levels than either heterozygotes or AA homozygotes (although there were only 
two GG individuals). In haplotype analysis, haplotypes were significantly associated 
with both IL-18 (see table 4.33 on page 182) and fIL-18 (see table 4.34 on page 182)at 
baseline, with hGTAATA being associated with significantly lower IL-18 and fIL-18. 
This haplotype was also borderline significantly associated with IL-18 and fIL-18 at 6 h 
in CABG. However, the 95% Cl for the estimated mean IL-18 and fIL-18 levels for 
hGTAATA were largely similar to those seen for hGTATA (see table 4.17 on page 153 
and table 4.19 on page 155). Furthermore given that the SNP itself is not associated 
with IL-18 levels at baseline or 6 h, strongly suggests that its inclusion does not clarify 
the association with hGTATA. Therefore, in conclusion, there is no evidence to suggest
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that including -1368 A > G  significantly alters the association between hGTATA and IL- 
18, and fIL-18, levels. What is more likely is that the SNP or SNPs responsible for the 
effect are common to both hGTAATA and hGTGATA.
With regard to epistatic effects, there is little evidence to suggest that tSNPs across 
genes interact to have effects on any of the IL-18 system proteins. Therefore, in con­
clusion, haplotypes in IL18, but not 1L18BP, are significantly associated with inter­
individual differences in IL-18, independent of other inflammatory factors. This effect 
is strong enough to also affect fIL-18 levels, and substantial enough that it could have 
pathophysiological effects. Importantly, the effect is present in both healthy individuals 
and those with CHD, and therefore could affect both future risk and severity of disease, 
once present.
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Table 4.33: LnIL-18 levels by IL18  haplotypes in CABG, using haplotypes inferred with the tSNP set and -1368 A >G . Haplotypes are ordered 
-9731;-5848;-1368;+105;+8855;+l 1015.
Haplotype Freq. (%) Baseline P
Haplotypic mean ln IL -18(95% Cl] 
6  h p 24 h P
hGCAATA h 1 2 1 1 1 1 27.0 2.799[2.627-2.972] Ref 3.144(2.989-3.299] Ref 2.786(2.593-2.9781 Ref
hTTACAC h2 1 1 2 2 2 24.8 2.660(2.408-2.913] 0.41 2.931(2.775-3.087] 0 . 1 1 2.789(2.467-3.111] 0.99
hGTAATA hi 1 1 1 1 1 13.9 2.195(1.817-2.573] 0.006 2.866(2.634-3.099] 0.05 2.705(2.321-3.090] 0.72
hTTAATC h2 1 1 1 1 2 9.4 2.699(2.241-3.157] 0.69 3.125(2.861-3.389] 0.90 2.808(2.438-3.179] 0.92
hGTGATA hi 1 2 1 1 1 8.7 2.584(2.200-2.969] 0.37 2.924(2.630-3.219] 0 . 2 2 2.355(2.124-2.586] 0 . 0 1
hGCACAC hi 2 1 2 2 2 3.4 3.321(2.420-4.221] 0.27 3.200(2.364-4.036] 0.90 3.005(2.136-3.874] 0.63
hTTAAAC h2 1 1 1  2 2 3.3 1.698(0.893-2.503] 0.009 2.95112.364-4.036] 0.54 2.686(2.135-3.238] 0.74
Global p/R2 0.004/13.0 0.40/4.4 0.70/3.0
Table 4.34: LnfIL-18 levels by IL18  haplotypes in CABG, using haplotypes inferred with the tSNP set and -1368 A >G . Haplotypes are ordered 
-9731 ;-5848;-1368;+105;+8855;+11015.
Haplotypic mean lnfIL-18[95% Cl]
Haplotype Freq. (%) Baseline P 6 h P 24 h P
hGCAATA h 1 2 1 1 1 1 27.0 2.573(2.385-2.762] Ref 2.991(2.832-3.149] Ref 2.304(2.071-2.537] Ref
hTTACAC h 2 1 1 2 2 2 24.8 2.376(2.139-2.614] 0.25 2.754(2.592-2.916] 0.08 2.262(1.953-2.572] 0.84
hGTAATA h i l l  111 13.9 2.010(1.661-2.360] 0.009 2.723(2.485-2.961] 0.06 2.174(1.779-2.568] 0.60
hTTAATC h 2 1 1 1 1 2 9.4 2.388(1.972-2.804] 0.43 2.979(2.713-3.246] 0.94 2.324(1.951-2.696] 0.94
hGTGATA h i 1 2 1 1 1 8.7 2.270(1.884-2.656] 0 . 2 1 2.784(2.464-3.475] 0.29 1.810(1.573-2.047] 0.007
hGCACAC h 1 2 1 2 2 2 3.4 3.083(2.252-3.914] 0.24 3.066(2.342-3.790] 0.85 2.475(1.631-3.320] 0.70
hTTAAAC h2 1 1 1  2 2 3.3 1.474(0.700-2.248] 0.006 2.860(2.245-3.475] 0.69 2.166(1.634-2.697] 0.64
Global p/R2 0.005/12.6 0.42/4.4 0.65/3.4
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Chapter 5
IL-18 Levels and Individual Disease 
Risk
This chapter will attempt to establish how well IL-18 levels predict or diagnose the 
existence and severity of disease. As IL-18 has been implicated in both CHD and 
obesity, both of these conditions will be explored in the context of the study groups 
used previously.
5.1 CABG
5.1.1 IL-18 and Risk of Major Complication Following Surgery
CABG is a model of post-event immuno-activation, and therefore a major complication 
following surgery may be analogous to serial events following the index MI. Patients 
within CABG were defined as having suffered a major complication following surgery 
for a number of reasons, with major causes being continued inotrope administration, 
increased ventilatory support (>  12 h) or extended intensive care unit (ICU) stay (> 2  d). 
There was missing data on major complication status for four individuals from the co­
hort used in chapter 4, therefore data from 244 individuals was used in these analyses. 
Due to the low numbers available, measures of IL-18 and IL-18BP at 48 h were not 
considered here.
5.1.1.1 Univariate Analysis
As can be seen in table 5.1 on the following page, baseline characteristics, and levels 
of inflammatory mediators following surgery, did not differ significantly between those 
who went on to suffer a major post-operative complication. However, both IL-18 and 
fIL-18 were significantly higher at 24 h in those who went on to suffer a major com ­
plication (p=0.001, and p=0.003, respectively, see figure 5.1 on page 188). IL-18 and
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Table 5.1: Baseline characteristics for those who did or did not suffer a major complication in CABG. Data is presented as mean or geometric 
mean[95% Cl].
Variable No Major Complication (n=145) M ajor Complication (n=99) P
Male, %[n] 86.9[ 126] 78.8(78] 0.09
Age (yr) 64.4[63.0-65.9] 65.0(63.1-66.8] 0.64
Caucasian, %[n] 88.2[82] 84.6(115] 0.81
BMI (kg/m2) 27.6[26.9-28.4] 28.4(27.4-29.3] 0.24
0 66.2[96] 61.2(60]
Past history of MI, %[n] 1 29.7[43] 26.5(26] 0.06
2 + 4.1 [6 ] 1 2 ( 1 2 .2 ]
Cholesterol-lowering medication, %[n] 76.8(109] 73.2(71] 0.53
Ever smoked, %[n] 77.8[112] 78.8(78] 0.57
Operation length (min) 198.8[ 191.4-206.2] 207.0(196.5-217.6] 0.19
Cardiopulmonary bypass (CPB) length (min) 68.2[65.1—71.3] 69.3(65.5-73.0] 0 . 6 6
Parsonnet score1 5.73(4.91-6.56] 6.98(5.71-8.25] 0.09
Baseline 4.13(3.70-4.62] 4.35(3.78-5.01] 0.56
IL - 6  (pg/ml) 6 h 190.76(164.19-221.85] 202.6(178.8-229.5] 0.57
24 h 151.9(133.1-173.5] 188.5(158.7-223.9] 0.05
Baseline 1.89(1.56-2.29] 1.96(1.55-2.48] 0.81
CRP (mg/1) 6 h 2.72(2.25-3.28] 2.10(1.63-2.71] 0 . 1 0
24 h 74.9(68.5-82.0] 73.5(67.3-80.3] 0.78
'The Parsonnet score is pre-operative mortality risk score for those undergoing adult heart surgery, taking into account several risk factors.
Table 5.2: Geometric mean[95% Cl] IL-18, IL-18BP, and fIL-18 levels in those who 
did, and those who did not, suffer a major complication following CABG surgery.
Variable No M ajor Complica­
tion (n= 145)
Major Complication 
(n=99)
P
Baseline 184.3[147.5-230.3] 223.8(176.5-283.7] 0.24
IL-18
6 h 391.5[340.5-450.0] 474.7(415.3-542.5] 0.06
24 h 202.6(163.9-250.5] 333.2(274.6-404.1] 0 .0 0 1
Baseline 4660(4223-5119] 5065(4547-5612] 0.25
IL-18BP
6 h 2813(2486-3161] 2730(2352-3136] 0.75
24 h 12727(11968-13509] 13513(12657-14397] 0.19
Baseline 110.5(88.5-137.9] 130.7(103.7-164.7] 0.30
fIL-18
6 h 285.7(248.7-328.2] 345.9(300.8-397.7] 0.06
24 h 74.7(60.3-92.5] 116.8(96.2-141.7] 0.003
Table 5.3: RRs[95% Cl] for a major post-operative complication following CABG 
surgery, by tertiles of IL -18 and fIL -18 at 6  h and 24 h.
RR[95% Cl]
Tertile 6 h P 24 h P
IL-18
1
2
1
1.60(1.16-2.21] 0.004
1
1.42(1.02--1.98] 0.04
3 1.27(0.92-1.75] 0.16 1.75(1.23--2.51] 0 . 0 0 2
fIL-18
1
2
1
1.33(0.97-1.82] 0.08
1
1 .2 1 (0 .8 6 --1.69] 0.29
3 1.28(0.92-1.77] 0.15 1.56(1.10--2 .2 2 ] 0 .0 1
fIL-18 levels were also borderline significantly higher at 6  h in those who suffered a 
complication post-operatively (p=0.06 for both). At 6  h, those who did go on to suffer a 
major complication had IL -18 and fIL -18 levels 1.2-fold higher than those who did not 
(p=0.06 for both), whilst at 24 h, this difference was 1.6 -fold (p=0.001 and p=0.003, re­
spectively). The RRs for tertiles of IL-18 and fIL-18 associated with these associations 
are shown in table 5.3. The effect appeared strongest and most consistent at 24 h, with 
those in the upper tertile of IL-18 having a 1.8-fold increase in risk compared to the 
lowest tertile (p=0.0()2), whilst for fIL-18 the increase in risk was 1.6-fold (p=0.01).
5.1.1.2 M ultivariate Analysis
As shown in table 5.1 on the previous page, there were few predictors of suffering a 
major complication following surgery. However both a past history o f MI and IL - 6
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Figure 5.1: Box plots o f IL-18 and fIL -18 at both 6  h and 24 h in CABG. Data is divided 
into those who suffered a major complication and those who did not. Line -  Median; 
Box -  75th to 25th percentile; o -  outlier (>1.5 box lengths out of box); ★ -  extreme 
(> 3  box lengths out o f box); whisker -  last value not an outlier.
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Table 5.4: P values from  m ultivariate analysis for IL -18, IL -18B P, and fIL -18 levels in
those w ho suffered a major com plication  in C A B G  com pared to those w ho did not.
Variable
Model 1
Sex and age
Model 2
Model 1 + Hx of 
Ml
Model 3
Model 2 + IL-62
Model 4
Model 3 + IL- 
18/1L-18BP
Baseline 0.25 0.28 0.29 0.28
IL-18 6 h 0.08 0.06 0.06 0.07
24 h 0 .0 0 1 0 .0 0 1 0 . 0 0 2 0.003
Baseline 0.44 0.53 0.91 0.79
IL-18BP 6 h 0.62 0.62 0.58 0.76
24 h 0.15 0.14 0.16 0.17
Baseline 0.29 0.31 0.27 ___3
fIL-18 6 h 0.08 0.07 0.06 —
24 h 0.003 0.004 0.006 —
2 IL-6 levels used as covariate is that o f the same timepoint as the dependent variable 
■'fIL-18 is calculated from both IL-18 and IL-18BP therefore model 4 can not be used in fIL-18 
analysis.
levels were significantly different between the two groups, therefore to take these into 
account the following models were used in multivariate analysis:
M odel 1 Sex and age
Model 2 Sex, age, and past history of MI
M odel 3 Sex, age, past history of MI, and IL - 6
M odel 4 Sex, age, past history of MI, IL-6 , and IL -18 /IL -18 BP
As can be seen in table 5.4, the associations detailed above remained significant fol­
lowing adjustment for the various factors. Importantly, the associations also remained 
when adjusted for IL-6 , another inflammatory mediator that differed between the two 
groups.
5.1.2 IL-18’s Relation to BMI and BSA
As detailed in section 1.4.2.1 on page 56, IL-18 appears to have a role in metabolic 
control and obesity, and therefore could be an important link between obesity and in­
flammation, and therefore CHD.
Neither IL-18, IL-18BP, or fIL-18 levels differed between those individuals in 
CABG who were obese (B M I> 30kg/m 2), and those who were not (B M I<30kg/m 2, 
see table 5.5 on the following page), or when the individuals were grouped according 
to tertiles of BMI or body surface area (BSA) (data not shown). However, peak IL-18
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Table 5.5: G eom etric m ean[95%  C l] IL -18, IL -18B P, and fIL-18 levels (pg/m l) by
obesity  status in C A B G .
Variable Non-obese (n=190) Obese (n=58) P
Baseline 205.0[ 169.5-248.0] 172.1(127.4-232.5] 0.33
IL-18 6 h 430.4[386.3-479.5] 411.1(328.5-514.4] 0.70
24 h 242.9(204.9-287.9] 300.4(225.6-400.0] 0.25 •
Baseline 4969(4582-5373] 4466(3833-5148] 0 .2 1
IL-18BP 6 h 2733(2462-3019] 3043(2465-3683] 0.32
24 h 13034(12390-13694] 13176(12011-14396] 0.83
Baseline 121.0(100.1-146.3] 102.5(77.8-135.1] 0.32
fIL-18 6 h 314.5(281.5-351.4] 292.5(235.1-363.8] 0.55
24 h 88.3(74.4-104.8] 104.2(78.9-137.6] 0.37
and fIL-18 levels (ie. 6 h) were negatively correlated with BSA (IL-18 -  Spearman’s 
p = -0 .16, p=0.04; fIL -18 -  p = -0 .16, p=0.05, see figure 5.2 on the next page).
5.2 NPHSII
NPHSII is a prospective study and therefore allows the study of the future impact of 
high/low IL-18 levels in otherwise healthy individuals. The study is ongoing and is 
presently in its 15th year of follow-up, with CHD events being recorded throughout this 
period and BMI being recorded at baseline and the following five years.
5.2.1 IL-18 as a Predictor of Future MI
5.2.1.1 Univariate Analysis
The sub-cohort from NPHSII in which IL-18, IL-18BP, and fIL-18 levels were mea­
sured was a nested case-control sample, with 167 individuals having a CHD event 
(stroke or MI) during follow-up. As shown in table 5.6 on page 192, those who suffered 
an event showed a risk factor profile consistent with increased risk. IL -18, IL -18BP, and 
fIL-18 levels were not significantly different between those who did, and those who did 
not suffer an event.
However, when only those who suffered an MI over 15 yr of follow-up were consid­
ered, both baseline IL -18 and fIL -18 were significantly higher in those who suffered an 
MI (n=95) than those who did not (n=330, see table 5.7 on page 192). For IL-18, levels 
in those who suffered an MI had geometric mean levels 1.2-fold higher than those who 
did not (p=0.008), whilst for fIL-18 levels, they were 1.1-fold higher (p=0.05, see fig­
ure 5.3 on page 193). The difference was such that those in the highest tertile of IL-18
190
BS
A 
(m
2)
O  IL-18 6 h 
O  fIL-18 6 h2 .4 -
3
P &°cP
2 .0 - o o
0 500 1000 1500 2000
IL-18 (pg/ml)
Figure 5.2: Scatter plot of both IL-18 and fIL-18 at 6 h with BSA, in CABG.
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Table 5.6: Baseline characteristics of NPHSII participants (with IL-18 levels) who went 
on to develop any CHD event during follow-up.
Variable No event (n=259) Event (n=167) P
Age 56.6(56.1-57.0] 56.4(55.9-57.0] 0.65
Ever smoked, %[n] 48.8(101] 65.4(70] 0.005
Hypertensive4 47.7(123] 59.3(99] 0 . 0 2
BMI (kg/m2) 26.1(25.7-26.5] 26.8(26.3-27.3] 0.06
Total cholesterol (mmol/1) 5.75(5.60-5.90] 5.67(5.50-5.85] 0 .2 1
LDL (mmol/1) 1.92(1.82-2.03] 1.90(1.78-2.02] 0.77
HDL (mmol/1) 0.82(0.79-0.86] 0.73(0.68-0.78] 0.004
Triglycerides (mmol/1) 1.68(1.57-1.80] 1.86(1.69-2.04] 0.007
Fibrinogen (mg/dl) 267.5(262.0-273.0] 278.5(271.0-286.2] 0.04
CRP (mg/1) 2.66(2.27-3.11] 3.64(3.00-4.43] 0.007
IL-18 (pg/ml) 241.2(226.9-256.4] 266.3(245.3-289.1] 0.14
IL-18BP (pg/ml) 5532(5027-6061] 5626(4940-6356] 0.62
fIL-18 (pg/ml) 137.8(129.2-146.9] 151.0(139.2-163.8] 0.24
Table 5.7: Geometric mean [95% Cl] IL-18, IL-18BP, and fIL-18 levels (pg/ml) in 
NPHSII participants who did or did not suffer an MI during follow-up.
No MI (n=331) MI (n=95) P
IL-18 239.6(227.7-252.2] 277.6(252.4-305.3] 0.008
IL-18BP 5580(5109-6072] 6028(5128-7001] 0.38
fIL-18 136.6(129.2-144.3] 153.2(140.0-167.7] 0.05
levels had an RR[95% Cl] for MI of 1.66[ 1.06-2.59] (p=0.03) compared to the lowest 
tertile, whilst for fIL-18 the RR was 1.32[0.85-2.06] (p=0.21, see table 5.8 on the next 
page).
5.2.1.2 M ultivariate Analysis
As shown in table 5.6, numerous factors were associated with an increased risk of CHD. 
The following models were used, concentrating on factors that may modulate the effect 
of IL-18 on MI risk:
Model 1 Age and ever smoked
Model 2 Age, ever smoked, and presence of hypertension
Model 3 Age, ever smoked, presence of hypertension, and CRP
Model 4 Age, ever smoked, presence of hypertension, CRP, and IL-18/IL- 
18BP (where appropriate)
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Figure 5.3: Box plots for both IL-18 and fIL-18 levels in NPHSII showing significantly 
higher levels in those who suffered an MI during follow-up than those who did not.
Table 5.8: RRs[95% Cl] for MI during follow-up by tertiles of EL-18 and fIL-18 in 
NPHSII
Tertile RR[95% Cl] P
1 1 —
IL-18 2 1.28[0.79-2.07] 0.31
3 1.66[ 1.06-2.59] 0.03
1 1 —
fIL-18 2 1.18[0.75—1.86] 0.48
3 1.32[0.85-2.06] 0 .2 1
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Table 5.9: P values from m ultivariate analysis on IL -18, IL -18B P, and fIL -18 levels
from NPHSII in those w ho w ent on to suffer an MI and those w ho did not.
Variable
Model 1
Age and ever smoked
Model 2
Model 1 + Hypertension
Model 3
Model 2 + CRP
Model 4
Model 3 + IL-I8/IL-18BP
IL-18 0 .2 1 0.25 0.48 0.60
IL-18BP 0 .6 8 0.76 0.41 0.51
fIL-18 0.38 0.39 0.83 ___5
5fIL-18 is calculated from both IL-18 and IL-18BP therefore model 4 can not be used in fIL-18 
analysis.
As shown in table 5.9, the associations of both IL-18 and fIL-18 levels with future 
risk of MI were no longer significant in multivariate analysis. Indeed, both associa­
tions were no longer present in model 1. It appeared that adjustment for having ever 
smoked was most responsible for this, as when age alone was used as a covariate both 
associations were still significant, whilst when smoking status alone was used both the 
association for IL-18 and fIL-18 were no longer significant (p=0.21 and p=0.38, respec­
tively). Neither IL-18 nor fIL-18 levels differed between those who had ever smoked 
and those who had not (p=0.78 and p=0.30, respectively), therefore it seems unlikely 
that smoking status is confounding the association.
5.2.2 IL-18 in Weight Control and Obesity
In NPHSII at baseline, 58 individuals from the subset with IL-18 and IL-18BP levels, 
were obese (B M I>30kg/m 2). Obese individuals on average had higher triglycerides, 
and also had elevated plasma concentrations of CRP suggesting activation o f the im­
mune system in obesity (see table 5.10 on page 197). Neither IL-18 nor IL-18BP were 
significantly different between the two groups, however there was a trend for fIL -18 
to be higher in obese than non-obese individuals (p=0.09). Plasma concentrations of 
all three proteins were significantly correlated with BMI (IL-18 -  p=0.10, p=0.03; 
IL-18BP -  p = -0 .10, p=0.04; fIL-18 -  p=0.15, p=0.003), with, overall, fIL-18 being 
positively correlated with increasing BMI.
Throughout the following five years of follow-up, BMI within the cohort in­
creased marginally but significantly (see figure 5.5 on page 196), with an, on average, 
0.35(0.19-0.52Jkg/m2 increase in BMI over this period (P<0.001). Neither baseline 
IL-18, IL-18BP, or fIL-18 differed between obese or non-obese individuals in any of 
these subsequent BMI measures. Furthermore, the correlation between baseline IL-18, 
IL-18BP, fIL-18, and BMI were diminished in these later measures, and they did not 
correlate with BMI increases/decreases over the six years (p=-0.04, p=0.45).
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Figure 5.5: Box plots of BMI at baseline and over the five years of follow-up in NPHSII.
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Table 5.10: B aseline Characteristics for those in NPH SII w ho w ere either o b ese  or
non-obese at baseline. Data is presented either as m ean or geom etric m ean[95%  C l].
Variable Non-obese (n=368) Obese (n=58) P
Age 56.7(56.2-57.1 ] 56.7(55.3-57.8] 0.85
Ever smoked, %[n] 53.6(143] 59.6(28] 0.45
Hypertensive 50.7[186] 62.1(36] 0 . 1 1
BMI (kg/m 2 25.5(25.2-25.9] 32.1(31.3-32.9] < 0 .0 0 1
Total cholesterol (mmol/1) 5.72(5.59-5.85] 5.68(5.36-6.03] 0.80
LDL (mmol/1) 1.93(1.84-2.02] 1.79(1.55-2.04] 0.25
HDL (mmol/1) 0.79(0.75-0.82] 0.81(0.73-0.90] 0.80
Triglycerides (mmol/1) 1.69(1.59-1.80] 2.08(1.81-2.39] < 0 .0 0 1
Fibrinogen (mg/dl) 271.5(266.9-276.2] 267.6(254.6-281.2] 0.54
CRP (mg/1) 2.42(2.05-2.84] 4.22(2.83-6.28] < 0 .0 0 1
IL-18 (pg/ml) 245.1(230.4-260.7] 251.9(209.1-303.4] 0.23
IL-18BP (pg/ml) 5158(4742-5592] 4791(3911-5761] 0.63
fIL -18 (pg/ml) 144.1(135.4-153.4] 151.7(127.0-181.2] 0.09
5.3 CUDAS
The analysis of IL-18’s relationship with both subclinical atherosclerosis and obesity is 
detailed in papers by Chapman et al. [2006] and Hung et al. [2005]. W hat follows is a 
brief summary of this data, the author of this thesis was not involved in such analyses 
but provides them here to place those results detailed in chapter 4, in context.
5.3.1 IL-18 and Subclinical Atherosclerosis [Chapman et al., 2006]
As shown in table 5.11 on the following page, males had higher IL-18 levels and mono­
cyte count than females (both p<0.001). IL-18 was significantly correlated with mean 
IMT (p=0.17, p<0.001), with equal trends seen in both males and females, but was 
not significantly different between those with evidence of carotid plaque (defined as fo­
cal increase of >1 mm in intima-media thickness) and those without. However, levels 
were elevated in those who had evidence of an atherosclerotic plaque (see table 5.12 
on the next page), although IL-18 levels did not differ by tertiles of IMT. IL-18 did 
differ significantly when hypertensives were compared to non-hypertensives, with hy­
pertensives having mean IL-18 levels 12% higher than non-hypertensives (p<0.001). A 
similar association was seen when comparing obese individuals to the non-obese, with 
those having a B M I>30kg/m 2 having mean IL-18 levels 17% higher than those with 
B M I< 30kg/m 2.
197
Table 5.11: Baseline characteristics o f males and females in the CUDAS sample. Data 
is mean or geometric mean[95% C l] [Chapman et al., 2006].
Variable Fem ales (n=550) Males (n=557) P
Age 53.2 [5 2 .1-54.3] 53.4[52.3-54.5] NS
BMI (kg/m2) 25.1 [24.7-25.4] 26.5[26.2-26.8] < 0 .0 0 1
WTHR 0.77[0.76-0.77] 0.90[0.90-0.90] < 0 .0 0 1
SBP (mmHg) 127.1 [ 125.4—128.8] 129.5[128.1-130.9] 0.03
HDL (mmol/1) 1.46[ 1.43-1.49] 1.13[ 1.11-1.15] < 0 .0 0 1
LDL (mmol/1) 3.56[3.48-3.64] 3.70[3.63-3.77] 0.009
Triglycerides (mmol/1) 1.01 [0.96-1.05] 1.28[ 1.23-1.34] < 0 .0 0 1
Mean IMT (mm) 0.68[0.67-0.69] 0.72[0.70-0.73] < 0 .0 0 1
IL-18 (pg/ml) 266.1 [257.0-275.5] 340.4[329.1-352.0] < 0 .0 0 1
CRP (mg/1) 1.84[ 1.67-2.02] 1.68[ 1.54-1.84] NS
IL - 6  (jug/1) 3.68[3.55-3.82] 3.61 [3.47-3.76] NS
Fibrinogen (g/1) 2.79[2.73-2.85] 2.70[2.65—2.75] 0.03
Monocyte count (109/1) 0.45[0.44-0.46] 0.53[0.52-0.55] < 0 .0 0 1
Table 5.12: Geometric mean[95% Cl] IL-18 levels (pg/ml) by hypertension, obesity, 
plaque, and past history of MI [Chapm an et al., 2006].
Geom etric mean[95% Cl] IL-18 (pg/ml)
Variable No Yes P
Hypertension 2 9 1.8[283.4-300.4] 327.7[311.4-344.8] < 0 .0 0 1
Obesity 292.4[284.3-300.4] 342.7[322.8-363.9] < 0 .0 0 1
Plaque 296.5[287.7-305.8] 311.1 [295.0-328.3] NS
History of MI and/or stroke 299 .5 [291.8-307.7] 309.5[283.2—338.3] NS
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5.3.2 IL-18 Levels and the Metabolic Syndrome [Hung et al., 2005]
IL-l 8  levels increased as the number of metabolic syndrome criteria increased, such that 
those with > 3  criteria had levels 40% higher than those with no criteria (see table 5.13 
on the following page). This association remained when adjusted for age, sex and BMI, 
such that individuals in the highest tertile of IL-18 had an OR[95% Cl] of 2.28[ 1.33— 
3.91 ], p=0.007. Both IL - 6  and CRP were associated with metabolic syndrome criteria, 
however these associations were attenuated when adjusted for age, sex and BMI.
5.4 SCARF
5.4.1 IL-18 Levels in Cases and Controls
A recently published paper by Hulthe et al. [2006] details levels of IL-18 in the SCARF 
cohort and related them to case/control status. The analysis presented below is separate 
from this paper and was carried out solely by the author of this thesis.
5.4.1.1 Univariate Analysis
As can be seen in table 5.14 on page 201, SCARF cases had a significantly worse risk 
factor profile than did controls, although both DBP and SBP were not significantly 
different between the two groups, a finding that is likely due to the large number of 
cases who were on anti-hypertensive treatment (95.3%). A treatment effect is also the 
most probable explanation for the significantly lower LDL concentrations seen in cases 
over controls, although there was no data available on statin treatment.
IL-18 levels were significantly higher in cases than controls (p=0.01), with cases 
having levels 7.1% higher than controls (see figure 5.6 on page 201). This translates 
into a 1.2-fold increase in risk for those in the highest tertile of IL-18 compared to 
those in the lowest tertile (p=0.05, see figure 5.7 on page 202). Within cases, IL-18 
was significantly positively correlated with normalized plaque area (p=0.17, p=0.01, 
see figure 5.8 on page 202), but not with mean % stenosis (p=0.07, p=0.33).
5.4.1.2 M ultivariate Analysis
Four models were used in multivariate analysis in assessing the difference in IL-18 
levels between cases and controls. Covariates were selected that differed between cases 
and controls and that were likely to have biologically plausible effects on IL-18 levels:
M odel 1 Age and ever smoked 
M odel 2 Age, ever smoked, and DBP 
M odel 3 Age, ever smoked, DBP, and CRP
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Table 5.13: Baseline characteristics of the CUDAS cohort according to the number of National Cholesterol Education Program Third Adult 
Treatment Panel (NCEP-ATPIII) metabolic syndrome criteria. Data are mean or geometric mean[95% Cl].
Variable 0 (n=243)
No. o f metabolic syndrome criteria 
1 (n=306) 2 (n=238) >3  (n=173) P
Age 45.8(44.3-47.3] 54.5[53.1-55.8] 56.0[54.4-57.5] 57. l[55.3-58.9] < 0 .0 0 1
Male, %[n] 37.0[90] 45.1 [138] 56.7[ 135] 60.71105] < 0 .0 0 1
BMI (kg/m2) 23.5[23.0—23.9] 25.1 [24.7-25.4] 27.3[26.9—27.7] 29.9(29.3-30.3] < 0 .0 0 1
Waist circumference (cm) 75.7[74.4-77.0] 81.6[80.5-82.8] 88.4[87.1-89.7] 96.4(94.8-97.9] < 0 .0 0 1
Triglyceride (mmol/1) 0.9[0.8-0.9] 1.0[0.9—1.1] 1.4[ 1 .3— 1.5] 2 .1  [2 .0 - 2 .2 ] < 0 .0 0 1
HDL (mmol/1) 1.56[1.52-1.60] 1.43[ 1.40-1.47] 1.24[ 1.19-1.28] 1.03(0.98-1.08] < 0 .0 0 1
LDL (mmol/1) 3.4[3.3-3.5] 3.6[3.5—3.7] 3.8[3.6—3.9] 3.8(3.7-3.9] < 0 .0 0 1
SBP (mmHg) 111 [110-114] 130[ 126—132] 134[ 132— 136] 139(136-141] < 0 .0 0 1
DBP (mmHg) 72[71—73] 81 [80-82] 83[81 —84] 87(85-88] < 0 .0 0 1
Smoking (pack years) 7.7[5.0—10.3] 10.4[8.0—12.8] 14.5(11.8-17.2] 18.1(15.0-21.3] < 0 .0 0 1
Glucose (mmol/1) 5 .2[5 .1-5.3] 5.5[5.4-5.6] 5.7[5.6—5.8] 6.2(6.1-6.3] < 0 .0 0 1
Insulin (mU/1) 4.2[3.5—4.8] 5.1 [4.5-5.6 ] 7.0[6.3-7.6] 10.7(10.0-11.4] < 0 .0 0 1
CRP (mg/1) 1.14[ 1.00—1.30] 1.57[ 1.39-1.77] 2.23(1.94-2.55] 2.70(2.30-3.17] < 0 .0 0 1
IL - 6  (pg/1) 3.08[2.92-3.26] 3.47[3.31—3.65] 3.93(3.71-4.15] 4.33(4.05-4.61] < 0 .0 0 1
IL-18 (pg/ml) 255[243-268] 279[267—292] 315(300-331] 356(340-381] < 0 .0 0 1
Table 5.14: B aselin e characteristics o f  SCA R F, by cases and controls. Data is either
mean or geom etric m ean[95%  C l].
Variable Controls (n=387) Cases (n=387) P
Age 53.0[52.5—53.5] 52.5[51.9-53.0] 0.16
Ever smoked, %[n] 59.9[230] 75.3[290] < 0 .0 0 1
BMI (kg/m2) 25.7[25.4-26.0] 27.1 [26.7-27.5] < 0 .0 0 1
SBP (mmHg) 128.0[ 126.3—129.7] 128.8[127.0-130.6] 0.55
DBP (mmHg) 81.6[80.6-82.6] 80.3 [79.3-81.3] 0.06
HDL (mmol/1) 1.35[ 1.31—1.39] 1.06 [1.03-1.09] < 0 .0 0 1
LDL (mmol/1) 3.47[3.38—3.55] 3.16[3.05L3.26] < 0 .0 0 1
Triglycerides (mmol/1) 1.21[1.16-1.27] 1.67[ 1.59-1.76] < 0 .0 0 1
Mean % stenosis ND 32.1 [31.0-33.3] —
Normalised plaque area6 ND 0 .2 1  [0 .2 0 - 0 .2 2 ] —
CRP (mg/1) 0.95 [0.86-1.06] 1.59[1.41—1.79] < 0 .0 0 1
EL- 6  (pg/ml) 0.71 [0.66-0.75] 0.95 [0.88-1.02] < 0 .0 0 1
IL-18 (pg/ml) 266.6[257.0-276.6] 285.6[274.2-297.4] 0 .0 1
6Total plaque area normalised to segment length
1 2 0 0 -
p=0.01
1 0 0 0 -
8 0 0 -
2  6 0 0 -
00
4 0 0 -
2 0 0 -
Controls C ases
Figure 5.6: Box plots of IL-18 levels in SCARF by cases and controls.
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Figure 5.8: Scatter plot o f IL-18 levels and normalized plaque area in SCARF cases.
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Table 5.15: P values from multivariate analysis in SCARF comparing IL-18 levels be­
tween cases and controls.
Model 1 Model 2 Model 3 Model 4
Variable Age and ever smoked Model 1 + DBP Model 2 + CRP Model 3 + IL-6
IL-18 0 . 0 1 0.005 0 . 0 2 0 . 0 2
Model 4 Age, ever smoked, DBP, CRP, and IL - 6
As shown in table 5.15, the association between IL-18 levels and case/control status 
remained statistically significant in all four models. Importantly, the association was 
still present following adjustment for both CRP and IL-6 , showing the effect of IL-18 
to be independent of these two inflammatory markers.
5.4.2 IL-18’s Influence on Obesity
5.4.2.1 Univariate Analysis
As shown in table 5.16 on the following page, IL-18 levels were significantly higher 
in those who were obese than those who were not (p=0.02) in the total SCARF study. 
However, when the sample was divided into cases and controls, the differences observed 
were no longer significant (p=0.23 and p=0.08, respectively). In both cases, IL -18 levels 
were elevated in the obese, and it is possible that the loss of significance, particularly in 
the controls, is due to the loss in statistical power when the sample was divided. When 
considered by tertiles of IL-18, those SCARF controls with IL-18 levels in the highest 
tertile had a 2 .2 -fold increased risk of obesity compared to those in the lowest tertile 
(p=0.05), whilst for cases this was a 1.2-fold increase in risk (p=0.34). As expected, in 
the total cohort the increase in risk for obesity was more significant than in controls but 
o f a lesser magnitude (RR=1.57, p=0.03, see table 5.17 on page 205).
In the total sample, IL-18 levels were significantly correlated with BMI (p=0.14, 
p< 0 .001 , see figure 5.9 on page 205). When divided into cases and controls, it remained 
significantly correlated, however the correlation was weaker in cases than controls (con­
trols -  p = 0.13, p=0.009; cases -  p = 0 .11, p=0.04). There was a significant interaction 
between case/control status and IL-18, on BMI (p=0.03) suggesting the relationship 
between IL-18 and BMI is influenced by case/control status.
5.4.2.2 M ultivariate Analysis
Four separate models were used in multivariate analysis with the following covariates 
used:
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Table 5.16: IL-18 levels in ob ese  and non-obese S C A R F individuals w ithin both cases and controls, and cases and controls individually.
Geometric mean[95% Cl] IL-18 (pg/ml)
Test Group Within group Non-obese Within group Obese p
%[n] %[n]
Total (n=774) 83.3[645] 271.7[263.7-279.9] 16.7[129] 297.6[278.0-318.6] 0.02
Controls (n=387) 89.7[347] 263.7[253.7-274.1] 10.3[40] 294.5[262.5-330.5] 0.08
Cases (n=387) 77.0[298] 281.7[268.9-295.0] 23.0[89] 299.0(274.4-325.7] 0.23
Table 5.17: RRs[95% Cl] for obesity by tertiles o f IL-18 in SCARF cases, controls, and 
cases and controls together.
Tertile Controls P
RR|95% C l| for obesity 
Case p Total P
1
2
3
1
1.75[0.76-4.03]
2.23(0.98-5.05]
0.18
0.05
1
0.80(0.48-1.35] 0.41 
1.23(0.79-1.92] 0.34
1
1.04(0.67-1.62]
1.57(1.05-2.34]
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Figure 5.9: The correlation o f IL-18 levels with BMI in SCARF cases, controls, and the 
total sample.
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Table 5.18: R esults (as p values) from multivariate analysis o f  d ifferences in IL-18
levels by obesity  status in SC A R F.
Model 1 Model 2 Model 3 Model 4
Variable Age and smoking Model 1 + ever smoked Model 2 + case/control status Model 3 + IL-6 and CRP
IL-18 0 . 0 2 0 . 0 1 0.05 0 . 1 1
Model 1 Age and sex
Model 2 Age, sex, and ever smoked
Model 3 Age, sex, ever smoked, and case/control status
M odel 4 Age, sex, ever smoked, case/control status, IL-6 , and CRP
As shown in table 5.18, the association remained significant (albeit borderline) un­
til adjusted for IL - 6  and CRP. However, adjustment for case/control status has a large 
impact on the association; adjustment for case/control status alone attenuates the asso­
ciation to a large degree.
5.5 Discussion
The studies used here differ to such a degree that forming a conclusion for the impact 
o f IL -18 levels on overall CHD risk is difficult. All studies differ in collection, purpose, 
and end-point, such that comparisons cannot easily be made. However, between them 
they do offer an insight into IL -18 production at disease initiation, development and 
establishment.
With regard to disease initiation, mean IL-18 levels were significantly elevated in 
those individuals within NPHSII who went on to suffer an MI over the 15 yr of follow- 
up (277.6 pg/ml vs. 239.6 pg/ml, p=0.008). As might be expected, given that IL-18BP 
was not different between those who suffered an MI and those who did not, this asso­
ciation was also seen with fIL-18 (153 .2pg/ml vs. 136.6pg/ml, p=0.05) although the 
scale of the difference was diminished and less significant. As such, when analysed by 
tertiles o f fIL -18 there was no significant increase in RR when comparing the top to the 
bottom tertile, but most likely this reflects the low statistical power available given only 
95 incident M is during follow-up, equating to 36 individuals in the top tertile of fIL-18 
suffering an MI. Furthermore, fIL-18 is not strictly an observed variable but a calcu­
lated one, and as such, how well the calculated levels truly reflect in vivo fIL-18 levels 
is unknown. The use of a bioassay for fIL-18, such as that published by Konishi et al. 
[1997], would help to assess how well calculated fIL-18 correlates with IFNy-inducing 
activity. However, these experiments have not been done.
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O f significant interest is the observation that this predictive ability of IL-18 is spe­
cific to MI and was not seen when analysing all CHD end-points together (stroke, MI, 
and angina). Therefore those with the highest levels of IL-18 were more likely to suf­
fer an MI as their first experience of disease, suggesting that the plaque responsible 
is significantly more prone to rupture than those for whom angina is the first sign of 
disease.
The study undertaken by Blankenberg et al. 12003] was comparable to the analy­
ses undertaken here. The PRIM E cohort was a prospective study composed of healthy 
middle-aged men collected from across Western Europe, with a combined end-point in­
cluding hard coronary events (MI, and coronary death) and angina. As detailed in sec­
tion 1.4.1.2 on page 47, IL-18 was significantly higher in those who suffered an event 
during the five-year follow-up than those who did not (p=0.005). However, contrary to 
the findings here, they found the effect to be weakest (though not significantly so) in 
those who suffered an actual MI over those who presented with angina (see figure 5.10 
on the next page). The increase in RR, top tertile vs. bottom tertile, for angina was 
1.79[ 1.23-1.61] (p for trend=0.003), whilst for Ml/coronary death it was 1.38[0.98- 
1.93] (p for trend=0.06). However the difference between the two RRs was not statisti­
cally significant (p=0.31). There was substantial differences between RRs when those 
from France and Belfast were analysed separately, however the risk was consistently 
greater in those from Belfast, and therefore this geographic difference is not likely to be 
responsible for the difference seen between PRIME and NPHSII.
The ability of IL -18 to predict future MI was weak and did not survive multivari­
ate analysis, indeed the association was lost with adjustment of smoking status alone. 
When separating the cohort into those who had ever smoked and those who had not, 
the association between IL-18 levels and future MI was not present in either subgroup, 
and IL-18 levels were not significantly different in those had smoked and those who 
had not. In logistic regression, with MI as the outcome variable, IL-18 was no longer a 
significant predictor of MI when smoking was included as a covariate, and there was no 
evidence for an interaction between smoking and IL-18 levels (p for interaction=0.42). 
Therefore the exact relationship between IL-18 and smoking status, and their relation­
ship with future risk of MI, remains unclear.
The CUDAS study, as an asymptomatic cohort, is also able to give an insight into 
the impact of IL-18 on early disease development. In this study, Chapman et al. [2006] 
showed a significant correlation between IL-18 levels and IMT. However IL-18 levels 
did not differ significantly between those who had evidence of asymptomatic plaque 
and those who did not, suggesting that in this cohort IL-18 was more closely related 
to CHD development than initiation. However, these results are somewhat contradicted 
by those found in SCARF where IL-18 levels were significantly higher in cases than 
controls (285.6 pg/ml vs. 266 .6pg/ml, p=0.01). Most likely this disagreement was due
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Figure 5.10: RRs[95% Cl] for PRIME coronary events according to tertiles of IL-18, taken from Blankenberg et al. [2003]. Data is separated by 
country and end-point, and adjusted for BMI, smoking status, diabetes, hypertension, total cholesterol, HDL, triglycerides, and CRP.
to differences in the timeline of disease; CUDAS is an asymptomatic cohort, whilst 
SCARF cases had already suffered an MI prior to recruitment.
This difference in IL-18 levels between cases and controls in SCARF was robust, 
and was not significantly attenuated following adjustment for other inflammatory fac­
tors (IL - 6  and CRP). Relating levels to plaque morphology, IL-18 was significantly 
positively correlated with normalized plaque area but did not appear to be related to 
degree of stenosis. Interestingly, in their paper on IL-18 levels in SCARF, Hulthe et al. 
[2006], note that IL-18 was significantly correlated with IFNy and therefore it is safe 
to assume that, of the IL -18 measured in this cohort, a significant proportion is both 
mature (ie. cleaved by a caspase) and free (ie. not bound to IL-18BP).
Being a case/control cohort, SCARF is unable to distinguish whether IL-18 is causal 
or reactive in CHD. However, the results from both NPHSII and, in part, CUDAS, allied 
with previously published data from Blankenberg et al. [2003], strongly suggests that 
IL -18 levels predict future incidence of disease in individuals with no outward signs of 
disease. However, to truly establish causality, the role of genetic variants that associate 
with life-time elevated IL -18 levels must be studied. This analysis is detailed in the next 
chapter.
Since levels of IL-18 are significantly higher in those who go on to suffer a major 
complication following surgery in CABG, this suggests that IL-18 may also play a role 
in post-event survival. The association between IL-18 levels 24 h after surgery and in­
creased risk of a major com plication following surgery, remained significant in subset 
analysis using increased ventilatory support (>  12 h) and extended ICU stay (> 2 d , data 
not shown) as outcomes, dem onstrating the longstanding effects of early IL-18 acti­
vation. How this surgical model of post-event immunoactivation used here equates to 
processes leading up to, and immediately after plaque rupture is unclear. However, there 
are animal models that suggest IL -18 levels may influence post-MI survival. In caspase- 
1 knockout mice no bioactive IL-18 is present in the plasma due to the requirement of 
caspase-1 processing for mature IL-18 production. When these animals undergo left 
coronary artery ligation to induce MI, they have significantly greater post-event sur­
vival than wild-type animals [Frantz et al., 2003]. Although caspase-1 has a number 
of functions other than IL -18 processing, IL -18 has been shown to predict long-term 
survival in patients with advanced disease [Chalikias et al., 2005; Blankenberg et al., 
2002; Seta et al., 2000; Blankenberg et al., 2006].
In humans, Blankenberg et al. [2002] found IL-18 levels were significantly higher 
among those in the AtheroGene  cohort (a prospective study of patients with documented 
CHD) who had a fatal cardiovascular event during follow-up than among those who did 
not (68.4 pg/ml vs. 58.7 pg/ml, p<0.001). Each quartile increase in baseline IL-18 con­
centration was associated with a L46[ 1.21-1.76] (p<0.001) increase in future cardio­
vascular death (see figure 5.11 on page 211). As in CABG, this association remained
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significant following adjustment for other inflammatory mediators.
There is now a good deal of data to implicate the IL-18 system in determining 
plaque stability, and from the data here it appears that, within the IL -18 system, research 
should concentrate on IL-18 as IL-18BP did not show any significant associations. It 
has not been feasible to study the expression of the IL-18 receptor complex here, and 
it is possible that the relative expression of IL-18R differs between stable and unstable 
plaques (perhaps due to differences in cell content or state of activation/differentiation). 
Although IL-18R has been localized to atherosclerotic plaques [Mallat et al., 2001a], 
it’s role in plaque stability has not been studied. Should a difference exist, then the 
effect of increased IL-18 expression in unstable vs. stable plaques could be exacerbated 
or reduced.
The realization that IL-18 may have effects beyond the immune system is a rela­
tively recent discovery. As a pro-inflammatory cytokine it had been studied in the con­
text of metabolic syndrome, but the observation that i l l8 ~ /~  mice were hyperphagic 
[Netea et al., 2006] suggested that IL-18 was closely involved in appetite regulation.
From the results presented here there is little evidence for an intimate relationship 
between plasma IL-18 and BMI. IL-18 levels did correlate with BMI and BSA how­
ever there was no real consensus between the studies, with CABG showing a negative 
correlation and both NPHSII and SCARF showing positive correlations. In any case, 
the degree of correlation, although significant, was not of a large degree with values of 
around p  =  ±0.1. In SCARF IL-18 levels were significantly higher in those who were 
obese than those who were not obese. However, there were substantially more obese 
individuals in the case group than the control (n=89 vs. n=40, p<0.001), and when 
analysed in cases and controls separately there was no difference between obese and 
non-obese. Furthermore, in multivariate analysis the association was borderline when 
adjusting for case/control status (p=0.05) and so it therefore seems likely that the asso­
ciation seen with obesity is simply reflecting the higher IL-18 levels seen in cases than 
controls.
Netea et al. [2006] suggested that because only intra-cerebral injection reversed 
the phenotype of the i l l8 ~ /~  mouse, the hypothalamus may be the target of IL-18. 
Therefore local, not systemic, production of IL-18 could be more important in appetite 
regulation. IL-18 mRNA expression has been observed in the bovine [Nagai et al., 
2005] and rat pituitary gland (functionally connected to the hypothalamus by the median 
eminence), where it was significantly increased following stress [Wang et al., 2006]. It 
therefore seems possible that IL-18 production within the brain is more important in 
appetite regulation than systemic production.
In conclusion, IL-18 levels were a significant predictor of, specifically, incidence 
of future MI over a period of 15 yr. The association was seen with both total and free 
IL-18, but was not independent of other risk factors and seemed particularly related to
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Figure 5.11: Kaplan-Meier curves for survival according to quartiles of IL -18; p(logrank test)< 0 .001 [Blankenberg et al., 2002]
smoking status. Furthermore both total and free IL-18 levels at 24 h following surgery 
were predictors of a major post-operative complication. There appeared little relevance 
of systemic IL-18 levels to BMI or future risk of obesity.
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Chapter 6
The Influence of IL-18 System Genetic 
Variation on Disease Risk
The aim of this chapter is to relate the results from chapter 4 to those presented in 
chapter 5. If those individuals possessing particular genetic variation that predisposes 
them to elevated/decreased fIL-18 levels throughout their life, were also at an increased 
risk of disease, it would suggest that IL-18 was causal in such diseases. This is the 
basis of mendelian randomization [Davey Smith and Ebrahim, 2005; Little and Khoury, 
2003], which has been shown to be of use in distinguishing between causality and 
reverse causality [Timpson et al., 2005; Herder et al., 2007; Casas et al., 2005]. CUDAS 
and CUPID data is not presented here as relevant data analysis was not possible.
6.1 CABG
6.1.1 Genetic Variation and Risk of Major Post-Operative Compli­
cation
6.1.1.1 Single SNP Analysis
As shown in table 6 .1 on the next page, in the CABG study only /ZJS+8855 T > A  geno­
type frequencies differed significantly between those who suffered a major complica­
tion and those who did not (p=0.007). The association was such that heterozygotes were 
more common in those who suffered a major complication, thus being heterozygote at 
+8855 was associated with a 1.3-fold increase in risk (p=0.007). Importantly IL18- 
5848 T > C  (the tSNP associated with differences in IL-18 and fIL-18 levels) genotype 
frequencies did not differ significantly between the two groups (p=0.76). There was 
also no significant difference in the frequency of IL18BP  tSNP genotype frequencies 
between the two groups (see table 6 . 2  on page 215).
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Table 6.1: A lle le  frequencies and RRs[95%  C l] for IL18  tSN Ps in those w ho suffered a m ajor post-operative com plication  fo llow in g  C A B G , and
those w ho did not.
tSNP and complete­
ness of genotyping 
(%)
Total HWE p
%[n]
No M ajor Complica- M ajor Complica­
tion (n=218) tion (n=2 0 2 )
X 2 P RR[95% Cl] P
GG 35.0[76] 34.8[70] 1 —
-9731 (99.5) GT 0.82 47.5[ 103] 50.2[ 101] 0.74 1.03[0.83-1.28] 0.77
TT 17.5[38] 14.9[30] 0.92[0.67-1.26] 0.60
TT 34.9[76] 38.1 [77] 1 —
-5848(100.0) TC 0.45 50.9[111] 47.5[96] 0.76 0 .92[0 .74-l. 14] 0.46
CC 14.2[31] 14.4[29] 0.96[0.71-1.30] 0.79
AA 51.4[112] 42.3[99] 1 —
+ 105 (99.8) AC 0.95 37.6[82] 49.3[99] 0.06 1.27[ 1.03-1.56] 0.03
CC 11.0[24] 8.5[17] 0.96[0.65— 1.43] 0.84
TT 49.5[ 108] 39.5[79] 1 —
+8855 (99.5) TA 0.57 38.1 [83] 53.0[ 106] 0.007 1.33[ 1.08-1.64] 0.007
AA 12.4[27] 7.5[15] 0.85[0.55—1.31] 0.44
AA 33.5[72] 28.4[57] 1 —
+ 11015(99.0) AC 0.28 47.4[102] 56.2[113] 0 . 2 0 1.19[0.94— 1.50] 0.13
CC 19.1 [41 ] 15.4[31] 0.97[0.70—1.35] 0 . 8 8
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Table 6.2: A lle le  frequencies and R R s[95%  C l] for IL18BP  tSN Ps in those w ho suffered a major post-operative com plication  fo llow in g  C A B G ,
and those w ho did not.
%[n]
tSNP and complete- Total HWE p No Major Complica- M ajor Complica- x 2 P RR[95% Cl] p
ness of genotyping tion(n=218)
(%)_____________________________________________
TT 86.1 [186]
-1765 (98.3) TC 0.02 12.5[27]
CC 1.4[3]
TT 76.9[ 166]
-559 (98.3) TG 0.49 22.2[48]
GG 0.9[2]
CC 94.0[204]
+3041 (99.3) CT 0.55 6.0[13]
TT —
tion (n=2 0 2 )
89.3(176] 1 —
9.6[19] 0.61 0.85(0.59-- 1 .2 2 ] 0.35
1 .0 [2 ] 0.82(0.28--2.42] 0.70
84.3[ 166] 1 —
15.2(30] 0.16 0.77(0.57--1.04] 0.07
0.5(1] 0.67(0.13--3.31] 0.57
94.5(189] 1 —
5.5(11] 0.83 0.95(0.61--1.49] 0.83
Table 6.3: H aplotype frequencies and O R s[95%  C l] for IL18 tSN P haplotypes in those
w ho suffered a major post-operative com plication  fo llow in g  C A B G , and those w ho did
not.
Frequency (%)
Haplotype Total No Major Major Com- OR[95% Cl] p
Complica- plication 
tion(n=179) (n=168)
hGCATA h 1 2 1 1 1 27.9 28.1 27.7 1 —
hTTCAC h2 1 2 2 2 24.7 24.1 25.4 1.02[0.69-1.50] 0.93
hGTATA hi 1 1 1 1 22.4 2 2 . 1 22.7 0.99[0.65-1.50] 0.95
hTTATC h2 1 1 1 2 9.3 1 0 . 8 7.7 0.68[0.38-1.20] 0.18
Table 6.4: Haplotype frequencies and ORs[95% Cl] for IL18BP tSNP haplotypes in 
those who suffered a major post-operative complication following CABG, and those 
who did not.
Frequency (%)
Haplotype Total No Major Major Com- OR[95% Cl] p 
Complica- plication 
tion(n=179) (n= 168)
hTTC h i l l 87.1 84.9 89.5 1
hTGC h 121 8 . 0 9.7 6 . 2 0.60[0.34-1.06] 0.08
hCTT h2 1 2 1 .8 1.4 2 .1 1.51 [0.47-4.88] 0.49
hCTC h2 1 1 1.4 1.5 1.3 0.86[0.20-3.59] 0.83
6 .1.1.2 Haplotype Analysis
As shown in table 6.3, table 6.4, and figure 6.1 on the next page, no IL18 or IL18BP  
haplotype was significantly associated with increased or decreased risk of a major com ­
plication following surgery.
6.1.1.3 MDR Analysis
There was no evidence for a significant epistatic effect between the IL18 and IL18BP 
tSNP sets, when considering a major complication following surgery as the outcome 
(see figure 6 . 2  on page 218).
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Figure 6 .1: ORs[95% Cl] associated with risk of major complication following CABG 
surgery for each IL18 and IL18BP  haplotype.
6.1.2 IL18’s Effect on Obesity and BMI
6.1.2.1 Single SNP Analysis
Univariate Analysis As shown in table 6.5 on page 219, only /L/tf-5848 T > C  geno­
type frequency differed significantly between those who were obese and non-obese in 
CABG (p=0.01). This equated to a lower RR for C allele carriers. Heterozygotes 
had an RR[95% Cl] of 0.57[0.40-0.83] (p=0.003), whilst for C homozygotes this was 
0.68[0.40-1.15] although this was not significant (p=0.13). 7L/S-5848 was also associ­
ated with significant differences in BMI (p=0.008, see table 6 . 6  on page 220) although 
the pattern was not a straightforward additive pattern with heterozygotes having lower 
BMI than both homozygote groups. This effect was similar when analysis was restricted 
to the non-obese, but was only borderline significant (p=0.06). In the obese no signifi­
cant differences were observed between the genotype groups (p=0.38, see figure 6.3 on 
page 2 2 1 ).
There were no significant associations between IL18BP tSNPs and risk of obesity 
or BMI (see table 6.7 on page 222 and table 6 . 8  on page 223).
Multivariate Analysis Four models were used in multivariate analysis to test the ef­
fect of covariates on the association between variation in IL18 and BMI:
Model 1 Sex and age
Model 2 Sex, age, and smoking
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Figure 6.2: Mean p values[SD] from MDR analysis in CABG using major complication 
following surgery as outcome.
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Table 6.5: IL18 tSN P  gen otype frequencies and R Rs[95%  C l] in ob ese and non-obese
individuals w ithin C A B G .
tSNP Non-
Obese
(n=320)
%[n]
Obese
(n = 1 0 0 )
X2 P RR[95% Cl] P
GG 35.8[114] 32.0[32] 1 —
-9731 GT 49.1 [156] 48.0[48] 0.48 1.07[0.72-1.59] 0.72
TT 15.1 [48] 2 0 .0 [2 0 ] 1.34[0.83-2.17] 0.23 .
TT 32.5[104] 49.0[49] 1 —
-5848 TC 52.8[ 169] 38.0[38] 0 . 0 1 0.57[0.40-0.83] 0.003
CC 14.7[47] 13.0[ 13] 0.68[0.40-1.15] 0.13
AA 47.3[ 151] 46.0[46] 1 —
+ 105 AC 42.3[135] 46.0[46] 0.71 1.09[0.76—1.55] 0.64
CC 10.3[33] 8 .0 [8 ] 0.84[0.43-1.63] 0.59
TT 45.3[ 144] 43.0[43] 1 —
+8855 TA 44.3[141] 48.0[48] 0.80 1.10[0.77—1.58] 0.59
AA 10.4[33] 9.0[9] 0.93[0.49-1.76] 0.83
AA 31.2[99] 30.3[30] 1 —
+11015 AC 50.5[ 160] 55.6[55] 0.56 1.10[0.75—1.62] 0.63
CC 18.3[58] 14.1 [14] 0.84[0.48-1.47] 0.53
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Table 6.6: G eom etric m ean[95%  C l] BM I (kg/m 2) by IL18 tSN P in both ob ese and n on-obese individuals in C A B G .
Geometric mean BMI[95% Cl] (kg/m2) 
tSNP Total p/R 2 Non-Obese (n=320) p/R2 Obese (n= 100) p/R 2
GG 28.3[27.4-29.1] 26.2125.5-26.9] 33.5132.6-34.5]
-9731 GT 27.9[27.1-28.6] 0.69/0.2 25.5[24.9-26.0] 0.26/1.4 33.3[32.4-34.2] 0.93/0.1
TT 28.4[27.1-29.7] 25.7[24.8-26.6] 33.3[31.5-35.1]
TT 28.9[28.1-29.7] 26.2125.6-26.8] 33.2132.3-34.2]
-5848 TC 27.3[26.5-28.0] 0.008/3.2 25.3[24.8-25.9] 0.06/2.8 33.2[32.4-34.1] 0.38/2.0
CC 28.8127.3-30.4] 26.4125.3-27.6] 34.5[32.7-36.5]
AA 28.4127.7-29.1] 26.2125.6-26.8] 33.3[32.5-34.2]
+ 105 AC 27.8[27.0-28.7] 0.59/0.4 25.1[24.5-25.7] 0.009/4.7 33.7[32.7-34.8] 0.20/3.3
CC 28.3[27.1-29.5] 26.8[25.8-27.8] 31.7[30.8-32.6]
TT 28.3[27.6-29.0] 26.2[25.6-26.8] 33.4132.5-34.2]
+8855 TA 27.9[27.1-28.7] 0.72/0.2 25.2[24.6-25.8] 0.02/4.0 33.7132.7-34.8] 0.17/3.6
AA 28.2[27.1-29.4] 26.7[25.8-27.6] 31.7[30.9-32.4]
AA 28.4[27.6-29.2] 26.4[25.7-27.1] 33.1[32.4-34.0]
+11015 AC 28.2[27.4-28.9] 0.52/0.4 25.5[25.0-26.0] 0 . 1 1 /2 . 2 33.7[32.8-34.6] 0.49/1.5
CC 27.5[26.3-28.7] 25.7124.7-26.7] 32.7[30.7-34.9]
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Figure 6.3: Box plots of BMI by IL18 tSNP genotype in the total CABG cohort and 
the obese and non-obese within it. Line -  Median; Box -  75th to 25th percentile; o -  
outlier (>  1.5 box lengths out of box); * -  extreme (> 3  box lengths out of box); whisker 
-  last value not an outlier.
221
Table 6.7: IL18BP  tSN P genotype frequencies and R Rs[95%  C l] in ob ese  and non-
ob ese individuals w ithin C A B G .
tSNP Non-
Obese
(n=320)
%[n]
Obese
(n = 1 0 0 )
X2 P RR[95% Cl] P
TT 87.0[274] 89.8[88] 1 —
-1765 TC 11.7[37] 9.2[9] 0.76 0.80[0.44-1.49] 0.48
CC L3[4] 1 .0 [ 1 ] 0.82[0.14-4.79] 0.82
TT 81.2[254] 78.0[78] 1 —
-559 TG 18.2[57] 2 1 .0 [2 1 ] 0.76 1.15(0.76-1.73] 0.52
GG 0 .6 [2 ] 1 .0 [ 1 ] 1.42(0.28-7.11] 0.69
CC 93.7[297] 96.0[96] 1 —
+3041 CT 6.3[20] 4.0[4] 0.39 0.68(0.27-1.70] 0.39
TT — — — —
Model 3 Sex, age, smoking, and IL-6
Model 4 Sex, age, smoking, baseline IL-6 , and baseline IL-18BP
As shown in table 6.9 on page 224, the association between 7L7S-5848 and BMI re­
mained significant in multivariate analysis following adjustment for sex, age, smoking, 
and IL - 6  (p=0.02), but was significantly attenuated following adjustment for IL-18BP 
(p=0.24).
6 .1.2.2 Haplotype Analysis
Univariate Analysis 1L18 haplotypes were not globally associated with differences 
in BMI, although hGTATA was associated with a 1.9-fold increase in risk of obesity 
in CABG (p=0.004, see table 6.10 on page 225 and figure 6.4 on page 224). This 
haplotype was also associated with significantly higher BMI with those homozygote 
for the haplotype estimated to have a BMI of 30.3 kg/m 2 compared to 27.5 kg/m 2 for 
the reference haplotype (hGCATA, see figure 6.5 on page 227). When analysing in 
both the obese and non-obese the effect of hGTATA on BMI was not significant in 
either group, although the estimated haplotypic mean InBMI was higher for hGTATA 
in the non-obese only (see table 6 . 1 2  on page 226).
No IL18BP haplotype was seen to differ in frequency between the obese and non- 
obese groups, and none was significantly associated with differences in BMI (see ta­
ble 6.11 on page 225 and table 6.13 on page 226).
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Table 6.8: G eom etric m ean[95%  C l] B M I (kg/m 2) by ILI8BP  tSN P  in both ob ese and n on-obese individuals in C A B G .
Geometric mean BMI[95% Cl] (kg/m 2)
tSNP Total p/R2 Non-Obese (n=320) p/R2 Obese (n=100) p/R2
TT 28.0[27.5-28.6] 25.7[25.3-26.2] 33.3[32.7—33.9]
-1765 TC 28.4[26.7-30.3] 0.61/0.3 26.1[24.7-27.7] 0.72/0.3 33.6[31.4-35.9] 0.77/0.2
CC 26.3[20.6-33.6] 25.0[ 18.6-33.5] —
TT 28.0[27.5-28.6] 25.7[25.2-26.1] 33.5[32.8-34.2]
-559 TG 28.4[27.3-29.5] 0.71/0.2 26.1 [25.3-27.1] 0.56/0.6 32.7[31.2-34.3] 0.30/2.8
GG 30.0[ 18.3-49.0] 26.7[19.1-37.4] —
CC 28.1 [27.6-28.6] 25.8[25.4—26.2] 33.3[32.7-34.0]
+3041 CT 27.7[24.4-31.4] 0 .7 2 /< 0 .1 25.0[22.2-28.3] 0.42/0.3 34.6[29.2-41.0] 0.43/0.6
TT — --- —
Table 6.9: R esults from multivariate analysis o f  IL18  tSN P ’s association  w ith  B M I in
CA BG .
IL18  SNP
Model 1
Sex and age
Model 2
Model 1 + smoking
Model 3
Model 2 + baseline IL-6
Model 4
Model 3 + baseline IL-18BP
-9731 0.73 0.79 0.92 0.42
-5848 0 . 0 0 2 0 . 0 0 2 0 . 0 2 0.24
+105 0.78 0.70 0.84 0.53
+8855 0.85 0.80 0.84 0.76
+11015 0.75 0.73 0.63 0.49
CT>
- □
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Figure 6.4: OR[95% Cl] for obesity associated with each IL18 haplotype in CABG; 
★-p=0.004.
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Table 6.10: IL18  haplotype frequencies and O Rs[95%  C l] in ob ese and non-obese individuals w ithin C A B G
Haplotype Total
Frequency (%) 
Non-obese (n=260) Obese (n=87) OR[95% Cl] P
hGCATA h 12111 27.8 28.7 24.9 1 —
hTTCAC h21222 24.8 24.4 26.1 1.39[0.90-2.17] 0.14
hGTATA h i 1111 22.5 2 0 . 1 29.6 1.93[ 1.23-3.05] 0.004
hTTATC h 2 1112 9.3 9.7 8 .1 1.09[0.54-2.19] 0.81
Table 6.11: IL18BP  haplotype frequencies and ORs[95% Cl] in obese and non-obese individuals within CABG
Haplotype Total
Frequency (%)
Non-obese (n=260) Obese (n=87) OR[95% Cl] P
hTTC h i l l 87.1 87.7 85.4 1 —
hTGC h i 21 8 . 0 7.2 10.5 1.48[0.82-2.70] 0 . 2 0
hCTT h212 1.7 2 . 0  1.1 0.55[0.12-2.48] 0.43
hCTC h211 1.4 1.3 2.0 1.77[0.41-7.75] 0.45
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Table 6.12: H aplotypic m ean lnBM I[95%  C l] by 1L18 haplotypes in the total C A B G  cohort, and in ob ese and n on-obese individuals separately.
Haplotypic mean lnBMI[95% Cl]
Haplotype Total p/R2 Non-obese (n=260) p/R 2 Obese (n=87) p/R2
hGCATA h 12111 1.658[ 1.639-1.677] — 1.623 [1.606-1.640] — 1.749[ 1.722-1.777] —
hTTCAC h21222 1.661 [ 1.631—1.691 ] 0.95 1.618[ 1.592—1.645] 0.83 1.732(1.699-1.765] 0.16
hGTATA h i 1111 1.706[ 1.677-1.735] 0 . 0 2 1.647[ 1.622-1.673] 0.16 1.766(1.743-1.788] 0.85
hTTATC h 2 1112 1.649[ 1.605-1.693] 0.81 1.609[ 1.572-1.647] 0.51 1.764(1.725-1.804] 0.94
Global p/R2 0.11/3.2 0.49/2.4 0.36/5.1
Haplotypic mean lnBMI[95% Cl] by 1L18BP haplotypes in the total CABG cohort, and in obese and non-obese individuals s
Haplotypic mean lnBMI[95% Cl]
Haplotype Total p/R2 Non-obese (n=260) p/R Obese (n=87) p/R2
hTTC h i l l 1.668[ 1.657-1.679] — 1.625[ 1.616—1.635] — 1.752(1.741-1.763] —
hTGC h 121 1.694[ 1.649-1.739] 0.29 1.636[ 1.587-1.685] 0.69 1.757(1.728-1.787] 0.76
hCTT h212 1.636[1.556-1.717] 0.45 1.586[1.518-1.653] 0.26 1.862(1.753-1.967] 0.06
hCTC h 2 1 1 1.656[ 1.542-1.771] 0.85 1.563[1.408-1.718] 0.43 1.715(1.572-1.857] 0.61
Global p/R 2 0.80/0.8 0.56/2.3 0.40/4.6
p=0.02
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Figure 6.5: Estimated BMI[95% Cl] for homozygotes of common 1L18 haplotypes in 
the total CABG cohort. P values refer to haplotypic mean analysis.
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Table 6.14: R esults from m ultivariate analysis o f  IL18  haplotypes and their association
with BM I in C A B G .
ILI8  haplotype
Model 1
Sex and age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + base­
line IL-6
Model 4
Model 3 + base­
line IL-18BP
hGCATA h 1 2 1 1 1 Ref Ref Ref Ref
hTTCAC h 2 1 2 2 2 0.31 0.30 0.39 0.90
hGTATA h l l l l l 0 . 0 1 0 . 0 1 0 . 0 2 0 . 0 2
hTTATC h2 1 1 1 2 0.85 0.81 0.93 0.97
Global p 0.09 0.08 0.14 0.06
Multivariate Analysis Contrary to the association between 7L7S-5848 T > C  and 
BMI, the association between hGTATA and BMI remained significant in all four mul­
tivariate models (see table 6.14). Adjustment for IL - 6  had no effect on the association, 
despite being significantly correlated with BMI (Spearm an’s p =  0.23, p<0.001), show­
ing the effect of IL-18 on BMI was independent of other inflammatory mediators.
6.1.2.3 MDR Analysis
The results from MDR analysis are shown in figure 6 . 6  on the following page, there 
appeared to be no significant interaction between IL18  and IL18BP  tSNPs on obesity in 
CABG.
6.2 NPHSII
6.2.1 Use of Genetic Variation in Predicting Future Risk of MI
6.2.1.1 Single SNP Analysis
As shown in table 6.15 on page 230 and table 6.16 on page 231, none of the IL18 or 
IL18BP  tSNPs were present at significantly different frequencies in those who suffered 
an MI during follow-up and those who did not. Of particular note, the genotype fre­
quencies of both IL18BP-M 65  and +3041 differed significantly from that expected by 
HWE (p<0.001 and p=0.007, respectively). For -1765 T > C  the observed [expected] 
genotype counts were: TT -  2443[2433]; TC -  230[249]; CC -  16[6], whilst for +3041 
C > T  they were: CC -  2577J2574]; CT -  103[109]; CC -  4[1]. Therefore in both cases 
the disequilibrium was due to an excess of rare allele homozygotes.
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Figure 6 .6 : Results from MDR analysis in CABG using obesity as the outcome variable.
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Table 6.15: A lle le  frequencies and RRs[95%  C l] for IL18  tSN Ps in those w ho suffered an MI during fo llow -u p  in NPH SII, and those w ho did not.
tSNP and com plete­
ness of genotyping 
(%)
Total HWE p
%[n]
No MI (n=2870) MI (n=182) X 2 P RR[95% Cl] P
GG 39.5[977] 44.2[73] 1 —
-9731 (86.4) GT 0.04 45.2[1118] 41.8[69] 0.49 0.84[0.61—1.15] 0.27
TT 15.2[376] 13.9[23] 0.83[0.53-1.31] 0.42
TT 39.8[981] 37.7[63] 1 —
-5848 (86.2) TC 0.81 46.3[1140] 49.1 [82] 0.78 1.11 [0.81—1.53] 0.51
CC 13.9[343] 13.2[22] 1.00[0.62-1.60] 0.99
AA 50.2[ 1244] 52.1 [87] 1 —
+105 (8 6 .6 ) AC 0 . 1 0 40.3 [999] 38.9[65] 0.90 0.93[0.68—1.28] 0.67
CC 9.4[233] 9.0[15] 0.93[0.54-1.57] 0.77
TT 50.3[ 1202] 52.8[85] 1 —
+8855 (83.6) TA 0 . 0 2 39.9[954] 37.9[61] 0.83 0.91 [0.66-1.25] 0.56
AA 9.8[233] 9.3[15] 0.92[0.54-1.56] 0.75
AA 37.1 [929] 38.9[65] 1 —
+11015(87.4) AC 0.07 46.3[1157] 45.5[76] 0 . 8 8 0.94[0.68-1.30] 0.72
CC 16.6[415] 15.6[26] 0.90[0.58-1.40] 0.64
Table 6.16: A lle le  frequencies and RRs[95%  C l] for IL18BP  tSN Ps in those w ho suffered an MI during fo llow -u p  and those w ho did not.
tSNP and complete­
ness of genotyping
(%)
Total HW E p
%[n]
No MI (n=2870) MI (n=182) X 2 P RR[95% Cl] P
TT 91.0[2295] 88.6[148] 1 —
-1765 (88.1) TC < 0 . 0 0 1 8.4[212] 10.8[18] 0.57 1.29[0.81-2.07] 0.29
CC 0.6[ 15] 0 .6 [ 1] 1.03(0.15-6.93] 0.97
TT 77.4[1947] 77.2[ 129] 1 —
-559 (87.9) TG 0.62 21.0[529] 21.6[36] 0.92 1.03(0.72-1.47] 0.89
GG 1.6[40] l-2 [2 ] 0.77(0.20-2.99] 0.70
CC 96.1 [2416] 95.3[ 161] 1 —
+3041 (87.9) CT 0.007 3.8[96] 4.1 [7] 0.30 1.09(0.52-2.26] 0.82
TT 0.1[3] 0 .6 [ 1 ] 4.00(0.73-21.99] 0 . 1 2
Table 6.17: H aplotype frequencies and O Rs[95%  C l] for IL18 haplotypes in those w ho
suffered an M I during fo llow -u p  and those w ho did not.
Frequency (%)
Haplotype Total No MI M I(n=182) OR[95% Cl] p
(n=2870)
hGCATA h 1 2 1 1 1 31.6 31.6 32.1 1 —
hTTCAC h 2 1 2 2 2 25.6 25.7 23.8 0.93[0.70-1.24] 0.63
hGTATA hi 1 1 1 1 26.6 26.4 28.4 1.07(0.81-1.42] 0.62
hTTATC h 2 1 1 1 2 9.9 9.9 1 0 . 0 1.01(0.67-1.54] 0.95
Table 6.18: Haplotype frequencies and ORs[95% Cl] for IL18BP haplotypes in those 
who suffered an MI during follow-up and those who did not.
Haplotype Total
Frequency (%) 
No MI (n=2870)
i
MI (n=182) OR[95% Cl] P
hTTC h i l l 84.2 84.3 83.7 1 —
hTGC h 12 1 10.9 10.9 1 0 .1 0.93(0.64-1.35] 0.70
hCTT h 2 12 2 .1 2 . 0 2.7 1.31(0.69-2.48] 0.41
hCTC h 2 1 1 1 .6 1 .6 1.7 1.05(0.42-2.64] 0.92
6.2.1.2 H aplotype Analysis
Neither IL18  nor 1L18BP haplotype frequencies differed significantly between those 
w ho suffered an MI during follow-up and those who did not (see table 6.17 and ta­
ble 6.18).
6.2.1.3 M D R  Analysis
The results from MDR analysis in NPHSII using incidence of MI during follow-up as 
the outcom e are shown in figure 6.7 on the next page. There was no evidence for a 
significant epistatic effect between IL18  and 1L18BP tSNPs, on MI risk.
6.2.2 Genetic Variation and Obesity 
6.2.2.1 S ingle SNP Analysis
No ILI8  or IL18BP  tSNP was seen at significantly different frequencies in those who 
were obese or non-obese in NPHSII at baseline (see table 6.19 on page 234 and ta­
ble 6.20 on page 235). However, after five years of follow-up (during which a further 50 
individuals becam e obese), the IL18-5848 C allele was significantly rarer in those who
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Figure 6.7: The results from M DR analysis in NPHSII using MI during follow-up as 
the outcome variable.
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Table 6.19: A lle le  frequencies and R Rs[95%  C l] for IL18  tSN Ps in those w ho were
obese or n on-obese at baseline in NPH SII.
tSNP Non-Obese
(n=2623)
%[n]
Obese (n=429) X 2 P RR[95% Cl] P
GG 40.1 [910] 37.9(140] 1 —
-9731 GT 45.2[1024] 44.2(163] 0.27 1.03(0.83-1.27] 0.78
TT 14.7[333] 17.9(66] 1.24(0.95-1.62] 0 . 1 2
TT 39.0(884] 43.6(160] 1 —
-5848 TC 47.1(1066] 42.5(156] 0 . 2 2 0.83(0.68-1.02] 0.08
CC 13.9(314] 13.9(51] 0.91(0.68-1.22] 0.53
AA 50.1(1139] 51.8(192] 1 —
+ 105 AC 40.4(917] 39.6(147] 0.79 0.96(0.78-1.17] 0.67
CC 9.5(216] 8.6(32] 0.89(0.63-1.27] 0.53
TT 50.2(1100] 52.1(187] 1 —
+8855 TA 40.0(876] 38.7(139] 0.79 0.94(0.77-1.16] 0.57
AA 9.8(215] 9.2(33] 0.92(0.65-1.29] 0.62
AA 37.4(858] 36.4(136] 1 —
+11015 AC 46.3(1062] 45.7(171] 0.73 1.01(0.82-1.25] 0.90
CC 16.3(374] 17.9(67] 1.11(0.85-1.45] 0.45
were obese than those who were not (33.9% vs. 37.8%, x 2 p=0.04, data not shown). No 
SNP was associated with significant differences in BMI at baseline or after five years 
of follow-up (data not shown).
6 2 .2 .2  Haplotype Analysis
Only 1L18 hTTATC was seen at a significantly different frequency in those who were 
obese and those who were not at baseline. The difference in frequency equated to an 
OR[95% Cl] of 1.39[ 1.06-1.82] (p=0.02), this association was also present using data 
from five years o f follow-up (data not shown). No IL18 or IL18BP haplotype was 
associated with differences in BMI at baseline or after five years of follow-up (data not 
shown).
6.2.2.3 MDR Analysis
As shown in figure 6 . 8  on page 236, there was no evidence for interaction between IL18 
and IL18BP SNPs in causing obesity inNPHSII at baseline, or five years.
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Table 6.20: A lle le  frequencies and RRs[95%  C l] for IL18BP  tSN P s in those w ho w ere
ob ese or n on-obese at baseline in NPH SII.
tSNP Non-Obese
(n=2623)
%[n]
Obese (n=429) x 2 p RR[95% Cl] P
TT 90.5(2093] 93.1(350] 1 —
-1765 TC 9.0(208] 5.9(22] 0.06 0.67(0.44-1.01] 0.05
CC 0.5(12] 1.1(4] 1.75(0.74-4.10] 0.23
TT 77.2(1782] 78.2(294] 1 —
-559 TG 21.1(486] 21.0(79] 0.43 0.99(0.78-1.24] 0.91
GG 1.7(39] 0.8(3] 0.50(0.17-1.51] 0 . 2 0
CC 96.1(2216] 95.8(361] 1 —
+3041 CT 3.8(88] 4.0(15] 0.81 1.04(0.64-1.68] 0.87
TT 0.1(3] 0.3(1] 1.78(0.33-9.77] 0.53
Table 6.21: IL18 haplotype frequencies and ORs[95% Cl] in those who were obese or 
non-obese at baseline in NPHSII.
Frequency (%)
Haplotype Total Non-
Obese
(n=2623)
Obese
(n=429)
OR[95% Cl] P
hGCATA h 1 2 1 1 1 31.5 31.9 29.2 1 —
hTTCAC h2 1 2 2 2 25.6 25.8 24.8 1.02(0.84-1.24] 0.82
hGTATA hi 1 1 1 1 26.6 26.5 27.0 1.08(0.89-1.32] 0.43
hTTATC h2 1 1 1 2 9.9 9.5 12.3 1.39(1.06-1.82] 0 . 0 2
Table 6.22: IL18BP  haplotype frequencies and ORs[95% Cl] in those who were obese 
or non-obese at baseline in NPHSII.
Frequency (%)
Haplotype Total Non- Obese OR[95% Cl] p
Obese (n=429)
(n=2623)
hTTC h i l l 84.2 84.0 85.3 1 —
hTGC h 121 10.9 10.9 1 0 . 6 0.96(0.74-1.24] 0.75
hCTT h2 1 2 2 . 0 2 . 0 2 . 2 1.10(0.66-1.81] 0.72
hCTC h 2 1 1 1.7 1.7 1.1 0.66(0.30-1.45] 0.30
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Figure 6 .8 : Results from MDR analysis in NPHSII using obesity at baseline as the 
outcome variable.
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Figure 6.9: Haplotype ORs[95% Cl] for case/control status in SCARF.
6.3 SCARF
6.3.1 Genetic Differences Between Cases and Controls
63.1 .1  Single SNP Analysis
Only IL18+ 11015 A > C  was seen to differ significantly in frequency between cases and 
controls in SCARF (p=0.04), with the rare allele being more common in cases than in 
controls (44.3% vs. 41.5%, see table 6.23 on the next page).
63 .1 .2  Haplotype Analysis
As shown in table 6.24 on page 239, hGTATA was seen to differ substantially in fre­
quency between cases and controls (20.9% vs. 24.5%) although this difference was not 
statistically significant (p=0.10, see figure 6.9).
6.3.2 7L7#’s Association with Plaque Morphology
63.2 .1  Single SNP Analysis
Univariate Analysis IL18 -9 1 3 1 G >T, -5848 T > C , and +11015 A > C  were all signif­
icantly associated with normalized (to segment length) plaque area (p=0.004, 0.05, and 
0.01 respectively, see table 6.25 on page 239) and all showed additive genotype patterns 
(see figure 6.10 on page 240).
Multivariate Analysis Four separate models were used in multivariate analysis: 
Model 1 Sex and age
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Table 6.23: A lle le  frequencies for IL18  tSN Ps in cases and controls w ithin SC A R F, with resulting RRs[95%  C l].
tSNP and complete­
ness of genotyping
(%)
Total HWE p Controls (n=
%[n]
=387) Cases (n=387) X 2 P RR[95% Cl] P
GG 35.8[138] 35.9[135] 1 —
-9731 (98.4) GT 0.71 49.7[ 192] 45.2[170] 0 . 2 2 0.95[0.81-1.12] 0.53
TT 14.5[56] 18.9[71] 1.13[0.93-1.37] 0.23
TT 39.5[ 152] 37.2[ 140] 1 —  •
-5848 (98.3) TC 0.62 47.8[184] 47.9[ 180] 0.64 1.03[0.88—1.21 ] 0.70
CC 12.7[49] 14.9[56] 1.11(0.90-1.38] 0.34
AA 43.8[169] 44.8[169] 1 —
+105 (98.6) AC 0.97 46.6[ 180] 42.4[160] 0.29 0.94(0.81-1.10] 0.44
CC 9.6[37] 12.7[48] 1.13(0.91-1.40] 0.29
TT 44.0[170] 44.8 [169] 1 —
+8855 (98.6) TA 0.90 46.4[179] 42.2[159] 0.25 0.94(0.81-1.10] 0.46
AA 9.6[37] 13.0[49] 1.14(0.92-1.41] 0.24
AA 33.3[ 129] 34.2[129] 1 —
+11015(98.7) AC 0 . 2 0 50.4[ 195] 43.0[ 162] 0.04 0.91(0.77-1.07] 0.26
CC 16.3[63] 2 2 .8 [8 6 ] 1.15(0.96-1.39] 0.13
Table 6.24: Haplotype frequencies and ORs[95% Cl] in cases and controls within 
SCARF.
Frequency (%)
Haplotype Total Controls Cases OR[95% Cl] p
(n=387) (n=387)
hGCATA h 1 2 1 1 1 33.1 33.2 33.1 1 —
hTTCAC h2 1 2 2 2 29.9 29.9 29.8 0.92[0.72-1.18] 0.52
hGTATA hi 111 1 22.7 24.5 20.9 0.80[0.61-1.04] 0 . 1 0
hTTATC h2 1 1 1 2 9.1 8.5 9.7 1.06[0.73-1.54] 0.77
Table 6.25: Normalized plaque area and % stenosis of diseased vessel by IL18 genotype 
in SCARF. Data available for cases only.
Normalized plaque area % stenosis
tSNP Geometric mean [95% Cl] p/R2 (%) Mean[95% Cl] p/R2 (%)
GG 0.192[0.178-0.207] 30.2[27.9—32.5]
-9731 GT 0.220[0.206-0.235] 0.004/4.6 33.0[31.4-34.6] 0.06/2.4
TT 0.230[0.211-0.252] 33.3[31.1-35.6]
TT 0.224[0.209-0.240] 32.7[31.1-34.4]
-5848 TC 0.208[0.195-0.222] 0.05/2.5 3 1.9[30.1-33.6] 0.52/0.6
CC 0.190[0.168-0.215] 30.6[26.4-34.9]
AA 0.201 [0.187-0.215] 31.2[29.1—33.3]
+ 105 AC 0.221 [0.207-0.237] 0 . 1 0 /2 . 0 32.4[30.9-34.0] 0.40/0.8
CC 0.219[0 .197-0.243] 33.6[30.8-36.3]
TT 0.201 [0.187—0.215] 31.2[29.1—33.3]
+8855 TA 0.222[0.208-0.237] 0 . 1 0 /2 . 0 32.5[31.0-34.1] 0.44/0.7
AA 0.217[0 .195-0.241] 33.2[30.5-35.9]
AA 0.195[0 .180—0.211] 30.5[28.1-33.0]
+11015 AC 0.215[0.201-0.230] 0.01/3.9 32.7[31.0-34.4] 0.18/1.4
CC 0.232[0.215-0.251] 33.1[31.1-35.1]
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Figure 6.10: The association o f IL18 tSNPs and normalized plaque area in SCARF.
Table 6.26: R esults from  m ultivariate an alysis w ith  IL18  tSN P s and norm alized  plaque
area in SC A R F.
IL18  SNP
Model 1
Sex and age
Model 2
Model 1 + smok­
ing and DBP
M odel 3
Model 2 + IL-6
M odel 4
Model 3 + CRP
-9731 0 . 0 1 0.03 0.03 0.03
-5848 0 . 1 0 0.05 0.03 0.03
+ 105 0 . 2 1 0.38 0.36 0.33
+8855 0 . 2 0 0.37 0.35 0.32
+11015 0.04 0.09 0.06 0.06
Model 2 Sex, age, smoking, and DBP  
M odel 3 Sex, age, smoking, DBP, and IL-6 
M odel 4 Sex, age, smoking, DBP, IL-6, and CRP
Only the associations between IL18-9731 G > T  and -5848 T > C , and normalized 
plaque area remained after full adjustm ent (see table 6.26). This adjustment included 
that for both IL - 6  and CRP, both o f which w ere significantly correlated with normalized 
plaque area (p = 0 .19, p=0.005 and p=0.14, p=0.03, respectively), suggesting that the 
effect of IL18  on plaque area is independent o f  o ther inflammatory mediators.
6.3.2.2 H aplotype Analysis
Univariate Analysis IL18 haplotypes w ere globally  associated with normalized 
plaque area (p=0.02, see table 6.27 on the next page), but not percentage stenosis of 
the diseased vessel (p=0.47). Both hTTCAC and hTTATC were associated with higher 
normalized plaque area when com pared with to the reference haplotype (hGCATA). In 
those homozygote for each haplotype the d ifference in mean normalized plaque area 
was estim ated to be 19% for hTTCAC, and 38%  for hTTATC (see figure 6.11 on the 
following page). This equated to a mean to ta l  p laque area o f 66.2[57.6-74.7]m m 2 for 
homozygotes o f hTTCAC and 72 .8[56 .7-88 .9]m m 2 for hTTATC, however these were
not significantly different from the mean for hom ozygotes o f hGCATA -  59.0[51.2-
66.7]m m 2 (p=0.28 and p= 0 .13, respectively).
M ultivariate Analysis Globally, IL18  hap lo types remain associated with signifi­
cant differences in normalized plaque area in m ultivariate analysis (see table 6.28 on 
page 243). Specifically, the association with hT T C A C  was no longer significant al­
though it remained borderline significant in all four m odels (p=0.06 in model 4). How­
ever, the association between hTTATC and norm alized  plaque area was highly signifi-
241
Table 6.27: Normalized plaque area (In transformed) and % stenosis of diseased vessel 
by IL18  haplotypes in SCARF. Data available for cases only.
In Normalized plaque area % stenosis
Haplotype Geometric mean p Mean [95% Cl] p
[95% Cl]
hGCATA h l2 1 11 -0.82[-0.87- -0.78] Ref 15.3[14.2-16.5] Ref
hTTCAC h21222 -0 .74[-0 .79--0.68] 0.03 16.7[15.1-18.3] 0.19
hGTATA h i l l  11 -0 .80[-0 .86--0.74] 0.60 15.6[13.9—17.3] 0.83
hTTATC h21112 -0 .66[-0 .77--0.54] 0 . 0 1 17.5[14.8—20.3] 0.17
Global p/R2 0.02/5.0 0.47/1.5
p=0.01
p=0.03
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Figure 6 .11: Estimated mean[95% Cl] normalized plaque area for homozygotes of I LI 8  
haplotypes in SCARF.
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Table 6.28: R esu lts from  m ultivariate analysis with IL18 haplotypes and norm alized
plaque area in SC A R F.
IL18 haplotype
Model 1
Sex and age
Model 2
Model 1 + smok­
ing and DBP
Model 3
Model 2 + IL-6
Model 4
Model 3 + CRP
hGCATA h 1 2 1 1 1 Ref Ref Ref Ref
hTTCAC h 2 1 2 2 2 0.06 0.06 0.08 0.06
hGTATA hi 1 1 1 1 0.56 0.37 0.38 0.39
hTTATC h 2 1 1 1 2 0.006 0.004 0.004 0.005
Global p 0 . 0 2 0 . 0 2 0.03 0 . 0 2
cant in all four models (p=0.005 in model 4), adding to the evidence of a role for IL-18 
in dictating plaque morphology, independent o f other inflammatory pathways and me­
diators.
6.3.3 I  LI 8 and Weight Control
6.3.3.1 Single SN P Analysis
Univariate Analysis As shown in both table 6.29 on page 245 and figure 6.12 on the 
next page, all tSNPs apart from IL18-5848 T > C  were seen at significantly different fre­
quencies in obese and non-obese individuals. In all cases the rare allele was associated 
with a higher risk o f obesity, and a co-dominant/additive pattern between the genotype 
groups was observed. The effects of each SNP appeared to be exclusive to cases, with 
genotype frequencies not significantly different between obese and non-obese individu­
als in controls, but significantly different (or borderline significantly different) in cases 
(data not shown). However, the number of obese individuals in the case group were 
double that o f the control group (n=89 vs. n=40, p<0.001).
Each of these tSNPs were associated with differences in BMI, with the effects ap­
pearing greatest in cases compared to controls (see table 6.30 on page 246 and table 6.31 
on page 247). IL18 -9731 was associated with BMI in the total SCARF cohort, but when 
divided into obese and non-obese, or cases and controls, the effect was only seen in 
cases, as was the case for +11015 (although +11015 was significantly associated with 
BMI in obese individuals also). 7L/5-5848 was also associated with significant dif­
ferences in BMI, but this effect was also observed only in cases and not in the total 
cohort.
M ultivariate Analysis The following four models were used in multivariate analysis: 
M odel 1 Sex and age
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- □
GG GT TT
IL18-9731
(a) Risk of obesity by 
IL18  -9731 genotype
in
CD
-Q
TT TA AA
IL18+8855
(c) Risk o f obesity by 
IL18 +8855 genotype
in
05,
CL
CL
i-------1------- r
AA AC CC
IL18+105
(b) Risk of obesity by 
IL18 +105 genotype
AA AC CC 
IL18+11015
(d) Risk o f obesity by 
IL18 +11015 genotype
Figure 6.12: Obesity RR[95% Cl] for IL18  SNPs in SCARF; ★ -  p<0.05, f  -  p<0.01.
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Table 6.29: G enotype frequencies and R R s[95%  C l]  for IL18  tSN Ps in ob ese  and non-
ob ese individuals in SC A R F
tSNP
%[n]
Non-Obese Obese 
(n=320) (n=100)
X 2 P RR[95% Cl] P
GG 37.3[238] 28.2[35] 1 —
-9731 GT 47.5[303] 47.6[59] 0.03 1.27[0.86—1.87] 0 . 2 2
TT 15.2[97] 24.2[30] 1.84[ 1.19-2.86] 0.006
TT 37.0[236] 45.2[56] 1 —
-5848 TC 48.8[311] 42.7[53] 0.24 0.76[0.54-1.07] 0 . 1 1
CC 14.1 [90] 12 .1 [ 15] 0.74[0.44-1.26] 0.26
AA 46.2[295] 34.7[43] 1 —
+ 105 AC 43.7[279] 49.2[61] 0.03 1.41 [0.98-2.02] 0.06
CC 10.2[65] 16.1 [2 0 ] 1.85[1.15-2.97] 0 . 0 1
TT 46.2[295] 35.2[44] 1 —
+8855 TA 43.4[277] 48.8[61] 0.04 1.39[0.97-1.99] 0.07
AA 10.3[66] 16.0[20] 1.79[1.12-2.87] 0 . 0 2
AA 35.7[228] 24.0[30] 1 —
+11015 AC 46.5[297] 48.0[60] 0.007 1.45 [0.96-2.17] 0.07
CC 17.8[ 114] 35[28.0] 2.02[ 1.30-3.15] 0 . 0 0 2
M odel 2 Sex, age, and sm oking 
M odel 3 Sex, age, smoking, and IL - 6  
M odel 4 Sex, age, smoking, IL-6 , and C R P
As shown in table 6.32 on page 247, the associations between the IL18 tSNPs and 
BMI are not substantially attenuated in m ultivariate analysis.
6.3.3.2 Haplotype Analysis
Univariate Analysis IL18 hTTCAC was associated w ith a 1.4-fold increase in risk 
o f obesity (p=0.04, see table 6.33 on page 249). A s shown in table 6.34 on page 249, 
IL18 haplotypes were globally associated with significant differences in BMI in the total 
SCARF cohort and in cases, but not in controls alone. hTTCAC was associated with 
significant differences in BMI in the total SCARF cohort, but this effect was exclusively 
found in cases and not controls (see figure 6.13 on page 250). The effect was such that 
those homozygous for hTTCAC were estimated to have BM I 6 .6 % higher than those 
homozygous for hGCATA. hTTATC was also associated with significant differences in
BMI but in cases alone. The difference was greater than that observed for hTTCAC,
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Table 6.30: G eom etric m ean BM I[95%  C l] (kg/m 2) by IL18  genotype in ob ese and n on-obese individuals in SCA R F.
Geometric mean BMI[95% Cl] (kg/m2) 
tSNP Total p/R2 Non-Obese (n=320) p/R2 Obese (n= 100) p/R 2
GG 25.9[25.5-26.3] 25.0[24.7-25.3] 32.7(31.8-33.6]
-9731 GT 26.4[26.0-26.8] 0.002/1.7 25.4[25.1-25.7] 0.08/0.8 32.2(31.7-32.8] 0.17/2.9
TT 27.3[26.6-28.0] 25.7[25.2—26.2] 33.3(32.1-34.5]
TT 26.7[26.2-27.1] 25.3[25.0-25.7] 32.9(32.2-33.7]
-5848 TC 26.2[25.8—26.5] 0.22/0.4 25.3[25.0-25.6] 0.95/C0.1 32.3(31.7-32.9] 0.40/1.5
CC 26.2[25.6-26.9] 25.3[24.8—25.8] 32.6(31.4-33.8]
AA 26.0[25.7-26.4] 25.2(24.9-25.4] 33.0(32.2-33.9]
+ 105 AC 26.5[26.2-26.9] 0.03/0.9 25.4(25.2-25.7] 0.36/0.3 32.2(31.6-32.8] 0.15/3.1
CC 27.0[26.2-27.9] 25.4(24.7-26.1] 33.2(32.0-34.4]
TT 26.1 [25.7-26.4] 25.2(24.9-25.4] 32.9(32.1-33.8]
+8855 TA 26.5[26.2-26.9] 0.04/0.9 25.4(25.1-25.7] 0.38/0.3 32.2(31.6-32.8] 0.16/2.9
AA 27.0[26.2-27.9] 25.4(24.7-26.1] 33.2(32.0-34.4]
AA 25.9[25.5—26.3] 25.1(24.8-25.4] 32.7(31.7-33.7]
+11015 AC 26.4[26.0-26.8] 0.003/1.5 25.4(25.1-25.7] 0.36/0.3 32.0(31.5-32.5] 0.03/5.8
CC 27.2[26.5-27.8] 25.5(25.0-26.0] 33.5(32.4-34.6]
Table 6.31: G eom etric mean BM I[95%  C l] (kg/m 2) by IL18  genotype in cases and
controls in SC A R F.
Geometric mean BMI[95% Cl] (kg/m2)
tSNP Controls (n=387) p/R2 Cases (n=387) p/R2
GG 25.5[25.0-25.9] 26.4[25.8-27.0]
-9731 GT 25.7[25.3-26.2] 0.33/0.6 27.2[26.7-27.7] 0.006/2.8
TT 26.2[25.3-27.1] 28.2[27.2-29.2]
TT 25.6[25.1-26.2] 27.8[27.1-28.5]
-5848 TC 25.7[25.3-26.2] 0.98/<0.1 26.7[26.2—27.2] 0 .0 2 /2 . 0
CC 25.7[24.9—26.6] 26.6[25.7-27.6]
AA 25.5[25.0-25.9] 26.6 [26 .1-27.2]
+ 105 AC 25.8 [25.4-26.3] 0.39/0.5 27.3[26.8-27.9] 0.09/1.3
CC 26.1 [24.7-27.5] 27.8[26.7-29.0]
TT 25.5[25.0-25.9] 26.6[26.1-27.2]
+8855 TA 25.8[25.4-26.3] 0.44/0.4 27.3[26.8-27.9] 0.09/1.3
AA 26.1 [24.7-27.5] 27.8[26.7—29.0]
AA 25.6[25.1-26.1] 26.2[25.6-26.8]
+11015 AC 25.6[25.2-26.0] 0.24/0.8 27.4[26.9-28.0] 0.004/3.0
CC 26.3[25.4—27.3] 27.8[26.9-28.7]
Table 6.32: Results from multivariate analysis with IL18  tSNPs and BMI in SCARF.
IL18  SNP
M odel 1
Sex and age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + IL-6
Model 4
Model 3 + CRP
-9731 0 . 0 0 1 0.003 0 . 0 0 1 0.003
-5848 0 . 2 2 0.27 0.13 0.09
+ 105 0.04 0.04 0.03 0.04
+8855 0.04 0.05 0.04 0.04
+11015 0.003 0.006 0 . 0 0 2 0.003
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with those homozygous for hTTATC estimated to have a BMI 8.1% higher than those 
homozygous for hGCATA.
M ultivariate Analysis IL18 haplotypes remained globally associated with BMI in 
all multivariate models (p=0.02 in model 4, see table 6.35 on page 251). The associ­
ation with hTTCAC remained in all four models (p=0.01 in model 4) whilst that with 
hTTATC is significantly attenuated in model 4 and was only borderline significantly 
associated with BMI (p=0.02). Therefore, despite IL - 6  and CRP being strongly cor­
related with BMI (p=  0.29, p<0.001 and p=0.33, p<0.001 , respectively), variation in 
IL18 remained associated with BM I, thereby suggesting a novel pathway independent 
o f these inflammatory mediators.
6.4 UDACS
The University College London Diabetes and Cardiovascular Study (UDACS) consists 
o f 1011 consecutive multiethnic patients recruited from  the diabetes clinic at Univer­
sity College London Hospitals National Health Service Trust between the years 2001 
and 2002 [Dhamrait et al., 2004; Stephens et al., 2004]. All participants had diabetes 
according to W HO criteria [Alberti and Zimmet, 1998]. Ethical approval was granted 
by the institutional ethical com m ittee and written inform ed consent was obtained be­
fore recruitment. Data on BM I was collected for 994 individuals, and this cohort is the 
basis for data analysis in this section. IL-18 levels were not measured in UDACS and 
therefore the study was not suitable for previous chapters.
6.4.1 Baseline Characteristics
UDACS is a m ultiethnic cohort including individuals o f African, Caucasian, Indian and 
Oriental origin. Num erous baseline characteristics, including BMI, differed between 
the ethnic groups (see table 6.36 on page 252). The genotype distribution o f 7L75-9731, 
-5848 and +11015 also differed significantly across the genotype ethnic groups (see 
table 6.37 on page 253), as did the frequency of common haplotypes (see figure 6.14 on 
page 251).
6.4.2 I  LI 8 ’s Association with Obesity Risk
6.4.2.1 Single SNP Analysis
No IL18 genotype was seen at significantly different frequencies between obese and 
non-obese individuals (see table 6.38 on page 254).
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Table 6.33: IL18 haplotype frequencies in ob ese and n on-obese individuals w ithin SCA R F.
Frequency (%)
Haplotype Total Non-obese (n=260) Obese (n=87) OR[95% Cl] p
hGCATA h 1 2 1 1 1 33.1 34.3 27.4 1 —
hTTCAC h2 1 2 2 2 29.7 28.7 35.2 1.40[1.01-1.95] 0.04
hGTATA h i 1 1 1 1 22.7 23.4 19.4 0.96[0.65-1.41] 0.84
hTTATC h2 1 1 1 2 9.2 8.9 1 1 . 2 1.42[0.90-2.26] 0.13
Table 6.34: Geometric mean BMI[95% Cl] (kg/m2) by IL18 haplotype in cases and controls in SCARF.
Haplotype Total p/R2
Haplotypic mean lnBMI[95% Cl] 
Controls (n=387) p/R2 Cases (n=387) p/R 2
hGCATA h 1 2 1 1 1 1.631 [1.620-1.641] Ref 1.624[1.611-1.637] Ref 1.635[ 1.621-1.650] Ref
hTTCAC h2 1 2 2 2 1.650[ 1.639-1.661] 0 . 0 2 1.631 [ 1.617— 1.646] 0.51 1.667[ 1.650-1.684] 0 . 0 1
hGTATA h i 1 1 1 1 1.622[ 1.609-1.635] 0.35 1.612[ 1.595—1.630] 0.34 1.638[1.619-1.657] 0.83
hTTATC h2 1 1 1 2 1.651 [1.632-1.669] 0.07 1.624[ 1.598-1.651] 0.99 1.674[ 1.647-1.701] 0 . 0 1
Global p/R2 0 .0 2 / 1 . 6 0.63/0.7 0.02/2.9
BM
I 
(k
g/
m
2)
3 0 -
2 8 -
2 6 -
2 4
O< O
p=0.01
p=0.01
3 0 -
2 6 -
O < o
IL18 Haplotype
(a) Controls
IL18 Haplotype
(b) Cases
F igure 6.13: Estim ated homozygote mean BMI[95% Cl] by IL18 haplotype in both 
cases and controls w ithin SCARF.
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Table 6.35: R e su lts  from  m ultivariate analysis with IL18  haplotypes and B M I in
SCARF.
1 H  8  h a p lo ty p e
Model 1
Sex and age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + IL-6
Model 4
Model 3 + CRP
hGCATA
hTTCAC
hGTATA
hTTATC
h l 2 1 11  
h 2 1 2 2 2  
h i  1 1 1 1  
h 2 1 1 1 2  
G lobal p
Ref
0.01
0.52
0.04
0.01
Ref
0.01
0.49
0.04
0.01
Ref
0.01
0.49
0.05
0.01
Ref
0.01
0.71
0.07
0.02
□  -hGCATA □ -h T T C A C  □ - hGTATA □-hTTATC □ - Others
(a) Africans (b) Caucasian
(d) Oriental
Figure 6.14: C om m on european IL18 haplotype frequencies by ethnicity in UDACS.
(c) Indians
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Table 6.36: B aselin e characteristics in U D A C S by ethnic group
Variable African (n=79) Caucasian (n=786) Indian (n=l 11) Oriental (n=18) P
Males, %[n] 63.3[50] 60.3[471] 73.9[82] 66.7(12] 0.05
Age (yr) 59.7[57.0-62.4] 62.5[61.5-63.4] 58.9[56.9-61.0] 58.8(55.0-62.6] 0 . 0 0 2
BMI (kg/m2) 27.7[26.6—28.9] 28.5[28.1-28.9] 26.5(25.7-27.2] 26.3(24.5-28.2] 0 . 0 0 1
SBP (mmHg) 136.7[131.8—141.8] 138.5[ 137.1—139.9] 136.8(133.1-140.6] 131.1(125.0-137.6] 0.34
DBP (mmHg) 83.0[80.3—85.7] 79.5[78.7-80.3] 81.1(79.1-83.1] 75.2(70.9-79.7] 0 . 0 1
TIIDM, %[n] 91.1 [72] 74.9[589] 94.6(105] 94.4(17] < 0 . 0 0 1
C H D 1 %[n] 11.4[9] 20.2[ 158] 26.4(29] 16.7(3] 0.09
Cholesterol-lowering medication, %[n] 17.9[ 14] 26.8[209] 27.3(30] 50.0(9] 0.04
Ever smoked, %[n] 31.6[25] 49.9[385] 37.0(40] 55.6(10] 0 . 0 0 2
Total cholesterol (mmol/1) 5 .10[4.88-5.32] 5.01 [4.94-5.09] 4.79(4.58-5.00] 4.88(4.46-5.32] 0.14
LDL (mmol/1) 2.75[2.55—2.97] 2.72[2.66-2.79] 2.65(2.44-2.87] 2.69(2.29-3.13] 0.87
HDL (mmol/1) 1.50[ 1.41—1.60] 1.36[1.33—1.39] 1.14(1.08-1.21] 1.18(1.07-1.30] < 0 . 0 0 1
Triglycerides (mmol/1) 2.28 [ 1.72—3.02] 3.05[2.78-3.34] 4.20(3.37-5.25] 5.01(3.15-7.99] 0 . 0 0 1
1 History o f  MI or angina
Table 6.37: IL18  tSN P  gen otype frequencies across ethnic groups in U D AC S.
African (n=79) Caucasian (n=786) Indian (n=l 1 1 ) Oriental (n= 18) 
tSNP an completeness %[n] HW E p %[n] HWE p %[n] HWE p %[n]  HWE p X 2 P 
of genotyping (%)
GG 31.6[24] 32.9(251 ] 47.6(50] 1 1 . 1 (2 ]
-9731 (96.8) GT 48.7[37] 0.91 50.3(384] 0.36 43.8(46] 0.73 55.6(10] 0.47 0.008
TT 19.7[ 15] 16.8(128] 8.6(9] 33.3(6]
TT 32.9[25] 39.2[296] 17.0(18] 33.3(6]
-5848 (96.2) TC 39.5[30] 0.07 46.4(351 ] 0.76 48.1(51] 0.95 50.0(9] 0.90 < 0 . 0 0 1
CC 27.6[21] 14.4(109] 34.9(37] 16.7(3]
AA 55.3[42] 48.7(368] 61.7(66] 50.0(9]
+105 (96.3) AC 36.8[28] 0 . 6 6 41.9(317] 0.82 31.8(34] 0.37 50.0(9] 0.16 0.17
CC 7.9[6] 9.4(71] 6.5(7] —
TT 55.3(42] 48.7(370] 62.6(67] 50.0(9]
+8855 (96.7) TA 35.5[27] 0.39 42.1(320] 0.95 30.8(33] 0.30 50.0(9] 0.16 0 . 1 2
AA 9.2(7] 9.2(70] 6.5(7] —
AA 24.0(18] 31.5(240] 47.7(52] 16.7(3]
+11015(96.9) AC 42.7(32] 0.23 50.7(386] 0.35 44.0(48] 0.65 50.0(9] 0.90 < 0 . 0 0 1
CC 33.3(25] 17.7(135] 8.3(9] 33.3(6]
Table 6.38: IL18  tSN P  gen otype frequencies in ob ese  and non-obese individuals, and
RR[95%  C l] for obesity, in U D A C S (all eth n ic groups).
tSNP
%[n]
Non-Obese Obese 
(n=320) (n=100)
X 2 P RR[95% Cl] P
GG 34.2[217] 33.5 [ 110] 1 —
-9731 GT 49.7[315] 49.4[162] 0.92 1.01 [0.83-1.23] 0.92
TT 16.1 [ 1 0 2 ] 17.1 [56] 1.05[0.81—1.37] 0.70
TT 34.3[216] 39.4[ 129] 1 —
-5848 TC 47.4[298] 43.7[ 143] 0.30 0.87[0.72—1.05] 0.15
CC 18.3[115] 16.8[55] 0.87[0.67-1.12] 0.26
AA 51.4[325] 49.2[ 160] 1 —
+ 105 AC 39.2[248] 43.1 [140] 0.44 1.09[0.91—1.31 ] 0.34
CC 9.3[59] 7.7[25] 0.90[0.63—1.28] 0.56
TT 51.7[327] 49.1 [ 161 ] 1 —
+8855 TA 39.0[247] 43.3[142] 0.37 1.11 [0.92-1.33] 0.28
AA 9.3[59] 7.6[25] 0.90[0.63-1.28] 0.56
AA 32.8[208] 32.0[105] 1 —
+11015 AC 49.6[315] 48.8[ 160] 0.84 1.00[0.82-1.23] 0.97
CC 17.6[112] 19.2[63] 1.07[0.83-1.38] 0.58
6.4.2.2 Haplotype Analysis
To avoid any confounding or bias caused by the substantial differences in haplotype fre­
quency between the ethnic groups (see figure 6.14 on page 251), all haplotype analysis 
in UDACS was limited to Caucasians. IL18  haplotype frequencies were not seen at sig­
nificantly different frequencies between obese and non-obese individuals (see table 6.39 
on the following page).
6.4.3 I  LI 8 Genetic Variation and BMI
6.4.3.1 Single SNP Analysis
Univariate Analysis As shown in table 6.40 on page 256, only 77JS-9731 G >T  was 
associated with significant differences in BMI, with the com m on allele being associated 
with higher BMI (p=0.007), however this association was seen only in the non-obese 
individuals.
As the effect o f IL18  variation on BM I appeared to be influenced by underlying 
disease, the association o f the IL18  tSNPs were also studied in those with and without 
TIIDM (see table 6.41 on page 257). 7L75-5848 T > C  was borderline significantly 
associated with differences in BMI (p=0.07) showing an additive effect.
2 5 4
Table 6.39: IL18  tSN P  haplotype frequencies in ob ese and n on-obese individuals, and O R[95%  C l] for obesity, in U D A C S (Caucasians only).
Haplotype Total
Frequency (%) 
Non-obese (n=260) Obese (n=87) OR[95% Cl] P
hGCATA h 12111 32.1 33.0 30.6 1 —
hTTCAC h21222 26.8 27.0 26.5 1.06[0.81—1.38] 0.67
hGTATA h l l l l  I 22.3 2 1 . 8 23.1 1.14[0.86-1.50] 0.37
hTTATC h 2 1112 12.5 1 1 . 8 13.8 1.24[0.89-1.73] 0 . 2 0
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Table 6.40: G eom etric m ean BM I[95%  C l] by IL18  tSN P  genotype in ob ese and n on-obese individuals in U D A C S (all ethnic groups).
Geometric mean BMI[95% Cl] (kg/nT )
tSNP Total p/R2 Non-Obese (n=320) p/R2 Obese (n=100) p/R2
GG 28.2(27.7-28.8] 25.7(25.3-26.0] 34.1(33.3-35.0]
-9731 GT 28.3(27.8-28.8] 0.29/0.3 25.5(25.1-25.8] 0.007/1.6 34.6(33.9-35.3] 0.51/0.4
TT 27.5(26.7-28.4] 24.5(23.9-25.2] 34.0(33.0-35.0]
TT 28.4(27.8-28.9] 25.3(24.8-25.7] 34.4(33.8-35.1]
-5848 TC 28.1(27.6-28.6] 0.55/0.1 25.4(25.0-25.8] 0 .6 8 /0 . 1 34.7(33.9-35.5] 0.09/1.5
CC 27.8(27.1-28.5] 25.6(25.0-26.1] 33.2(32.1-34.4]
AA 28.2(27.7-28.6] 25.6(25.3-25.9] 34.2(33.5-34.9]
+ 105 AC 28.3(27.7-28.8] 0.29/0.3 25.2(24.8-25.6] 0.15/0.6 34.7(33.9-35.5] 0.48/0.5
CC 27.3(26.1-28.5] 25.0(24.0-26.0] 33.7(32.4-35.0]
TT 28.2(27.7-28.6] 25.6(25.3-25.9] 34.2(33.6-34.9]
+8855 TA 28.3(27.7-28.9] 0.34/0.2 25.2(24.8-25.6] 0.16/0.6 34.7(33.9-35.4] 0.51/0.4
AA 27.4(26.2-28.5] 25.1(24.1-26.1] 33.7(32.4-35.0]
AA 28.3(27.7-28.9] 25.6(25.2-26.0] 34.5(33.6-35.5]
+11015 AC 28.2(27.7-28.6] 0.79/<0.1 25.4(25.1-25.8] 0.19/0.5 34.4(33.8-35.1] 0.91/0.1
CC 27.9(27.1-28.8] 24.9(24.3-25.6] 34.2(33.2-35.2]
Table 6.41: G eom etric m ean B M I[95%  C l] by IL18 tSN P genotype in in those with and
w ithout T IID M  in U D A C S  (a ll ethnic groups).
Geometric mean BMI(95% Cl] (kg/m2)
tSNP No TIIDM  (n=211) p/R2 TIIDM (n=783) p/R2
GG 26.5[25.3—27.8] 28.7(28.2-29.4]
-9731 GT 25.8[25.0-26.8] 0.58/0.5 28.9(28.4-29.5] 0.46/0.2
TT 25.6[24 .1-27.2] 28.2(27.2-29.3]
TT 25.7(24.8-26.7] 29.2(28.6-29.9]
-5848 TC 25.8(24.8-26.8] 0.31/1.2 28.7(28.2-29.3] 0.07/0.7
CC 27.3(25.1-29.6] 27.9(27.2-28.7]
AA 26.7(25.7-27.7] 28.6(28.1-29.1]
+ 105 AC 25.5(24.5-26.6] 0.10/2.3 29.0(28.4-29.7] 0.35/0.3
CC 24.6(22.4-27.0] 28.2(26.9-29.5]
TT 26.7(25.7-27.7] 28.6(28.1-29.1]
+8855 TA 25.6(24.6-26.6] 0.16/1.8 29.1(28.4-29.7] 0.30/0.3
AA 24.8(22.5-27.3] 28.2(26.9-29.5]
AA 26.9(25.7-28.2] 28.7(28.0-29.3]
+11015 AC 25.5(24.6-26.4] 0.17/1.8 28.9(28.3-29.4] 0.84/C0.1
CC 25.7(24.1-27.4] 28.6(27.7-29.6]
M ultivariate A nalysis Four different models were used in multivariate analysis:
M odel 1 Sex and age 
M odel 2 Sex, age, and smoking 
M odel 3 Sex, age, sm oking and IL - 6  
M odel 4 Sex, age, sm oking, IL-6 , and CRP
M ultivariate analysis was limited to those in UDACS who had TIIDM. As shown in 
table 6.42 on the next page, the association between IL15-5848 and BM I remained sig­
nificant in both m odel 1 and 2, but was significantly attenuated when BM I was further 
adjusted for IL - 6  and CRP.
6.4.3.2 H aplotype Analysis
Univariate A nalysis IL18  haplotypes were significantly associated with significant 
differences in BM I but in non-obese individuals only (see table 6.43 on page 259), with 
this effect most likely attributable to hTTCAC alone -  the only haplotype significantly 
associated with differences in BM I (p=0.006). This association was such that those non- 
obese Caucasians hom ozygous for hTTCAC were estimated to have a mean BMI[95%
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Table 6.42: R esults from m ultivariate analysis o f  IL18  tSN P s and BM I in th ose w ith
TIIDM  in U D A C S.
I LI 8  SNP
Model 1
Sex and age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + IL-6
Model 4
Model 3 + CRP
-9731 0.45 0.53 0.49 0.41
-5848 0.04 0.04 0.09 0 . 1 1
+ 105 0.28 0.33 0.25 0.27
+8855 0.25 0.29 0.23 0.26
+11015 0.76 0.79 0 . 8 6 0.84
Cl] of 24.5[24.0-25.1]kg/m 2, which was 95% of that estimated for homozygotes of 
hGCATA (25.8[25.2-26.4]kg/m 2).
W hen UDACS was divided into those with and without TIIDM, 1L18 haplotypes 
were no longer globally associated with BMI (see table 6.44 on the next page). In this 
analysis, hTTCAC remained associated with lower BMI but only in those individuals 
who did not suffer from TIIDM  (p=0.05). In those with TIIDM, hGTATA was asso­
ciated with significantly higher BM I, such that those homozygote for hGTATA were 
estimated to have mean BMI of 31.0 kg/m 2 compared to 28.8 kg/m 2 for those hom ozy­
gote for hGCATA (see figure 6.15 on page 260).
M u ltiv a ria te  A nalysis The association between hGTATA and BM I was no longer 
significant in multivariate analysis (see table 6.45 on page 262). Adjustment for age 
alone was sufficient to significantly attenuate the association (p=0 . 1 1 ), despite not being 
significantly correlated with BM I (p=-0.04, p=0.33).
6.5 Discussion
The results from this chapter suggest that, although variation within 1L18 is not as­
sociated with CHD initiation, it appears to influence plaque development. The IL18  
tSNP set was also associated with significant differences in BMI and therefore implies 
a causal role for IL-18 in weight control. However, there was no evidence that IL18BP  
had any role in these conditions, and furthermore there was no evidence o f interac- 
tions/epistasis between the two genes. A summary of the IL18 results are shown in 
figure 6.16 on page 261, and it serves to illustrate the inconsistent nature of the associ­
ations found across all study groups.
Chapter 5, details an association between elevated IL-18 levels and risk o f a major 
complication following CPB surgery. Despite genetic variants in IL18 being associated
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Table 6.43: G eom etric mean lnBM I[95%  C l] by IL18  tSN P haplotype in ob ese and non-obese individuals in U D A C S (Caucasians only).
Haplotype Total p/R2
Haplotypic mean lnBMI[95% Cl] 
Non-obese (n=260) p/R2 Obese (n=87) p/R2
hGCATA h 1 2 1 1 1 1.672[ 1.657-1.687] Ref 1.625[1.613-1.637] Ref 1.766[ 1.749-1.782] Ref
hTTCAC h2 1 2 2 2 1.662[ 1.646-1.679] 0.46 1.600[ 1.588-1.611] 0.006 1.775[ 1.753-1.797] 0.56
hGTATA hi 1 1 1 1 1.693[ 1.673-1.712] 0.14 1.632[1.614-1.651] 0.56 1.785[ 1.764-1.806] 0.19
hTTATC h2 1 1 1 2 1.678[ 1.651-1.'705] 0.71 1.620[ 1.599-1.641] 0 . 6 8 1.749[1.715-1.783] 0.39
Global p/R2 0.32/0.6 0.04/2.0 0.38/1.5
Table 6.44: Geometric mean lnBMI[95% Cl] by IL18  tSNP haplotype in those with and without TIIDM in UDACS (Caucasians only).
Haplotype
Haplotypic mean lnBMI[95% Cl] 
No TIIDM (n= 197) p/R2 TIIDM (n=589) p/R2
hGCATA h 1 2 1 1 1 1.646[ 1.622-1.669] Ref 1.680[ 1.662-1.698] R ef
hTTCAC h 2 1 2 2 2 1.602[1.567-1.637] 0.05 1.682[ 1.663-1.700] 0.89
hGTATA hi 1 1 1 1 1.631 [1.587-1.675] 0.59 1.717[ 1.694-1.740] 0 . 0 2
hTTATC h2 1 1 1 2 1.646[ 1.578-1.714] 0.99 1.686[ 1.658-1.714] 0.74
Global p/R2 0.42/2.1 0.12/1.3
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Figure 6.16: Graphical summary of the IL18 association results; a -  outcome is major complication following surgery; b -  cases only; c 
individuals with TIIDM only.
Table 6 .45: R esu lts from m ultivariate an alysis with IL18  haplotypes and BM I in those
C aucasians w ith TIID M  in U D A C S.
IL18  haplotype
Model 1
Sex and age
Model 2
Model 1 + smok­
ing
Model 3
Model 2 + IL-6
Model 4
Model 3 + CRP
hGCATA h 12 11 1 Ref Ref Ref Ref
hTTCAC h 2 1 2 2 2 0.90 0.92 0.77 0.69
hGTATA hi 1 1 1 1 0 . 1 0 0 . 1 0 0 . 1 2 0 . 1 2
hTTATC h2 1 1 1 2 0.75 0.77 0.89 0.84
Global p 0.34 0.33 0.35 0.34
with significant differences in IL-18 levels, there was no evidence for a direct associa­
tion between variation in IL18  and risk of a major complication. Given that IL-18 levels 
at 24 h were most strongly associated with risk, and yet IL18 variation did not appear 
to play a role in influencing IL-18 levels at this time-point, this was not unexpected. 
Causality for IL-18 has not been established and it is therefore possible that IL-18 lev­
els are simply reflecting those of some other factor, itself causal (reverse causality). The 
evidence presented here is wholly com pliant with this theory. However, if IL-18 were 
causal then it is possible that environmental factors, operative, or treatment regimen, 
are playing a greater role in dictating the effect of IL-18 levels, than the genetic variants 
studied here. The influence o f IL18  hGTATA in CABG is substantial -  those homozy­
gous for hGTATA were estimated to have mean IL-18 levels at baseline 35% of that for 
hGCATA hom ozygotes -  and this suggests that, were IL-18 playing an important role 
in post-event survival, then the genetic effect would become apparent over the other 
influences. Sim ilar arguments can be used to explain the lack of genetic association 
between IL18 and risk o f MI in NPHSII.
The analysis in NPHSII concentrated on risk of MI, in which IL-18 levels were 
im plicated (see chapter 5). MI is a complex event with a number of different biologi­
cal system s interacting, and therefore for variation in one protein to have an impact on 
individual disease risk, that protein must play a key role. Furthermore, it follows that 
the individual variation in protein levels must be considerable and of a scale that could 
have biological consequences. The effect of hGTATA on IL-18 (and fIL-18) does ap­
pear to be considerable in NPHSII and other studies, furthermore given its association 
with BM I it is likely to have biological consequences. However, this haplotype is not 
associated with risk o f MI, therefore suggesting that IL-18 itself is not causal in CHD 
initiation. It must be noted, however, that the number of cases in NPHSII is relatively 
small and therefore any small increases/decreases in risk caused by genetic variants 
would not be detectable because o f low power. Further analysis in a larger prospective
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study with a greater number of events is required.
Analysis in SCARF revealed that, despite allele frequencies not differing between 
cases and controls, a number of SNPs were associated with significant differences in 
normalized plaque area. Most importantly, the only SNP found to be associated with 
differences in IL-18 levels (77JS-5848 T > C ) was also associated with borderline signif­
icant differences in normalized plaque area (p=0.05). However, the association seems 
slightly counterintuitive, with the C allele, associated with higher IL-18 levels, being 
associated with smaller plaque area. With regard to haplotypes, both hTTCAC and hG ­
TATA were associated with significant differences in IL-18 levels when compared to 
hGCATA. However, of these only hTTCAC was associated with significantly different 
normalized plaque area. The haplotype results match those of the single SNP analysis, 
with hTTCAC being associated with lower IL-18 levels, but higher normalized plaque 
area.
The extent of disease in SCARF was assessed by quantitative coronary angiogra­
phy, a procedure that assesses the area of plaque that encroaches above the vessel line, 
a significant proportion of which will be made up of the fibrous cap. As detailed in 
section 1.4.1.2 on page 47, IL-18 has been implicated in plaque stability. IFNy, the 
major downstream of IL-18 activation, has been shown to decrease collagen and ECM 
synthesis, as well as SMC proliferation [Amento et al., 1991; Yuan et al., 1999]. This, 
along with it’s induction of M M P production [Schonbeck et al., 1997] and SMC apop- 
tosis [Geng et al., 1996] leads to an overall thinning of the fibrous cap, a process that 
would lead to an decrease in plaque stability but perhaps also a decrease in plaque area, 
when assessed by coronary angiography. Therefore, in the context of the genetic effects 
described here, a decrease in IL-18 would also lead to a decrease in IFNy, resulting in 
a thickening of the fibrous cap and therefore an overall increase in plaque area (when 
assessed by coronary angiography). That hGTATA, the haplotype most commonly as­
sociated with lower IL -18 levels, was not associated with plaque area may be due to a 
difference in the cells involved. The genetic effect of this haplotype is likely to differ 
between the different IL -18-producing cells, and it is possible that those cells responsi­
ble for systemic IL -18 production are either not the same type, or not in the same state, 
as those responsible for IL-18 production within the plaque. Indeed IL-18 expression 
has been observed in SMC within the plaque [Mallat et al., 2001a] and may be respon­
sible for IL-18 production within the fibrous cap, and it is therefore likely that IL18 is 
regulated differently in these cells and that the effect of hGTATA may not be present.
In multivariate analysis, with both IL - 6  and CRP included as covariates, the effects 
of hTTCAC were significantly attenuated but remained borderline significant (p=0.06) 
in the full model (sex, age, smoking status, DBP, IL-6 , and CRP as covariates), whilst 
the association with hTTATC remained highly significant (p=0.005). Indeed, IL18  hap­
lotypes remained globally associated with normalized plaque area, suggesting that this
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Table 6.46: Results from W TCCC GWA study using CHD cohort and those SNPs 
occurring within the IL18  region considered here. P values quoted are frequentist p- 
values for both an additive (add) and a general (gen) model. Data accessed through 
www.wtccc.org.uk in M ay 2008.
SNP rs number p(add) P(gen)
-8963 G > T rs360718 0.48 0.56
-927 C > T rs360722 0.48 0.57
+ 1949 G > C rs 1834481 0.15 0.36
+8855 T > A rs360729 0.89 0.90
effect o f IL-18 is independent o f other inflammatory processes and pathways. There­
fore, from the data presented here, it appears that IL-18 is not causal in atherogenesis 
p e r  s e , but may be a factor that determines overall plaque stability. However, this is a 
hypothesis built on data from only one study and therefore needs replication and further 
investigation.
The increasing efficiency o f large-scale genotyping has led to a rise in the num­
ber o f genome-wide association (GWA) studies being conducted in recent years, and 
they have been shown to be a powerful approach in identifying genes involved in hu­
man disease. One recent study was carried out using the Wellcome Trust Case Control 
Consortium (W TCCC) population, representing 2000 cases and 3000 shared controls 
for seven complex hum an diseases of m ajor public health importance, including CHD 
[W TCCC, 2007]. All data has been released freely through their website. In total, 
four SNPs within IL18  were genotyped, none of which returned significant p values in 
case-control analysis using the CHD cohort (see table 6.46), or any o f the other disease 
cohorts (data not shown). None o f these SNPs were in sufficiently high LD with -5848 
T > C  to mark hGTATA, and therefore do not serve to represent the m ajor genetic effect 
seen here.
GWA studies are o f potentially great use in both identifying new potentially causal 
variants and replicating previous results, and it is likely that GWA will become the main 
genetic association analysis methodology replacing the single SNP/tSNP methods used 
here. However, much work remains to make the most o f the available data. Establishing 
m ethodologies for assessing both epistatic and haplotypic effects will be important steps 
forward, as will be an agreed standardization of analysis to account for the intrinsic risk 
of type I error.
Publication of data from  i l l8 ~ /~  mice has suggested that IL-18 may also play an 
important role in weight control [Netea et al., 2006]. Data presented here is the first to 
suggest a causal role for IL -18 in determining weight gain, possibly through influencing 
feeding behaviour. In CABG, SCARF cases, and those in UDACS with TIIDM, IL18-
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Figure 6.17: Graphical summary o f the association between 7L7&-5848 T > C  and BMI. 
Data is ratio o f mean BM I o f T T  genotype group compared to TC and CC group. Line 
represents average ratio o f those studies that showed significant results (CABG, SCARF 
cases, and UDACS individuals w ith TIIDM).
5848 T > C  was associated with significant differences in BMI. However, as shown in 
figure 6.17, the pattern is not a straightforward additive/co-dominant effect. In these 
groups, those heterozygous at -5848 had, on average, 3.7% lower BMI, whilst those 
who were CC homozygous had 3.0% lower BMI, than TT homozygotes. This lack of 
additivity could be explained by a dominant or recessive effect, yet in each of the studies 
the genotype pattern was different. In SCARF cases, the genotype pattern appears dom ­
inant, with C allele carriers having similar BMI whether homozygous or heterozygous; 
in CABG both homozygote groups have similar BMI, and the heterozygote group had 
lower BMI; in those UDACS participants with TIIDM, the genotype pattern appeared 
additive.
The different pattern for -5848 could be due to chance fluctuations in the small 
samples available, and the CIs for the TC and TT groups, in general, overlap. However
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it could also be due to a m ore complex haplotypic effect; those homozygous for a 
single SNP are not necessarily homozygous for a haplotype. In both CABG and those 
in UDACS with TIIDM , IL 18  hGTATA was associated with significantly higher BMI 
when compared to hGCATA. As shown in figure 6.18 those homozygous for hGTATA 
within CABG and UDACS (Caucasians with TIIDM only), had, on average, BMI 9% 
higher than those hom ozygous for hGCATA. This equates to a 7 kg weight difference 
for an 1.75 m tall individual w ith a BMI o f 25 kg/m2.
The results presented in chapter 5 showed significant positive correlations between 
IL-18 (and fIL-18 in NPHSII) and BMI. However, there appeared no significant dif­
ference in IL-18 levels between those who were obese and those who were not. In 
the il l8 ~ l~  mice, only intra-cerebral injection of IL-18 reversed the phenotype [Netea 
et al., 2006], therefore it can be assumed that local IL-18 production is most important, 
and also that the hypothalamus is the most likely target given its major role in regulating
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hunger and thirst [Horvath, 2005]. Expression o f il-18, il-18bp, and il-18 receptor has 
been detected, by QPCR, in the rat hypothalamus [W heeler et al., 2000]. The nature of 
il-18 transcriptional regulation in the hypothalamus is not yet known, and neither is the 
nature o f proil-18 cleavage ie. whether it is intra- or extracellular. Indeed, the activity 
of caspase-1 could be an important modulating factor for any /L/S-associated effect.
From the data available, it appears that the effect is most apparent in those individ­
uals who were overweight or obese. This may be because in the cohorts with a higher 
mean BMI, the CIs were wide and therefore genetic effects were more easily observed. 
Alternatively it is possible that the metabolic dysregulation, or underlying activation of 
the immune system, present in obesity may affect the expression of IL18. In CABG 
no subdivision o f the study group was required as all individuals had advanced disease, 
and it therefore seems likely that their immune system were already activated, allowing 
the effect of hGTATA to become apparent. The NPHSII is a healthy cohort, and there­
fore this might explain why there was no significant association between hGTATA and 
BMI, although in those individuals who go on to suffer a CHD event during follow- 
up, and therefore those who may have a degree of immunoactivation, hGTATA was 
associated with significantly higher BMI when compared to hGCATA (p=0.02, data 
not shown). The cases in SCARF were all under 60 yr, and only 8.5% of these had a 
glucose concentration exceeding 7 mmol/1 (the WHO diagnostic criteria for diabetes), 
whilst 15.9% of those in CABG were diabetic, and 12% had a glucose concentration 
exceeding 7 mmol/1. These observations, along with the substantial differences in BMI 
(SCARF cases -  2 6 .4 kg/m 2 vs. CABG -  28.1 kg/m2), suggests that there was greater 
metabolic dysregulation in CABG than in SCARF, and may explain why there was no 
observed effect o f hGTATA on BMI.
In SCARF IL18-5848 T > C  was associated with both normalized plaque area and 
BMI, but this did not translate into an association with hGTATA as it did in both CABG 
and UDACS. The T allele is carried by both hTTATC and hTTCAC, both of which 
are associated with significant differences in BMI and normalized plaque area (whilst 
only hTTCAC was associated with significant differences in IL-18 levels). This appears 
to suggest that the genetic effect in SCARF marked by -5848, is not the same as that 
in CABG and UDACS, but that it may mark a separate functional polymorphism that 
appears on the hTTCAC haplotype. The SCARF study group is a Swedish cohort, 
whilst the analysis in both CABG and UDACS was carried out in British Caucasians, 
therefore there could be genetic heterogeneity between the samples although this seems 
unlikely.
The associations seen between variation within 1L18 and BMI were largely unaf­
fected by adjustment for numerous factors, including other inflammatory mediators, 
suggesting a degree of independence for IL-18’s effect on weight control. However, 
the association between hGTATA and BMI in UDACS participants with TIIDM was no
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longer significant following adjustm ent for age alone, the cause of this remains unclear 
as there appeared no obvious relationship between age and BMI, and age did not dif­
fer by IL18  genotype (data not shown). In a minimal model with just IL - 6  and CRP 
as covariates, hGTATA was borderline significantly associated (p=0.06) with BMI in 
UDACS participants with TIID M .
Therefore, in summary, this data suggests that IL-18 does indeed play an impor­
tant role in weight control in hum ans, independent of other inflammatory mediators. 
However, this effect does not becom e apparent until a degree of immunoactivation or 
metabolic dysregulation, is present. This effect requires further study to establish IL- 
18 ’s exact role, its mode and site o f action, and the nature of the requisite activation.
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Chapter 7
The Frequency of IL18 Haplotypes 
Across Africa
Data presented in chapter 6  showed there were considerable differences in SNP and hap­
lotype frequency, between African and Caucasian groups (see figure 6.14 on page 251). 
The analysis in this chapter investigates the genotype distribution of the IL18 tSNPs 
across Africa and attempts to establish the historic causes of any differences.
7.1 Introduction
7.1.1 EHH Test
Under neutral evolution, new variants require a long time to reach a high frequency in 
the population, and LD around the variants will decay substantially during this period 
owing to recombination. As a result, common alleles will most likely be old and only 
have short-range LD surrounding them. Rare variants will either be young or old and 
will therefore have short- or long-range LD surrounding them. A key characteristic of 
positive selection, however, is that it causes a rapid rise in frequency over a short time, 
so short that recombination does not substantially break down the haplotype on which 
the mutation occurred. This is the basis of the extended haplotype homozygosity (EHH) 
test. EHH is defined as the probability that two randomly chosen chromosomes carrying 
the core haplotype of interest are identical by descent (as shown by homozygosity at all 
SNPs) from the core region to point x. The EHH score can therefore be used to assess 
the degree of long-range LD on a specific allele [Sabeti et al., 2002].
Such a method has been implemented by Voight et al. [2006] in the web-based tool, 
Haplotter (http://hg-wen.uchicago.edu/selection/haplotter.htm ), and this was used here 
to test for recent positive selection at each of the single SNPs. To test for recent positive 
selection at the haplotype level, scripts were developed by Krishna Veeramah at The 
UCL Centre for Genetic Anthropology, London.
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7.1.2 Samples Used
The NPHSII study, with its samples collected from nine general practices across UK, 
was used as the European sample. Each practice was analysed as a sub-group in this 
chapter. DNA samples from males over 18 yr from locations in and around Africa 
(see table 7.1 on the following page and figure 7.1 on page 272) were grouped based 
on their cultural identity and, together with NPHSII, form the basis for the analyses 
presented here. All African samples were kindly provided by Drs Neil Bradman and 
Mark Thomas at The UCL Centre for Genetic Anthropology, London.
7.2 Sample Differentiation
7.2.1 Single SNP Analysis
Each o f the IL18  tSNPs were genotyped in the African samples with genotypes recorded 
for > 8 8 % of all samples (see table 7.2 on page 273). The number of samples that 
deviated from HW E (n=9, data not shown) were no more than that expected by chance 
alone.
To assess whether allele frequencies differed between the samples, an analysis of 
molecular variance (AMOVA) test was used, the results of which are shown in table 7.3 
on page 275. Overall the am ongst population variance decreased across all SNPs (ex­
cept -9731) when analysis was restricted to sub-Saharan samples. An exact test for 
population differentiation (Raymond and Rousset’s exact test [Raymond and Rousset,
1995]) was highly significant (p<0.001) for all single SNPs.
In each single SNP, principal co-ordinate analysis (PCO) (a representation of hom o­
geneity between samples that uses F statistic matrices) showed few consistent patterns, 
although, as might be expected, the NPHSII samples were clustered tightly whilst the 
African samples were more diffusely scattered (see figure 7.2 on page 274).
7.2.2 Haplotype Analysis
The frequency of the four IL18  haplotypes, studied in the previous chapters, in the 
African and NPHSII populations are shown in table 7.4 on page 276. There is consid­
erable variation across the populations, with the most marked variations being in the 
frequency o f hGTATA which ranges from 29% (in HARE, an NPHSII sub-sample), to 
<1%  in 19 of the populations. Amongst-population variance in haplotype frequency 
was 2.56% when all samples were included and decreased to 2.28% when the NPHSII 
samples were excluded. Limiting analysis to sub-Saharan samples further reduced the 
variance to 1.36%. W hen using haplotype frequencies, Raymond and Rousset’s exact 
test returned a p value < 0 .0 0 1 , demonstrating that there is significant differentiation
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Table 7.1: Summary of the African samples used, and the longitude and latitude of their 
collection point.
Population
Code
Population Place Collected Longitude Latitude
AF Ethiopian Afar Assaita (Asayita), Ethiopia 41°26'00" 11°34/00 //
ALG -LN Algerian Arabs Port Say, Algeria -2°14'00" 35°05'00"
A R B Cameroonian Arabe Kousseri, Cameroon 15°OT55" 12°04/33//
AT Anatolian Turks Ankara, Turkey 32°5T12" 39°55'45"
AYL European Aylesbury, England -0°48'30" 51°48/57//
BAN South African Bantu Johannesburg, SA 28°03/01" -26°08'39//
BBR M oroccan Berbers Ifrane, M orocco -5°09'55" 33°35'17"
CA M B European Camberley, England -0°44'34" 51°20 '07"
C A RN European Carnoustie, Scotland -2°42'08" 5 6 °3 0 '1 1"
CH EST European Chesterfield, England -1°25'18" 53°14'06"
EAM Ethiopian Amhara Mekane Selam, Ethiopia 38°09'00" 11°41/00 //
E A N Ethiopian Anuak Gambela, Ethiopia 34°35'33" 8°14'36"
EOR Ethiopian Oromo Jimma, (Jima, Kefa), 
Ethiopia
36°49'51" 7°39'50"
G PN -B U L Ghanaian Bulsa Sandema, Ghana -1°16'44" 10°43/34"
HALE European Halesworth, England l o30'04" 52°20'35"
HARE European Harefield, England -0°28'52" 51°36'10"
HAU Cameroonian Hausa M ayo Darle, Cameroon 11°33'05" 6°28'38"
IGB Nigerian Igbo Calabar, Nigeria 8°18'52" 4°57'26"
K A N Cameroonian Kanuri Waza, Cameroon 14°34'13" l l ° 2 4 /06//
KOT Cameroonian Kotoko Makari, Cameroon 14°29'00" 12°35/00"
LBB Zimbabwean Lemba Mberengwa, Zim 29°54'50" -20°28'48"
LOM M alawian Lom we Lilongwe, Malawi 33°46'26" -13058'57"
M ANJ Senegalese Manjak Dakar, Senegal -17o27'07" 14°4T l2"
M D Cameroonian Fulbe M ayo Darle, Cameroon ira 'os" 6°28'38"
MLW M alawian Chewa Lilongwe, Malawi 33°46'26" -13°58'57"
M P M ozam bican M posi M posi, Zimbabwe 29°54'50" -20°28'48"
NG O M alawian Ngoni M angochi (M angoche), 
M alawi
35°15'49" -14°28'39"
N M Y European North M ymms, England -0°12'18" 5 1 043'16"
N S D Northern Sudanese Dunqulah, Sudan 30°28'27" 19° l O W
PARK European Parkstone, England -1°56'41" 50°43'13"
S A M ozam bican Sena (Vila de) Sena, M ozam­
bique
35°01'56" -17°26/4 3 //
SM M ozam bican Sena (Vila de) Sena, M ozam ­
bique
35°01'56" -17°26/43 //
SOM Cameroonian M ambila M ayo Darle, Cameroon 11°33'05" 6 °28 /38//
S S D Southern Sudanese Bor, Sudan 31°34'02" 6°13'38"
STAN European St Andrews, Scotland -2°47/51" 56°20'28"
TAN Tanzanian Chagga Dodoma, Tanzania 35°42'29" -6°05'34"
TBK M alawian Tumbuka Mzuzu, Malawi 34°0T 22" - 1 1°27'53//
UJW Ugandan Ssese Ssese Islands in Lake V ic­
toria, Bujumba, Uganda 
used as focus
32°17'00" -0°20'00"
YAM Cam eroonian Yamba M ayo Darle, Cameroon ira 'os" 6°28 /38 //
YAO M alawian Yao M angochi (M angoche), 
Malawi
35015'49" -14°28/39//
YM H Yemeni Al Mukalla, Yemen 49°07'38" 14°32'37"
YM S Yemeni Sena (Sanaa), Yemen 44°14'31" 15°24/31"
ZIM Zimbabwean Harare, Zimbabwe 31°03'14" -17°49'45"
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Figure 7.1: Location of African populations used.
Table 7.2: IL18  S N P  frequencies in the study sam ples used. N PH SII sam ples are
marked w ith an asterisk.
A llele Frequency
Population Code n -9731 G -5848 T + 105 A +8855 T +11015 A
AF 14 0.571 0.571 0.786 0.714 0.536
ALG-LN 162 0.522 0.581 0.681 0.678 0.513
ARB 91 0.626 0.450 0.862 0.828 0.500
AT 96 0.617 0.553 0.801 0.806 0.644
AYL* 114 0.619 0.649 0.690 0.689 0.597
BAN 101 0.672 0.450 0.931 0.882 0.505
BBR 108 0.495 0.575 0.639 0.638 0.481
CAM B* 432 0.587 0.659 0.690 0.688 0.577
C ARN* 408 0.604 0.646 0.696 0.697 0.591
CHEST* 263 0.611 0.631 0.692 0.694 0.583
EAM 263 0.637 0.390 0.805 0.802 0.551
EAN 95 0.758 0.350 0.909 0.903 0.413
EOR 94 0.620 0.441 0.800 0.788 0.478
G PN -BUL 90 0.700 0.455 0.865 0.850 0.544
HALE* 435 0.618 0.634 0.705 0.704 0.592
HARE* 299 0.680 0.600 0.737 0.733 0.665
HAU 27 0.595 0.519 0.692 0.704 0.407
IGB 100 0.645 0.537 0.846 0.835 0 .464
KAN 9 0.611 0.556 0.833 0.750 0 .444
KOT 42 0.756 0.381 0.878 0.869 0.512
LBB 102 0.723 0.416 0.911 0.876 0.579
LOM 19 0.667 0 .500 0.972 0.921 0.472
MANJ 85 0.706 0.494 0.776 0.768 0.488
MD 57 0.550 0.518 0.731 0.746 0.453
MLW 92 0.714 0.462 0.923 0.885 0.516
MP 18 0.500 0.618 0.875 0.853 0.444
NGO 17 0.529 0.676 0.900 0.900 0.294
NM Y* 294 0.647 0.571 0.727 0.722 0 .620
N SD 147 0.595 0.491 0.816 0.821 0.446
PARK* 419 0.624 0.635 0.674 0.673 0.587
SA 15 0.700 0.400 0.933 0.893 0.567
SM 69 0.709 0.396 0.932 0.912 0.566
SOM 96 0.633 0.526 0.797 0.786 0.464
SSD 129 0.780 0.373 0.920 0.919 0.384
STAN* 388 0.638 0.629 0.740 0.742 0.639
TAN 40 0.590 0.488 0.872 0.882 0 .500
TBK 65 0.619 0.484 0.879 0.823 0 .500
UJW 39 0.444 0.667 0.786 0.736 0.316
YAM 20 0.794 0.475 0.950 0.950 0 .550
YAO 53 0.654 0.462 0.868 0.798 0.519
YMH 83 0.543 0.512 0.774 0.768 0.543
YMS 37 0.643 0.457 0.770 0.800 0.542
Z1M 56 0.620 0.514 0.883 0.869 0.521
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Figure 7.2: Results from PCO analysis in the African and NPHSII populations. 
sub-Saharan populations; •  -  north African populations; • -  NPHSII populations.
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Table 7.3: Amongst population variances o f IL18  tSNPs within the NPHSII and African 
samples.
Amongst-population variance (%)
SNP All samples African sam ples1 Sub-Saharan samples2
-9731 G > T 1.07 2.38 1.74
-5848 T > C 3.29 1.29 0 . 8 8
+ 105 A > C 3.66 4.58 2.41
+8855 T > A 2.92 3.39 1.63
+ 11015 A > C 1 . 6 6 0.91 0.64
'Excluding NPHSII sam ples.
2Excluding NPHSII sam ples, and ALG -LN, AT, and BBR.
among all samples. W hen only sub-Saharan samples were analysed the test remained 
highly significant (p<0.001). In PCO analysis the pattern observed in single SNP anal­
ysis became more distinct, with the NPHSII populations clustering together, and the 
north African samples occurring closest to them. The sub-Saharan samples formed a 
diffuse scatter away from these populations (see figure 7.3 on page 277).
7.3 Geographic and Genetic Distances
Geographic distances (d) between samples and from the most northern population 
(CARN -  Carnoustie, Scotland) were calculated using the haversine formula where R 
is the radius of the earth, <j)\ and the two latitudes (and so A0 the latitude difference), 
AA the longitude separation, and haversin(0)=sin2 (0 /2 ) :
d  =  27?arcsin ^> /haversin(A 0) +  cos(0 i)c o s (0 2 )haversin(AA)^ (7.1)
7.3.1 Single SNP Analysis
All single SNP M AFs were significantly correlated with distance from Carnoustie ex­
cept IL18-9731 G > T  (R2=-0.13, p=0.41; -5848 T > C  R 2=0.58, p<0.001; +105 A > C  
R2= -0 .81, p< 0 .0 0 1 ; +8855 T > A  R 2 =-0.75, p < 0 .001 ; +11015 A > C  R2=0.52, p<0.001, 
see figure 7.4 on page 278). To test for a correlation between matrices of genetic dis­
tances (F statistic) and geographic distances, the Mantel test was used [Mantel, 1967]. 
All but -9731 G > T  (p=0.93) showed significant correlations (p<0.001).
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Table 7.4: Common European IL18 haplotype frequencies in the study samples used. 
NPHSII samples are marked with an asterisk.
Population
hGCATA 
h 12111
Haplotype 
hTTCAC hGTATA 
h21222 h i l l  11
hTTATC 
h 2 1 112 Other
AF 0.35 0.21 0.14 0.12 0.18
ALG-LN 0.40 0.31 0.09 0.15 0.05
ARB 0.48 0.14 0.02 0.20 0.17
AT 0.41 0.20 0.20 0.15 0.04
AYL* 0.31 0.27 0.27 0.09 0.07
BAN 0.49 0.10 0.01 0.20 0.20
BBR 0.41 0.35 0.06 0.14 0.05
CAM B* 0.29 0.27 0.26 0.11 0.06
CARN* 0.29 0.26 0.27 0.10 0.07
CHEST* 0.30 0.26 0.26 0.11 0.07
EAM 0.44 0.18 0.05 0.13 0.19
EAN 0.38 0.09 <0.01 0.11 0.41
EOR 0.45 0.21 <0.01 0.15 0.18
G PN -BUL 0.54 0.14 — 0.15 0.17
HALE* 0.32 0.26 0.26 0.11 0.05
HARE* 0.35 0.23 0.29 0.07 0.06
HAU 0.39 0.30 <0.01 0.08 0.23
IGB 0.47 0.16 — 0.18 0.18
KAN 0.39 0.13 <0.01 0.13 0.35
KOT 0.51 0.12 <0.01 0.12 0.25
LBB 0.57 0.09 <0.01 0.15 0.19
LOM 0.22 <0.01 0.09 0.11 0.58
MANJ 0.46 0.22 0.01 0.08 0.23
M D 0.42 0.25 <0.01 0.14 0.19
MLW 0.51 0.08 — 0.17 0.25
MP 0.40 0 .14 0.03 0.33 0.10
NGO 0.29 0.10 — 0.36 0.25
NM Y* 0.36 0.22 0.24 0.10 0.07
N SD 0.40 0.19 0.02 0.20 0.18
PARK* 0.32 0.28 0.25 0.08 0.07
SA 0.54 0.04 <0.01 0.18 0.23
SM 0.57 0.07 — 0.21 0.16
SOM 0.44 0.20 — 0.14 0.22
SSD 0.37 0.08 <0.01 0.12 0.43
STAN* 0.31 0.23 0.30 0.10 0.06
TAN 0.50 0.13 — 0.28 0.09
TBK 0.49 0.12 0.01 0.20 0.18
UJW 0.31 0.22 <0.01 0.28 0.18
YAM 0.47 0.03 0.02 0.12 0.37
YAO 0.51 0.13 — 0.13 0.23
YMH 0.46 0.22 0.05 0.20 0.06
YM S 0.51 0.20 0.02 0.16 0.11
Z1M 0.52 0.11 <0.01 0.26 0.11
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Figure 7.3: Results from PCO analysis of IL18 haplotypes in the African and NPHSII 
samples. • -  sub-Saharan populations; -  north African populations; -  NPHSII 
populations.
7.3.2 Haplotype Analysis
The Mantel test showed a highly significant correlation between genetic distance 
and geographic distance (p<0.001), however limiting analysis to sub-Saharan anal­
ysis gave no significant correlation (p=0.56). Each of the four common European 
haplotypes showed significant correlation between haplotype frequency and distance 
from Carnoustie (hGTATA R 2 =-0.86, p < 0 .001 ; hGCATA R2=0.60, p< 0 .001 ; hTTATC 
R2=0.62, p<0.001; hTTCAC R2 =-0.74, p<0.001, see figure 7.5 on page 279 and fig­
ure 7.6 on page 280). The most striking results were that for hGTATA which was seen 
at frequencies <1%  in the majority of the sub-Saharan Africa populations, 5-20%  in 
north African samples, and 25-30%  in the UK populations.
7.4 EHH Test
The above results suggested a significant cline in haplotype and single SNP frequency 
from southern Africa to northern Europe. As haplotypes, in particular hGTATA, have 
been shown to be associated with significant differences in IL-18 levels, it was possible 
this difference in haplotype frequency could be due to a positive selective pressure.
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7.4.1 Single SNP Analysis
Haplotter [Voight et al., 2006] was used to assess the degree of positive selection that 
has acted on each of the ILJ8  tSNPs. This tool uses the EHH approach but quantifies the 
degree o f recent positive selection at a locus with the integrated haplotype score (iHS) 
statistic. Only three o f the five IL18 tSNPs have been surveyed by Haplotter, of these 
none had potentially significant (>  2 or <  —2) iHS scores (-5848 T > C  -  -1.28; +105 
A > C  -  0.99; +8855 T > A  -  0.99).
7.4.2 Haplotype Analysis
The EHH analysis presented here uses HapMap release #21. Of the 5 IL18 tSNPs 
used here, 4 were previously typed in the HapMap project (-9731 G >T, -5848 T >C , 
+ 105 A > C , and +8855 T > A ). In the CEPH population they defined 7 haplotypes, with 
the haplotype o f interest (hGTAT) found at a frequency of 21.7%. In total this core 
haplotype was 0.0033 cM in length from first to last SNP. Haplotypes were extracted 
from HapMap data for each o f the three populations over a region extending 2 cM either 
side of the core haplotype region with SNP density maintained at around one SNP every 
0.05 cM. Those haplotypes that held the core haplotype of interest were then used to 
calculate EHH scores at regular points 0.1 cM either side of IL18 over 4cM .
To test whether any of the EHH values generated from this analysis indicated posi­
tive selection in the CEPH dataset, 1000 core haplotypes consisting of the same number 
of SNPs, of sim ilar frequency (± 5% ), and over a similar genetic distance (±20% ) as 
hGTAT were selected. EHH scores were then generated either side of these core haplo­
types in the same m anner as above, resulting in an empirical distribution of 1000 EHH 
values at each of the twenty pre-defined genetic distances.
The p values associated with the EHH scores over a distance of 2cM  either side 
of IL18 (roughly equalling a total distance o f 4M bp) are shown in figure 7.7 on the 
following page. If there had been recent positive selection at this locus then a number 
of EHH values within the upper 5% would be expected over a relatively continuous 
region. No such pattern was observed and therefore there is no evidence of positive 
selection at this locus.
7.5 Discussion
Despite advances in lifestyle and medical management, CHD remains the leading cause 
of death in the developed world [Anderson and Smith, 2003]. To date, much o f the 
research into the hereditary com ponent of disease risk has been carried out in Caucasian 
subjects, despite CHD being a m ajor contributor to the disparity in life expectancy and
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Figure 7.7: A graph o f p-values and genetic distance showing the results of EHH anal­
ysis in individuals carrying hGTATA.
mortality rate between blacks and whites in US [Cooper et al., 2000; Geronimus et al.,
1996]. Therefore the distribution across Africa of genetic variation within IL18 was 
studied and a common haplotype, previously shown to be protective in Caucasians, was 
found to be non-existent in much o f Africa.
The results from this study suggests that the genetic architecture and variation within 
IL18, is similar across much o f sub-Saharan Africa; from AMOVA analyses combining 
all five SNPs, the amongst-population variance was 1.36%, substantially less than when 
all samples were included (2.56%). Observing the gradient in common UK haplotype 
frequencies from South A frica to north Scotland, the correlation between matrices of 
genetic and geographic distances were assessed using the Mantel test. When including 
only sub-Saharan sam ples no significant correlation was observed (p=0.56), however 
including all samples in the analysis returned a highly significant correlation (p > 0 .0 0 1 ).
Correlations o f haplotype frequency with distance from Carnoustie (the most north­
ern sample), showed all com m on UK haplotypes had significant correlations, with hG­
TATA being the strongest (R2 =-0.86). However the EHH test showed no evidence of 
recent positive selection on hGTATA. The differences in haplotype frequency between 
Europe and Africa could be due to negative selective pressure (for which there is cur­
rently no test) on hGTATA in sub-Saharan Africa; hGTATA is associated with lower 
production of IL-18 and therefore this selective pressure could be due to poor reaction 
to infection (eg. both Plasm odium  falciparum  [Kojima et al., 2004] and Trypanosoma
*
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cruzi [M eyer Zum Buschenfelde et al., 1997] infection induce IL-18 expression). A l­
ternatively, it could be due to population bottlenecks and the increased genetic drift and 
inbreeding resulting from them. The data suggests that there is not necessarily a cline 
in frequency (suggesting a gradual, constant decrease/increase in frequency), more that 
the Sahara acts as a natural boundary preventing admixture between populations above 
(where hGTATA is com m on) and below it (where hGTATA is rare). This natural bound­
ary, in tandem with a population bottleneck, appears the most likely explanation for this 
difference in haplotype frequency. However, one point that must be brought up is the 
temporal resolution o f the EHH test. It is only able to detect recent positive selection, 
in the order of 20000 yr ago [Sabeti et al., 2002]. Given that is is believed that modem 
hum an’s migration out o f Africa occurred in the region of 45000-75000 yr ago [Liu 
et al., 2006], then it is obvious that the EHH test is ignorant to all of early Caucasian’s 
evolution.
Another problem with the EHH test is that analysis was not carried out on the full 
five-SNP core haplotype, however LD between +8855 T > A  and +11015 A > C  is very 
strong. In both IGB and GPN-BUL, the two closest populations to Ibadan, Nigeria 
(place of YRI collection), there was LD o f D ’= l between +8855 and +11015, as it was 
for NPHSII. Therefore it is possible, with reasonable accuracy, to apply the HapMap 
four SNP haplotypes to the five SNP haplotypes described here. In doing so it is obvi­
ous that the Yoruba have a far higher hGTATA frequency than any other sub-Saharan 
population sampled here (17%). That the Yoruba seem genetically more similar to 
Caucasian populations than their geographic neighbours suggests that it may not be the 
correct population to test for positive selection at hGTATA (and indeed raises doubts as 
to its suitability as a ‘representative’ population of Africa), however there is no other 
African population available with the requisite genotype density.
The results in this thesis have not truly confirmed or refuted the association between 
hGTATA and protection from CHD risk, shown by Tiret et al. [2005]. The association 
was found in a prospective study o f individuals with advanced disease, and given that 
the association between hGTATA and IL-18 levels appears especially strong in those 
with disease, it is likely that the effect of hGTATA on disease risk may not be suf­
ficiently apparent in ostensibly healthy individuals. The only prospective study used 
here, NPHSII, recruited healthy middle-aged individuals.
However if hGTATA was found to be protective of CHD, then its complete absence 
in sub-Saharan Africa predisposes over 770 million people [World Bank, 2006] to an 
increased risk of death from cardiovascular disease. Potentially of greater importance, 
given the current low incidence of CHD in Africa, it may also predispose around 35 
million US African-Am ericans to greater risk. The distribution of IL18  haplotype fre­
quencies in African-Am ericans was not studied directly here, but they are primarily 
descended from slaves sold during the Atlantic slave trade that occurred from 16th to
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the 19th century. M ost slaves were shipped from west and central Africa, and given the 
only recent (1970s) abolition o f racial segregation in US (and the resultant rise in in­
terracial marriage) it is highly unlikely that IL18  haplotype frequencies deviate greatly 
from that seen in sub-Saharan Africa.
In conclusion, this chapter demonstrates the importance of studying genetic deter­
minants of CHD in populations other than Caucasians. Data presented here shows a 
highly significant difference in SNP and haplotype frequency, between Caucasian and 
African populations. Given that hGTATA is a potentially protective factor in (Cau­
casian) CHD, further study o f its effect in African-Americans is required.
2 8 4
Chapter 8 
Assessing the Role of Genetic Variation 
on I  L I 8 Transcription In Vitro
This chapter aims to assess the impact o f hGTATA on IL18  transcription in vitro using 
QPCR. A num ber o f carriers o f IL18  hGTATA and hGCATA were recruited and the 
concentration o f IL18  mRNA species assessed in their circulating monocytes. The Pfaffl 
method [Pfaffl, 2001 ] was then used to compare expression between the two groups and 
assess the significant o f any differences.
8.1 Introduction
8.1.1 Potential Functional Variants
As there are no non-synonym ous variants within IL18, the effect of hGTATA must de­
rive from an effect on either prom oter activity, splicing, or mRNA stability. If this effect 
derives from a single SNP, then this SNP must be in strong LD with 7L/S-5848, with 
the allele differing between hGCATA and hGTATA. As shown in figure 8.1 on the next 
page, within the region resequenced by IIPGA there are 18 SNPs whose allele differs 
between hGCATA and hGTATA, one o f which is 7L7S-5848. One of these, IL 18-11238 
C > A , occurs within the proxim al prom oter and is therefore a good potentially func­
tional proximal prom oter variant.
As discussed in section 4.3 on page 175, 7L7S-11238 C > A  was genotyped in 85 
CABG individuals, and haplotypes (of -11238 C > A  and the IL18 tSNP set) were in­
ferred. As shown in table 8.1 on page 287, haplotypes inferred from the CABG data 
confirm that -11238 A is only seen on hGTATA. There were two other haplotypes that 
also carry the A allele, however these were relatively rare and may simply be errors 
in haplotype inference. Therefore it is possible that -11238 C > A  is the SNP respon­
sible for the effect o f hGTATA on IL-18 levels, however the SNP is not seen in a re­
gion of between-species conservation. Unfortunately -11238 C > A  is outside of the re-
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Table 8.1: Frequencies for common (>  1 %) haplotypes inferred from the IL18 tSNP set 
and IL18A  1238 C > A . Haplotypes are ordered: -11238 C >A ; -9731 G >T; -5848 T >C ; 
+ 105 A > C ; +8855 T > A ; +11015 A >C .
Haplotype Frequency
hCGCATA hi 1 2 1 1 1 27.5
hCTTCAC h i 2 1 2 2 2 25.5
hAGTATA h2 1 1 1 1 1 2 0 . 0
hCTTATC h 1 2 1 1 1 2 8.3
hCGCCAC h i 1 2 2 2 2 4.0
hCGTCAC h i 1 1 2 2 2 3.0
hCTCATA h 1 2 2 1 1 1 1.9
hAGTCAC h 2 1 1 2 2 2 1.4
hCGCCTA h i 1 2 2 1 1 1 . 2
hCGTATC h i 1 1 1 1 2 1 . 2
hCTTAAC h 1 2 1 1 2 2 1 . 2
hAGTCTA h 2 1 1 2 1 1 1 . 2
hATTCTC h 2 2 1 2 1 2 1 . 2
gion searched by cisRED (a database o f conserved regulatory elements www.cisred.org 
[Robertson et al., 2006]), but the A allele does create a muscle TATA box (whilst the C 
allele does not) when the sequence is processed through a transcription factor database 
(Genomatix [Cartharius et al., 2005]).
With regard to the possibility o f differential splicing, as detailed in section 1.3.1.1 
on page 30, there is a splice variant, lacking exon 3, produced by ovarian carcinoma 
cell lines that is not processed by caspase-1 [Gaggero et al., 2004]. There are no SNPs 
present within the im m ediate exon-intron boundaries of exon 3, however it is possible 
that SNPs outside o f these im m ediate regions are responsible for differential splicing.
As regards mRNA stability, IL 18+ 11640 A > G  occurs in the 3’ UTR. This SNP was 
studied by Barbaux et al. [2007] and found not to be intrinsically functional. No other 
SNPs were found in the 3’ UTR that differ between hGCATA and hGTATA.
Therefore to assess whether differences in IL18 transcription or IL18 splicing are the 
basis for the effect o f hGTATA on IL-18 levels, the relative levels of total IL18  mRNA, 
and IL 18A e\3 , were assessed in carriers of both hGTATA and hGCATA using the Pfaffl 
method.
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8.1.2 Assessing Differences in Gene Expression
8.1.2.1 Traditional M ethod
Traditionally, the relative expression of control gene to target gene (ACt) was calculated 
by:
A C t  =  C t  Jarget C tcon trol (8 -1)
Assuming that levels o f control gene mRNA remained consistent across samples 
and treatments, ACt values were compared, thereby assessing differences in target gene 
expression between samples. This was calculated by:
AA C t  — A C tsa m p le  A C tp ej erence (8.2)
The fold-difference in target mRNA between sample and reference was then calcu­
lated by an assum ption o f 100% efficiency in the PCR reaction (ie. a doubling of PCR 
product at each cycle)1:
mRNA sam pie—Re fere nee =  2 _AAC? (8.3)
However, this approach has a num ber of problems. Firstly, the assumption that the 
expression of the control gene remains constant across patients, treatments, and runs, 
is contentious; some studies show housekeeping genes remain stable across treatments 
and tissues [Marten et al., 1994; Foss et al., 1998; Thellin et al., 1999], whilst others 
show the opposite [Bhatia et al., 1994; Bereta and Bereta, 1995; Chang et al., 1998; 
Zhang and Snyder, 1992]. D ifferences in control gene expression will have a large 
impact on the resulting values o f AACt, possibly leading to unrepresentative values. As 
there is no easy way to recognize or assess control gene instability (without relying on 
other potentially unstable control genes), this assumption can be dangerous.
Secondly, the efficiency o f PCR (the fold-change in PCR products at each cycle) 
is not consistent across prim er pairs. Again, any difference in assay efficiency could 
lead to unrepresentative values. As shown in equation (8.3), with a 100% efficiency we
can assume that a ACt o f two PCR cycles is equal to a four-fold difference in starting
material. However, if the efficiency of that assay were 1.6, then a ACt of two would 
equal an mRNA sample-Reference o f 2.6. As ACt increases, the potential error grows 
exponentially (see figure 8 . 2  on the next page).
Thirdly, although the m ethod provides a measure of the difference between samples 
and reference it gives no indication o f the statistical significance of that difference.
'The sign o f  AACt is sw itched in equation (8.3) so that a negative AACt (equivalent to higher levels 
of mRNA than a positive AACt) gives rise to a correspondingly higher mRNAsa m p ie-R eference
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Figure 8.2: Chart showing the effect o f differing PCR efficiency (E) on
^^^^■Sample—Reference Over a range o f ACt.
8.1.2.2 The Pfaffl M ethod
The Pfaffl method [Pfaffl, 2001 ] is an adaptation of the AACt method that calculates the 
relative expression ratio (RER), taking into account the efficiency of target and control 
assays. The key equation is:
(  p  \ & C t t a r g e t  (control-sam ple)
R E R  ±= I tar8et)     (8.4)
( Erej-) Tef(c samP )
Both E target and E ref  are calculated from a regression slope of Ct against cDNA 
input, using:
E  =  i o ( - i / sl°P*) (8.5)
Relative Expression Software Tool (REST) is a software package that adopts 
the Pfaffl approach and runs a simulated data exchange to assess statistical signif­
icance of any observed differences. The software is freely available at http://rest.
gene-quantification.info/.
REST utilizes a pairw ise fixed reallocation randomization test to assess differences 
in expression between control and treated sample group means. Permutation or ran­
domization tests are a useful alternative to standard parametric tests for analysing exper­
imental data. They have the advantage o f making no distributional assumptions about
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Figure 8.3: Schematic o f both mature IL18  and 7L/#Aex3 mRNA showing the exon 
sizes ( -  exon 3), UTRs (■  -  UTR; 3  -  translated region), and the IL18 QPCR assays 
used for each transcript. Exact position of primers not known.
the data, while rem aining as powerful as more standard tests. Standard parametric tests 
(analysis o f variance (ANOVA), t-tests, etc.) depend on assumptions, such as normality 
of distributions, whose validity is doubtful. RER is a ratio, therefore its distribution is 
unlikely to be normal and it is difficult to see how a parametric test could be constructed 
[Pfaffl et al., 2002].
Standard statistical tests are based on the probability of an effect as large as that 
observed occurring under the null hypothesis of no treatment effect. If this hypothesis 
were true, the values in one treatm ent group were just as likely to have occurred in the 
other group. The randomization test repeatedly and randomly reallocates the observed 
values to the two groups, and notes the apparent effect each time. The proportion of 
these effects that are as large as those actually observed gives the p-value of the test 
[Pfaffl et al., 2002].
8.2 Results
8.2.1 QPCR Assays Used
Two IL18  TaqMan assays were used so that the amount of total IL-18 and IL18Aex3 
mRNA could be measured (see figure 8.3). As REST is able to normalize target gene ex­
pression to multiple control genes, three control genes were used -  GAPDH, BACT and 
UBC. This reduces errors caused by differential expression of ‘housekeeping’ genes. 
Total IFN y was also measured using a TaqMan probe that targeted the ex3-ex4 bound­
ary.
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Table 8.2: R esu lts from  the assay effic ien cy  experim ents.
Assay
R2
Run 1
(Pearson)
Run 2 Run 3 Overall slope Efficiency
IL18 -0.994 -0.941 -0.961 -2.935 2.191
7L75Aex3 -0.977 -0.965 -0.874 -3.366 1.982
IF N y -0.989 -0.980 -0.971 -3.537 1.917
GAPD H -0.999 -0.998 — -3.494 1.933
BACT -0.999 -0.999 — -3.639 1.883
UBC -0.998 -0.987 — -3.662 1.875
8.2.2 Control Selection
The cell line M D A -M B-231 (ECACC 92020424) is a human Caucasian breast adeno­
carcinoma cell line that is known to express the IL18Aex3  transcript (personal commu­
nication with Silvano Ferrini, Instituto Nazionale par la Ricerca sul Cancro, Genova, 
Italy, 2007, corresponding author on paper by Gaggero et al. [2004]). This cell line 
therefore served as the tem plate for the 7L7SAex3 assay efficiency experiments. A sam­
ple of M D A-M B-231 cells was kindly donated by Jonathan Abbott (UCL Centre for 
Cardiovascular Biology) and RNA aliquots were prepared as described in section 2.2.2 
on page 85.
8.2.3 Assay Efficiencies
To calculate the efficiency o f each QPCR assay, serial dilutions of cDNA were made 
and then used for each QPCR assay. Each experiment used triplicates for each cDNA 
concentration, and three experim ents were carried out on separate days using separate 
aliquots of the same PBM C RNA sample (except for the control genes, for which only 
two experiments were carried out, see figure 8.4 on the following page). All assays gave 
an acceptable relationship betw een Ct and cDNA concentration. A regression line was 
drawn for each assay from the results of all experiments, and this figure gave the assay 
efficiency (see table 8.2).
8.2.4 Recruitment and Genotyping of Study Participants
The recruitment o f hGTATA and hGCATA carriers was done in collaboration with 
the Cauldwell X treme Everest project (www.xtreme-everest.co.uk). Cauldwell Xtreme 
Everest is a research project coordinated by the UCL Centre for Altitude, Space and 
Extreme environment m edicine. The group placed a research team on the summit of 
Mount Everest in M ay 2007 and made the first measurement of the level of oxygen
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Figure 8.4: Graphs showing the decrease in C t associated with decrease in cDNA con­
centrations for each QPCR assay. Data is triplicated for each cDNA concentration, over 
three separate experiments ( •  • *) for IL-18, IL-18Aex3, and IFNy, and two separate 
experiments for the control genes {G APD H , BACT , and UBC). The overall trend line 
is shown in black.
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Table 8.3: G enotype frequencies and H W E  p values for C auldw ell cohort.
tSNP and com plete­
ness o f genotyping
(%)
HW E p %[n]
GG 33.3[18]
-9731 (98.2) GT 0.31 42.6[23]
TT 24.1 [13]
TT 38.9[21]
-5848 (98.2) TC 0.41 42.6[23]
CC 18.5[ 10]
AA 45.5[25]
+ 105 (100.0) AC 0.39 40.0[22]
CC 14.5[8]
TT 44.4[24]
+8855 (98.2) TA 0.43 40.7 [22]
AA 14.8[8]
AA 27.5[11]
+ 11015 (72.7) AC 0.21 40.0[16]
CC 32.5[13]
in human blood at 8400 m, on the balcony of Everest. This was the centrepiece of an 
extensive and continuing program m e of research into hypoxia. Part of this research in­
volved the recruitm ent o f a num ber o f individuals for aerobic performance testing, as 
such a database o f healthy London-based men was established. Ethical approval was 
granted by UCL Research Ethics Com mittee to approach individuals for a saliva sample 
for DNA extraction and potential later blood sampling and processing.
Individuals were approached by letter to take part in the study, and if they agreed 
sent back a saliva sam ple using the DNAgenotek Oragene DNA Self Collection Kit. 
In total, out of the 150 packs that were sent out, 55 individuals returned spit samples 
from which an aliquot o f 500 pi was taken and DNA extracted. The concentration of 
DNA varied widely across the samples, ranging from 5-50pg/m l. Each sample was 
diluted to a concentration o f 5 ng/pl for TaqMan genotyping, and all five IL18 tSNPs 
were successfully genotyped in the cohort, although there was a high rate of drop-outs 
for ILI8+] 1015 A > C  (27%). Given the high degree of LD between +8855 and +11015 
this was unlikely to significantly affect the accuracy of haplotype inference. All SNPs 
had genotype distributions consistent with HW E (see table 8.3).
PHASE was used to infer the most likely haplotype pair for each individual (see 
table 8.4 on page 295). Those individuals who were homozygous for hGCATA were 
selected as the ‘control’ group, whilst those who were homozygous or heterozygous
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for hGTATA (with hGCATA as the other haplotype) were recruited as the test group. 
Unfortunately, the only individual who was homozygous for hGTATA (#38) was not 
able to donate a blood sample.
8.2.5 QPCR of Selected Samples
In total, 10 individuals (five hGCATA/hGTATA heterozygotes and five hGCATA ho­
mozygotes) attended for blood-taking, where a 15-20 ml sample of venous blood was 
collected. Immediately following this, two aliquots of PBMCs were isolated and pre­
served in RNAlater before being stored at —80 °C (see section 2.2.1 on page 84). When 
all PBMC samples had been collected, RNA was extracted as detailed in section 2.2.2 
on page 85. RNA extraction was successful in all samples, with concentrations rang­
ing from 15-45 ng/pl with a high purity (A 260/A 280 - 1.99-2.34; A260/A 230 - 0 .07- 
1.02). The relative concentrations o f IL18  and IF N y  transcripts were then measured 
using QPCR in three separate repeat experiments on three consecutive days, using fresh 
cDNA prepared each day. On all three occasions 75 ng of RNA was used in cDNA 
synthesis, resulting in sim ilar cDNA concentrations across each run (mean for all sam­
ples in run 1=961.7 ng/pl; run 2=966.9 ng/pl; run 3=892.1 ng/pl) with within-sample 
coefficient of variations (CVs) being 6.6% on average (range 0.9-12.5% ).
Unfortunately sample 27 failed to produce any QPCR traces across all three runs 
and has therefore not been included in the following analysis. The first significant 
observation was that there is little evidence for significant expression of 77JSAex3 in 
the samples (see figure 8.5 on page 296). IL18Aex3  expression is evident in MDA- 
M B-231 cells but is substantially lower than that o f IL18. The ACtiu8Aex3-iLi8 for 
the M DA-M B-231 is, on average, 2.5. This therefore equates to a 5.7-fold excess of 
IL 18 to IL18 Ae,x3. For the Cauldwell cohort, no consistent expression of IL18 Aex3 was 
observed in any o f the samples. In some cases a QPCR trace arose with a Ct of 35+ 
cycles. If a real finding and not due to contamination, this would suggest that 1L18Aqx3 
represents <1%  of IL18  mRNA, and is therefore unlikely to be responsible for the 
association between hGTATA and IL-18 levels.
1L18 expression was observed at sim ilar levels to IF N y  but at substantially lower 
levels compared to the reference genes (G A PD H , UBC, and BACT, see figure 8.6 on 
page 297). 1L18 mRNA levels were 2.4-fold higher in hGTATA/hGCATA heterozy­
gotes compared to hGCATA homozygotes, although this difference was not significant 
(p=0.39). IFNy's expression was 1.2-fold higher in heterozygotes compared to homozy­
gotes, but again this difference was not significant (p=0.83).
Only one of the individuals recruited for this study was involved in the ascent of 
Everest. To allow the effects o f extreme altitude to subside, PBMC isolation from this 
individual was delayed by three months. There was no evidence that either IF N y  or IL18
29 4
295
Table 8.4: IL18 haplotype pairs within Cauldwell cohort; prob. -  probability given by PHASE that haplotype pair prediction is correct, selected 
samples are highlighted.
Ind. Prob. hG
T
A
T
A
hG
T
A
T
C
hG
T
C
A
C
hG
C
A
T
A
hG
C
C
A
C
hT
T
A
T
C
hT
T
C
A
C
hT
C
A
T
A
Ind. Prob. hG
T
A
T
A
hG
T
A
T
C
hG
T
C
A
C
hG
C
A
T
A
hG
C
C
A
C
hT
T
A
T
C
hT
T
C
A
C
1 0.997 ■ ■ 29 1.000 ■ ■
2 1.000 ■ ■ 30 1.000 ■ ■
3 0.997 ■ ■ 31 0.993 ■ ■
4 1.000 ■ ■ 32 1.000 ■ ■
5 1.000 ■ ■ 33 1.000 ■ ■
6 1.000 ■ ■ 34 0.993 ■ ■
7 1.000 ■ ■ 35 1.000 ■ ■
8 0.978 ■ ■ 36 0.993 ■ ■
9 0.993 ■ ■ 37 0.531 ■ ■
10 0.996 ■ ■ 38 1.000 ■ ■
11 0.993 ■ ■ 39 1.000 ■ ■
12 0.978 ■ ■ 40 1.000 ■ ■
13 0.993 ■ ■ 41 0.942 ■
14 0.978 ■ ■ 42 0.994 ■ ■
15 1.000 ■ ■ 43 0.962 ■ ■
16 1.000 ■ ■ 44 0.879 ■ ■
17 1.000 ■ ■ 45 0.848 ■ ■
18 0.993 ■ ■ 46 0.940 ■■
19 1.000 ■ ■ 47 0.962 ■ ■
20 0.991 ■ ■ 48 0.877 ■ ■
21 1.000 ■ ■ 49 0.941 ■ ■
22 1.000 ■ ■ 50 0.877 ■ ■
23 0.999 ■ ■ 51 0.937 ■■
24 1.000 ■■ 52 0.481 ■ ■
25 1.000 ■ ■ • 53 0.876 ■ ■
26 1.000 ■■ 54 0.938 ■■
27 1.000 ■ ■ 55 0.878 ■ ■
28 0.978 ■ ■
10
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Figure 8.5: The difference in Rn (reporter dye fluorescence normalized to passive ref­
erence dye) by cycle num ber for G A P D H , IL18  and IL18Aex3 assays. Those traces 
associated with RNA from M DA -M B-231 cells are shown as dotted lines. Data is a 
representative selection o f traces from a single experiment and plotted on a logarithmic 
scale.
Table 8.5: Ct[95% Cl] for all assays in those homozygous for hGCATA or heterozygous 
for hGTATA. Results presented are average o f triplicates in three separate experiments, 
with p values derived from REST analysis.
Ct[95% Cl]
Assay hGCATA Homozygotes hGCATA/hGTATA
Heterozygotes
P
IL18 33.8[32.2-35.4] 32.1 [30.5-33.7] 0.39
IFN y 34.2[33.1-35.3] 33.2[31.9-34.5] 0.83
GAPDH 27.2[25.9-28.4] 26.2[24.9-27.5] —
UBC 27.0[26.0-28.1] 26.4[25.3-27.4] —
BACT 25.1 [24.1-26.2] 24.5 [23.4-25.6] —
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Figure 8 .6 : ACt (Ctxarget-CtReference) plots for the two hapltoype groups, using each housekeeping gene as the reference. Whiskers represent 95% 
CIs derived from the raw Ct data, and do not take into account the base 2 nature of the scale.
expression was out o f the ordinary in this individual (p=0.79 and p=0.88, respectively 
when com pared to the rest o f the cohort).
8.3 Discussion
The data presented here attem pted to establish whether the differences in serum IL-18 
levels between carriers o f hGCATA and hGTATA, was due to differential gene expres­
sion in PBMCs. However, no significant difference in total IL18 mRNA was observed 
between hGCATA/hGTATA heterozygotes and hGCATA homozygotes. Furthermore 
consistent expression o f the 7L75Aex3 transcript, expressed in ovarian carcinoma cells 
[Gaggero et al., 2004], was not observed in any of samples used here.
Of the PBM C population, the cells that are most relevant to the atherosclerosis 
(when considering the im pact o f innate immunity) are the monocyte and macrophage. 
Experiments were carried out prior to volunteer recruitment to assess the feasibility of 
purifying CD 14+ cells (m onocytes and macrophages) from a PBMC population. This 
was done using the M iltenyi B iotech Inc. (Auburn, US) MACS system. This system 
uses small param agnetic beads that are linked to antibodies. By changing the antibodies 
used different cell populations can be m agnetically labelled. Those cells are retained 
on a magnetized column, whilst unlabelled cells pass through. Using this approach the 
CD 14+ population was isolated using both a positive approach (using anti-CD 14 anti­
bodies) and a negative approach (using a pool of antibodies that labels all but CD 14+ 
cells).
From a 30 ml sam ple of blood (twice that taken from the Cauldwell cohort) around 
3 x 107 cells were isolated. Using the positive magnetic beads approach, an input of 
2 x  107 cells yielded 1.45 x  106 cells, whilst for the negative approach an input of 
1 x 107 resulted in 1.29 x 106 cells. From these numbers it can be estimated that only 
around 10% of PBM Cs are m onocytes or macrophages. Therefore in order to obtain 
sufficient quantities o f m onocyte or macrophage RNA a large increase in the volume 
of blood taken would be needed. This was not practical and therefore a decision was 
made, based on efficacy, cost, and ability to standardize across extractions, to isolate the 
RNA from the PBM C population. The possibility of extracting PBMCs and differenti­
ating them into m acrophages in tissue culture was dismissed, as it was felt this would 
be difficult to standardize across samples and might therefore introduce potential error.
A non-synonymous variant in IL18  has not been found, therefore any genetic variant 
which affects IL -18 levels m ust function at the mRNA level (ie. transcription, splicing or 
stability). Given that no significant difference in IL18  mRNA production was observed 
between hGTATA and hGCATA carriers, a number of possible explanations present 
themselves:
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1. PBM Cs are not the cells responsible for the bulk of serum IL-18 pro­
duction
2. The hypothesized difference in 1L18 transcription only becomes ap­
parent upon cell activation/stress
3. The haplotype effect only becomes apparent in hGTATA homozy­
gotes
4. The effect of hGTATA on IL -18 production is not simply through a 
difference in rate o f transcription
5. The num ber o f individuals used in the study was too few
6 . The observed association between hGTATA and IL-18 serum levels 
was a chance finding, not a true biological phenomena
Which tissue is the m ajor contributor to serum IL-18 concentrations is not known. 
The assumptions made in this work were that circulating PBMCs made a major con­
tribution to serum IL-18 levels, and that even if this were not the case, the effect of 
hGTATA on 1L18 expression would be the same. The monocyte appears the best can­
didate for serum production o f IL-18, but it is possible that an as yet unidentified other 
source of IL-18 has a greater contribution. Given the observation that adipocyte IL18  
mRNA levels correlate with IL-18 plasm a levels [Leick et al., 2007], it is possible that 
adipose tissue is a major contributor to plasm a IL-18 levels. All the associations pre­
sented here were between hGTATA and serum IL-18 levels, it is possible therefore that 
the regulation of IL -18 production, and therefore the effect o f hGTATA, differs between 
the source of serum IL-18 and monocytes, and so no effect on monocytes would be 
observed.
What seems more likely is that the monocyte requires a degree of activation/stress, 
modifying IL18  mRNA production or regulation, before the effect o f hGTATA can be 
observed with the techniques used here. As detailed in section 4.3 on page 175 the 
association between hGTATA and serum IL-18 levels became especially apparent in 
those study groups that recruited individuals with advanced disease, and therefore ac­
tivated immune systems. On the whole, the volunteers used here were very healthy. 
The initial recruitment involved a free VO2 test of physical fitness that otherwise would 
cost around £200, and therefore attracted amateur sportsmen. None of the individu­
als recruited were overweight, and it is likely that they did not suffer from underlying 
cardiovascular disease that m ight serve to amplify any genetic effect. Despite their be­
ing healthy, this cohort was used as they had no underlying health issues and were not 
therefore on any medication. M edication is likely to have effects on IL-18 production 
(eg. Fluvastatin reduces serum IL-18 levels [Leu et al., 2005]), and it is probable that if 
subjects with disease had been recruited, differences in medication between individuals
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would mask any actual differences in IL18  mRNA concentration between the haplotype 
groups. As m entioned above, the process of individually isolating macrophages and 
then further activating them would have to be done sample by sample, and eliminating 
any variance caused by this process would be very difficult.
Despite successful PBM C extraction, mRNA extraction, and cDNA synthesis, sam­
ple 27 failed to produce any QPCR traces in all three runs. Why this was the case is 
not known, most likely it is due to contamination or degradation of the RNA or PBMC 
sample. However, sample 27 was one of the later samples to be collected (one and 
a half months before QPCR), and its RNA sample was sufficiently pure (30.0ng/pl, 
A 2 6 o/A2 8 o= 1-92, A 26o/A230=0.45). W hat cannot be ascertained is the quality of this 
RNA, and this may be the cause o f the failure. Due to the loss of sample 27, analysis 
was carried out in a cohort o f 9 individuals, four heterozygous for hGCATA/hGTATA 
and five homozygous for hGCATA. It is difficult to say whether this is too few without 
a good estimate o f the ACt betw een the two haplotype groups (if one exists).
The control group from SCA RF is the most similar to the Cauldwell cohort in terms 
of health and age. A lthough significant (p=0.001) the difference in haplotypic mean IL- 
18 associated with hGTATA and hGCATA was only modest, such that those homozy­
gous for hGTATA m ight be expected to have mean[95% Cl] IL-18 levels (pg/ml) of 
225.9[204.4-249.6] whilst for hGCATA this was 2 8 1.5[265.1-304.9] (see figure 4.13 
on page 164). Assuming additivity o f the haplotype effect, we can assume that hG ­
CATA/hGTATA heterozygotes m ight have serum IL-18 levels ~ 2 5 0  pg/ml. Given this 
relatively minor decrease in IL-18 production (10%), it is unlikely that QPCR would 
have sufficient statistical power to identify such a difference when only a small number 
of individuals were recruited. The observed data suggest that a greater difference may 
occur but was not statistically significant in this small sample.
However, how well differences in mRNA concentration relate to serum IL-18 levels 
is not clear from the data here. Barbaux et al. [2007] carried out experiments to assess 
the difference in IL18  transcription between carriers of three different haplotypes as­
sociated with IL-18 levels by Tiret et al. [2005]. Data presented by Tiret et al. [2005] 
show a similar magnitude o f haplotypic effect when compared to that observed here in 
SCARF controls. Barbaux et al. [2007] showed that individuals (n= l 1) homozygous for 
the haplotype equivalent to hGTATA (see section 3.2.6.2 on page 120) had an approx­
imately 2.5-fold lower expression of IL18  than those homozygous for the haplotype 
equivalent to hGCATA (p=0.03). This amounts to a ACt of log2 (2 .5 )= 1 .3 2. Given that 
the effect of hGTATA is believed to operate in an additive manner, the ACt between 
those heterozygous for hGTATA/hGCATA and those homozygous for hGCATA, that 
might theoretically be observed in these experiments would be log2 .i9 i ( l +  ^ = ^ )= 0 .7 .
2This assumes an efficiency o f  2 for the IL18 QPCR assay as Barbaux et al. [2007] did not perform 
any efficiency studies
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The two haplotype groups analysed here show a fold-difference in expression (when 
norm alized to control genes) of 2.36 (data not shown), and a ACt that ranges from 0.74- 
1 . 1 1  (depending on which control genes serves as the reference), yet it is not significant 
in the random reallocation test. Given that the effect of hGTATA would, presumably, 
be doubled in hom ozygotes this suggests that recruitment of hGTATA homozygotes in 
larger numbers (2 0 + individuals) should have reasonable power to detect such an effect 
with statistical certainty.
However, o f more concern is that the difference observed between the two haplotype 
groups is contrary to that which one would expect given the results presented in chapter 
4, with hGCATA/hGTATA heterozygotes having 2.4-fold higher expression than hG­
CATA hom ozygotes (although this was not significant). Assessing and presenting the 
error in these measures is difficult as the Ct scale itself is base 2, therefore the 95% CIs 
presented in figure 8 . 6  on page 297, are most likely misleading as these measures rely 
on normally distributed data. The expression ratio for IL18 between the two haplotype 
groups is 2.36 (norm alized to all three control genes), however if we consider that this 
figure has a standard error o f ± 2 .3 2  it becomes apparent that the difference observed is 
more than likely due to random  error.
It is possible that the effect o f hGTATA is not simply due to a difference in rate of 
transcription. As discussed above, Barbaux et al. [2007] demonstrated a significant dif­
ference in total IL18  mRNA produced by Epstein-Barr virus-transformed lymphoblas- 
toid cell lines. In an attem pt to identify the underlying cause of this difference they 
carried out luciferase reporter assays, mRNA stability, and allelic imbalance assays us­
ing the 3’ UTR (where their particular SNP [+11640] o f interest was found). Despite 
an observed difference in IL18  expression, the exact functional mechanism was not 
elucidated. The effect o f hGTATA may also not lie simply in transcriptional activity. 
But without further experim ents, assessing mRNA stability etc., no conclusions can be 
made.
Finally, it m ust be considered that the association between hGTATA and IL-18 is 
simply an anom alous statistical result and, in reality, no actual difference exists. A l­
though plausible, this explanation becomes difficult to reconcile with the data from 
different studies and groups, which, on the whole, agree. Given that hGTATA does 
also appear to be associated with BMI, the data strongly suggests that genetic variation 
present on hGTATA has an effect on the production of IL-18.
In conclusion, the data presented in this chapter gives no evidence for differential 
expression of 1L18 between hGCATA homozygotes and hGCATA/hGTATA heterozy­
gotes, in monocytes obtained from healthy individuals. However, the lack of any hG­
TATA homozygotes means that the expected deviations were most likely beyond the 
resolution of the technique given the measurement errors. This chapter also demon­
strates that the 1L18Aex3 transcript is not expressed in normal tissues, and therefore the
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isoform identified by Gaggero et al. [2004] must be considered either pathological or 
produced as a result o f pathology.
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Chapter 9 
Discussion
CHD remains the most serious health issue facing the Western world despite improve­
ments in medical managem ent, costing the UK in excess of £7 billion per year [Liu 
et al., 2002]. The epidem iological transition towards the end of the last century led to 
significant increase in life-expectancy, and, coupled with rises in population, has left 
the deaths due to CHD in the US fairly constant over the last quarter century. The inci­
dence o f global CVD deaths looks set to increase to 6 .2-8.2 million per year by 2030 
[Mathers and Loncar, 2006] as the developing world becomes industrialized, therefore 
knowledge of CHD risk factors in these countries (and associated ethnic groups) will 
be ever more important.
Numerous CHD risk biom arkers have been identified, but family history remains the 
strongest independent risk factor [Lusis et al., 2004]. Although social and behavioural 
factors inevitably play their part within this, it is highly likely that genetic variation 
within the biom arker genes, passed down from parents to offspring, significantly con­
tribute to CHD risk. So far, identification o f disease-causing variants has been slow, and 
to date the variants only explain a small fraction o f disease heritability [Watkins and 
Farrall, 2006]. However, as genom ic technologies progress and we gain ever greater 
insight into the 3.1 billion bps o f the human genome, it is hoped that targeted genetic 
testing, studying genes collectively rather than in isolation, will become a powerful tool 
in risk stratification [Drenos et al., 2007].
This thesis has been concerned with assessing the impact o f genetic variation within 
the IL-18 system, on both CHD risk and obesity. As an IFNy-inducing factor, IL-18 
promotes the T h 1 lineage o f cells [Elhage et al., 2003], encouraging foam cell formation 
[Bjorkbacka et al., 2004], and potentially influencing the stability of the atherosclerotic 
plaque [Mallat et al., 2001 a]. This cytokine also appears to have a role in weight control 
with knockout mice having higher fat mass, possibly caused by eating dysregulation 
and increased feed efficiency [Zorrilla et al., 2007]. The system comprises two secreted 
proteins (along with two receptor proteins), IL-18BP and IL-18, both of which were 
studied in tandem. In essence this work has loosely applied a Mendelian randomization
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[Davey Smith and Ebrahim, 2005] approach. The impact of the gene on the protein, and 
the protein on the disease are assessed separately. If associations are found in both of 
these ‘arm s’, then, if the protein is causal in the disease, a matching association between 
the gene and the disease should be found.
Initially this thesis was concerned with establishing an association between genetic 
variation with IL18  and IL-18 serum levels. Consistently a single IL18 haplotype, 
hGTATA (frequency o f ~ 25% ), was associated with roughly 30% lower IL-18 levels 
when compared to the most common haplotype (hGCATA). Importantly, this associa­
tion was also observed when analysing fIL-18 levels. The relative difference between 
hGTATA and hGCATA was greater in individuals with established disease (mean IL- 
18 hGTATA/mean hGCATA IL -18=0.61) than in healthy individuals (mean IL-18 hG- 
TATA/mean hGCATA IL -18=0.80). The difference was therefore considerable and of a 
magnitude that, given previous published data, could have pathological consequences.
On the basis o f M endelian randomization, from the work presented here, there does 
not appear to be strong support o f a causal role for IL -18 in CHD. Despite capturing 
near total genetic variation within 1L18 and IL18BP, strong and consistent associations 
between IL18 haplotypes and fIL-18 levels, and mild associations between IL-18 serum 
levels and future risk o f M l/post-event survival, there was no consistent difference in 
the frequency of 1L18 haplotypes between cases and controls. This contradicts work 
from the AtheroGene investigators.
The Athero Gene study is a cohort o f 1229 patients with at least one stenosis >30%  
in a major coronary artery, followed-up for death from cardiovascular causes. Blanken- 
berg et al. [2 0 0 2 ] dem onstrated that in this cohort the risk of death from cardiovascular 
causes increased near-linearly with increasing quartiles of IL-18, an association that re­
mained significant following adjustm ent for potential confounders including IL-6 , CRP, 
and BMI. Using a set o f SNPs that marked genetic variation throughout IL18, Tiret et al. 
[2005] then dem onstrated that an IL18  haplotype was associated with both IL-18 serum 
levels and cardiovascular mortality, although the association was most strong in those 
deaths occurring within 4 yr o f follow-up.
The largest prospective study used here, NPHSII, recruited ostensibly healthy 
middle-aged men. However, with an average age of 56 yr it would be surprising if a 
significant number did not have some evidence o f atherosclerosis; within CUDAS (a 
population-based sample with sim ilar age distribution to NPHSII) 29% of males have 
an asymptomatic carotid plaque [Chapman et al., 2006]. In NPHSII, IL-18 was signifi­
cantly higher in those who went on to suffer an MI during the 15 yr of follow-up (fIL-18 
was also higher, but only m arginally significant). Furthermore IL18 hGTATA was also 
associated with significantly lower IL-18 levels in the sub-group with IL-18 measures. 
However, there was no significant difference in hGTATA frequency between those who 
suffered an MI (n= 182) and those who did not (n=2870), in fact the frequency of hG-
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TATA was marginally higher in those who suffered an MI (28.4% vs. 26.4%, p=0.62).
The num ber of cases are comparable between the studies (NPHSII -  182; 
Athero Gene -  142), but do differ in their nature. AtheroGene considers cardiovas­
cular mortality, whilst NPHSII (in the analysis here) is concerned with MI incidence, 
therefore it is possible that the role of IL-18 may differ between the two end-points. 
NPHSII does record mortality data, however, at present only 42 fatal MI events have 
occurred within the cohort. As might be expected given the low number of cases, no 
significant difference in hGTATA frequency was observed (data not shown).
CHD is a complex disease and therefore no single genetic variant will be respon­
sible. It is possible that the studies used here lack the statistical power necessary to 
identify what is likely to be a small effect of IL18 on CHD risk. In total the studies used 
here (SCARF and NPHSII) represent 569 CHD cases. At present there is on-going work 
to genotype the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort 
[Day et al., 1999], a prospective study that currently contains 1035 CHD cases [Arse­
nault et al., 2007]. Com bined with SCARF and NPHSII, and potentially with published 
data, there should be sufficient cases for a well-powered meta-analysis that will give 
greater confidence to the estim ate of IL 18 's role in CHD.
Obesity is known to be a m ajor CHD risk factor, with mortality rates over 30 yr es­
timated to be 3.9 times higher for overweight individuals than normal weight [Garrison 
and Castelli, 1985], a worrying observation considering that the global obesity epi­
demic continues apace with over half o f adult Americans being overweight [National 
Task Force on the Prevention and Treatm ent o f Obesity, 2000]. IL-18 has recently been 
assigned a role in weight control, appearing to act through regulation of eating cycle 
and feed efficiency [Zorrilla et al., 2007]. The data presented here is the first demon­
stration that genetic variation within 1L18 is associated with BMI, and therefore the first 
to suggest that IL -18 may be an im portant regulator o f weight in humans.
To date, the data regarding IL-18 and obesity has largely concentrated on its be­
haviour either following weightloss [Esposito et al., 2002c, 2003b; Vilarrasa et al.,
2007] or in isolated adipocytes cultured from biopsies [Leick et al., 2007; Skurk et al., 
2005; Wood et al., 2005]. The results from such studies, although providing associa­
tive evidence, are not able to imply causality. Indeed, further studies showing IL-18 
levels are modulated by food intake [Esposito et al., 2003a, 2002b] tends to suggest 
that elevated levels in obesity may simply be reactive and not causative. However, the 
demonstration that injection of IL-18 into i l l8 ~ /~  mice reverses the adipogenic phe­
notype, strongly suggested IL-18 plays a central, active role in murine weight control 
[Zorrilla et al., 2007]. That hGTATA is associated with significantly higher BMI further 
implicates IL-18 in human weight control, however this association was only found 
in UDACS and CABG. These studies had the highest average BMI and the widest 
95%CIs (CABG -  28.1 [27.6-28.6]kg/m 2; UDACS -  28.5[28.1-28.9]kg/m 2; NPHSII -
305
23.2[23.1-26.3]kg/m 2; SCARF -  26.4[26.1-26.7]kg/m 2) of all the studies in which this 
analysis was carried out, therefore they represent the studies in which the spread of data 
is greatest and so the effect of IL-18 would most likely be apparent. However, it is also 
possible that the regulation o f IL-18 undergoes some change during disease that results 
in it participating to a greater degree in weight control. Given that IL-18 secretion by 
adipocytes from obese donors is greater than that from non-obese (5 .5±4.2pg/m l vs. 
1.8±0.9 pg/ml, p=0.09 [Skurk et al., 2005]), it is possible that the adipocyte is the site 
of this dysregulation.
The exact m ethod o f action for IL-18 in this instance is not wholly clear and will re­
quire further study. From the mouse studies it appears that serum IL-18 p e r  se does not 
play a role as only intra-cerebral and intra-peritoneal injection reversed the phenotype 
[Zorrilla et al., 2007; N etea et al., 2006], this may explain the lack of any consistent 
association between serum IL -18 levels and BMI in the study groups used here. Human 
intestinal epithelial cells express IL-18 [Takeuchi et al., 1997] whilst IL-18R and IL-18 
is expressed in the hypothalam us o f adult rats [W heeler et al., 2000]. There is therefore 
the potential for a regulatory loop linking food intake (serum IL-18 levels are known to 
be modulated by fam iliar foodstuffs [Esposito et al., 2003a]) and feeding behaviour (the 
hypothalamus play a critical role in the regulation o f food intake and weight) mediated 
by IL-18. In such circum stances the temporal dimension of IL-18 production, to which 
all studies used here were ignorant, will be important (ie. it may take longer for hG­
TATA carriers’ serum IL-18 levels to reach a threshold that activates the hypothalamus, 
therefore allowing greater food intake and subsequent weight gain).
The data regarding IL-18BP suggests that genetic variation within IL18BP  has no 
effect on either IL-18BP or fIL-18 levels, and furthermore does not have any bearing 
on incidence of CHD or obesity. However, the studies here are only concerned with 
one of the isoforms -  IL-18BPa. This is the most abundant isoform and is able to 
effectively inhibit IL-18, however, so is IL-18BPc (see section 1.3.1.2 on page 33, [Kim 
et al., 2000]). IL-18 is a cytokine with a pivotal role in determining immune reactions, 
and is therefore likely to be under very tight regulation. Given IL-18BP’s key role 
in IL-18 regulation, and that it is potentially under the control of IFNy [Paulukat et al., 
2 0 0 1  ], it is difficult to believe that it is not influenced by/influencing disease initiation or 
progression. It could be that IL-18BPc, or IL-1F7 (as an enhancer of IL-18BP function 
[Bufler et al., 2002]) becom e more important in disease.
As regards the genetic data, all o f the IL18BP  tSNPs used here are relatively rare 
(the most common has a M AF of 12% in NPHSII) and inevitably this leads to a number 
of rare haplotypes; one haplotype accounts for 84% of all haplotypes in NPHSII. This 
lack of diversity does not lend itself to identifying differentially expressing haplotypes 
as the rarer a haplotype the greater the effect needs to be for it to be identified.
Throughout this thesis both IL-18 and IL-18BP, and IL18  and 1L18BP, have been
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considered together. For the serum measures this was done by calculating fIL-18, whilst 
for the two genes evidence of epistasis was searched for using the MDR approach. flL- 
18 was calculated for each individual given their IL-18 and IL-18BP levels, and as 
a calculated value (albeit using well-established biological laws) it has potential for 
greater error. Exactly how well this calculated value reflects the true concentration of 
fIL-18 across individuals (especially when it only considers the influence of IL-18BPa) 
is not clear, as at present there remains no other suitable method for measuring flL -18 
within the plasma.
MDR is an attractive m ethod for searching for epistasis as its intuitive approach 
lends itself well to straightforw ard analysis. However the problem remains with the 
interpretation of results; as the data are split in numerous dimensions the root of a 
positive result becomes harder and harder to identify. As high-throughput genotyping 
platforms have become cheaper and more efficient, population genetics has now reached 
a point whereby generation o f data is no longer the bottleneck, rather its processing and 
analysis. There is no doubt that in multi-factorial diseases, such as CHD or obesity, 
gene-gene interactions will exist and must be considered. At present this field is in its 
infancy and will no doubt develop as com puting resources and statistical techniques 
evolve.
The MDR data presented here shows no significant interaction between IL18 and 
IL18BP, although it is difficult to assess the size o f the dataset needed to identify any 
interactions. IL -18R a and IL-18R/3 (possibly with SIGIRR also) bind together to form 
IL -18R and, given their proxim ity on chrom osom e 2, it is possible that there are signif­
icant interactions between both the proteins and the genes. A num ber of SNPs within 
IL 18R a  and IL18R(5 have been genotyped within HapM ap and therefore both genes 
lend themselves well to the tSN P approach. Indeed tSNPs have been selected and geno­
typed in NPHSII and are awaiting analysis, both individually and together. Given that 
there is no way to assess the SNPs effect on protein production, analysis must rely on 
intermediate phenotypes.
A striking observation was the considerably lower frequency of hGTATA in the 
UDACS subjects of African origin when compared to the Caucasian subjects. Given 
that this haplotype was shown to have significant effects on IL-18 production, a col­
laboration with the UCL Centre for Gene Genetic Anthropology was established and 
the distribution o f hGTATA across Africa was studied. The results showed a definite 
cline in frequency of hGTATA, with it being seen at very low frequencies in much of 
southern Africa, and only rising to prom inence at the very north of Africa. One of the 
reasons for this distribution could be positive selection at this locus, however using the 
EHH approach revealed no evidence for this, although it would only be able to detect 
positive selection that occurred within roughly the last 2 0 0 0 0 yr. More work to assess 
the role of IL-18 in disease within Africa is required, but it is possible for this differ­
307
ence in hGTATA frequency to account to some extent for the heterogeneity in disease 
susceptibility seen across Africa.
For example, a recent publication showed higher expression of IL18 in an African 
population with low susceptibility to malaria. Torcia et al. [2008] assessed the rela­
tive expression o f a panel o f genes involved in the immune response, in PBMCs taken 
from two sympatric populations (Fulani and Mossi, living in Barkoundouba, Burkina 
Faso). Both populations are homogenously exposed to P. fa lciparum , yet the Mossi 
show higher P. fa lciparum  parasite rates than Fulani, and have have higher incidence 
of clinical malaria. Despite sim ilar percentages o f the different T-cell subsets, IL18 
mRNA was around five-fold higher in the Fulani than Mossi (p=0.04, [Torcia et al.,
2008]). Since IL18  may be im portant in m alaria susceptibility it would be interesting 
to investigate the frequency of hGTATA in the Fulani and Mossi, or conversely, to as­
sess the relative P. fa lciparu m  parasite rates, along with the incidence of other common 
infectious diseases, in the African populations genotyped here.
The results from the previous chapter, detailing the expression of IL18 in PBMCs 
isolated from hGTATA carriers, were disappointing. No significant difference was ob­
served in the expression of IL18  mRNA, between individuals heterozygous for hG- 
TATA/hGCATA and those hom ozygous for hGCATA. If anything, the heterozygous 
group was seen to have slightly higher IL18  expression, however the difference was 
within the bounds of experimental error. The comparable work by Barbaux et al. [2007] 
was done using homozygotes o f both (comparable) haplotypes, and it is clear that this 
significantly added to their ability to observe any difference. Further work is needed 
to better characterize the effect o f hGTATA on IL18. In vitro  work using cells isolated 
from individuals with known haplotypes, rather than cell lines with prom oter constructs 
would be preferable, as the functional SNP is not yet known and may lie some distance 
from IL18. In terms of cell types, PBM Cs remain a valid choice, and are particularly 
suitable given the ease with which they can be collected and isolated. However adipose 
tissue biopsies are relatively easily isolated and are a good candidate for contributing to 
circulating IL-18. M ost importantly, hGTATA homozygotes need to be included which 
therefore means establishing a cohort of > 300  individuals. Such a study aimed also 
at understanding the reactivity o f IL-18 to common foodstuffs would be particularly 
relevant, and could establish the point of regulation whether it be IL18 transcription or 
mature IL-18 release.
Ultimately the SNP(s) responsible for the association between hGTATA and de­
creased serum IL -18 levels m ust be identified. Once identified the factors responsible 
can be isolated and assessed as potential drug targets. Within the small region rese­
quenced there are few serious candidates and therefore the search must be broadened 
beyond this region. An in silico  approach, identifying potential regulatory or enhancer 
sites, in tandem with targeted genotyping of SNPs within those sites could yield a
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number of candidate SNPs. It is also possible that extended genotyping and IL-18 
measurement within the African cohorts may yield associations with novel haplotypes, 
that, when compared to com m on European haplotypes, isolate potentially functional 
SNPs/regions.
In conclusion, this thesis presents novel data that suggests a role for IL-18 in weight 
control. A single common IL18  haplotype was consistently associated with lower serum 
fIL-18 levels, whilst also being associated with higher BMI, findings in agreement with 
previously published data. IL-18 is therefore an attractive anti-obesity therapeutic strat­
egy. With regard to CHD the data does not support the theory that IL-18 is causal in 
atherosclerosis.
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